AU2021323515A1 - Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as LPA receptor antagonists - Google Patents
Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as LPA receptor antagonists Download PDFInfo
- Publication number
- AU2021323515A1 AU2021323515A1 AU2021323515A AU2021323515A AU2021323515A1 AU 2021323515 A1 AU2021323515 A1 AU 2021323515A1 AU 2021323515 A AU2021323515 A AU 2021323515A AU 2021323515 A AU2021323515 A AU 2021323515A AU 2021323515 A1 AU2021323515 A1 AU 2021323515A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- methyl
- ealkyl
- substituted
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 title abstract description 10
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 title abstract description 10
- 125000000218 acetic acid group Chemical class C(C)(=O)* 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title description 2
- 229940044551 receptor antagonist Drugs 0.000 title description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 33
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 230000008482 dysregulation Effects 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 388
- 229910052739 hydrogen Inorganic materials 0.000 claims description 167
- 239000001257 hydrogen Substances 0.000 claims description 166
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 130
- 229910052757 nitrogen Inorganic materials 0.000 claims description 102
- 125000000623 heterocyclic group Chemical group 0.000 claims description 99
- 229910052736 halogen Inorganic materials 0.000 claims description 92
- 150000002367 halogens Chemical class 0.000 claims description 90
- 125000005842 heteroatom Chemical group 0.000 claims description 78
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 69
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 67
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 66
- 229920006395 saturated elastomer Polymers 0.000 claims description 65
- 229910052799 carbon Inorganic materials 0.000 claims description 64
- 229910052760 oxygen Inorganic materials 0.000 claims description 64
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 62
- 239000001301 oxygen Chemical group 0.000 claims description 62
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 59
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 57
- 229910052717 sulfur Chemical group 0.000 claims description 53
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 51
- 239000011593 sulfur Chemical group 0.000 claims description 51
- 229910003827 NRaRb Inorganic materials 0.000 claims description 47
- 150000001721 carbon Chemical group 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 42
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 41
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 125000006413 ring segment Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 229910052705 radium Inorganic materials 0.000 claims description 29
- 229910052701 rubidium Inorganic materials 0.000 claims description 29
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 22
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 17
- 206010016654 Fibrosis Diseases 0.000 claims description 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 17
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 16
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 claims description 15
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 15
- 230000004761 fibrosis Effects 0.000 claims description 14
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 12
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 101710149745 Lysophosphatidic acid receptor 1 Proteins 0.000 claims description 8
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 8
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 7
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 5
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 3
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 3
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 325
- 239000000203 mixture Substances 0.000 description 294
- 235000019439 ethyl acetate Nutrition 0.000 description 158
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 153
- 239000000243 solution Substances 0.000 description 147
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 140
- 238000000132 electrospray ionisation Methods 0.000 description 138
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 123
- -1 digluconate Chemical compound 0.000 description 120
- 239000000543 intermediate Substances 0.000 description 107
- 150000002431 hydrogen Chemical class 0.000 description 106
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 95
- 229910001868 water Inorganic materials 0.000 description 95
- 239000007832 Na2SO4 Substances 0.000 description 87
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 87
- 239000012267 brine Substances 0.000 description 87
- 229910052938 sodium sulfate Inorganic materials 0.000 description 87
- 235000011152 sodium sulphate Nutrition 0.000 description 87
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 87
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 82
- 239000004698 Polyethylene Substances 0.000 description 73
- 239000012299 nitrogen atmosphere Substances 0.000 description 72
- 239000007787 solid Substances 0.000 description 72
- 239000012044 organic layer Substances 0.000 description 52
- 238000003818 flash chromatography Methods 0.000 description 49
- 235000002639 sodium chloride Nutrition 0.000 description 45
- 238000005481 NMR spectroscopy Methods 0.000 description 43
- 235000011054 acetic acid Nutrition 0.000 description 43
- 125000004432 carbon atom Chemical group C* 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 40
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 39
- 239000003921 oil Substances 0.000 description 39
- 235000019198 oils Nutrition 0.000 description 39
- 125000001424 substituent group Chemical group 0.000 description 39
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 37
- 239000011541 reaction mixture Substances 0.000 description 37
- 238000003786 synthesis reaction Methods 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 32
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 31
- 230000015572 biosynthetic process Effects 0.000 description 31
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 31
- 239000000651 prodrug Substances 0.000 description 30
- 229940002612 prodrug Drugs 0.000 description 30
- 125000000217 alkyl group Chemical group 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- 230000002829 reductive effect Effects 0.000 description 26
- 239000000741 silica gel Substances 0.000 description 25
- 229910002027 silica gel Inorganic materials 0.000 description 25
- 239000000706 filtrate Substances 0.000 description 24
- 239000002585 base Substances 0.000 description 23
- 239000000126 substance Substances 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 150000001243 acetic acids Chemical class 0.000 description 20
- 150000002148 esters Chemical class 0.000 description 17
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 239000012230 colorless oil Substances 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 125000004429 atom Chemical group 0.000 description 15
- 238000010511 deprotection reaction Methods 0.000 description 15
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 15
- 238000010898 silica gel chromatography Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 14
- 150000003254 radicals Chemical class 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 13
- 125000005843 halogen group Chemical group 0.000 description 13
- 235000015320 potassium carbonate Nutrition 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 125000003342 alkenyl group Chemical group 0.000 description 12
- 125000000304 alkynyl group Chemical group 0.000 description 12
- 230000008901 benefit Effects 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- 238000003419 tautomerization reaction Methods 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- KORIJXKQGMTQTO-UHFFFAOYSA-N 1h-pyrrol-2-ylmethanol Chemical compound OCC1=CC=CN1 KORIJXKQGMTQTO-UHFFFAOYSA-N 0.000 description 11
- 238000005516 engineering process Methods 0.000 description 11
- 239000012453 solvate Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 125000004452 carbocyclyl group Chemical group 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 9
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 description 7
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 125000003367 polycyclic group Chemical group 0.000 description 7
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- SUGXRJHYTSXVGY-LURJTMIESA-N methyl 2-[(3S)-5,5-difluoropiperidin-3-yl]acetate Chemical compound COC(C[C@@H](C1)CNCC1(F)F)=O SUGXRJHYTSXVGY-LURJTMIESA-N 0.000 description 6
- 238000002953 preparative HPLC Methods 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- QLSWIGRIBOSFMV-UHFFFAOYSA-N 1h-pyrrol-2-amine Chemical compound NC1=CC=CN1 QLSWIGRIBOSFMV-UHFFFAOYSA-N 0.000 description 4
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 description 4
- YFTHTJAPODJVSL-UHFFFAOYSA-N 2-(1-benzothiophen-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(SC=C2)C2=C1 YFTHTJAPODJVSL-UHFFFAOYSA-N 0.000 description 4
- HTVIXEWSWWUNAQ-UHFFFAOYSA-N 5-(cyclopropylmethyl)-2-methoxypyridine Chemical compound COC1=NC=C(CC2CC2)C=C1 HTVIXEWSWWUNAQ-UHFFFAOYSA-N 0.000 description 4
- HVDJHGCGCDVLEY-UHFFFAOYSA-N 5-cyclopropyl-4-methyl-1H-pyridin-2-one Chemical compound CC(C(C1CC1)=CN1)=CC1=O HVDJHGCGCDVLEY-UHFFFAOYSA-N 0.000 description 4
- QRADWQRLPKZFFZ-UHFFFAOYSA-N 5-propyl-1h-pyridazin-6-one Chemical compound CCCC1=CC=NNC1=O QRADWQRLPKZFFZ-UHFFFAOYSA-N 0.000 description 4
- ICHCXRMAPXMSOZ-UHFFFAOYSA-N 5-propyl-1h-pyridin-2-one Chemical compound CCCC=1C=CC(=O)NC=1 ICHCXRMAPXMSOZ-UHFFFAOYSA-N 0.000 description 4
- BBQAYXRZKXRPNQ-ZDUSSCGKSA-N COC(C[C@@H](CC(C1)(F)F)CN1C(OCC1=CC=CC=C1)=O)=O Chemical compound COC(C[C@@H](CC(C1)(F)F)CN1C(OCC1=CC=CC=C1)=O)=O BBQAYXRZKXRPNQ-ZDUSSCGKSA-N 0.000 description 4
- BBQAYXRZKXRPNQ-CYBMUJFWSA-N COC(C[C@H](CC(C1)(F)F)CN1C(OCC1=CC=CC=C1)=O)=O Chemical compound COC(C[C@H](CC(C1)(F)F)CN1C(OCC1=CC=CC=C1)=O)=O BBQAYXRZKXRPNQ-CYBMUJFWSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000005605 benzo group Chemical group 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 229940097362 cyclodextrins Drugs 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 208000037765 diseases and disorders Diseases 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- XJLSEXAGTJCILF-UHFFFAOYSA-N nipecotic acid Chemical compound OC(=O)C1CCCNC1 XJLSEXAGTJCILF-UHFFFAOYSA-N 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 125000006574 non-aromatic ring group Chemical group 0.000 description 4
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 238000000844 transformation Methods 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 3
- UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 3
- VTVXWKKTZDSIOR-UHFFFAOYSA-N 2-methoxy-5-prop-1-en-2-ylpyridine Chemical compound COC1=CC=C(C(C)=C)C=N1 VTVXWKKTZDSIOR-UHFFFAOYSA-N 0.000 description 3
- WGYQCWCCWDHOBW-UHFFFAOYSA-N 3-propyl-1h-pyridazin-6-one Chemical compound CCCC=1C=CC(=O)NN=1 WGYQCWCCWDHOBW-UHFFFAOYSA-N 0.000 description 3
- JJYMYVNRWLXPPT-UHFFFAOYSA-N 4-(cyclopropylmethyl)-3-methyl-1H-pyridin-2-one Chemical compound C1(CC1)CC1=C(C(NC=C1)=O)C JJYMYVNRWLXPPT-UHFFFAOYSA-N 0.000 description 3
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 3
- XADICJHFELMBGX-UHFFFAOYSA-N 5-bromo-2-methoxypyridine Chemical compound COC1=CC=C(Br)C=N1 XADICJHFELMBGX-UHFFFAOYSA-N 0.000 description 3
- WWGBULGVHGACLV-UHFFFAOYSA-N 5-propoxy-1H-pyridin-2-one Chemical compound CCCOC(C=C1)=CNC1=O WWGBULGVHGACLV-UHFFFAOYSA-N 0.000 description 3
- QQFOXWFPCYCCJS-UHFFFAOYSA-N 6-propyl-1h-pyrimidin-4-one Chemical compound CCCC1=CC(=O)N=CN1 QQFOXWFPCYCCJS-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- STQLVJQYJRHAFI-UHFFFAOYSA-N C1CC1CC2=CNC(=O)C=C2 Chemical compound C1CC1CC2=CNC(=O)C=C2 STQLVJQYJRHAFI-UHFFFAOYSA-N 0.000 description 3
- GEGIEDJTRXPWRX-LBPRGKRZSA-N CCC1=NC(C2=C(CO)N(C)N=C2)=NC=C1N(C[C@@H](CC(OC)=O)C1)CC1(F)F Chemical compound CCC1=NC(C2=C(CO)N(C)N=C2)=NC=C1N(C[C@@H](CC(OC)=O)C1)CC1(F)F GEGIEDJTRXPWRX-LBPRGKRZSA-N 0.000 description 3
- BXGCGFIXGRFUOJ-UHFFFAOYSA-N CCC1=NC(C2=C(COC3OCCCC3)N(C)N=C2)=NC=C1Br Chemical compound CCC1=NC(C2=C(COC3OCCCC3)N(C)N=C2)=NC=C1Br BXGCGFIXGRFUOJ-UHFFFAOYSA-N 0.000 description 3
- ICHOVHNBZAYAHD-UHFFFAOYSA-N CCOC(CC(CCC1)CN1C(C(C)=[N+](C(Br)=C1)[O-])=C1[N+]([O-])=O)=O Chemical compound CCOC(CC(CCC1)CN1C(C(C)=[N+](C(Br)=C1)[O-])=C1[N+]([O-])=O)=O ICHOVHNBZAYAHD-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000006887 Ullmann reaction Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 3
- 235000019798 tripotassium phosphate Nutrition 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GKRRTFCDSZGFSZ-MRVPVSSYSA-N (2r)-3-cyclopropyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CC1CC1 GKRRTFCDSZGFSZ-MRVPVSSYSA-N 0.000 description 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
- QAPUHHJVIIWWLM-UHFFFAOYSA-N 1-cyclopropyl-3-dimethoxyphosphorylpropan-2-one Chemical compound COP(=O)(OC)CC(=O)CC1CC1 QAPUHHJVIIWWLM-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- SLDLYYHHCLNJMY-UHFFFAOYSA-N 1h-pyrrol-2-ylmethyl carbamate Chemical compound NC(=O)OCC1=CC=CN1 SLDLYYHHCLNJMY-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- RKKNRDFCDMIIDM-UHFFFAOYSA-N 2-(4-cyclopropyl-5-methylpyridin-2-yl)oxyethyl-trimethylsilane Chemical compound CC(C(C1CC1)=C1)=CN=C1OCC[Si](C)(C)C RKKNRDFCDMIIDM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- ZEGGJNVXZIQQNH-UHFFFAOYSA-N 2-chloro-4-cyclopropyl-5-methylpyridine Chemical compound CC(C(C1CC1)=C1)=CN=C1Cl ZEGGJNVXZIQQNH-UHFFFAOYSA-N 0.000 description 2
- WKVJISDVJWJDAC-UHFFFAOYSA-N 2-methoxy-5-propan-2-ylpyridine Chemical compound COC1=CC=C(C(C)C)C=N1 WKVJISDVJWJDAC-UHFFFAOYSA-N 0.000 description 2
- ZDVLZFZLSOEBRN-UHFFFAOYSA-N 2-methoxy-5-propylpyridine Chemical compound CCCC1=CC=C(OC)N=C1 ZDVLZFZLSOEBRN-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- TWJNJRHAJNBKMO-UHFFFAOYSA-N 3,6-dibromo-2-ethylpyridine Chemical compound CCC1=NC(Br)=CC=C1Br TWJNJRHAJNBKMO-UHFFFAOYSA-N 0.000 description 2
- NVMMYGMBTZIOAR-UHFFFAOYSA-N 3-(5-bromo-6-ethylpyridin-2-yl)prop-2-yn-1-ol Chemical compound CCc1nc(ccc1Br)C#CCO NVMMYGMBTZIOAR-UHFFFAOYSA-N 0.000 description 2
- JWXGMEPXXGDMAH-UHFFFAOYSA-N 3-(cyclopropylmethyl)-1H-pyridazin-6-one Chemical compound OC1=CC=C(CC2CC2)N=N1 JWXGMEPXXGDMAH-UHFFFAOYSA-N 0.000 description 2
- WYXHPRLZHHYGQN-UHFFFAOYSA-N 3-bromo-4-phenylmethoxypyridine Chemical compound BrC1=CN=CC=C1OCC1=CC=CC=C1 WYXHPRLZHHYGQN-UHFFFAOYSA-N 0.000 description 2
- FVMBBNDBRRLRPG-UHFFFAOYSA-N 3-chloro-5-propyl-1H-pyridazin-6-one Chemical compound CCCC1=CC(Cl)=NNC1=O FVMBBNDBRRLRPG-UHFFFAOYSA-N 0.000 description 2
- UAFUYZFLVUEGEW-UHFFFAOYSA-N 3-propyl-1H-pyridin-4-one Chemical compound CCCC1=CNC=CC1=O UAFUYZFLVUEGEW-UHFFFAOYSA-N 0.000 description 2
- OLXBPFICPFZYRP-UHFFFAOYSA-N 4-(cyclopropylmethyl)-2-fluoro-3-methylpyridine Chemical compound CC1=C(CC2CC2)C=CN=C1F OLXBPFICPFZYRP-UHFFFAOYSA-N 0.000 description 2
- JFRRCDFABHILGQ-UHFFFAOYSA-N 4-chloro-6-cyclobutylpyrimidine Chemical compound C1=NC(Cl)=CC(C2CCC2)=N1 JFRRCDFABHILGQ-UHFFFAOYSA-N 0.000 description 2
- ROFVKJROTVNTLN-UHFFFAOYSA-N 4-cyclopropyl-5-methyl-1H-pyridin-2-one Chemical compound CC(C(C1CC1)=C1)=CNC1=O ROFVKJROTVNTLN-UHFFFAOYSA-N 0.000 description 2
- ACPVEQDERAKKSC-UHFFFAOYSA-N 5-(2-cyclopropylethynyl)-2-methoxypyridine Chemical compound COC(C=C1)=NC=C1C#CC1CC1 ACPVEQDERAKKSC-UHFFFAOYSA-N 0.000 description 2
- MWZSNZAKXATJIS-UHFFFAOYSA-N 5-(azetidin-1-yl)-1H-pyridin-2-one Chemical compound O=C(C=C1)NC=C1N1CCC1 MWZSNZAKXATJIS-UHFFFAOYSA-N 0.000 description 2
- LLARJZZYJYBXEL-UHFFFAOYSA-N 5-(azetidin-1-yl)-2-phenylmethoxypyridine Chemical compound C(C1=CC=CC=C1)OC(C=C1)=NC=C1N1CCC1 LLARJZZYJYBXEL-UHFFFAOYSA-N 0.000 description 2
- CTQRGLNCRMMRSZ-UHFFFAOYSA-N 5-(cyclobutylmethyl)-1H-pyridin-2-one Chemical compound O=C1NC=C(CC2CCC2)C=C1 CTQRGLNCRMMRSZ-UHFFFAOYSA-N 0.000 description 2
- LXSSTXFGZLTAAU-UHFFFAOYSA-N 5-bromo-2-chloro-4-ethylpyrimidine Chemical compound CCC1=NC(Cl)=NC=C1Br LXSSTXFGZLTAAU-UHFFFAOYSA-N 0.000 description 2
- LXKTVNFZAFTUNZ-UHFFFAOYSA-N 5-bromo-2-phenylmethoxypyridine Chemical compound N1=CC(Br)=CC=C1OCC1=CC=CC=C1 LXKTVNFZAFTUNZ-UHFFFAOYSA-N 0.000 description 2
- CQDLHGPTPLVBDN-UHFFFAOYSA-N 5-bromo-4-ethyl-2-iodopyrimidine Chemical compound CCC1=NC(I)=NC=C1Br CQDLHGPTPLVBDN-UHFFFAOYSA-N 0.000 description 2
- RPWFIXIHRGVKCM-UHFFFAOYSA-N 5-cyclobutyl-1h-pyridin-2-one Chemical compound N1C(=O)C=CC(C2CCC2)=C1 RPWFIXIHRGVKCM-UHFFFAOYSA-N 0.000 description 2
- DTIXHUIVJAJESA-UHFFFAOYSA-N 5-cyclobutyl-2-methoxypyridine Chemical compound C1=NC(OC)=CC=C1C1CCC1 DTIXHUIVJAJESA-UHFFFAOYSA-N 0.000 description 2
- MCTZYXFPQIKUGO-UHFFFAOYSA-N 5-cyclopropyl-2-methoxy-4-methylpyridine Chemical compound CC1=CC(OC)=NC=C1C1CC1 MCTZYXFPQIKUGO-UHFFFAOYSA-N 0.000 description 2
- JLPNSLFQXWCJLN-UHFFFAOYSA-N 5-cyclopropyloxy-2-phenylmethoxypyridine Chemical compound C(C1=CC=CC=C1)OC(C=C1)=NC=C1OC1CC1 JLPNSLFQXWCJLN-UHFFFAOYSA-N 0.000 description 2
- GKBBAKRTWRPRJL-UHFFFAOYSA-N 5-prop-2-enylpyrazin-2-amine Chemical compound NC1=CN=C(CC=C)C=N1 GKBBAKRTWRPRJL-UHFFFAOYSA-N 0.000 description 2
- DGTAAIBINZROPM-UHFFFAOYSA-N 5-propan-2-yl-1h-pyridin-2-one Chemical compound CC(C)C=1C=CC(=O)NC=1 DGTAAIBINZROPM-UHFFFAOYSA-N 0.000 description 2
- QZGYBWJSTUTFSO-UHFFFAOYSA-N 5-propyl-1h-pyrazin-2-one Chemical compound CCCC1=CNC(=O)C=N1 QZGYBWJSTUTFSO-UHFFFAOYSA-N 0.000 description 2
- MXSNTJDGJBXLHR-UHFFFAOYSA-N 5-propyl-1h-pyrimidin-2-one Chemical compound CCCC=1C=NC(=O)NC=1 MXSNTJDGJBXLHR-UHFFFAOYSA-N 0.000 description 2
- FVJQKBPRVHGLDI-UHFFFAOYSA-N 5-pyrazol-1-yl-1H-pyridin-2-one Chemical compound C1=CN(N=C1)C2=CNC(=O)C=C2 FVJQKBPRVHGLDI-UHFFFAOYSA-N 0.000 description 2
- VZVVIHGLJGCFCO-UHFFFAOYSA-N 6-bromo-2-ethyl-3-fluoro-1-oxidopyridin-1-ium Chemical compound CCC(C(F)=CC=C1Br)=[N+]1[O-] VZVVIHGLJGCFCO-UHFFFAOYSA-N 0.000 description 2
- AHAHQWIOTMCCAF-UHFFFAOYSA-N 6-bromo-2-ethyl-3-fluoropyridine Chemical compound CCC1=NC(Br)=CC=C1F AHAHQWIOTMCCAF-UHFFFAOYSA-N 0.000 description 2
- PSNKSEHKWXMETD-UHFFFAOYSA-N 6-bromo-3-fluoro-2-methyl-1-oxidopyridin-1-ium Chemical compound CC1=C(F)C=CC(Br)=[N+]1[O-] PSNKSEHKWXMETD-UHFFFAOYSA-N 0.000 description 2
- JYIGVDRPXPMNLM-UHFFFAOYSA-N 6-bromo-3-fluoro-2-methyl-4-nitro-1-oxidopyridin-1-ium Chemical compound BrC1=CC(=C(C(=[N+]1[O-])C)F)[N+](=O)[O-] JYIGVDRPXPMNLM-UHFFFAOYSA-N 0.000 description 2
- BFQONZCQHGIKIY-UHFFFAOYSA-N 6-bromo-3-fluoro-2-methylpyridine Chemical compound CC1=NC(Br)=CC=C1F BFQONZCQHGIKIY-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- JOQZGKRWLSYBJC-SNVBAGLBSA-N CC(C)(C)OC(N(C)[C@H](CC1CC1)CN)=O Chemical compound CC(C)(C)OC(N(C)[C@H](CC1CC1)CN)=O JOQZGKRWLSYBJC-SNVBAGLBSA-N 0.000 description 2
- UCVIUJFTKUTLOF-SNVBAGLBSA-N CC(C)(C)OC(N(C)[C@H](CC1CC1)CN=[N+]=[N-])=O Chemical compound CC(C)(C)OC(N(C)[C@H](CC1CC1)CN=[N+]=[N-])=O UCVIUJFTKUTLOF-SNVBAGLBSA-N 0.000 description 2
- LRWYZSWQCLUNPC-SECBINFHSA-N CC(C)(C)OC(N[C@H](CC1CC1)CN=[N+]=[N-])=O Chemical compound CC(C)(C)OC(N[C@H](CC1CC1)CN=[N+]=[N-])=O LRWYZSWQCLUNPC-SECBINFHSA-N 0.000 description 2
- LQTZRBDGYPWEIZ-UHFFFAOYSA-N CCOC(CC(CCC1)CN1C(C(C)=NC(Br)=C1)=C1F)=O Chemical compound CCOC(CC(CCC1)CN1C(C(C)=NC(Br)=C1)=C1F)=O LQTZRBDGYPWEIZ-UHFFFAOYSA-N 0.000 description 2
- OUAJCWJHADHWGY-ZETCQYMHSA-N CN([C@@H](CC1CC1)CN1)C1=O Chemical compound CN([C@@H](CC1CC1)CN1)C1=O OUAJCWJHADHWGY-ZETCQYMHSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 description 2
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 description 2
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000652292 Homo sapiens Serotonin N-acetyltransferase Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- LEGZAPJFLIXWNB-UHFFFAOYSA-N O=C(C=C1)NC=C1OC1CC1 Chemical compound O=C(C=C1)NC=C1OC1CC1 LEGZAPJFLIXWNB-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102100030547 Serotonin N-acetyltransferase Human genes 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- QDPVRZJAEMWCNP-SNVBAGLBSA-N [(2R)-3-cyclopropyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propyl] methanesulfonate Chemical compound CC(C)(C)OC(N[C@H](CC1CC1)COS(C)(=O)=O)=O QDPVRZJAEMWCNP-SNVBAGLBSA-N 0.000 description 2
- GHUWMWQZNLLACT-UHFFFAOYSA-N [N-]=[N+]=CC(C(CC(C1)(F)F)CN1C(OCC1=CC=CC=C1)=O)=O Chemical compound [N-]=[N+]=CC(C(CC(C1)(F)F)CN1C(OCC1=CC=CC=C1)=O)=O GHUWMWQZNLLACT-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000005042 acyloxymethyl group Chemical group 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 229940063655 aluminum stearate Drugs 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 2
- RSKOYTSFQPTTDH-UHFFFAOYSA-N cyclopropyl-(2-fluoro-3-methylpyridin-4-yl)methanol Chemical compound CC1=C(C(C2CC2)O)C=CN=C1F RSKOYTSFQPTTDH-UHFFFAOYSA-N 0.000 description 2
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- MXFYYFVVIIWKFE-UHFFFAOYSA-N dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane Chemical compound CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 MXFYYFVVIIWKFE-UHFFFAOYSA-N 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- RJFIWCWTENIBKC-MRVPVSSYSA-N ethyl 2-[(3r)-piperidin-3-yl]acetate Chemical compound CCOC(=O)C[C@H]1CCCNC1 RJFIWCWTENIBKC-MRVPVSSYSA-N 0.000 description 2
- FSWZUWHCBPGBPJ-UHFFFAOYSA-N ethyl 2-[1-(6-bromo-2-methyl-4-nitropyridin-3-yl)piperidin-3-yl]acetate Chemical compound CCOC(CC(CCC1)CN1C(C(C)=NC(Br)=C1)=C1[N+]([O-])=O)=O FSWZUWHCBPGBPJ-UHFFFAOYSA-N 0.000 description 2
- ONNIVOPXQGVKOA-UHFFFAOYSA-N ethyl 2-[1-[4-fluoro-6-(3-hydroxyprop-1-ynyl)-2-methylpyridin-3-yl]piperidin-3-yl]acetate Chemical compound CCOC(CC(CCC1)CN1C(C(C)=NC(C#CCO)=C1)=C1F)=O ONNIVOPXQGVKOA-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 2
- 235000019793 magnesium trisilicate Nutrition 0.000 description 2
- 229940099273 magnesium trisilicate Drugs 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- JZZXXYACSDVNCG-WDSKDSINSA-N methyl (3S,5S)-5-fluoropiperidine-3-carboxylate Chemical compound COC(=O)[C@@H]1CNC[C@@H](F)C1 JZZXXYACSDVNCG-WDSKDSINSA-N 0.000 description 2
- SUGXRJHYTSXVGY-ZCFIWIBFSA-N methyl 2-[(3R)-5,5-difluoropiperidin-3-yl]acetate Chemical compound COC(C[C@H](C1)CNCC1(F)F)=O SUGXRJHYTSXVGY-ZCFIWIBFSA-N 0.000 description 2
- QKLKGDSAPVXGNZ-RQJHMYQMSA-N methyl 2-[(3S,5S)-5-fluoropiperidin-3-yl]acetate Chemical compound COC(C[C@@H](C1)CNC[C@H]1F)=O QKLKGDSAPVXGNZ-RQJHMYQMSA-N 0.000 description 2
- BCDBHIAXYFPJCT-UHFFFAOYSA-N methyl piperidine-3-carboxylate Chemical compound COC(=O)C1CCCNC1 BCDBHIAXYFPJCT-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- RQIAYLLGYGPVOH-UHFFFAOYSA-N n-cyanocyclopropanecarboxamide Chemical compound N#CNC(=O)C1CC1 RQIAYLLGYGPVOH-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000000466 oxiranyl group Chemical group 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002206 pro-fibrotic effect Effects 0.000 description 2
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 2
- 229950008679 protamine sulfate Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RFVQRCOBBCPFEL-SECBINFHSA-N tert-butyl n-[(2r)-1-cyclopropyl-3-hydroxypropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)CC1CC1 RFVQRCOBBCPFEL-SECBINFHSA-N 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XGUXJMWPVJQIHI-RXMQYKEDSA-N (2r)-2-azaniumyl-3-cyclopropylpropanoate Chemical compound [O-]C(=O)[C@H]([NH3+])CC1CC1 XGUXJMWPVJQIHI-RXMQYKEDSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- XGUXJMWPVJQIHI-YFKPBYRVSA-N (2s)-2-azaniumyl-3-cyclopropylpropanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1CC1 XGUXJMWPVJQIHI-YFKPBYRVSA-N 0.000 description 1
- QGRPPKXRMWZVMA-RYUDHWBXSA-N (3S,5S)-5-fluoro-1-phenylmethoxycarbonylpiperidine-3-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@H](F)CN(C1)C(=O)OCc1ccccc1 QGRPPKXRMWZVMA-RYUDHWBXSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- LOVPHSMOAVXQIH-UHFFFAOYSA-N (4-nitrophenyl) hydrogen carbonate Chemical compound OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-N 0.000 description 1
- DHADXDMPEUWEAS-UHFFFAOYSA-N (6-methoxypyridin-3-yl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=N1 DHADXDMPEUWEAS-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 1
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- TVPVAGUBJCNUSJ-UHFFFAOYSA-N 1,1-diazidoguanidine Chemical compound [N-]=[N+]=NN(C(=N)N)N=[N+]=[N-] TVPVAGUBJCNUSJ-UHFFFAOYSA-N 0.000 description 1
- GLUABPSZMHYCNO-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropyrrolo[3,2-b]pyrrole Chemical compound N1CCC2NCCC21 GLUABPSZMHYCNO-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- 125000005895 1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl group Chemical group 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- 125000005851 1-(N-(alkoxycarbonyl)amino)ethyl group Chemical group 0.000 description 1
- 125000005846 1-(alkanoyloxy)ethyl group Chemical group 0.000 description 1
- 125000005848 1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- 125000005849 1-methyl-1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- UPSXAPQYNGXVBF-UHFFFAOYSA-N 2-bromobutane Chemical compound CCC(C)Br UPSXAPQYNGXVBF-UHFFFAOYSA-N 0.000 description 1
- QVNRRVVLYBTXPQ-UHFFFAOYSA-N 2-chloro-4-cyclobutylpyrimidine Chemical compound ClC1=NC=CC(C2CCC2)=N1 QVNRRVVLYBTXPQ-UHFFFAOYSA-N 0.000 description 1
- QILQSGMEWRSKHW-UHFFFAOYSA-N 2-chloro-4-cyclopropylpyrimidine Chemical compound ClC1=NC=CC(C2CC2)=N1 QILQSGMEWRSKHW-UHFFFAOYSA-N 0.000 description 1
- AOZNIFQUCUSYLD-UHFFFAOYSA-N 2-chloro-4-propan-2-ylpyrimidine Chemical compound CC(C)C1=CC=NC(Cl)=N1 AOZNIFQUCUSYLD-UHFFFAOYSA-N 0.000 description 1
- WVPHBBSAPVBUGZ-UHFFFAOYSA-N 2-chloro-5-propylpyrimidine Chemical compound CCCC1=CN=C(Cl)N=C1 WVPHBBSAPVBUGZ-UHFFFAOYSA-N 0.000 description 1
- IALGRRFZGRXFKT-UHFFFAOYSA-N 2-cyclopropylacetyl chloride Chemical compound ClC(=O)CC1CC1 IALGRRFZGRXFKT-UHFFFAOYSA-N 0.000 description 1
- XWSVFBVCHYQCLO-UHFFFAOYSA-N 2-fluoro-4-iodo-3-methylpyridine Chemical compound CC1=C(I)C=CN=C1F XWSVFBVCHYQCLO-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- PVCYHRGPWALJNC-UHFFFAOYSA-N 2-methyl-1h-pyrrol-3-ol Chemical compound CC=1NC=CC=1O PVCYHRGPWALJNC-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- DFNJKJJPJAVTNY-UHFFFAOYSA-N 2-methylsulfonyl-1h-pyrrole Chemical compound CS(=O)(=O)C1=CC=CN1 DFNJKJJPJAVTNY-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZNGINKJHQQQORD-UHFFFAOYSA-N 2-trimethylsilylethanol Chemical compound C[Si](C)(C)CCO ZNGINKJHQQQORD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UCHKRHGVKYVGTC-UHFFFAOYSA-N 3,6-dibromo-2-methylpyridine Chemical compound CC1=NC(Br)=CC=C1Br UCHKRHGVKYVGTC-UHFFFAOYSA-N 0.000 description 1
- LIFXSPSMIVWHHP-UHFFFAOYSA-N 3,6-dichloro-4-propylpyridazine Chemical compound CCCC1=CC(Cl)=NN=C1Cl LIFXSPSMIVWHHP-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JWHZKNRXTDYNJO-UHFFFAOYSA-N 3-bromo-1h-pyridin-4-one Chemical compound OC1=CC=NC=C1Br JWHZKNRXTDYNJO-UHFFFAOYSA-N 0.000 description 1
- PNEPCDPKMXJYIQ-UHFFFAOYSA-N 3-chloro-6-iodopyridazine Chemical compound ClC1=CC=C(I)N=N1 PNEPCDPKMXJYIQ-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 125000006057 3-methyl-4-pentenyl group Chemical group 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- OCMKFCVEMJCTLD-UHFFFAOYSA-N 3-propylpyrazin-2-amine Chemical compound CCCC1=NC=CN=C1N OCMKFCVEMJCTLD-UHFFFAOYSA-N 0.000 description 1
- XYVMOLOUBJBNBF-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical compound OC1=NC=CO1 XYVMOLOUBJBNBF-UHFFFAOYSA-N 0.000 description 1
- 125000005902 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl group Chemical group 0.000 description 1
- 125000005903 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl group Chemical group 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- RTGZYKFHMYNNSM-UHFFFAOYSA-N 4-(2-cyclopropylethynyl)-1H-pyridin-2-one Chemical compound O=C1NC=CC(C#CC2CC2)=C1 RTGZYKFHMYNNSM-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QGMCCRKFZDLEBP-UHFFFAOYSA-N 4-bromo-2-chloro-5-methylpyridine Chemical compound CC1=CN=C(Cl)C=C1Br QGMCCRKFZDLEBP-UHFFFAOYSA-N 0.000 description 1
- HDRFFLHBLUPAKE-UHFFFAOYSA-N 4-chloro-6-pyrazol-1-ylpyrimidine Chemical compound C1=NC(Cl)=CC(N2N=CC=C2)=N1 HDRFFLHBLUPAKE-UHFFFAOYSA-N 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- JWIBTPMTSDSVQR-UHFFFAOYSA-N 4-iodo-2-methoxypyridine Chemical compound COC1=CC(I)=CC=N1 JWIBTPMTSDSVQR-UHFFFAOYSA-N 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- 125000005896 5,6-dihydro-4H-furo[3,2-b]pyrrolyl group Chemical group 0.000 description 1
- 125000005898 5,7-dihydro-4H-thieno[2,3-c]pyranyl group Chemical group 0.000 description 1
- NOAFYYIFVHACAL-UHFFFAOYSA-N 5-(2-cyclopropylethynyl)-1H-pyridin-2-one Chemical compound O=C(C=C1)NC=C1C#CC1CC1 NOAFYYIFVHACAL-UHFFFAOYSA-N 0.000 description 1
- XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 1
- HTBPXLJKMNBQMS-UHFFFAOYSA-N 5-bromo-2-methoxy-4-methylpyridine Chemical compound COC1=CC(C)=C(Br)C=N1 HTBPXLJKMNBQMS-UHFFFAOYSA-N 0.000 description 1
- KRRTXVSBTPCDOS-UHFFFAOYSA-N 5-bromopyrazin-2-amine Chemical compound NC1=CN=C(Br)C=N1 KRRTXVSBTPCDOS-UHFFFAOYSA-N 0.000 description 1
- NTXRNCUPGYOZCN-UHFFFAOYSA-N 5-iodo-2-methoxypyridine Chemical compound COC1=CC=C(I)C=N1 NTXRNCUPGYOZCN-UHFFFAOYSA-N 0.000 description 1
- IJZFDJSHXBBULN-UHFFFAOYSA-N 5-propylpyrazin-2-amine Chemical compound CCCC1=CN=C(N)C=N1 IJZFDJSHXBBULN-UHFFFAOYSA-N 0.000 description 1
- 125000005897 6,7-dihydro-5H-furo[3,2-b]pyranyl group Chemical group 0.000 description 1
- NRGGKXAPJAUFRA-UHFFFAOYSA-N 6-bromo-2-ethyl-3-fluoro-4-nitro-1-oxidopyridin-1-ium Chemical compound CCC(C(F)=C(C=C1Br)[N+]([O-])=O)=[N+]1[O-] NRGGKXAPJAUFRA-UHFFFAOYSA-N 0.000 description 1
- HRFKBSKWXGWARS-UHFFFAOYSA-N 6-cyclobutyl-1h-pyrimidin-4-one Chemical compound N1C=NC(=O)C=C1C1CCC1 HRFKBSKWXGWARS-UHFFFAOYSA-N 0.000 description 1
- VKPWAEVWZUALPZ-UHFFFAOYSA-N 6-phenylmethoxypyridin-3-ol Chemical compound N1=CC(O)=CC=C1OCC1=CC=CC=C1 VKPWAEVWZUALPZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 240000004178 Anthoxanthum odoratum Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- HWMCVYBFXSRDJB-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(C=C1)=NC=C1N1N=CC=C1 Chemical compound C(C1=CC=CC=C1)OC(C=C1)=NC=C1N1N=CC=C1 HWMCVYBFXSRDJB-UHFFFAOYSA-N 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- OUAJCWJHADHWGY-SSDOTTSWSA-N CN([C@H](CC1CC1)CN1)C1=O Chemical compound CN([C@H](CC1CC1)CN1)C1=O OUAJCWJHADHWGY-SSDOTTSWSA-N 0.000 description 1
- VRSQVKCLXNTSPD-KGLIPLIRSA-N COC(C[C@@H](C[C@@H](C1)F)CN1C(OCC1=CC=CC=C1)=O)=O Chemical compound COC(C[C@@H](C[C@@H](C1)F)CN1C(OCC1=CC=CC=C1)=O)=O VRSQVKCLXNTSPD-KGLIPLIRSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 101100326607 Danio rerio cahz gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 101150086964 LPAR1 gene Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- LWZRVYAUXARTOZ-RYUDHWBXSA-N O=C([C@@H](C[C@@H](C1)F)CN1C(OCC1=CC=CC=C1)=O)Cl Chemical compound O=C([C@@H](C[C@@H](C1)F)CN1C(OCC1=CC=CC=C1)=O)Cl LWZRVYAUXARTOZ-RYUDHWBXSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- XGUXJMWPVJQIHI-UHFFFAOYSA-N S-cyclopropylalanine Natural products OC(=O)C(N)CC1CC1 XGUXJMWPVJQIHI-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000003428 Staudinger Azide reduction reaction Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000045404 acyltransferase activity proteins Human genes 0.000 description 1
- 108700014220 acyltransferase activity proteins Proteins 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000012435 analytical chromatography Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- 150000001501 aryl fluorides Chemical class 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005873 benzo[d]thiazolyl group Chemical group 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
- 229960005286 carbaryl Drugs 0.000 description 1
- 125000005884 carbocyclylalkyl group Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- AHWRJPOOFGXEKF-UHFFFAOYSA-M chlororuthenium(1+);1,2,3,4,5-pentamethylcyclopenta-1,3-diene;triphenylphosphane Chemical compound [Ru+]Cl.CC=1C(C)=C(C)[C-](C)C=1C.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 AHWRJPOOFGXEKF-UHFFFAOYSA-M 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000007881 chronic fibrosis Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- INVYSLWXPIEDIQ-UHFFFAOYSA-N cyclobutanecarbaldehyde Chemical compound O=CC1CCC1 INVYSLWXPIEDIQ-UHFFFAOYSA-N 0.000 description 1
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 1
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 1
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- QHMOWPJARYQHOB-UHFFFAOYSA-M cyclopenta-1,3-diene;ruthenium(2+);triphenylphosphane;chloride Chemical compound [Ru+]Cl.C=1C=C[CH-]C=1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QHMOWPJARYQHOB-UHFFFAOYSA-M 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 125000005892 decahydro-1,8-naphthyridinyl group Chemical group 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 125000005891 decahydronaphthyridinyl group Chemical group 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- YKGNYWJQQQKLMD-WAYWQWQTSA-N ethyl (Z)-5-cyclopropyl-4-oxopent-2-enoate Chemical compound CCOC(/C=C\C(CC1CC1)=O)=O YKGNYWJQQQKLMD-WAYWQWQTSA-N 0.000 description 1
- RJFIWCWTENIBKC-UHFFFAOYSA-N ethyl 2-piperidin-3-ylacetate Chemical compound CCOC(=O)CC1CCCNC1 RJFIWCWTENIBKC-UHFFFAOYSA-N 0.000 description 1
- KQWWVLVLVYYYDT-UHFFFAOYSA-N ethyl 3-oxohexanoate Chemical compound CCCC(=O)CC(=O)OCC KQWWVLVLVYYYDT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- DBPFRRFGLYGEJI-UHFFFAOYSA-N ethyl glyoxylate Chemical compound CCOC(=O)C=O DBPFRRFGLYGEJI-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- HZAIHFIZXXSPFA-UHFFFAOYSA-N ethynylcyclopropane Chemical compound [C+]#CC1CC1 HZAIHFIZXXSPFA-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002190 fatty acyls Chemical group 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000005643 gamma-butyrolacton-4-yl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 125000005059 halophenyl group Chemical group 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 150000002373 hemiacetals Chemical group 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- YCCXQARVHOPWFJ-UHFFFAOYSA-M magnesium;ethane;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C YCCXQARVHOPWFJ-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NAKVATYMNAEXID-PLNGDYQASA-N methyl (Z)-5-cyclopropyl-4-oxopent-2-enoate Chemical compound COC(/C=C\C(CC1CC1)=O)=O NAKVATYMNAEXID-PLNGDYQASA-N 0.000 description 1
- HFRSPMJJWZHUBQ-BJQOMGFOSA-N methyl 2-[(3S)-5,5-difluoro-1-[4-methyl-2-[1-methyl-5-(oxan-2-yloxymethyl)pyrazol-4-yl]pyrimidin-5-yl]piperidin-3-yl]acetate Chemical compound CC1=NC(C2=C(COC3OCCCC3)N(C)N=C2)=NC=C1N(C[C@@H](CC(OC)=O)C1)CC1(F)F HFRSPMJJWZHUBQ-BJQOMGFOSA-N 0.000 description 1
- CRBILHZMYDIQRQ-UHFFFAOYSA-N methyl 2-cyclopropylacetate Chemical compound COC(=O)CC1CC1 CRBILHZMYDIQRQ-UHFFFAOYSA-N 0.000 description 1
- VOLSRTAMKIBBTQ-UHFFFAOYSA-N methyl 3-cyclobutyl-3-oxopropanoate Chemical compound COC(=O)CC(=O)C1CCC1 VOLSRTAMKIBBTQ-UHFFFAOYSA-N 0.000 description 1
- VVHLPPLZWIWHPY-UHFFFAOYSA-N methyl 5,5-difluoropiperidine-3-carboxylate Chemical compound COC(=O)C1CNCC(F)(F)C1 VVHLPPLZWIWHPY-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- AEVYOOWHCJTENF-UHFFFAOYSA-N n'-[(2-nitrophenyl)methyl]ethane-1,2-diamine Chemical compound NCCNCC1=CC=CC=C1[N+]([O-])=O AEVYOOWHCJTENF-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000005893 naphthalimidyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 238000004305 normal phase HPLC Methods 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000005889 octahydrochromenyl group Chemical group 0.000 description 1
- 125000005890 octahydroisochromenyl group Chemical group 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 125000001828 phenalenyl group Chemical group C1(C=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- MBEGFNBBAVRKLK-UHFFFAOYSA-N sodium;iminomethylideneazanide Chemical compound [Na+].[NH-]C#N MBEGFNBBAVRKLK-UHFFFAOYSA-N 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000003883 substance clean up Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000005864 sulfonamidyl group Chemical group 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000004962 sulfoxyl group Chemical group 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 125000005887 tetrahydrobenzofuranyl group Chemical group 0.000 description 1
- 125000005886 tetrahydrobenzothienyl group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940055764 triaz Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
This application relates to novel substituted azacyclohexyl acetic acid compounds, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for treating a disease associated with dysregulation of lysophosphatidic acid receptors (LPA).
Description
TRIAZ OLE-PYRIDINYL SUBSTITUTED AZACYCLOHEXYL ACETIC ACID COMPOUNDS AS LPA RECEPTOR ANTAGONISTS
FIELD
[0001] This application relates to novel substituted azacyclohexyl acetic acid compounds and analogues, their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for treating a disease associated with dysregulation of lysophosphatidic acid receptors (LPAR).
BACKGROUND
[0002] Lysophosphatidic acid (LPA) is a small glycerolphospholipid (1- or 2-acyl-sn-glycerol 3- phosphate) with a molecular weight of 430 - 480 Dalton, consisting of a glycerol backbone which is esterified with a phosphate group and a fatty acid with variable chain length and degree of saturation (Yang and Chen, World J Gastroenterol 24:4132-4151, 2018). LPA can be formed from precursor molecules in plasma, serum or tissues (membrane phospholipids) via several pathways: (1) hydrolysis of the choline group off lysophosphatidylcholine by lysophospholipase D (lysoPLD or autotaxin); (2) hydrolysis of a fatty acyl chain from phosphatidic acid to produce 2-acyl or 1- acyl LPA by phospholipase Al or A2; and (3) de novo synthesis from glycerol-3 -phosphate by acyltransferases (Kihara et al., Experimental Cell Res 333: 171-177, 2015). In tissues or cells, LPA represents a mixture of 1- or 2-acyl-sn-glycerol 3-phosphates.
[0003] Lysophosphatidic acid (LPA) acts as a signaling molecule and exerts its effects by binding to G protein-coupled receptors, termed LPA receptors (LPAR). To date, there are six identified LPA receptors (LPAR1-6), which are expressed in various tissues and/or cells. LPA, through binding to its receptors, plays important roles in pathophysiological processes, such as autoimmune diseases, fibrotic diseases, cancer, inflammation, neuropathic pain, etc. (Budd and Qian, Future Med Chem 5: 1935-52, 2013; Valdes-Rives and Gonzalez- Arenas, Mediators Inflamm 2017:9173090, 2017; Lopane et al., Biochim Biophys Acta Rev Cancer 1868:277-282, 2017; Ueda H. Pain 158 Suppl ES55-S65, 2017).
[0004] Fibrosis is a reparative (or “healing”) process characterized by the excessive accumulation of extracellular matrix (ECM). When tissue injury (caused by infections, autoimmune reactions, mechanical injuries, etc.) is chronic, a sustained production of pro-fibrotic mediators leads to an uncontrolled healing process, and the replacement of injured cells occurs with connective tissues
associated with over production of ECM (Weiskirchen et al., Molecular Aspects Med. 65:2-15, 2019). Because it alters organs’ architecture and function, fibrosis is tightly associated with and often responsible for morbidity and mortality. It is estimated that 45% of all deaths in the developed world are attributed to some type of chronic fibrosis, such as idiopathic pulmonary fibrosis, systemic sclerosis, liver cirrhosis, chronic cardiovascular diseases, progressive kidney diseases (kidney fibrosis) or diabetes (Wynn T.A. Nat. Rev. Immunol. 4:583-594, 2004).
[0005] The profibrotic action of LPA via binding to its receptor LPAR1 has been established in lung, liver and other organs or tissues with two main characteristics: 1) the existence of a positive correlation between the apparition of fibrosis markers and the increased production of LPA associated with an increased expression of the LPAR1; 2) the attenuation of fibrosis in LPAR1-/- mice or by treatment with LPAR antagonists (Rancoule et al., Expert Opin. Investig. Drugs 20:657- 667, 2011). For example, in the bleomycin model of pulmonary fibrosis, LPA levels increased significantly in the bronchoaveolar lavage fluid following lung injury, and mice lacking the LPAR1 gene (LPAR1-/- mice) were remarkably protected from fibrosis and mortality (Tager et al., Nat. Med. 14:45-54, 2008). Treatment with small molecule LPAR1 antagonists could reduce the lung fibrosis in the bleomycin mouse model (Swanet et al., Br. J. Pharmacol. 160: 1699-1713, 2010). More recently, in a chemical-induced cirrhosis and HCC rat model, the expression of Laprl was markedly increased in hepatic stellate cells, while lysoPLD (autotaxin) was higher in hepatocytes (Nakagawa et al., Cancer Cell. 30:879-890, 2016). Transcriptome analysis of human and rat liver tissues indicated that the LPA pathway via the activation of LPAR1 was a functional driver of cirrhosis and HCC. Consequently, inhibition of LPAR1 and lysoPLD by chemical inhibitors attenuated fibrosis progression and reduced HCC nodules in the cirrhosis-driven HCC rat model Id).
SUMMARY
[0006] In one aspect, the present invention relates to a compound of formula (I)
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
L1 is a covalent bond or CH2 optionally substituted with 1 or 2 methyl groups;
L2 is a covalent bond or (CR7R7)P;
L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;
Q is C(=O)NR9R10, C(=O)OR10, or a ring selected from a 5- or 6-membered heteroaryl group or a 5- or 6-membered heterocyclyl group, wherein the ring comprises at least one carbon atom, at least one nitrogen atom, and optionally 1-4 additional heteroatoms selected from nitrogen, oxygen and sulfur wherein oxygen may be a ring member and/or an oxo group attached to a ring member, and wherein the ring is substituted with (R3)n and one R4;
X1 is N, O or CR6a;
X2 is N or NR6;
X3 is N, NR6 or CR6, wherein the dashed circle denotes bonds forming a five-membered aromatic ring;
Y1, Y2, Y3 and Y4 are each independently N or CR5, provided that at least one but no more than two of Y1, Y2, Y3 and Y4 are N;
Z is CH2 or O;
R1 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi -ealkyl, OH, Ci- ealkyl-OH, Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, Ci-ealkyl-NRaRb, or 4-6- membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O;
R2 is (CR7R7)q-R8;
R3 at each occurrence is independently hydrogen, halogen, CN, Ci-ealkyl, or C3-7cycloalkyl;
R4 is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, C2-ealkenyl, C2-ealkynyl, Ci- ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P- C3-7cycloalkyl, C2-ealkenyl-C3-7cycloalkyl, C2-ealkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7-membered
heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy;
R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi -ealkyl, OH, Ci- ealkyl-OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci- 6alkyl-NRaRb; each occurrence of R6a and R6 is independently hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;
R7 at each occurrence is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or twoR7 groups together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring;
R8 is C(=O)OR7, C(=O)NRaRb, CN, C(=O)NHC(=O)R7, C(=O)NHS(=O)2R7,
each occurrence of R9 and R10 is independently hydrogen, Ci-ealkyl substituted with 1-4 R11, (CR12R12)q-C2-ealkenyl substituted with 1-4 R11, (CR12R12)q-C2-ealkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
R11 at each occurrence is independently hydrogen, Ci-ealkyl, haloCi-ealkyl, C2-ealkenyl, C2- ealkynyl, Ci-ealkoxy, (CH2)p-Ci-6alkoxy, phenyl, (CH2)p-phenyl, O(CH2)p-phenyl, CN, C3- 7cycloalkyl, (CH2)p-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)p-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy;
R12 at each occurrence is independently hydrogen, Ci-4alkyl, C3-7cycloalkyl, or two R12 groups, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring
containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; m is 1, or 2; n is 0, 1, or 2; p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4.
[0007] The invention also relates to a pharmaceutical composition comprising a compound of formula (I), its manufacture and use as medicaments for treating a disease associated with dysregulation of lysophosphatidic acid receptor 1 (LPAi). Accordingly, the compounds of formula (I) are useful for treatment of pathological fibrosis (e.g., pulmonary, liver, renal, cardiac, demal, ocular, or pancreatic fibrosis), idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, or systemic sclerosis.
DETAILED DESCRIPTION
[0008] In one aspect, the present technology provides compounds, and their pharmaceutically acceptable forms, including, but not limited to, salts, hydrates, solvates, isomers, sterioisomers, enantiomers, prodrugs, and isotopically labeled derivatives thereof.
[0009] In another aspect, the present technology provides methods of treating and/or managing various diseases and disorders, which comprises administering to a patient a therapeutically effective amount of a compound provided herein, or a pharmaceutically acceptable form (e.g., salts, hydrates, solvates, isomers, sterioisomers, enantiomers, prodrugs, and isotopically labeled derivatives) thereof. Non-limiting examples of diseases and disorders are described herein.
[0010] In another aspect, the present technology provides methods of preventing various diseases and disorders, which comprises administering to a patient in need of such prevention a prophylactically effective amount of a compound provided herein, or a pharmaceutically acceptable form (e.g., salts, hydrates, solvates, isomers, sterioisomers, prodrugs, and isotopically labeled derivatives) thereof. Non-limiting examples of diseases and disorders are described herein.
[0011] In another aspect, the present technology, a compound provided herein, or a pharmaceutically acceptable form (e.g., salts, hydrates, solvates, isomers, sterioisomers, prodrugs, and isotopically labeled derivatives) thereof, can be administered in combination with another drug ("second active agent") or treatment. Second active agents include small molecules and large molecules (e.g., proteins and antibodies).
[0012] Also provided herein are pharmaceutical compositions (e.g., single unit dosage forms) that can be used in the methods provided herein. In one embodiment, pharmaceutical compositions comprise a compound provided herein, or a pharmaceutically acceptable form (e.g., salts, hydrates, solvates, isomers, sterioisomers, prodrugs, and isotopically labeled derivatives) thereof, and optionally one or more second active agents.
[0013] While specific embodiments have been discussed, the specification is illustrative only and not restrictive. Many variations of this disclosure will become apparent to those skilled in the art upon review of this specification.
[0014] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this specification pertains.
Definitions
[0015] As used in the specification and claims, the singular form "a", "an" and "the" includes plural references unless the context clearly dictates otherwise.
[0016] As used herein, "agent," "additional agent," “therapeutic agent,” or "second active agent" refers to a biological, pharmaceutical, or chemical compound or another moiety. Non-limiting examples include simple or complex organic or inorganic molecules, a peptide, a protein, an oligonucleotide, an antibody, an antibody derivative, an antibody fragment, a vitamin, a vitamin derivative, a carbohydrate, a toxin, or a chemotherapeutic compound, and metabolites thereof. Various compounds can be synthesized, for example, small molecules and oligomers (e.g., oligopeptides and oligonucleotides), and synthetic organic compounds based on various core structures. In addition, various natural sources can provide active compounds, such as plant or animal extracts, and the like. A skilled artisan can readily recognize that there is no limit as to the structural nature of the agents of this disclosure.
[0017] “Administration” of a disclosed compound encompasses the delivery to a subject of a compound as described herein, or a prodrug or other pharmaceutically acceptable derivative thereof, using any suitable formulation or route of administration, as discussed herein.
[0018] The term "co-administration," "administered in combination with," and their grammatical equivalents, as used herein, encompasses administration of two or more agents to the subject so that both agents and/or their metabolites are present in the subject at the same time. Coadministration includes simultaneous administration in separate compositions, administration at separate times in separate compositions, or administration in a composition in which both agents are present.
[0019] The term "effective amount" or "therapeutically effective amount" refers to that amount of a compound or pharmaceutical composition described herein that is sufficient to affect the intended application including, but not limited to, disease treatment, as illustrated below. In some embodiments, the amount is that effective for detectable inhibition of LPA1, which, for example, can be determined in an LPA1 functional antagonist assay. The therapeutically effective amount can vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a response in target cells, e.g., reduction of cell migration. The specific dose will vary depending on, for example, the compounds chosen, the species of subject and their age/existing health conditions or risk for health conditions, the dosing regimen to be followed, the severity of the disease, whether it is administered in combination with other agents, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.
[0020] All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.
[0021] As used herein, the terms "treatment", "treating", "palliating" “managing” and "ameliorating" are used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results including, but not limited to, therapeutic benefit and/or a prophylactic benefit. By therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient can still be afflicted with the underlying disorder. For prophylactic benefit, the pharmaceutical compounds and/or compositions can be administered to a patient at risk of developing a disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease may not have been made.
[0022] The terms “preventing” and “prophylaxis” as used herein refer to administering a pharmaceutical compound or medicament or a composition including the pharmaceutical compound or medicament to a subject before a disease, disorder, or condition fully manifests itself, to forestall the appearance and/or reduce the severity of one or more symptoms of the disease, disorder or condition. The person of ordinary skill in the art recognizes that the term “prevent” is not an absolute term. In the medical art it is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or seriousness of a disease, disorder or condition, or a symptom thereof, and this is the sense that such terms are used in this disclosure.
[0023] A "therapeutic effect," as that term is used herein, encompasses a therapeutic benefit and/or a prophylactic benefit as described above. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof.
[0024] The "subjects" to which administration is contemplated includes, but is not limited to, humans (i.e., a male or female of any age group, e.g., a pediatric subject (e.g., infant, child, adolescent) or adult subject (e.g., young adult, middle-aged adult or senior adult)) and/or other primates (e.g., cynomolgus monkeys, rhesus monkeys); mammals, including rodents (e.g., mice, rats), cattle, pigs, horses, sheep, goats, cats, and/or dogs; and/or birds, including birds such as chickens, ducks, geese, quail, and/or turkeys.
[0025] The term "in vivo" refers to an event that takes place in a subject’s body. In vivo also includes events occurring in rodents, such as rats, mice, guinea pigs, and the like.
[0026] The term "in vitro" refers to an event that takes places outside of a subject’s body. For example, an in vitro assay encompasses any assay conducted outside of a subject. In vitro assays encompass cell-based assays in which cells, alive or dead, are employed. In vitro assays also encompass cell-free assays in which no intact cells are employed.
[0027] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. (incorporated by referene herein) describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66: 1-19. Pharmaceutically acceptable salts of the compounds provided herein include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid,
sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, besylate, benzoate, bisulfate, borate, butyrate, camphorate, camphor sulfonate, citrate, cyclopentane propionate, digluconate, dodecyl sulfate, ethane sulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemi sulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3 -phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. In some embodiments, organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, lactic acid, trifluoracetic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid, and the like.
[0028] The salts can be prepared in situ during the isolation and purification of the disclosed compounds, or separately, such as by reacting the free base or free acid of a parent compound with a suitable base or acid, respectively. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(Ci-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In some embodiments, the pharmaceutically acceptable base addition salt can be chosen from ammonium, potassium, sodium, calcium, and magnesium salts.
[0029] As used herein, the term "solvate" refers to compounds that further include a stoichiometric or non-stoichiometric amount of solvent bound by non-covalent intermolecular forces. The solvate can be of a disclosed compound or a pharmaceutically acceptable salt thereof. Where the solvent is water, the solvate is a "hydrate". Pharmaceutically acceptable solvates and hydrates are complexes that, for example, can include 1 to about 100, or 1 to about 10, or 1 to about 2, about 3
or about 4, solvent or water molecules. It will be understood that the term "compound" as used herein encompasses the compound and solvates of the compound, as well as mixtures thereof.
[0030] In some embodiments, the pharmaceutically acceptable form is a prodrug. As used herein, the term "prodrug" refers to compounds that are transformed in vivo to yield a disclosed compound or a pharmaceutically acceptable form of the compound. A prodrug can be inactive when administered to a subject, but is converted in vivo to an active compound, for example, by hydrolysis (e.g., hydrolysis in blood). In certain cases, a prodrug has improved physical and/or delivery properties over the parent compound. Prodrugs can increase the bioavailability of the compound when administered to a subject (e.g., by permitting enhanced absorption into the blood following oral administration) or which enhance delivery to a biological compartment of interest (e.g., the brain or lymphatic system) relative to the parent compound. Exemplary prodrugs include derivatives of a disclosed compound with enhanced aqueous solubility or active transport through the gut membrane, relative to the parent compound.
[0031] The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in a mammalian organism (see, e.g., Bundgard, H., Design of Prodrugs (1985), pp. 7- 9, 21-24 (Elsevier, Amsterdam). A discussion of prodrugs is provided in Higuchi, T., et al., "Pro-drugs as Novel Delivery Systems," A.C.S. Symposium Series, Vol. 14, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated in full by reference herein. Exemplary advantages of a prodrug can include, but are not limited to, its physical properties, such as enhanced water solubility for parenteral administration at physiological pH compared to the parent compound, or it can enhance absorption from the digestive tract, or it can enhance drug stability for long-term storage.
[0032] The term "prodrug" is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a subject. Prodrugs of an active compound, as described herein, can be prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of an alcohol or acetamide, formamide and benzamide derivatives of an amine functional group in the active compound and the like. Other examples of prodrugs include compounds that comprise -NO, -NO2, -ONO, or -ONO2moieties. Prodrugs can typically be
prepared using well known methods, such as those described in Burger ’s Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., 5th ed., 1995), and Design of Prodrugs (H. Bundgaard ed., Elselvier, New York, 1985).
[0033] For example, if a disclosed compound or a pharmaceutically acceptable form of the compound contains a carboxylic acid functional group, a prodrug can comprise a pharmaceutically acceptable ester formed by the replacement of the hydrogen atom of the acid group with a group such as (Ci-s)alkyl, (Ci-i2)alkanoyloxymethyl, 1- (alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1 -methyl- l-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxy carbonyloxymethyl having from 3 to 6 carbon atoms, 1 -(alkoxy carbonyloxy)ethyl having from 4 to 7 carbon atoms, 1 -methyl- 1 -(alkoxy carbonyl oxy )ethyl having from 5 to 10 carbon atoms, N-(alkoxycarbonyl)aminom ethyl having from 3 to 9 carbon atoms, 1-(N- (alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(Ci-2)alkylamino(C2-3)alkyl (such as [3 -dimethylaminoethyl), carbamoyl-(Ci-2)alkyl, N,N-di(Ci-2)alkylcarbamoyl-(Ci-2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-3)alkyl .
[0034] Similarly, if a disclosed compound contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (Ci- 6)alkanoyloxymethyl, l-((Ci-6)alkanoyloxy)ethyl,l -methyl- l-((Ci-6)alkanoyloxy)ethyl, (Ci- 6)alkoxycarbonyloxymethyl, N-(Ci-6)alkoxycarbonylaminomethyl, succinoyl, (Ci- e)alkanoyl, a- amino(Ci-4)alkanoyl, arylacyl, and a-aminoacyl, or a-aminoacyl-a- aminoacyl, where each a- aminoacyl group is independently selected from the naturally occurring L-amino acids, - P(O)(OH)2, -P(O)(O(Ci-e)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).
[0035] If a disclosed compound incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as R-carbonyl, RO- carbonyl, NRR’ -carbonyl where R and R’ are each independently selected from (Ci-io)alkyl, (C3- ?)cycloalkyl, benzyl, a natural a-aminoacyl or natural a-aminoacyl-natural-a-aminoacyl,- C(OH)C(O)OY1 wherein Y1 is H, (Ci-e)alkyl or benzyl;-C(OY2)Y3 wherein Y2 is (Ci-4)alkyl and Y3 is (Ci-e)alkyl, carboxy(Ci-e)alkyl, amino(Ci-4)alkyl or mono-N- or di-N,N-(Ci- 6)alkylaminoalkyl; and -C(Y4)Y5 wherein Y4 is H or methyl andY5 is mono-N- or di-N-(Ci 6)alkylamino, morpholino, piperidin-l-yl or pyrrolidin-l-yl.
[0036] In some embodiments, the disclosed compounds may encompass an isomer. "Isomers" are different compounds that have the same molecular formula. "Stereoisomers" are isomers that differ only in the way the atoms are arranged in space. As used herein, the term "isomer" includes any
and all geometric isomers and stereoisomers. For example, "isomers" include geometric double bond cis- and trans-i somers, also termed E- and Z-isomers; R- and S-enantiomers; diastereomers, (d)-isomers and (l)-isomers, racemic mixtures thereof; and other mixtures thereof, as falling within the scope of this disclosure.
[0037] Geometric isomers can be represented by the symbol - which denotes a bond that can be a single, double or triple bond as described herein. Provided herein are various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carboncarbon double bond or arrangement of substituents around a carbocyclic ring. Substituents around a carbon-carbon double bond are designated as being in the "Z" or "E" configuration wherein the terms "Z" and "E" are used in accordance with IUPAC standards. Unless otherwise specified, structures depicting double bonds encompass both the "E" and "Z" isomers.
[0038] Substituents around a carbon-carbon double bond alternatively can be referred to as "cis" or"trans," where “cis" represents substituents on the same side of the double bond and "trans" represents substituents on opposite sides of the double bond. The arrangement of substituents around a carbocyclic ring can also be designated as "cis" or "trans." The term "cis" represents substituents on the same side of the plane of the ring, and the term "trans" represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated "cis/trans." [0039] "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. "Diastereoisomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other. The absolute stereochemistry is specified according to the Cahn-Ingold-Prelog R-S system. When a compound is an enantiomer, the stereochemistry at each chiral carbon can be specified by either R or S. Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line. Certain of the compounds described herein contain one or more asymmetric centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined, in terms of absolute stereochemistry at each asymmetric atom, as (R)- or (S)-. The present chemical entities, pharmaceutical compositions and methods are meant to include all such possible isomers, including racemic mixtures, optically substantially pure forms and intermediate mixtures. Optically active (R)- and (S)-isomers can be prepared, for example, using chiral synthons or chiral reagents, or resolved using conventional techniques.
[0040] A mixture of a pair of enantiomers in any proportion can be known as a "racemic" mixture. The term "(±)" is used to designate a racemic mixture where appropriate. In some embodiments,
a compound of the present technology is a racemic mixture of (S)- and (R)-isomers. In some embodiments, the racemic mixture has equal amounts of two enantiomers.
[0041] In some embodiments, an enantiomer is provided partly or substantially free of the corresponding enantiomer, and may be referred to as “optically enriched,” “enantiomerically enriched,” “enantiomerically pure,” and “non-racemic,” as used interchangeably herein. The "enantiomeric excess" or "% enantiomeric excess" of such a composition can be calculated using the equation shown below. In the example shown below, a composition contains 90% of one enantiomer, e.g., the S enantiomer, and 10% of the other enantiomer, e.g., the R enantiomer. ee=(90-10)/l 00=80%.
Thus, a composition containing 90% of one enantiomer and 10% of the other enantiomer is said to have an enantiomeric excess of 80%. In some embodiments, compositions described herein contain an enantiomeric excess of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 99.5% of the S enantiomer, or a range between and including any two of the foregoing values (e.g., 50-99.5% ee). In other words, the compositions contain an enantiomeric excess of the S enantiomer over the R enantiomer. In other embodiments, some compositions described herein contain an enantiomeric excess of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 99.5% of the R enantiomer or a range between any two of the foregoing values (e.g., 50-99.5% ee). In other words, the compositions contain an enantiomeric excess of the R enantiomer over the S enantiomer. Where the enrichment of one enantiomer is much greater than about 80% by weight, the compositions are referred to as "substantially enantiomerically enriched," "substantially enantiomerically pure" or a "substantially non-racemic" preparation.
[0042] Enantiomers can be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC), the formation and crystallization of chiral salts, or prepared by asymmetric syntheses. See, for example, Enantiomers, Racemates and Resolutions (Jacques, Ed., Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Stereochemistry of Carbon Compounds (E. L. Eliel, Ed., McGraw- Hill, NY, 1962); and Tables of Resolving Agents and Optical Resolutions p. 268 (E. L. EIM, Ed., Univ, of Notre Dame Press, Notre Dame, Ind. 1972).
[0043] Optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids include, but are not limited to, tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid. The separation of
the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts affords separation of the isomers. Another method involves synthesis of covalent diastereoisomeric molecules by reacting disclosed compounds with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically enriched compound. Optically active compounds can also be obtained by using active starting materials. In some embodiments, these isomers can be in the form of a free acid, a free base, an ester or a salt.
[0044] In any embodiments, the pharmaceutically acceptable form is a tautomer. As used herein, the term "tautomer" is a type of isomer that includes two or more interconvertible compounds resulting from at least one formal migration of a hydrogen atom and at least one change in valency (e.g., a single bond to a double bond, a triple bond to a single bond, or vice versa). "Tautomerization" includes prototropic or proton-shift tautomerization, which is considered a subset of acid-base chemistry. "Prototropic tautomerization" or"proton-shift tautomerization" involves the migration of a proton accompanied by changes in bond order. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Where tautomerization is possible (e.g., in solution), a chemical equilibrium of tautomers can be reached. Tautomerizations (i.e., the reaction providing a tautomeric pair) can be catalyzed by acid or base, or can occur without the action or presence of an external agent. Exemplary tautomerizations include, but are not limited to, keto-to-enol; amide-to-imide; lactam-to-lactim; enamine-to-imine; and enamine-to-(a different) enamine tautomerizations. A specific example of keto-enol tautomerization is the interconversion of pentane-2, 4-dione and 4-hydroxypent-3-en-2-one tautomers. Another example of tautomerization is phenol-keto tautomerization. A specific example of phenol-keto tautomerization is the interconversion of pyridin-4-ol and pyridin-4(lH)-one tautomers.
[0045] Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by13C- or 14C-enriched carbon are within the scope of this disclosure.
[0046] The disclosure also embraces pharmaceutically acceptable forms that are “isotopically labeled derivatives” which are compounds that are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated
into disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2H, 3H, 13C 14C, 15N, 180, 17O,31P, 32P,35S, 18F, and 36C1, respectively. Certain isotopically-labeled disclosed compounds (e.g., those labeled with 3H and 14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes can allow for ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) can afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). Isotopically labeled disclosed compounds can generally be prepared by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. In some embodiments, provided herein are compounds that can also contain unnatural proportions of atomic isotopes at one or more of atoms that constitute such compounds. All isotopic variations of the compounds as disclosed herein, whether radioactive or not, are encompassed within the scope of the present disclosure. In some embodiments, radiolabeled compounds are useful for studying metabolism and/or tissue distribution of the compounds or to alter the rate or path of metabolism or other aspects of biological functioning.
[0047] "Pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The pharmaceutically acceptable carrier or excipient does not destroy the pharmacological activity of the disclosed compound and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions as disclosed herein is contemplated. Non-limiting examples of pharmaceutically acceptable carriers and excipients include sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as polyethylene glycol and propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate; coloring agents; releasing agents; coating agents; sweetening, flavoring and perfuming agents; preservatives; antioxidants; ion exchangers; alumina; aluminum stearate; lecithin; self emulsifying drug delivery systems (SEDDS) such as d-atocopherol
polyethyleneglycol 1000 succinate; surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices; serum proteins such as human serum albumin; glycine; sorbic acid; potassium sorbate; partial glyceride mixtures of saturated vegetable fatty acids; water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, and zinc salts; colloidal silica; magnesium trisilicate; polyvinyl pyrrolidone; cellulose-based substances; polyacrylates; waxes; and polyethylene-polyoxypropylene-block polymers. Cyclodextrins such as a-, P-, and y-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3- hydroxypropyl-cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein.
[0048] Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sansalito,1999; Smith and March March ’s Advanced Organic Chemistry, 5th ed., John Wiley & Sons, Inc., NewYork, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., NewYork, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd ed., Cambridge University Press, Cambridge, 1987.
[0049] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value and sub-range falling within the range, unless otherwise indicated herein, and each separate value and sub-range is incorporated into the specification as if it were individually recited herein. For example, "Ci-6 alkyl" is intended to encompass, Ci, C2, C3, C4, C5, Ce, C1-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6 alkyl.
[0050] "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to ten carbon atoms (e.g., Ci-10 alkyl). Whenever it appears herein, a numerical range such as " 1 to 10" refers to each integer in the given range; e.g., " 1 to 10 carbon atoms" means that the alkyl group can consist of 1, 2, 3, ,4 5, 6, 7, 8, 9, or 10 carbon atoms, although the present definition also covers the occurrence of the term "alkyl" where no numerical range is designated. In some embodiments, alkyl groups have 1 to 10, 1 to 8, 1 to 6, or 1 to 3 carbon atoms. Representative saturated straight chain alkyls include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, and n-hexyl groups; while
saturated branched alkyls include, but are not limited to, isopropyl, sec-butyl, isobutyl, tert-butyl, isopentyl, 2-methylbutyl, 3 -methylbutyl, 2-methylpentyl, 3 -methylpentyl, 4-methylpentyl, 2- methylhexyl, 3 -methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, and the like. The alkyl is attached to the parent molecule by a single bond. Unless stated otherwise in the specification, an alkyl group may be optionally substituted by one or more of substituents disclosed herein. In a non-limiting embodiment, a substituted alkyl can be selected from fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3 -fluoropropyl, hydroxymethyl, 2-hydroxy ethyl, 3- hydroxypropyl, benzyl, and phenethyl.
[0051] "Alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond, and having from two to ten carbon atoms (i.e., C2-10 alkenyl). Whenever it appears herein, a numerical range such as "2 to 10" refers to each integer in the given range; e.g., "2 to 10 carbon atoms" means that the alkenyl group can consist of 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms. In any embodiments, an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to six carbon atoms (e.g., C2-6 alkenyl). The alkenyl is attached to the parent molecular structure by a single bond, for example, ethenyl (i.e., vinyl), prop-l-enyl (i.e., allyl), but- 1-enyl, pent-l-enyl, penta- 1,4-dienyl, and the like. The one or more carbon-carbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). Examples of C2-4 alkenyl groups include ethenyl (C2), 1 -propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), 2-methylprop-2-enyl (C4), butadienyl (C4) and the like. Examples of C2-6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (Ce), 2,3-dimethyl-2-butenyl (Ce) and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (Cs), octatrienyl (Cs) and the like. Unless stated otherwise in the specification, an alkenyl group may be optionally substituted by one or more of substituents disclosed herein.
[0052] " Alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to ten carbon atoms (i.e., C2-10 alkynyl). Whenever it appears herein, a numerical range such as "2 to 10" refers to each integer in the given range; e.g., "2 to 10 carbon atoms" means that the alkynyl group can consist of 2 carbon atoms, 3 carbon atoms, etc., up to and including 10 carbon atoms. In any embodiments, an alkynyl comprises two to eight carbon atoms. In other embodiments, an alkynyl has two to six carbon atoms (e.g., C2-6 alkynyl). The alkynyl is attached to the parent molecular structure by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, 3-methyl-4-pentenyl, hexynyl, and the like. Unless stated otherwise in the specification, an alkynyl group may be optionally substituted by one or more of substituents disclosed herein.
[0053] "Alkoxy" refers to the group -O-alkyl, including from 1 to 10 carbon atoms of a straight, branched, saturated cyclic configuration and combinations thereof, attached to the parent molecular structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t- butoxy, pentoxy, cyclopropyloxy, cyclohexyloxy and the like. "Lower alkoxy" refers to alkoxy groups containing one to six carbons. In some embodiments, Ci-4alkoxy is an alkoxy group which encompasses both straight and branched chain alkyls of from 1 to 4 carbon atoms. Unless stated otherwise in the specification, an alkoxy group may be optionally substituted by one or more of substituents disclosed herein. The terms "alkenoxy" and "alkynoxy" mirror the above description of "alkoxy" wherein the prefix "alk" is replaced with "alken" or "alkyn" respectively, and the parent "alkenyl" or "alkynyl" terms are as described herein.
[0054] " Aromatic" or "aryl" refers to a radical with 6 to 14 ring atoms (e.g., Ce-14 aromatic or Ce- 14 aryl) which has at least one ring having a conjugated pi electron system which is carbocyclic (e.g., phenyl, fluorenyl, and naphthyl). In some embodiments, the aryl is a Ce-io aryl group. For example, bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals. In other embodiments, bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in"-yl" by removal of one hydrogen atom from the carbon atom with the free valence are named by adding idene" to the name of the corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene. Whenever it appears herein, a numerical range such as "6 to 14 aryl “refers to each integer in the given range; e.g., "6 to 14 ring atoms" means that the aryl group can consist of 6 ring atoms, 7 ring atoms, etc., up to and including 14 ring atoms. The term includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. Polycyclic aryl groups include bicycles, tricycles, tetracycles, and the like. In a multi-ring group, only one ring is required to be aromatic, so groups such as indanyl are encompassed by the aryl definition. Non-limiting examples of aryl groups include phenyl, phenalenyl, naphthalenyl, tetrahydronaphthyl, phenanthrenyl, anthracenyl, fluorenyl, indolyl, indanyl, and the like. Unless stated otherwise in the specification, an aryl group may be optionally substituted by one or more of substituents disclosed herein.
[0055] "Cycloalkyl" and "carbocyclyl" each refer to a monocyclic or polycyclic radical that contains only carbon and hydrogen, and can be saturated or partially unsaturated. Partially unsaturated cycloalkyl groups can be termed "cycloalkenyl" if the carbocycle contains at least one double bond, or "cycloalkynyl" if the carbocycle contains at least one triple bond. Cycloalkyl groups include groups having from 3 to 13 ring atoms (i.e., C3-13 cycloalkyl). Whenever it appears herein, a numerical range such as "3 to 10" refers to each integer in the given range; e.g., "3 to 13
carbon atoms" means that the cycloalkyl group can consist of 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, etc., up to and including 13 carbon atoms. The term "cycloalkyl" also includes bridged and spiro-fused cyclic structures containing no heteroatoms. The term also includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. Polycyclic aryl groups include bicycles, tricycles, tetracycles, and the like. In some embodiments, “cycloalkyl” can be a C3-8 cycloalkyl radical. In some embodiments, “cycloalkyl” can be a C3-5 cycloalkyl radical. Illustrative examples of cycloalkyl groups include, but are not limited to the following moieties: C3-6 carbocyclyl groups include, without limitation, cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (Ce), cyclohexenyl (Ce), cyclohexadienyl (Ce) and the like. Examples of C3-7 carbocyclyl groups include norbornyl (C7). Examples of C3-8 carbocyclyl groups include the aforementioned C3-7 carbocyclyl groups as well as cycloheptyl(C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (Cs), bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, and the like. Examples of C3-13 carbocyclyl groups include the aforementioned C3-8 carbocyclyl groups as well as octahydro- 1H indenyl, decahydronaphthal enyl, spiro[4.5]decanyl and the like. Unless stated otherwise in the specification, a cycloalkyl group may be optionally substituted by one or more of substituents disclosed herein. The terms “cycloalkenyl" and "cycloalkynyl" mirror the above description of "cycloalkyl" wherein the prefix "alk" is replaced with "alken" or "alkyn" respectively, and the parent "alkenyl" or "alkynyl" terms are as described herein. For example, a cycloalkenyl group can have 3 to 13 ring atoms, such as 5 to 8 ring atoms. In some embodiments, a cycloalkynyl group can have 5 to 13 ring atoms.
[0056] "Halo", "halide", or, alternatively, "halogen" means fluoro, chloro, bromo or iodo. The terms "haloalkyl," "haloalkenyl," "haloalkynyl" and "haloalkoxy" include alkyl, alkenyl, alkynyl and alkoxy structures that are substituted with one or more halo groups or with combinations thereof, preferably substituted with one, two, or three halo groups. For example, the terms "fluoroalkyl" and "fluoroalkoxy" include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine, such as, but not limited to, trifluoromethyl, difluoromethyl, 2,2,2- trifluoroethyl, l-fluoromethyl-2-fluoroethyl, -O-CHF2, and the like. Each of the alkyl, alkenyl, alkynyl and alkoxy groups are as defined herein and can be optionally further substituted as defined herein.
[0057] "Heteroaryl" or, alternatively, "heteroaromatic" refers to a refers to a radical of a 5-18 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic, tetracyclic and the like) aromatic ring system (e.g., having 6, 10 or 14 it electrons shared in a cyclic array) having ring carbon atoms and 1-6 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is
independently selected from nitrogen, oxygen, phosphorous and sulfur ("5-18 membered heteroaryl"). Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. Whenever it appears herein, a numerical range such as "5 to 18" refers to each integer in the given range; e.g., "5 to 18 ring atoms" means that the heteroaryl group can consist of 5 ring atoms, 6 ring atoms, etc., up to and including 18 ring atoms. In some instances, a heteroaryl can have 5 to 14 ring atoms. In some embodiments, the heteroaryl has, for example, bivalent radicals derived from univalent heteroaryl radicals whose names end in "-yl" by removal of one hydrogen atom from the atom with the free valence are named by adding "-ene" to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylene. [0058] For example, an N-containing "heteroaromatic" or "heteroaryl" moiety refers to an aromatic group in which at least one of the skeletal atoms of the ring is a nitrogen atom. One or more heteroatom(s) in the heteroaryl radical can be optionally oxidized. One or more nitrogen atoms, if present, can also be optionally quaternized. Heteroaryl also includes ring systems substituted with one or more nitrogen oxide (-O-) substituents, such as pyridinyl N-oxides. The heteroaryl is attached to the parent molecular structure through any atom of the ring(s).
[0059] "Heteroaryl" also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment to the parent molecular structure is either on the aryl or on the heteroaryl ring, or wherein the heteroaryl ring, as defined above, is fused with one or more cycloalkyl or heterocyclyl groups wherein the point of attachment to the parent molecular structure is on the heteroaryl ring. For polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl and the like), the point of attachment to the parent molecular structure can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl). In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur ("5-10 membered heteroaryl"). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur ("5-8 membered heteroaryl"). In some embodiments, a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous, and sulfur ("5-6 membered heteroaryl"). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur. In some embodiments, the
5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, phosphorous, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, phosphorous, and sulfur.
[0060] Examples of heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][l,4]dioxepinyl, benzo[b][l,4] oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodi oxolyl, benzodioxinyl, benzoxazolyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzopyranonyl, benzofurazanyl, benzothiazolyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[ 1,2- a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H- cyclopenta[4,5]thieno [2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6- dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H benzo[6,7]cyclohepta[ l,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furazanyl, furanonyl, furo [3,2 -c]pyridinyl,
5.6.7.8.9.10-hexahydrocycloocta[d] pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl,
5.6.7.8.9.10- hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, 5,8-methano- 5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyri dinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-lH-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyranyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4- d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5, 6,7,8- tetrahydrobenzo [4,5 ] thieno [2,3 -d]pyrimdinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno [2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, thiapyranyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno [2,3-c]pridinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise in the specification, a heteroaryl group may be optionally substituted by one or more of substituents disclosed herein.
[0061] "Heterocyclyl", "heterocycloalkyl" or “heterocarbocyclyl" each refer to any 3 to 18- membered non-aromatic radical monocyclic or polycyclic moiety comprising at least one carbon atom and at least one heteroatom selected from nitrogen, oxygen, phosphorous and sulfur. A heterocyclyl group can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein the polycyclic ring systems can be a fused, bridged or spiro ring system. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings. A heterocyclyl group can be saturated or partially unsaturated. Partially unsaturated heterocycloalkyl groups can be termed
"heterocycloalkenyl" if the heterocyclyl contains at least one double bond, or "heterocycloalkynyl" if the heterocyclyl contains at least one triple bond. Whenever it appears herein, a numerical range such as "5 to 18" refers to each integer in the given range; e.g., "5 to 18 ring atoms" means that the heterocyclyl group can consist of 5 ring atoms, 6 ring atoms, etc., up to and including 18 ring atoms. For example, bivalent radicals derived from univalent heterocyclyl radicals whose names end in "-yl" by removal of one hydrogen atom from the atom with the free valence are named by adding "-ene" to the name of the corresponding univalent radical, e.g., a piperidine group with two points of attachment is a piperidylene.
[0062] An N-containing heterocyclyl moiety refers to a non-aromatic group in which at least one of the ring atoms is a nitrogen atom. The heteroatom(s) in the heterocyclyl radical can be optionally oxidized. One or more nitrogen atoms, if present, can be optionally quaternized. Heterocyclyl also includes ring systems substituted with one or more nitrogen oxide (-O-) substituents, such as piperidinyl N-oxides. The heterocyclyl is attached to the parent molecular structure through any atom of any of the ring(s).
[0063] "Heterocyclyl" also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment to the parent molecular structure is on the heterocyclyl ring. In some embodiments, a heterocyclyl group is a 5- 14 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous and sulfur ("5-14 membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 3-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous and sulfur ("3-10 membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5-8 membered non- aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous and sulfur ("5-8 membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, phosphorous and sulfur ("5-6 membered heterocyclyl"). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen phosphorous and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, phosphorous and sulfur. In
some embodiments, the 5-6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, phosphorous and sulfur.
[0064] "Heterocyclyl" may include one or more ketone group (-C(=O)-) as part of the ring. Examples of a ketone-contianing heterocycle include, without limitation, pyridin-2(lH)-one, pyrazin-2(lH)-one, pyrimidin-2(lH)-one, pyrimidin-4(3H)-one, pyridazin-3(2H)-one, pyridin- 4(lH)-one, imidazolidin-2-one, l,3-dihydro-2H-imidazol-2-one, 2,4-dihydro-3H-l,2,4-triazol-3- one, oxazol-2(3H)-one, and oxazolidin-2-one. A ketone-containing heterocyclyl is obtainable by removing a hydrogen atom from its corepsonding ketone-contianing heterocycle at any available N-H or C-H position.
[0065] Exemplary 3-membered heterocyclyls containing 1 heteroatom include, without limitation, azirdinyl, oxiranyl, and thiorenyl. Exemplary 4-membered heterocyclyls containing 1 heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl. Exemplary 5-membered heterocyclyls containing 1 heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2, 5-dione. Exemplary 5-membered heterocyclyls containing 2 heteroatoms include, without limitation, dioxolanyl, oxathiolanyl, thiazolidinyl, and dithiolanyl. Exemplary 5- membered heterocyclyls containing 3 heteroatoms include, without limitation, triazolinyl, diazol onyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing 1 heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6 membered heterocyclyl groups containing 2 heteroatoms include, without limitation, piperazinyl, morpholinyl, thiomorpholinyl, dithianyl, dioxanyl, and triazinanyl. Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, benzoxanyl, benzopyrrolidinyl, benzopiperidinyl, benzoxolanyl, benzothiol any 1, benzothianyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, 3-lH-benzimidazol-2-one, (l-substituted)-2-oxo- benzimidazol-3-yl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro- 1,8-naphthyridinyl, octahydropyrrolo[3,2 -b]pyrrole, phenanthridinyl, indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, lH-benzo[e] [l,4]diazepinyl, 1, 4,5,7- tetrahydropyrano[3,4-b]pyrrolyl, 5,6-dihydro-4H-furo[3,2-b]pyrrolyl, 6,7-dihydro-5H-furo [3,2- b]pyranyl, 5,7-dihydro-4H-thieno [2,3-c]pyranyl, 2,3-dihydro-lH-pyrrolo[2,3-b]pyridinyl,
hydrofuro[2,3-b]pyridinyl, 4, 5, 6, 7 tetrahydro- lH-pyrrolo[2,3-b]pyridinyl, 4, 5,6,7- tetrahydrofuro[3,2-c]pyridinyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl, l,2,3,4-tetrahydro-l,6- naphthyridinyl, and the like.
[0066] Unless stated otherwise in the specification, a heterocyclyl group may be optionally substituted by one or more of substituents disclosed herein.
[0067] Where substituent groups are specified by their conventional chemical Formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., -CH2O- is equivalent to -OCH2- .
[0068] A "leaving group or atom" is any group or atom that will, under the reaction conditions, cleave from the starting material, thus promoting reaction at a specified site. Suitable non-limiting examples of such groups unless otherwise specified include halogen atoms, mesyloxy, p- nitrobenzensulphonyloxy, trifluoromethyloxy, and tosyloxy groups.
[0069] "Protecting group" has the meaning conventionally associated with it in organic synthesis, i.e., a group that selectively blocks one or more reactive sites in a multifunctional compound such that a chemical reaction can be carried out selectively on another unprotected reactive site and such that the group can readily be removed after the selective reaction is complete. Non-limiting embodiments of functional groups that can be masked with a protecting group include an amine, hydroxy, thiol, carboxylic acid, and aldehyde. For example, a hydroxy protected form is where at least one of the hydroxy groups present in a compound is protected with a hydroxy protecting group. A variety of protecting groups are disclosed, for example, Greene’s Protective Groups in Organic Synthesis, Fifth Edition, Wiley (2014), incorporated herein by reference in its entirety. For additional background information on protecting group methodologies (materials, methods and strategies for protection and deprotection) and other synthetic chemistry transformations useful in producing the compounds described herein, see in R. Larock, Comprehensive organic Transformations, VCH Publishers (1989); Greene’s Protective Groups in Organic Synthesis, Fifth Edition, Wiley (2014); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995). These references are incorporated herein by reference in their entirety.
[0070] The terms "substituted" or "substitution" mean that at least one hydrogen present on a group atom (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution for the hydrogen results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a "substituted" group can have a substituent at one
or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. Substituents include one or more group(s) individually and independently selected from acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylaryl, cycloalkyl, aralkyl, aryl, aryloxy, amino, amido, amidino, imino, azide, carbonate, carbamate, carbonyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, hydroxy, cyano, halo (i.e., F, Cl, Br, I), haloalkoxy, haloalkyl, ester, ether, mercapto, thio, alkylthio, arylthio, thiocarbonyl, nitro, oxo, phosphate, phosphonate, phosphinate, silyl, sulfinyl, sulfonyl, sulfonamidyl, sulfoxyl, sulfonate, urea, -Si(Ra)3 , -ORa, -SRa, -OC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -OC(O)N(Ra)2, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -N(Ra)C(O)Ra, -N(Ra)C(O)N(Ra)2, -N(Ra)C(NRa)N(Ra)2, -N(Ra)S(O)tN(Ra)2 (where t is 1 or 2), -P(=O)(Ra)(Ra), or -O-P(=O)(ORa)2 where each Ra is independently hydrogen, alkyl, haloalkyl, carbocyclyl, carbocyclylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl or heteroaryl alkyl, and each of these moi eties (other than hydrogen) can be optionally substituted with one or more substituents (up to six, valence permitting) selected from OH, NH2, oxo, halo, nitro, COOH, C(O)NH2 or cyano. For example, a cycloalkyl substituent can have a halide substituted at one or more ring carbons, and the like. The protecting groups that can form the protective derivatives of the above substituents are known to those of skill in the art and can be found in references such as Greene and Wuts, above.
[0071] Suitable substituents include, but are not limited to, haloalkyl and trihaloalkyl, alkoxyalkyl, halophenyl, -M-heteroaryl, -M-heterocycle, -M-aryl, -M-0Ra, -M-SRa, -M-N(Ra)2, -M- OC(O)N(Ra)2, -M-C(=NRa)N(Ra)2, -M-C(=NRa)0Ra, -M-P(0)(Ra)2, Si(Ra)3, -M-NRaC(0)Ra -M- NRaC(O)ORa, -M-C(0)Ra, -M-C(=S)Ra, -M-C(=S)NRaRa, -M-C(0)N(Ra)2, -M-C(0)NRa-M- N(Ra)2, -M-NRaC(NRa)N(Ra)2, -M-NRaC(S)N(Ra)2, -M-S(O)2Ra, -M C(O)Ra, -M-0C(0)Ra, - MC(O)SRa, -M-S(O)2N(Ra)2,-C(O)-M-C(O)Ra, -MC02Ra, -MC(=0)N(Ra)2, -M-C(=NH)N(Ra)2, and -M-0C(=NH)N(Ra)2 (wherein M is a C1-6 alkyl group).
[0072] When a ring system (e.g., cycloalkyl, heterocyclyl, aryl, or heteroaryl) is substituted with several substituents varying within an expressly defined range, it is understood that the total number of substituents does not exceed the normal available valencies under the existing conditions. Thus, for example, a phenyl ring substituted with "p" substituents (where "p" ranges from 0 to 5) can have 0 to 5 substituents, whereas it is understood that a pyridinyl ring substituted with "p" substituents has several substituents ranging from 0 to 4. The maximum number of substituents that a group in the disclosed compounds can have can be easily determined. The substituted group encompasses only those combinations of substituents and variables that result in a stable or chemically feasible compound. A stable compound or chemically feasible compound is
one that, among other factors, has stability sufficient to permit its preparation and detection. In some embodiments, disclosed compounds are sufficiently stable that they are not substantially altered when kept at a temperature of 40° C or less, in the absence of moisture (e.g., less than about 10%, less than about 5%, less than about 2%, less than about 1%, or less than about 0.5%) or other chemically reactive conditions, for e.g., at least about 3 days, at least about a week, at least about 2 weeks, at least about 4 weeks, or at least about 6 weeks.
[0073] The terms “combine, combining, to combine, combination” refer to the action of adding at least one chemical substance to another chemical substance(s) either sequentially or simultaneously. In some embodiments, bringing these chemical substances together can result in transformation of the initial chemical substances into one or more different chemical substances. This transformation can occur through one or more chemical reactions, e.g., where covalent bonds are formed, broken, rearranged and the like. A non-limiting example can include hydrolysis of an ester into an alcohol and carboxylic acid which can result from the combination of the ester with a suitable base. In another non-limiting example, an aryl fluoride can be combined with an amine to provide an aryl amine through a substitution process. These terms also include changes in association of charged chemical substances and creation of charged chemical substances, such as, but not limited to, N-oxide formation, acid addition salt formation, basic addition salt formation, and the like. These terms include the creation and/or transformation of radical chemical substances and isotopically labeled chemical substances.
[0074] The terms “convert, converting, to convert, conversion” refer to a subset of “combination” and its grammatical equivalents, where the action of one or more reagents transforms one or more functional groups on a chemical substance to another functional group(s). For example, a conversion includes, but is not limited to, transforming a nitro functional group on a chemical substance to an amine with a reducing agent. Conversions also include changes in charged chemical substances, radical chemical substances and isotopically labeled chemical substances. However, the term “convert” does not include alteration of conserved bonds in disclosed genuses and compounds.
Compounds
[0075] In one aspect, the present invention relates to a compound of Formula (I):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
Z is CH2 or O;
Y1, Y2, Y3 and Y4 are each independently N or CR5, provided that at least one but no more than two of Y1, Y2, Y3 and Y4 are N;
X1 is N, O or CR6a;
X2 is N or NR6;
X3 is N, NR6 or CR6, wherein the dashed circle denotes bonds forming a five-membered aromatic ring;
L1 is a covalent bond or CH2 optionally substituted with 1 or 2 methyl groups;
L2 is a covalent bond or (CR7R7)P;
L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;
Q is C(=O)NR9R10, C(=O)OR10, or a ring selected from a 5- or 6-membered heteroaryl group or a 5- or 6-membered heterocyclyl group, wherein the ring comprises at least one carbon atom, at least one nitrogen atom, and optionally 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein oxygen may be a ring member and/or an oxo group attached to a ring member, and wherein the ring is substituted with (R3)n and one R4;
R1 at each occurrence is independently hy drogen, halogen, Ci-ealkyl, haloCi-ealkyl, OH, Ci- ealkyl-OH, Ci-ealkoxy, haloCi-ealkoxy, CN, C3-?cycloalkyl, NRaRb, Ci-ealkyl-NRaRb, or 4-6-
membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O;
R2 is (CR7R7)q-R8;
R3 at each occurrence is independently hydrogen, halogen, CN, Ci-ealkyl, or C3-7cycloalkyl;
R4 is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, C2-ealkenyl, C2-ealkynyl, Ci- ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P- C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy;
R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi -ealkyl, OH, Ci- ealkyl-OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci- 6alkyl-NRaRb; each occurrence of R6a and R6 is independently hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;
R7 at each occurrence is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or twoR7 groups together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring;
R8 is C(=O)OR7, C(=O)NRaRb, CN, C(=O)NHC(=O)R7, C(=O)NHS(=O)2R7,
each occurrence of R9 and R10 is independently hydrogen, Ci-ealkyl substituted with 1-4 R11, (CR12R12)q-C2-ealkenyl substituted with 1-4 R11, (CR12R12)q-C2-ealkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
R11 at each occurrence is independently hydrogen, Ci-ealkyl, haloCi -ealkyl, C2-ealkenyl, C2- ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- vcycloalkyl, (CH2)P-C3-7cycloalkyl, C2-ealkenyl-C3-7cycloalkyl, C2-ealkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy;
R12 at each occurrence is independently hydrogen, Ci-4alkyl, C3-7cycloalkyl, or two R12 groups, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; m is 1, or 2; n is 0, 1, or 2; p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4.
[0076] In some embodiments, the compound of Formula (I) includes a compound of Formula (II):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
L1 is a covalent bond or CH2 optionally substituted with 1 or 2 methyl groups;
L2 is a covalent bond or (CR7R7)P;
L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;
Q is a ring selected from the group consisting of 5-membered heteroaryl, 5-membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring comprises at least one carbon atom, at least one nitrogen atom and optionally 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein oxygen may be a ring member and/or an oxo (=0) attached to a ring member, and wherein the ring is substituted with (R3)n and one R4;
X1 is N, or CR6a;
Z is CH2 or O;
R1 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, OH, Ci-ealkyl- OH, Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, Ci-ealkyl-NRaRb, or 4-6-membered heterocylyl, or twoR1 groups, together with the carbon atom to which they are attached, form C=O;
R3 at each occurrence is independently hydrogen, halogen, CN, Ci-ealkyl, or C3-7cycloalkyl;
R4 is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, C2-ealkenyl, C2-ealkynyl, Ci- ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P- C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1- 3 of halogen, Ci-ealkyl, or Ci-ealkoxy;
R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, OH, Ci-ealkyl- OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci-ealkyl- NRaRb;
R6a is hydrogen, or methyl;
R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;
R7 at each occurrence is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or R7 andR7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring;
R11 at each occurrence is independently hydrogen, Ci-ealkyl, haloCi -ealkyl, C2-ealkenyl, C2- ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- vcycloalkyl, (CH2)P-C3-7cycloalkyl, C2-ealkenyl-C3-7cycloalkyl, C2-ealkynyl, O(CH2)P-C3- 7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci- ealkyl, or Ci-ealkoxy;
R13 at each occurrence is independently hydrogen, Ci-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; n is 0, 1 or 2; p at each occurrence is independently 1, 2, 3 or 4; t is 0, 1, 2 or 3; and w is 0 or 1, provided that when L1 is a covalent bond, w is 1, and further provided that when L1 is CH2 optionally substituted with 1 or 2 methyl groups, w is 0.
[0077] In some embodiments, the compound of Formula I includes a compound of Formula (Ila) or (Ilaa):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
L2 is a covalent bond or (CR7R7)P;
L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;
Q is a ring selected from the group consisting of 5-membered heteroaryl, 5-membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring comprises at least one carbon atom, at least one nitrogen atom and optionally 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein oxygen may be a ring member and/or an oxo attached to a ring member, and wherein the ring is substituted with (R3)n and one R4;
X1 is N, or CR6a;
R1 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi -ealkyl, OH, Ci-ealkyl- OH, Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, Ci-ealkyl-NRaRb, or 4-6-membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O;
R3 at each occurrence is independently hydrogen, halogen, CN, Ci-ealkyl, or C3-7cycloalkyl;
R4 is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, C2-ealkenyl, C2-ealkynyl, Ci- ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P- C3-7cycloalkyl, C2-ealkenyl-C3-7cycloalkyl, C2-ealkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1- 3 of halogen, Ci-ealkyl, or Ci-ealkoxy;
R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, OH, Ci-ealkyl- OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci-ealkyl- NRaRb;
R6a is hydrogen, or methyl;
R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;
R7 at each occurrence is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or R7 andR7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring;
R11 at each occurrence is independently hydrogen, Ci-ealkyl, haloCi -ealkyl, C2-ealkenyl, C2- ealkynyl, Ci-ealkoxy, (CH2)P-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-
vcycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)p-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy;
R13 at each occurrence is independently hydrogen, Ci-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; n is 0, 1 or 2; p at each occurrence is independently 1, 2, 3 or 4; and t is 0, 1, 2 or 3.
[0078] In some embodiments, the compound of Formula I includes a compound of Formula (lib) or (Ilbb):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
L2 is a covalent bond or (CR7R7)P;
L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;
Q is a ring selected from the group consisting of 5-membered heteroaryl, 5-membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring comprises at least one
carbon atom, at least one nitrogen atom and optionally 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and wherein the ring is substituted with (R3)n and one R4;
X1 is N, or CR6a;
R3 at each occurrence is independently hydrogen, halogen, CN, Ci-ealkyl, or C3-7cycloalkyl;
R4 is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, C2-ealkenyl, C2-ealkynyl, Ci- ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P- C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1- 3 of halogen, Ci-ealkyl, or Ci-ealkoxy;
R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, OH, Ci-ealkyl- OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci-ealkyl- NRaRb;
R6a is hydrogen, or methyl;
R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;
R7 at each occurrence is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or R7 andR7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring;
R11 at each occurrence is independently hydrogen, Ci-ealkyl, haloCi -ealkyl, C2-ealkenyl, C2- ealkynyl, Ci-ealkoxy, (CH2)P-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- 7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-ealkenyl-C3-7cycloalkyl, C2-ealkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy;
R13 at each occurrence is independently hydrogen, Ci-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be
optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; n is 0, 1 or 2; p at each occurrence is independently 1, 2, 3 or 4; and t is 0, 1, 2 or 3.
[0079] In some embodiments, the compound of Formula I includes a compound of Formula (lie) or (IIcc):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
L2 is a covalent bond or (CR7R7)P;
L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;
Q is a ring selected from the group consisting of 5-membered heteroaryl, 5-membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring contains at least one carbon atom, at least one nitrogen atom, and optionally contains 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and wherein the ring is substituted with (R3)n and one R4;
X1 is N, or CR6a;
R3 at each occurrence is independently hydrogen, halogen, CN, Ci-ealkyl, or C3-7cycloalkyl;
R4 is hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, C2-ealkenyl, C2-ealkynyl, Ci-ealkoxy, (CH2)p-Ci- ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-
6alkenyl-C3-7cycloalkyl, C2-ealkynyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, or (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci- ealkoxy;
R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, OH, Ci-ealkyl- OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci-ealkyl- NRaRb;
R6a is hydrogen, or methyl;
R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;
R7 at each occurrence is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or R7 andR7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring;
R11 at each occurrence is independently hydrogen, Ci-ealkyl, haloCi -ealkyl, C2-ealkenyl, C2- ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- 7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-ealkenyl-C3-7cycloalkyl, C2-ealkynyl, O(CH2)P-C3- 7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci- ealkyl, or Ci-ealkoxy;
R13 at each occurrence is independently hydrogen, Ci-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; n is 0, 1 or 2; p at each occurrence is independently 1, 2, 3 or 4; and t is 0, 1, 2 or 3.
[0080] In some embodiments, the compound of Formula I includes a compound of Formula (lid) or (Ildd):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
* in Formula (Ildd) represents a chiral center with R or S configutation;
L2 is a covalent bond or (CR7R7)P;
L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;
Q is a ring selected from the group consisting of 5-membered heteroaryl, 5-membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring comprises at least one carbon atom, at least one nitrogen atom, and optionally 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, wherein oxygen may be a ring member and/or an oxo (=0) attached to a ring member, and wherein the ring is substituted with (R3)n and one R4;
X1 is N, or CR6a;
R1 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi -ealkyl, OH, Ci- ealkyl-OH, Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, Ci-ealkyl-NRaRb, or 4-6- membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O;
R3 at each occurrence is independently hydrogen, halogen, CN, Ci-ealkyl, or C3-7cycloalkyl;
R4 is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, C2-ealkenyl, C2-ealkynyl, Ci- ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P- C3-7cycloalkyl, C2-ealkenyl-C3-7cycloalkyl, C2-ealkynyl, O(CH2)P-C3-7cycloalkyl, (CH2)q-5-6- membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7-membered heterocyclyl ring
substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy;
R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, OH, Ci-ealkyl- OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci-ealkyl- NRaRb;
R6a is hydrogen, or methyl;
R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;
R7 at each occurrence is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or two R7 groups together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring;
R11 at each occurrence is independently hydrogen, Ci-ealkyl, haloCi -ealkyl, C2-ealkenyl, C2- ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- vcycloalkyl, (CH2)P-C3-7cycloalkyl, C2-ealkenyl-C3-7cycloalkyl, C2-ealkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; n is 0, 1 or 2; p at each occurrence is independently 1, 2, 3 or 4; and t is 0, 1, 2 or 3.
[0081] In some embodiments, the compound of Formula I includes a compound of Formula (III):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
X1 is N, or CR6a;
Z is CH2 or O;
L1 is a covalent bond or CH2 optionally substituted with 1 or 2 methyl groups;
L2 is a covalent bond or (CR7R7)P;
L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;
R1 at each occurrence is independently hy drogen, halogen, Ci-ealkyl, haloCi-ealkyl, OH, Ci- ealkyl-OH, Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, Ci-ealkyl-NRaRb, or 4-6- membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O;
R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, OH, Ci-ealkyl- OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci-ealkyl- NRaRb;
R6a is hydrogen, or methyl;
R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;
R7 at each occurrence is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or two R7 groups together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring;
each occurrence of R9 and R10 is independently hydrogen, Ci-ealkyl substituted with 1-4 R11, (CR12R12)q-C2-ealkenyl substituted with 1-4 R11, (CR12R12)q-C2-ealkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
R11 at each occurrence is independently hydrogen, Ci-ealkyl, haloCi -ealkyl, C2-ealkenyl, C2- ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- vcycloalkyl, (CH2)P-C3-7cycloalkyl, C2-ealkenyl-C3-7cycloalkyl, C2-ealkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy;
R12 at each occurrence is independently hydrogen, Ci-4alkyl, C3-7cycloalkyl, or two R12 groups, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring;
R13 at each occurrence is independently Ci-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; p at each occurrence is independently 1, 2, 3 or 4; q at each occurrence is independently 0, 1, 2, 3 or 4; t is 0, 1, 2 or 3; and w is 0 or 1, provided that when L1 is a covalent bond, w is 1, and further provided that when L1 is CH2 optionally substituted with 1-2 methyl, w is 0.
[0082] In some embodiments, the compound of Formula I includes a compound of Formula (Illa) or (Illaa):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
L2 is a covalent bond or (CR7R7)P;
L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;
X1 is N, or CR6a;
R1 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi -ealkyl, OH, Ci- ealkyl-OH, Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, Ci-ealkyl-NRaRb, or 4-6- membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O;
R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi -ealkyl, OH, Ci- ealkyl-OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci- ealkyl-NRaRb;
R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;
R7 at each occurrence is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or twoR7 groups together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; each occurrence of R9 and R10 is independently hydrogen, Ci-ealkyl substituted with 1-4 R11, (CR12R12)q-C2-ealkenyl substituted with 1-4 R11, (CR12R12)q-C2-ealkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered
heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
R11 at each occurrence independently hydrogen, Ci-ealkyl, haloCi-ealkyl, C2-ealkenyl, C2-ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3- 7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci- ealkyl, or Ci-ealkoxy;
R12 at each occurrence is independently hydrogen, Ci-4alkyl, C3-7cycloalkyl, or R12 and R12, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring;
R13 at each occurrence is independently hydrogen, Ci-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; t is 0, 1, 2 or 3; p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4.
[0083] In some embodiments, the compound of Formula I includes a compound of Formula (Illb) or (Ilbb) :
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
L2 is a covalent bond or (CR7R7)P;
L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;
X1 is N, or CR6a;
R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, OH, Ci-ealkyl- OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci-ealkyl- NRaRb;
R6a is hydrogen, or methyl;
R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; each occurrence of R7 is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or R7 andR7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; each occurrence of R9 and R10 is independently hydrogen, Ci-ealkyl substituted with 1-4 R11, (CR12R12)q-C2-ealkenyl substituted with 1-4 R11, (CR12R12)q-C2-ealkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
each occurrence of R11 is independently hydrogen, Ci-ealkyl, haloCi-ealkyl, C2-ealkenyl, C2- ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- vcycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-ealkynyl, O(CH2)P-C3- 7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci- ealkyl, or Ci-ealkoxy; each occurrence of R12 is independently hydrogen, Ci-4alkyl, C3-7cycloalkyl, or R12 and R12, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring;
R13 at each occurrence is independently hydrogen, Ci-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; t is 0, 1, 2 or 3; p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4.
[0084] In some embodiments, the compound of Formula I includes a compound of Formula (IIIc) or (IIIcc):
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
L2 is a covalent bond or (CR7R7)P;
L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;
X1 is N, or CR6a;
R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, OH, Ci-ealkyl- OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci-ealkyl- NRaRb;
R6a is hydrogen, or methyl;
R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;
R7 at each occurrence is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or R7 andR7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; each occurrence of R9 and R10 is independently hydrogen, Ci-ealkyl substituted with 1-4 R11, (CR12R12)q-C2-ealkenyl substituted with 1-4 R11, (CR12R12)q-C2-ealkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;
R11 at each occurrence is independently hydrogen, Ci-ealkyl, haloCi -ealkyl, C2-ealkenyl, C2- ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- 7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-ealkenyl-C3-7cycloalkyl, C2-ealkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy;
R12 at each occurrence is independently hydrogen, Ci-4alkyl, C3-7cycloalkyl, or R12 and R12, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring;
R13 at each occurrence is independently hydrogen, Ci-4alkyl, or C3-5cycloalkyl; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring
containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; t is 0, 1, 2 or 3; p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4.
[0085] In some embodiments, the compound of Formula I includes a compound of Formula (Hid) or (Illdd):
wherein:
* in Formula (Illdd) represents a chiral center with R or S configutation;
L2 is a covalent bond or (CR7R7)P;
L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;
X1 is N, or CR6a;
R1 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi -ealkyl, OH, Ci- ealkyl-OH, Ci-ealkoxy, haloCi-ealkoxy, CN, C3-?cycloalkyl, NRaRb, Ci-ealkyl-NRaRb, or 4-6- membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O;
R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, OH, Ci-ealkyl- OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci-ealkyl- NRaRb;
R6a is hydrogen, or methyl;
R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl; each occurrence of R7 is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or R7 andR7, together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring; each occurrence of R9 and R10 is independently hydrogen, Ci-ealkyl substituted with 1-4 R11, (CR12R12)q-C2-ealkenyl substituted with 1-4 R11, (CR12R12)q-C2-ealkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; each occurrence of R11 is independently hydrogen, Ci-ealkyl, haloCi-ealkyl, C2-ealkenyl, C2- ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- 7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-ealkynyl, O(CH2)P-C3- 7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci- ealkyl, or Ci-ealkoxy; each occurrence of R12 is independently hydrogen, Ci-4alkyl, C3-7cycloalkyl, or R12 and R12, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; t is 0, 1, 2 or 3;
p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4.
[0086] In any embodiments, Z is CH2. In certain other embodiments, Z is O.
[0087] In any embodiments, L1 is a covalent bond. In certain other embodiments, L1 is CH2 optionally substituted with 1-2 methyl. In yet other embodiments, L1 is CH2.
[0088] In any embodiments, L1 is a covalent bond, and w is 1. In certain other embodiments, L1 is CH2 optionally substituted with 1-2 methyl, and w is 0.
[0089] In any embodiments, each occurrence of R1 is independently hydrogen. In certain other embodiments, each occurrence of R1 is independently halogen. In yet other embodiments, m is 2, one R1 is hydrogen, and the other R1 is halogen. In yet other embodiments, m is 2, one R1 is hydrogen, and the other R1 is F. In yet other embodiments, each occurrence of R1 is independently F.
[0090] In any embodiments, Y2 is N, and each of Y1, Y3 and Y4 is independently CR5. In certain other embodiments, Y1 is CR5, Y2 is N, and each of Y3 and Y4 is independently CH. In yet other embodiments, Y1 is CR5, Y2 is N, Y3 is N, and Y4 CH.
[0091] In any embodiments, the moiety
Formulae (II), (Ila), (Ilaa), (lib), (Ilbb),
(lie), (IIcc), (Hd), (Ildd), and (III), (Illa), (Illaa), (Illb), (IHbb), (IIIc), (IIIcc), (Hid), and (Illdd), is
[0092] In any embodiments, R5 is methyl or ethyl. In certain other embodiments, R5 is CHF2 or CF3. In yet other embodiments, R5 is hydrogen, or CN.
[0093] In any embodiments, t is 0. In certain other embodiments, t is 1. In yet other embodiments, t is 2. In yet other embodiments, t is 3.
[0094] In any embodiments, X1 is N, X2 is N, and X3 is NR6. In certain other embodiments, X1 is CH, X2 is N, and X3 is NR6. In yet other embodiments, X1 is O, X2 is N, and X3 is CR6.
[0095] In any embodiments, R6 is hydrogen. In certain other embodiments, R6 is methyl. In yet other embodiments, R6 is ethyl. In yet other embodiments, R6 is cyclopropyl.
[0096] In any embodiments, R6a is hydrogen. In certain other embodiments, R6ais methyl. In yet other embodiments, R6ais ethyl. In yet other embodiments, R6ais cyclopropyl.
[0097] In any embodiments, L2 is a covalent bond. In certain other embodiments, L2 is (CR7R7)P. In yet other embodiments, L2 is CH2.
[0098] In any embodiments, L3 is a covalent bond. In certain other embodiments, L3 is O. In yet other embodiments, L3 is NR7.
[0099] In any embodiments, each occurrence of R7 is independently hydrogen. In certain other embodiments, each occurrence of R7 is independently Ci-4alkyl. In yet other embodiments, each occurrence of R7 is independently C3-5cycloalkyl. In yet other embodiments, each occurrence of R7 is independently hydrogen or methyl.
[0100] In any embodiments, q is 0. In certain other embodiments, q is 1. In yet other embodiments, q is 2.
[0101] In any embodiments, R8 is COOH.
[0102] In any embodiments, R9 is Ci-4alkyl. In certain other embodiments, R9 is methyl. In yet other embodiments, R9 is ethyl.
[0103] In any embodiments, R10 is Ci-ealkyl substituted with 1-4 R11, (CR12R12)q-C2-ealkenyl substituted with 1-4 R11, (CR12R12)q-C2-ealkynyl substituted with 1-4 R11, (CR12R12)q-C3- vcycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6- membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11. In certain other embodiments, R10 is Ci-ealkyl. R10 is (CH2)p-C3- vcycloalkyl. In yet other embodiments, R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
[0104] In any embodiments, Q is C(=O)NR9R10. In certain other embodiments, Q is a ring (also referred to herein the “Q ring”) selected from the group consisting of 5-membered heteroaryl, 5- membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring comprises at least on carbon atom, at least one nitrogen atom and optionally 1-3 heteroatoms selected from nitrogen, oxygen and sulfur wherein oxygen may be a ring member and/or an oxo attached to a ring member, and wherein the ring is substituted with (R3)n and R4.
and each of which is substituted with (R3)n and one R4 at any available carbon or nitrogen position.
[0106] In any embodiments,
substituted with (R3)n and one R4 at any available carbon position.
each of which is substituted with (R3)n and one R4 at any available carbon or nitrogen position.
[0108] In any embodiments, each occurrence of R3 is independently hydrogen, halogen, or Ci- 4alkyl. In certain other embodiments, each occurrence of R3 is independently Ci-4alkyl. In yet other embodiments, each occurrence of R3 is independently methyl.
[0109] In any embodiments, n is 0. In certain other embodiments, n is 1. In yet other embodiments, n is 2.
[0110] In any embodiments, R4is independently hydrogen, Ci-ealkyl, C2-ealkenyl, C2-ealkynyl, Ci- ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P- C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci- ealkoxy. In certain other embodiments, R4 is independently (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, or (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11. In yet other embodiments, R4 is independently Ci-ealkyl, C2-ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, or C2-6alkenyl-C3-7cycloalkyl.
[OHl] In any embodiments, each occurrence of R11 is independently hydrogen. In certain other embodiments, each occurrence of R11 is independently Ci-ealkyl. In yet other embodiments, each occurrence of R11 is independently Ci-ealkoxy. In yet other embodiments, each occurrence of R11
is independently (CH2)p-Ci-6alkox. In yet other embodiments, each occurrence of R11 is independently phenyl. In yet other embodiments, each occurrence of R11 is independently (CH2)p- phenyl. In yet other embodiments, each occurrence of R11 is independently C3-7cycloalkyl. In yet other embodiments, each occurrence of R11 is independently (CH2)P-C3-7cycloalkyl. In yet other embodiments, each occurrence of R11 is independently C2-6alkynyl-C3-7cycloalkyl. In yet other embodiments, each occurrence of R11 is independently O(CH2)P-C3-7cycloalkyl. In any embodiments, each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy.
[0112] In any embodiments, each occurrence of R12 is independently hydrogen. In certain other embodiments, each occurrence of R12 is independently Ci-4alkyl. In yet other embodiments, each occurrence of R12 is independently C3-7cycloalkyl. In yet other embodiments, R12 andR12, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring.
[0113] In any embodiments, each occurrence of Ra and Rb is independently hydrogen. In certain other embodiments, each occurrence of Ra and Rb is independently Ci-ealkyl. In yet other embodiments, each occurrence of R12 is independently C3-7cycloalkyl. In yet other embodiments, Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl.
[0114] In any embodiments, the
moiety in Formula (II) and (III) is
[0115] In any embodiments, R13 is hydrogen. In certain other embodiments, R13 is methyl. In yet other embodiments, R13 is cyclopropyl.
[0116] In any embodiments, the compound is selected from:
[0117] In any embodiments, the compound is selected from:
[0118] In any embodiments, the compound is selected from:
[0119] In any embodiments, the compound is selected from:
[0120] In another aspect, the present invention relates to a pharmaceutical composition comprising a compound disclosed herein, and a pharmaceutically acceptable carrier..
[0121] In yet another aspect, the present invention relates to a method for treating a disease associated with dysregulation of lysophosphatidic acid receptor 1 (LPAi) in a subject in need thereof, comprising administering an effective amount of a compound disclosed herein to the subject. In some embodiments, the disease is pathological fibrosis (e.g., pulmonary, liver, renal, cardiac, demal, ocular, or pancreatic fibrosis), idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, or systemic sclerosis.
[0122] In yet another aspect, the present invention relates to a process of making a compound of Formulae (I), (II), (Ila), (Ilaa), (lib), (Hbb), (lie), (IIcc), (lid), (Ildd), (III), (Illa), (Illaa), (Illb), (Illbb), (IIIc), (IIIcc), (Illd), and (Illdd), including each exemplified compound and intermediates described herein.
[0123] In any embodiments, the present invention relates to an intermediate selected from:
General Synthetic Methods
[0124] The compounds of the present invention can be synthesized using the methods describled herein, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Proffered methods include, but are not limited to, those exemplary schemes and working examples described below. All substituents are as defined hereinabove unless otherwise indicated. The reactions are performed in a solvent or solvent mixture appropriate to the reagents and materials employed and suitable for the transformations proposed. This will sometimes require a judgment to modify the order of syntheitic
steps or to select on particular process scheme over another in order to obtain a desired compound of the invention.
[0125] It will be recongnized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account descrbing the many alternatives to the trained practitioner is by Greene et al., Greene’s Protective Groups in Organic Synthesis, Fifth Edition, Wiley (2014). It will also be recongnized that the compound names referred to in the decriptions of Schemes 1-12 are for convinience only, and do not necesrrily reflect the actual chemical names of those compounds.
Scheme 1
[0126] Scheme 1 describes the synthesis of carbonyl azine azole N-heteroaryl-azacyclohexyl acetic acids 8. PGi and PG2 each represents a protecting group, and L2 is (CR7R7)P(e.g., CEE). The halo azine derivative 1 is reacted with piperidine acetic ester 2 under Buckwald conditions with appropriate catalyst (e.g. Pd(OAc)2/BINAP) or nucleophilic aromatic substitution reaction or Ullmann reaction to give the corresponding carbonyl azine N-heteroaryl-piperidine acetic carboxylate 3. Deprotection of the protected hydroxylmethyl azole 3 provides the hydroxylmethyl azole 4, which is then reacted with MsCI (or PBn) to give the mesylate (or Br) 5. Treatment of the mesylate (or Br) 5 with 2-hydroxy azine 6 in the presence of an appropriate base (e.g. K2CO3, nucleophilic substitution reactions) gives the corresponding carbonyl azine N-heteroaryl-
piperidine acetic carboxylate 7, which then undergoes ester deprotection to give the desired carbonyl azine L2-azole N-heteroaryl-azacyclohexyl acetic acids 8.
Scheme 2
[0127] Scheme 2 describes an alternative synthetic route to the carbonyl azine N-heteroaryl- azacyclohexyl acetic acids 8. PGi and PG2 each represents a protecting group, and L2 is (CR7R7)P (e.g., CH2). Deprotection of the protected hydroxylmethyl azole derivative 1 gives hydroxylmethyl azole 9, which is then reacted with MsCl (or PBn) to give the mesylate (or Br) 10. Treatment of mesylate (or Br) 10 with 2-hydroxy azine in the presence of an appropriate base (e.g. K2CO3, nucleophilic substitution reactions) gives the corresponding N-substituted carbonyl azine 11. The halo azine derivative 11 is reacted with piperidine acetic carboxylate under Buckwald conditions with appropriately catalyst (e.g. Pd(OAc)2/BINAP) or nucleophilic aromatic substitution reaction or Ullmann reaction to give the corresponding piperidine acetic carboxylate 7, which then undergoes ester deprotection to give the desired carbonyl azine L2-azole N-heteroaryl- azacyclohexyl acetic acids 8.
Scheme 3
[0128] Scheme 3 describes the synthesis of N-substituted aza-heterocyclopentyl ketone N- heteroaryl-azacyclohexyl acetic acids 13. Treatment of the mesylate (or Br) 5 with aza- heterocyclopentyl ketone 6a in the presence of an appropriate base (e.g. t-BuOK, nucleophilic substitution reactions) gives the corresponding N-substituted aza-cyclopentyl ketone 12, which then undergoes ester deprotection to give the desired N-substituted aza-cyclopentyl ketone-N- heteroaryl-azacyclohexyl acetic acids 13.
Scheme 4
[0129] Scheme 4 describes the synthesis of oxy-Q ring N-heteroaryl-azacyclohexyl acetic acid 16, wherein Q represents a 5-membered heteroaryl or heterocyclyl or 6-membered heteroaryl or heterocyclyl. Base-mediated SNAT reaction of hydroxyl methyl azole 4 with an appropriate halo- or methylsulfonyl-substitued Q ring 14 (X is halo or methyl sulfonyl) provides the oxy-Q ring N- heteroaryl piepridine acetic ester 15, which then undergoes ester deprotection to give the desired oxy-Q ring N-heteroaryl-azacyclohexyl acetic acids 16.
Scheme 5
[0130] Scheme 5 describes an alternative synthesis of oxy-Q ring N-heteroaryl-azacyclohexyl acetic acid 16, wherein Q represents a 5-membered heteroaryl or heterocyclyl or 6-membered heteroaryl or heterocyclyl. Base-mediated SNAT reaction of hydroxylmethyl azole 9 with an appropriate halo- or methylsulfonyl-substitued Q ring 14 (X is halo or methyl sulfonyl) provides the oxy-Q ring 17, which is reacted with piperidine ethyl ester derivative under Buckwald conditions with appropriately catalyst (e.g. Pd(OAc)2/BINAP) or nucleophilic aromatic substitution reaction or Ullmann reaction to give the corresponding oxy-Q ring N-heteroaryl piepridine acetic ester 15, which then undergoes ester deprotection to give the desired oxy-Q ring N-heteroaryl-azacyclohexyl acetic acids 16.
Scheme 6
[0131] Scheme 6 describes the synthesis of amino-Q ring N-heteroaryl-azacyclohexyl acetic acids 21. The hydroxylmethyl azole 4 is reacted with MsCl with appropriately base (e.g. TEA) to give the corresponding mesylate 17. Displacement of the mesylate 17 with NaNs (or other azide reagent) gives azide 18, which then undergoes reduction (e.g. Staudinger reduction with PPhV water) to give the amine 19. Amine 19 is then reacted with halo- or methylsulfonyl-substitued Q ring 14 (X is halo or methyl sulfonyl) in the presence of an appropriate base or via Pd catalyzed amination to give amino-azine piepridine acetic ester 20, which then undergoes ester deprotection to give the desired amino-Q ring N-heteroaryl-azacyclohexyl acetic acids 21.
Scheme 7
[0132] Scheme 7 describes the synthesis of oxy-azole N-heteroaryl-azacyclohexyl acetic acids 24. The hydroxylmethyl azole 4 is reacted with an appropriate haloazole or methyl sulfonyl azole 22 (which is a 5-membered heteroaryl ring that contains at least one nitrogen and may contain additional 1-3 heteroatoms selected from N, O and S) in the presence of an appropriate base (nucleophilic aromatic substitution reaction) to give oxy-azole N-heteroaryl piepridine acetic ester 23, which then undergoes ester deprotection to give the desired oxy-azole N-heteroaryl- azacyclohexyl acetic acids 24.
Scheme 8
[0133] Scheme 8 describes the synthesis of amino-azole N-heteroaryl-azacyclohexyl acetic acids 28. The hydroxylmethyl azole 4a is oxidized to the corresponding aldehyde 25 (e.g. with Dess- Martin periodinane or Swern Oxidation). The aldehyde 25 can then undergo reductive amination with an appropriate amino-azole 26 (which is a 5-membered heteroaryl ring that contains at least one nitrogen and may contain additional 1-3 heteroatoms selected from N, O and S) to give amino-
azole N-heteroaryl piepridine ecetic ester 27. Subsequent deprotection of ester 27 provides the amino-azole N-heteroaryl-azacyclohexyl acetic acids 28.
Scheme 9
[0134] Scheme 9 describes the synthesis of alkylated-triazole N-heteroaryl-azacyclohexyl acetic acids 32. Treatment of the mesylate or Br-substitued compound 10 with triazole 29 in the presence of appropriate base gives the alkylated triazole 30. The halo-azine 30 is then reacted with piperidine acetic ester 2 under Buckwald conditions with appropriately catalyst (e.g. Pd(OAc)2/BINAP) to give the corresponding alkylated-triazole N-heteroaryl piepridine acetic ester 31, which then undergoes ester deprotection to give the desired alkylated-triazole N-heteroaryl-azacyclohexyl acetic acids 32.
Scheme 10
[0135] Scheme 10 describes the synthesis of alkylated-tetrazoleN-heteroaryl-azacyclohexyl acetic acids 36 and 37. The hydroxylmethyl azole 4 is reacted with tetrazole 33 under Mitsunobu conditions to provide the regioisomeric tetrazoles 34 and 35. Deprotection piepridine acetic ester 34 and 35 provides the regioisomeric alkylated-tetrazole N-heteroaryl-azacyclohexyl acetic acids 36 and 37.
Scheme 11
[0136] Scheme 11 describes the synthesis of carbamoyloxymethyl azole N-heteroaryl- azacyclohexyl acetic acids 41. The hydroxylmethyl azole 4 is reacted with 4-nitrophenyl chloroformate in the presence of an appropriate base to give the corresponding 4-nitrophenyl carbonate 38, which is then reacted with an amine 39 in the presence of an appropriate base to give the carbomate 40. Subsequent deprotection of ester 40 provides the carbamoyloxymethyl azole N- heteroaryl-azacyclohexyl acetic acids 41.
Scheme 12
[0137] Scheme 12 describes the synthesis of l-azinemethyl-piperidine-3 -carboxylic acids 48, 49 and 50. Carbonyl insertion of azine halide 1 in the presence of CO gas and appropriate catalyst in methanol gives azine carboxylate 42, which is then reduced with appropriate reductant to give azine methyl alcohol 43. Treatment of azine methyl alcohol 43 with MsCl in the presence of appropriate base gives the corresponding mesylate 44. Alkylation piperidine carboxylate 45 with mesylate 44 in the presence appropriate base affords azine methyl-piperidine-3 -carboxylate 46. Deprotection of azine methyl-piperidine-3 -carboxylate 46 gives hydroxylmethyl azole 47, which is then converted to corresponding acids 48, 49 and 50 using similar methods as described herein over several steps.
Pharmaceutical Compositions and Methods
[0138] The compounds utilized in the methods described herein may be formulated together with a pharmaceutically acceptable carrier or adjuvant into pharmaceutically acceptable compositions
prior to be administered to a subject. In another embodiment, such pharmaceutically acceptable compositions further comprise additional therapeutic agents in amounts effective for achieving a modulation of disease or disease symptoms, including those described herein.
[0139] The term “pharmaceutically acceptable carrier or adjuvant” refers to a carrier or adjuvant that may be administered to a subject, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
[0140] Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d- a-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as a-, 0- , and y-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-0-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
[0141] The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
[0142] The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be
formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3 -butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer’s solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
[0143] The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
[0144] The pharmaceutical compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
[0145] Topical administration of the pharmaceutical compositions of this invention is useful when the desired treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a
suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2- octyl dodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.
[0146] The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
[0147] When the compositions of this invention comprise a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition. [0148] The compounds described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.5 to about 100 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the mode of
administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations contain from about 20% to about 80% active compound.
[0149] Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any subject will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the subject’s disposition to the disease, condition or symptoms, and the judgment of the treating physician.
[0150] Upon improvement of a subject’s condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Subjects may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
[0151] The pharmaceutical compositions described above comprising a compound of Formula (I) may further comprise another therapeutic agent useful for treating a disease associated with dysregulation of lysophosphatidic acid receptor 1 (LPAi). In particular, such combination may be useful for treating pathological fibrosis (e.g., pulmonary, liver, renal, cardiac, dernal, ocular, or pancreatic fibrosis), idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, or systemic sclerosis.
[0152] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
[0153] The examples herein are provided to illustrate advantages of the present technology and to further assist a person of ordinary skill in the art with preparing or using the compounds of the present technology or salts, pharmaceutical compositions, derivatives, solvates, metabolites, prodrugs, racemic mixtures or tautomeric forms thereof. The examples herein are also presented in order to more fully illustrate the preferred aspects of the present technology. The examples should in no way be construed as limiting the scope of the present technology, as defined by the appended claims. The examples can include or incorporate any of the variations, aspects or aspects of the present technology described above. The variations, aspects or aspects described above may
also further each include or incorporate the variations of any or all other variations, aspects or aspects of the present technology.
EXAMPLES
[0154] Abbreviations used herein are as follows:
General Conditions and Procedures
[0155] In the following examples, the chemical reagents were purchased from commercial sources (such as Alfa, Acros, Sigma Aldrich, TCI and Shanghai Chemical Reagent Company), and used without further purification. THF was continuously refluxed and freshly distilled from sodium and benzophenone under nitrogen, dichloromethane was continuously refluxed and freshly distilled from CaHz under nitrogen.
[0156] Flash chromatography was performed on an Ez Purifier III via column with silica gel particles of 200-300 mesh. Analytical and preparative thin layer chromatography plates (TLC) were HSGF 254 (0.15-0.2mm thickness, Shanghai Anbang Company, China). Nuclear magnetic resonance (NMR) spectra were recorded using Brucker AMX-300 or AMX-400 NMR (Brucker, Switzerland) at around 20 - 30 °C unless otherwise specified. The following abbreviations are used: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublets; ddd, doublet of doublet of doublet; dt, doublet of triplets; bs, broad signal. Chemical shifts were reported in parts per million (ppm, 6) downfield from tetramethylsilane. Mass spectra were run with electrospray ionization (ESI) from a Waters LCT TOF Mass Spectrometer (Waters, USA). Compound purification was carried out as needed using a variety of traditional methods including, but not limited to, preparative chromatography under acidic, neutral, or basic conditions using either normal phase or reverse phase HPLC or flash columns or Prep-TLC plates.
[0157] Preparative HPLC: unless otherwise described, the compounds were purified using a WATERS Fractionlynx system equipped with a YMC Pack Pro ds Column (5 pm, 120A, 50 x 20 mm) and the following solvent system: H2O, AcCN, and 2% TFA in H2O. Specific elution gradients were based on the retention times obtained with an analytical LC-MS, however, in general all elution gradients of H2O and MeCN were run over a 7 minute run time with a flow rate of 35 mL/min. An autoblend method was used to ensure a concentration of 0.1 % TFA throughout each run. Specific elution gradients were based on the retention times obtained with an analytical LC-MS, however, in general, all elution gradients of H2O and MeCN were run over at 8 minute run time with a flow rate of 50 mL/min.
[0158] Analytical LC-MS: analytical LC-MS was performed on a WATERS Acquity UPLC-MS instrument equipped with a ACQUITY UPLC BEH Cig Column (2.1 x 50 mm, 1 .7 pu|), a column temperature of 45 °C and using the following solvent system: Solvent A: 0.1 % HCOOH in H2O; and Solvent B: 0.1 % HCOOH in AcCN. All compounds were run using the same elution gradient, i.e., 5% to 95% Solvent B over a 1 .5 min run time with a flow rate of 0.6 mL/min.
[0159] Preparative Chiral SFC Separation: stereoisomer mixtures were separated using a Berger Minigram SFC instrument on one of the following columns: ChiralPak AS-H (10 x 250 mm), ChiralPak IA (10 x 250 mm), ChiralPak AD-H (21 x 250 mm), Phenomenex Lux-2 (21.2 x 250 mm), or ChiralPak IC (10 x 250 mm); eluting with either 0.1 % diethylamine in MeOH / CO2, or 0.1 % diethylamine in EtOH / CO2 or 0.1 % diethylamine in isopropanol / CO2 with a flow rate of 2.5 mL/min and a column temperature of 35°C.
[0160] Analytical Chiral SFC Separation: stereoisomer mixtures or single enantiomers were analyzed using a JASCO analytical SFC instrument on one of the following columns: ChiralPak AS-H (4.6 x 250 mm), ChiralPak IA (4.6 x 250 mm), ChiralPak AD-H (4.6 x 250 mm), Phenomenex Lux-2 (4.6 x 250 mm), or ChiralPak IC (4.6 x 250 mm); eluting with either 0.1 % diethylamine in MeOH / CO2, or 0.1 % diethylamine in EtOH / CO2 or 0.1 % diethylamine in isopropanol / CO2, with a flow rate of 6.0 imL/min and a column temperature of 35°C. Intermediate 1 : 3-bromo-2-ethyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridine
Step 1: 3,6-dibromo-2-ethylpyridine
[0161] To a solution of 3,6-dibromo-2-methylpyridine (75 g, 0.299 mol) in THF (1 L) was added NaHMDS (180 mL, 0.36 mol, 2M in THF) drop-wisely at -50 °C and the mixture was stirred at this temperature for 30 mins. Mel (46.5 mL, 0.75 mol) was added to the above mixture and the resulting mixture was stirred at -50 °C to room temperature for 16 hrs. The reaction mixture was quenched with saturated aq.TMLCl solution (500 mL) at 0 °C, and extracted with EtOAc (2 x 500 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by silica column chromatography (PE: DCM=300: 1 to 200: 1) to give the title compound (47 g, 59.1% yield) as
yellow oil. XH NMR (400 MHz, CD3OD) 8 7.61-7.59 (d, J = 8 Hz, 1H), 7.61-7.59 (d, J = 8.4 Hz, 1H), 2.94-2.88 (q, 2H), 1.38-1.27 (t, 3H).
Step 2: 3-(5-bromo-6-ethylpyridin-2-yl)prop-2-yn-l-ol
[0162] To a solution of 3,6-dibromo-2-ethylpyridine (47 g, 0.177 mol) in THF (0.65 L) was added prop-2-yn-l-ol (11.9 g, 0.212 mol), Cui (3.4 g, 17.7 mmol), DIPEA (35.1 mL, 0.212 mol) and Pd(PPh3)2C12 (12.4 g, 17.7 mmol) and the mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at r.t. for 16 hrs. The mixture was diluted with EtOAc (500 m L) and filtered. The filtrate was washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica column chromatography (DCM: EtOAc= 10: 1 to 4: 1) to give the title compound (40 g, 94.1% yield) as brown solid. LC/MS (ESI) m/z: 240/242 (M+H)+.
Step 3: (4-(5-bromo-6-ethylpyridin-2-yl)-l-((trimethylsilyl)methyl)-lH-l,2,3-triazol-5- yl)methanol
[0163] To a solution of intermediate 3-(5-bromo-6-ethylpyridin-2-yl)prop-2-yn-l-ol (20 g, 0.083 mol) in THF (400 mL) was added Chlorocyclopentadienylbis(triphenylphosphine)ruthenium(II) (3.5 g, 4.16 mmol) and TMS-methyl azide (14 g, 0.108 mol) at 0 °C under N2 atmosphere. The mixture was degassed under N2 atmosphere for three times and stirred at room temperature for 16 hrs. The mixture was diluted with EtOAc (500 mL) and filtered. The filtrate was concentrated to dryness to give crude product, which was triturated with PEZEtOAc (1000 mL, 10/1 v/v) to give the title compound (28 g, 91.3% yield) as white solid. XH NMR (400 MHz, CDCh) 6 8.03 - 8.01 (d, J = 8.4 Hz, 1H), 7.95-7.93 (d, J = 8.4 Hz, 1H), 6.77 - 6.74 (t, J = 6.8 Hz, 1H), 4.79 - 4.78 (d, J = 6.8 Hz, 1H), 3.80 (s, 3H), 3.03 - 3.01 (q, 1H), 1.34 - 1.30 (t, J= 7.6 Hz, 3H), 0.20 (s, 9H).
Step 4: (4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methanol
[0164] To a solution of (4-(5-bromo-6-ethylpyridin-2-yl)-l-((trimethylsilyl)methyl)-lH-l,2,3- triazol-5-yl)methanol (25 g, 67.7 mmol) in THF (300 mL) was added TBAF.3H2O (25.6 g, 81.2 mmol) and the mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc (500 mL), washed with saturated aq.NH-tCl solution (3 x 50 mL) and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica column chromatography (DCM: EtOAc= 8: 1 to 4: 1) to give the title compound (19 g, 94.4% yield) as gray solid. LC/MS (ESI) m/z: 297/299 (M+H)+.
Step 5: 3-bromo-2-ethyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridine
[0165] To the mixture of (4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methanol (25 g, 0.084 mol) and TosOH (2.2 g, 12.6 mmol) in DCM (300 mL) was added DHP
(10.6 g, 0.126 mol) at 0 °C and the mixture was stirred at room temperature for 16 hrs. The mixture was washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica column chromatography (DCM: EtOAc= 8: 1) to give the title compound (30 g, 93.6% yield) as yellow solid. LC/MS (ESI) m/z: 381/383 (M+H)+. ’H NMR (400 MHz, CDCh) 6 7.91 (d, J= 8.3 Hz, 1H), 7.86 (d, J= 8.3 Hz, 1H), 5.36 (dd, J= 36.5, 12.8 Hz, 2H), 4.75 - 4.67 (m, 1H), 4.16 (s, 3H), 3.88 - 3.80 (m, 1H), 3.55 - 3.46 (m, 1H), 3.00 (q, J= 7.5 Hz, 2H), 1.84 - 1.67 (m, 2H), 1.65 - 1.58 (m, 2H), 1.54 - 1.45 (m, 2H), 1.34 (t, J= 7.5 Hz, 3H).
Intermediate 2: 3-bromo-2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridine
[0166] Intermediate 2 was synthesized according the same sequence as was used for the synthesis of intermediate 1. LC/MS (ESI) m/z: 367/369 (M+H)+. 'H NMR (400 MHz, CDCh) 6 7.73 (d, J = 8.3 Hz, 1H), 7.69 (d, J= 8.3 Hz, 1H), 5.15 (q, J= 12.7 Hz, 2H), 4.61 - 4.54 (m, 1H), 3.99 (s, 3H), 3.74 - 3.64 (m, 1H), 3.38 - 3.30 (m, 1H), 2.51 (s, 3H), 1.66 - 1.50 (m, 2H), 1.46 - 1.40 (m, 2H), 1.39 - 1.32 (m, 2H).
Intermediate 3: (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methanol
Step 1: 2-ethyl-3-iodo-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridine
[0167] To a mixture of 3-bromo-2-ethyl-6-{ l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3-triazol- 4-yl}pyridine(7.2 g, 18.9 mmol) and Nal (14.2 g, 94.4 mmol) in l,4-dioxane(80 mL) was added Ni,N2-diMethylethane-l,2-diaMine (1.55 g, 11.3 mmol) and Cui (1.80 g, 9.44 mmol) and the mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 20 hrs. The mixture was filtered and the filter cake was washed with EtOAc (2 x 50 mL). The combined filtrate was washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give crude product, which was purified by silica gel chromatography (PE: EtOAc= 4: 1 to 1 : 1) to give the title compound (6.1 g, 74.2%) as light yellow solid. LC/MS (ESI) (m/z): 429 (M+H)+. 'H NMR (400 MHz, CDCh) 6 8.11-8.09 (d, J= 8.4 Hz, 1H), 7.75-7.73 (d, J= 8.3 Hz, 1H), 5.42 - 5.29 (q, J
= 12.7 Hz, 2H), 4.72 - 4.70 (m, 1H), 4.16 (s, 3H), 3.84 - 3.82 (m, 1H), 3.56 - 3.49 (m, 1H), 3.02-
2.97 (q, J= 7.2 2H), 1.63 - 1.59 (m, 2H), 1.56 - 1.53 (m, 4H), 1.34 - 1.30 (t, J= 7.6 Hz, 3H).
Step 2: (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl) methanol (6)
[0168] To a solution of 2-ethyl-3-iodo-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridine (1.0 g, 2.34 mmol) in MeOH (10 mL) was added PPTS (0.59 g, 2.34 mmol) and the mixture was stirred at 60 °C for 16 hrs. The mixture was diluted with EtOAc, washed with saturated aq.NaHCCh solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (698 mg, 86.9% yield) as white solid. LC/MS (ESI) m/z: 345 (M+H)+.
Intermediate 4: 5-bromo-4-ethyl-2-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-pyrazol-4-yl)pyrimidine
Step 1: 5-bromo-2-chloro-4-ethylpyrimidine
[0169] To a solution of 5-bromo-2-chloropyrimidine (60 g, 0.31 mol) in THF (600 mL) was added EtMgCl (186 mL, 0.37 mol, 2M in THF) drop-wisely at 10 °C under N2 atmosphere and the resulting mixture was stirred at this temperature for 1 hr. TEA (43 mL, 0.31 mol) was added to the mixture drop-wisely at 0 °C under N2 atmosphere. After stirring at 0 °C for 20 min, a solution of iodine (79.0 g, 0.31 mol) in THF (120 mL) was added and the resulting mixture was stirred at r.t. for 16 hrs. The reaction was quenched with water and extracted with EtOAc (2 x 300 mL). The combined organic layers were washed with saturated aq.Na2SO3 solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography (EtOAc: PE= 0 to 200: 1) to give the title compound (35.3 g, 51.4% yield) as light yellow solid. ’H NMR (400 MHz, DMSO-tL) 8 8.87 (s, 1H), 2.89-2.83 (q, J= 7.5 Hz, 2H), 1.22- 1.18 (t, J= 7.5 Hz, 3H).
Step 2: 5-bromo-4-ethyl-2-iodopyrimidine
[0170] To a solution of 5-bromo-2-chloro-4-ethylpyrimidine (20 g, 0.09 mol) in DCM (50 mL) was added aq.HI (200 mL, 57% wt) drop-wisely followed by Nal (30 g, 0.2 mol) at 0 °C and the mixture was stirred at 5 °C for 16 hrs. The reaction mixture was quenched with saturated aq.Na2S2Ch solution (100 mL) and extracted with DCM (2 x 200 mL). The combined organic layers
were concentrated under reduced pressure to give a colorless residue. The resulting residue was purified by silica gel column chromatography (PE: EtOAc= 4: 1) to give the title compound (25.3 g, 89.8% yield) as light yellow solid. XH NMR (400 MHz, DMSO-PL) 6 8.64 (s, 1H), 2.82-2.75 (q, J = 7.5 Hz, 2H), 1.19-1.16 (t, J = 7.5 Hz, 3H).
Step 3: 5-bromo-4-ethyl-2-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH- pyrazol-4-yl)pyrimidine
[0171] To a solution of 5-bromo-4-ethyl-2-iodopyrimidine (17.5 g, 55.9 mmol) and l-methyl-5- (((tetrahydro-2H-pyran-2-yl)oxy)methyl)-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazole (15.8 g, 46.6 mmol, prepared as W02014081619) in 1,4-dioxane (300 mL) and water (60 mL) were added Na2CCh (9.9 g, 93.2 mmol), Pd(dppf)C12 (1.7 g, 2.3 mmol) in one portion under N2 atmosphere, the mixture was degassed under N2 for three times and stirred under N2 atmosphere at 75 °C for 16 hrs. The mixture was poured into ice-water and extracted with DCM (2 x 200 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to dryness. The resulting residue was purified by silica gel chromatography (PE: EtOAc= 10: 1) to give the title compound (12.7 g, 59.6% yield) as yellow solid. LC/MS (ESI) m/z: 381/383 (M+H)+. 'H NMR (400 MHz, DMSO-PL) 8 8.80 (s, 1H), 8.01 (s, 1H), 5.32-5.29 (d, J= 12 Hz, 1H), 5.14-5.11 (d, J= 12 Hz, 1H), 4.73-4.69 (m, 1H), 3.90 (s, 3H), 3.79-3.72 (m, 1H), 3.45-3.41 (m, 1H), 2.88-2.83 (q, J = 7.4 Hz, 2H), 1.68-1.55 (m, 2H), 1.55-1.42 (m, 4H), 1.28-1.24 (t, J = 7.5 Hz, 3H).
Intermediate 5: methyl (S)-2-(5,5-difluoropiperidin-3-yl)acetate (intermediate 5A)
Step 1: benzyl 5-(2-diazoacetyl)-3,3-difluoropiperidine-l-carboxylate
[0172] To a solution of l-((benzyloxy)carbonyl)-5,5-difluoropiperidine-3-carboxylic acid (51 g, 0.17 mol) in DCM (500 mL) was added DMF (2 mL) followed by drop-wise addition of (COC1)2 (43 g, 0.34 mol) at 0 °C and the mixture was stirred at 0 °C to r.t. for 2 hrs. The reaction was concentrated to dryness and the residue was co-evaporated with toluene for three times. The residue
was dissolved in THF (500 mL) and TMSCHN2 solution (250 mL, 0.5 mol, 2M in hexane) was added drop-wisely at 0 °C. The resulting mixture was stirred at r.t. for 16 hrs. The reaction was quenched with AcOH (60 mL) at 0 °C and the mixture was concentrated to dryness to give the title compound (55 g, 100% yield) as yellow oil, which was directly used to the next reaction without purification. LC/MS (ESI) m/z: 324 (M+H)+.
Step 2: benzyl (S)-3,3-difluoro-5-(2-methoxy-2-oxoethyl)piperidine-l-carboxylate (3A) and benzyl (R)-3,3-difluoro-5-(2-methoxy-2-oxoethyl)piperidine-l-carboxylate (3B)
[0173] To a solution of benzyl 5-(2-diazoacetyl)-3,3-difluoropiperidine-l-carboxylate (55 g, 0.17 mol) in MeOH (500 mL) was added CFsCOOAg (7.4 g, 0.03mol) and TEA (67.6 g, 0.67mol) and the mixture was stirred at 20 °C for 2 hrs. The reaction mixture was concentrated to dryness and the residue was purified by silica gel chromatography (PE: EtOAc= 3 : 1) to give the title compound (37 g, 62.9% yield) as light yellow oil. LC/MS (ESI) m/z: 328 (M+H)+. The two enantiomers were separated by chiral SFC to give benzyl (S)-3,3-difluoro-5-(2-methoxy-2-oxoethyl)piperidine-l- carboxylate (peak 2, retention time: 4.414 min) (13.8 g, 24.8% yield) and benzyl (R)-3,3-difluoro- 5-(2-methoxy-2-oxoethyl)piperidine-l-carboxylate (peak 1, retention time: 4.109 min) (16.1 g, 28.9% yield) as light yellow oil. 1H NMR (400 MHz, CDCh) 6 7.41 - 7.28 (m, 5H), 5.15 (s, 2H), 4.25 - 3.94 (m, 2H), 3.66 (d, J= 25.3 Hz, 3H), 3.30 - 3.12 (m, 1H), 2.91 - 2.67 (m, 1H), 2.42 - 2.23 (m, 4H), 1.75 - 1.60 (m, 1H). SFC condition: Column: ChiralPak IC-H, 250x4.6mm I.D., 5pm; Mobile phase: A for CO2 and B for Methanol (0.05% NH4OH); Gradient: B 5%-40%; Flow rate: 50 mL /min;
Step 3: Methyl (S)-2-(5,5-difluoropiperidin-3-yl)acetate
[0174] To a solution of benzyl (S)-3,3-difluoro-5-(2-methoxy-2-oxoethyl)piperidine-l- carboxylate (4.2 g, 12.83 mmol) in EtOAc (40 mL) was added Pd/C (300 mg, 10% wt) at 0 °C. The mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room temperature for 2 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (2.37 g, 95.6%) as off-white solid. LC/MS (ESI) (m/z): 194 (M+H)+. ’H NMR (400 MHz, CDCh) 6 3.69 (s, 3H), 3.18 - 3.06 (m, 2H), 2.85 - 2.65 (m, 1H), 2.36 - 2.20 (m, 5H), 1.62 - 1.48 (m, 1H).
Intermediate 6: Methyl (R)-2-(5,5-difluoropiperidin-3-yl)acetate
intermediate 6
[0175] The title compound was prepared from benzyl (R)-3,3-difluoro-5-(2-methoxy-2- oxoethyl)piperidine-l -carboxylate using the same procedure as methyl (S)-2-(5,5- difluoropiperi din-3 -yl)acetate. LC/MS (ESI) (m/z): 194 (M+H)+.
Intermediate 7: methyl (S)-2-(5,5-difluoro-l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate
Step 1 : 2-((3S)-5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
[0176] To a mixture of 3-bromo-2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridine (1.5 g, 4.1 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3 -yl)acetate (790 mg, 4.1 mmol) in dry 1,4-dioxane (30 mL) was added CS2CO3 (2.66 g, 8.2 mmol), RuPhos (381 mg, 0.82 mmol) and RuPhos-Pd-G3 (342 mg, 0.41 mmol) under N2 atmosphere. The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 100 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (1.6 g, 81.7% yield) as light yellow solid. LC/MS (ESI) m/z: 480 (M+H)+. TH NMR (400 MHz, CDCh) 6 7.97 (d, J= 8.3 Hz, 1H), 7.33 (d, J= 8.3 Hz, 1H), 5.38 - 5.26 (m, 2H), 4.77 (t, J= 3.2 Hz, 1H), 4.15 (s, 3H), 3.92 - 3.85 (m, 1H), 3.70 (s, 3H), 3.57 - 3.50 (m, 1H), 3.32 - 3.22 (m, 2H), 3.03 - 2.93 (m, 1H), 2.63 - 2.53 (m, 2H), 2.57 (s, 3H), 2.44 - 2.41 (m, 2H), 2.35 - 2.25 (m, 1H), 1.84 - 1.77 (m, 1H), 1.75 - 1.67 (m, 2H), 1.62 - 1.55 (m, 2H), 1.54 - 1.45 (m, 2H).
Step 2: methyl (S)-2-(5,5-difluoro-l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)- 2-methylpyridin-3-yl)piperidin-3-yl)acetate
[0177] To a solution of methyl 2-((3S)-5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((tetrahydro-2H- pyran-2-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (1.6 g, 3.3 mmol) in MeOH (20 mL) was added PPTS (1.6 g, 6.6 mmol) and the mixture was stirred at 50 °C for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in EtOAc (20 mL). The mixture was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 60% EtOAc in PE) to give the title compound (1.2 g, 90.0% yield) as light yellow solid. LC/MS (ESI) m/z: 396
(M+H)+. XH NMR (400 MHz, CDCh) 5 8.11 (d, J= 8.4 Hz, 1H), 7.44 (d, = 8.4 Hz, 1H), 4.82 (s, 2H), 4.08 (s, 3H), 3.70 (s, 3H), 3.36 - 3.21 (m, 2H), 3.06 - 2.96 (m, 1H), 2.65- 2.56 (m, 2H), 2.61 (s, 3H), 2.46 - 2.40 (m, 2H), 2.37 - 2.28 (m, 1H), 1.78 - 1 ,70(m, 1H).
Intermediate 8: methyl (S)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
intermediate 8
[0178] Intermediate 8 was synthesized according the same sequence as was used for the synthesis of intermediate 7. LC/MS (ESI) m/z: 410 (M+H)+. XH NMR (400 MHz, CDCh) 6 8.12 (d, J= 8.4 Hz, 1H), 7.48 (d, J= 8.4 Hz, 1H), 4.84 (s, 2H), 4.08 (s, 3H), 3.70 (s, 3H), 3.30 - 3.17 (m, 2H), 3.07 - 2.99 (m, 1H), 2.99 - 2.93 (m, 2H), 2.63 - 2.58 (m, 2H), 2.48 - 2.38 (m, 2H), 2.36 - 2.28 (m, 1H), 1.74 - 1.63 (m, 1H), 1.34 (t, J= 7.5 Hz, 3H).
Intermediate 9: methyl (S)-2-(l-(4-ethyl-2-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4- yl)pyrimidin-5-yl)-5,5-difluoropiperidin-3-yl)acetate
Step 1: methyl 2-((3S)-5,5-difluoro-l-(4-methyl-2-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-pyrazol-4-yl)pyrimidin-5-yl)piperidin-3-yl)acetate
[0179] To a solution of 5-bromo-4-ethyl-2-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-pyrazol-4-yl)pyrimidine (420 mg, 1.1 mmol) in toluene(5 mL) were added methyl (S)-2-(5,5- difluoropiperi din-3 -yl)acetate (212 mg, 1.1 mmol), followed by the addition of CS2CO3 (710 mg, 2.2 mmol), BINAP (135 mg, 0.20 mmol ) and Pd(OAc)2 (49 mg, 0.22 mmol ) under N2 atmosphere. The reaction was stirred under N2 atmosphere at 100 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (160 mg, 28.7% yield) as a yellow oil. LC-MS (ESI) m/z 494 (M+H)+.
Step 2: methyl (S)-2-(l-(4-ethyl-2-(5-(hydroxymethyl)-l-methyl-lH-pyrazol-4-yl)pyrimidin- 5-yl)-5,5-difluoropiperidin-3-yl)acetate
[0180] Intermediate 9 was synthesized according the same sequence as was used for the synthesis of intermediate 5. LC/MS (ESI) m/z: 410 (M+H)+.
Intermediate 10: ethyl (R)-2-(l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridin-3-yl)piperidin-3-yl)acetate
intermedaite 10
[0181] Intermediate 10 was synthesized from commercial available ethyl (R)-2-(piperi din-3 - yl)acetate according the same sequence that was used for the synthesis of intermediate 7. LC/MS (ESI) m/z: 374 (M+H)+ 1H NMR (400 MHz, CDCh) 6 8.07 (d, J= 8.4 Hz, 1H), 7.43 (d, J= 8.4 Hz, 1H), 4.81 (s, 2H), 4.14 (q, J= 7.1 Hz, 2H), 4.07 (s, 3H), 3.21 - 3.14 (m, 1H), 3.09- 3.02 (m, 1H), 2.72- 2.67 (m, 1H), 2.57 (s, 3H), 2.48 - 2.39 (m, 1H), 2.35 - 2.26 (m, 3H), 1.93 - 1.86 (m, 1H), 1.84 - 1.68 (m, 2H), 1.26 (t, J = 7.1 Hz, 3H), 1.23 - 1.15 (m, 1H).
Intermediate 11: ethyl (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)piperidin-3-yl)acetate
intermedaite 11
[0182] Intermediate 11 was synthesized from commercial available ethyl (R)-2-(piperi din-3 - yl)acetate according the same sequence that was used for the synthesis of intermediate 7. LC/MS (ESI) m/z: 388 (M+H)+. ’H NMR (400 MHz, CDCh) 6 8.09 (d, J= 8.4 Hz, 1H), 7.47 (d, J= 8.4 Hz, 1H), 4.83 (s, 2H), 4.14 (q, = 7.5 Hz, 2H), 4.08 (d, = 6.8 Hz, 3H), 3.12 (d, J= 10.8 Hz, 1H), 3.05- 2.98 (m, 1H), 2.92 (q, J= 7.5 Hz, 2H), 2.73-2.67 (m, 1H), 2.50 - 2.40 (m, 1H), 2.35 - 2.25 (m, 3H), 1.95 - 1.85 (m, 1H), 1.84 - 1.80 (m, 1H), 1.79 - 1.71 (m, 1H), 1.33 (t, J = 7.5 Hz, 3H), 1.26 (t, J= 7.5, 0.7 Hz, 3H), 1.23 - 1.13 (m, 1H).
Intermediate 12: Methyl 5,5-difluoro-l-((6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)-2-methylpyridin-3-yl)methyl)piperidine-3-carboxylate
Step 1: Methyl 2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3- triazol-4-yl)nicotinate
[0183] To a solution of 3-bromo-2-methyl-6-{ l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3- triazol -4-yl (pyridine (5.0 g, 13.6 mmol) in MeOH (50 mL) was added TEA (9.5 mL, 68.1 mmol) followed by Pd(dppf)C12 (1.0 g, 1.4 mmol). The mixture was degassed under N2 atmosphere for three times and stirred under 60 psi of CO gas at 70 °C for 16 hrs. The mixture was filtered through Celite pad and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (3.8 g, 80.6% yield) as yellow solid. LC-MS (ESI) m/z 347 (M+H)+. ’H NMR (400 MHz, CDCh) 6 8.28 (d, J= 8.2 Hz, 1H), 8.10 (d, J= 8.2 Hz, 1H), 5.39 (dd, J = 292, 12.7 Hz, 2H), 4.77 - 4.75 (m, 1H), 4.17 (s, 3H), 3.93 (s, 3H), 3.90 - 3.83 (m, 1H), 3.55 - 3.50 (m, 1H), 2.86 (s, 3H), 1.84 - 1.66 (m, 2H), 1.65 - 1.57 (m, 2H), 1.55 - 1.48 (m, 2H).
Step 2: (2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3-triazol- 4-yl)pyridin-3-yl)methanol
[0184] To a solution of Methyl 2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)nicotinate (1.50 g, 4.33 mmol) in THF (20 mL) was added LiBHi (5.20 mL, 10.40 mmol, 2M in THF) drop-wisely at 0 °C. After addition, the mixture was stirred at 55 °C for 3 hrs. The mixture was poured into saturated aq.NH-tCl solution and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (1.3 g, 94.3% yield) as light yellow solid. LC/MS (ESI) (m/z): 319 (M+H)+. ’H NMR (400 MHz, CDCh) 6 8.00
(d, = 7.9 Hz, 1H), 7.74 (d, = 8.0 Hz, 1H), 5.34 (dd, J= 33.4, 12.6 Hz, 2H), 4.80 - 4.75 (m, 1H), 4.74 (s, 2H), 4.16 (s, 3H), 3.92 - 3.84 (m, 1H), 3.55 - 3.48 (m, 1H), 2.57 (s, 3H), 1.82 - 1.71 (m, 2H), 1.58 - 1.48 (m, 4H).
Step 3: 3-(chloromethyl)-2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridine
[0185] To a solution of (2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methanol (1.3 g, 4.1 mmol) in DCM (30 mL) were added TEA (1.7 mL, 12.25 mmol) followed by drop-wise addition of MsCl (0.70 g, 6.1 mmol) at 0 °C. The reaction was stirred at r.t. for 2 hrs. The mixture was washed with saturated aq.NaHCCh solution and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (1.7 g, 87.3% yield) as yellow solid. LC/MS (ESI) (m/z): 367 (M+H)+. 1HNMR (400 MHz, CDCh) 8 8.03 (d, J= 8.0 Hz, 1H), 7.68 (d, J= 8.0 Hz, 1H), 5.35 (dd, J= 33.2, 12.7 Hz, 2H), 4.80 - 4.73 (m, 1H), 4.62 (s, 2H), 4.16 (s, 3H), 3.93 - 3.82 (m, 1H), 3.56 - 3.42 (m, 1H), 2.66 (s, 3H), 1.81 - 1.67 (m, 2H), 1.61 - 1.49 (m, 4H).
Step 4: Methyl 5,5-difluoro-l-((2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)methyl)piperidine-3-carboxylate
[0186] To the solution of 3-(chloromethyl)-2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridine (935 mg, 2.78 mmol) in C LCN (20 mL) was added methyl 5,5-difluoropiperidine-3-carboxylate (994 mg, 3.6 mmol) followed by DIPEA (1.2 mL, 7.1 mmol) and the reaction was stirred at 80 °C for 3.5 hrs. The mixture was diluted with EtOAc (10 mL) and was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (800 mg, 60.1% yield) as yellow oil. LC/MS (ESI) (m/z): 480 (M+H)+. XH NMR (400 MHz, CDCh) 6 7.98 (d, J= 7.9 Hz, 1H), 7.62 (d, J= 7.9 Hz, 1H), 5.43 - 5.30 (m, 2H), 4.78 - 4.76 (m, 1H), 4.15 (s, 3H), 3.93 - 3.85 (m, 1H), 3.68 (s, 3H), 3.65 - 3.57 (m, 2H), 3.56 - 3.49 (m, 1H), 3.12 - 3.01 (m, 2H), 2.92 - 2.85 (m, 1H), 2.81 - 2.75 (m, 1H), 2.58 (s, 3H), 2.42 - 2.35 (m, 1H), 2.32 - 2.22 (m, 1H), 1.93 - 1.86 (m, 1H), 1.82 - 1.66 (m, 2H), 1.62 - 1.48 (m, 4H).
Step 5: Methyl 5,5-difluoro-l-((6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridin-3-yl)methyl)piperidine-3-carboxylate
[0187] To the solution of Methyl 5,5-difluoro-l-((2-methyl-6-(l-methyl-5-(((tetrahydro-2H- pyran-2-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)methyl)piperidine-3-carboxylate (800 mg, 1.67 mmol) in MeOH (15 mL) was added PPTS (0.84 g, 3.34 mmol) and the reaction was
stirred at 50 °C for 16 hrs. The mixture was concentrated to dryness and the residue was diluted with EtOAc (10 mL). The mixture was washed with saturated aq.NaHCCh solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 60% EtOAc in PE) to give the title compound (620 mg, 94.0% yield) as yellow oil. LC/MS (ESI) (m/z): 396 (M+H)+. XH NMR (400 MHz, CDCh) 6 8.14 (d, J = 8.0 Hz, 1H), 7.73 (d, J= 8.0 Hz, 1H), 4.85 (s, 2H), 4.09 (s, 3H), 3.69 (s, 3H), 3.62 (d, J= 3.2 Hz, 2H), 3.12 - 2.97 (m, 2H), 2.95 - 2.83 (m, 1H), 2.62 (s, 3H), 2.48 - 2.38 (m, 2H), 2.34 - 2.28 (m, 1H), 2.03 - 1.86 (m, 1H).
Intermediate 13: methyl l-((2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate
intermediate 13
[0188] The title compound was prepared from 3-bromo-2-ethyl-6-(l-methyl-5-(((tetrahydro-2H- pyran-2-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridine using the same sequence as the synthesis of intermediate 12. LC/MS (ESI) (m/z): 410 (M+H)+. XH NMR (400 MHz, CDCh) 6 8.13 (d, J= 8.0 Hz, 1H), 7.75 (d, J= 8.0 Hz, 1H), 4.85 (s, 2H), 4.10 (s, 3H), 3.69 (s, 3H), 3.64 (s, 2H), 3.12 - 3.00 (m, 2H), 2.94 - 2.88 (m, 2H), 2.44 - 2.37 (m, 2H), 2.33 - 2.27 m, 1H), 2.07 - 1.86 (m, 2H), 1.31 (t, J = 7.6 Hz, 3H).
Intermediate 14: 4-(cyclopropylmethyl)-3-methylpyridin-2(lH)-one
Step 1: cyclopropyl(2-fluoro-3-methylpyridin-4-yl)methanol
[0189] To a solution of 2-fluoro-4-iodo-3-methylpyridine (4 g, 16.9 mmol) in THF (40 mL) was added z-Pr-MgCl (16.9 mmol, 8.4 mL, 2 M in THF) drop-wisely at 0 °C under N2 and the mixture was stirred at r.t. for 1 hr. Cyclopropanecarbaldehyde (1.18 g, 16.9 mmol) was added and the mixture was stirred at r.t. for 2 hrs. The mixture was quenched with ice-water (20 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash
chromatography (eluted with PE: EtOAc = 100: 1 to 10: 1) to give the title compound (2.37 g, 77.6% yield) as colorless oil. LC/MS (ESI) m/z: 182 (M+H)+.
Step 2: 4-(cyclopropylmethyl)-2-fluoro-3-methylpyridine
[0190] To a solution of cyclopropyl(2-fluoro-3-methylpyridin-4-yl)methanol (810 mg, 4.47 mmol) in CEECN (8 mL) were added Nal (2.68 g, 17.9 mmol) and TFA (2.61 g, 22.4 mmol) followed by drop-wise addition of EtsSiH (2.60 g, 22.4 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at r.t. for 16 hrs. The mixture was quenched with saturated aq.NaHCCh solution and extracted with EtOAc (2 x 15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 100: 1 to 10: 1) to give the title compound (420 mg, 56.9% yield) as colorless oil. LC/MS (ESI) m/z: 166 (M+H)+.
Step 3: 4-(cyclopropylmethyl)-3-methylpyridin-2(lH)-one
[0191] To a solution of 4-(cyclopropylmethyl)-2-fluoro-3-methylpyridine (420 mg, 2.54 mmol) in 1,4-dioxane (4.2 mL) and water (4.2 mL) was added aq.HCl (0.84 mL, 36% wt) and the mixture was stirred at 100 °C for 16 hrs. The mixture was diluted with water and extracted with DCM (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (322 mg, 77.6% yield) as light yellow solid. ’H NMR (400 MHz, DMSO-tL) 8 11.13 (s, 1H), 6.95 (d, J= 6.8 Hz, 1H), 5.97 (d, J= 6.8 Hz, 1H), 2.19 (d, J= 6.8 Hz, 2H), 1.75 (s, 3H), 0.78-0.67 (m, 1H), 0.32-0.23 (m, 2H), 0.02-0.04 (m, 2H). LC/MS (ESI) m/z: 164 (M+H)+.
Intermediate 15: 4-(cyclopropylmethyl)-3-methylpyridin-2(lH)-one
Step 1: 5-allyl-2-methoxypyridine
[0192] To a solution of 5-bromo-2-methoxypyridine (4.2 g, 22.3 mmol) and 2-allyl-4, 4,5,5- tetramethyl-l,3,2-dioxaborolane (5.63 g, 33.5 mmol) in 1,4-dioxane (42 mL) and water (8.4 mL) were added K3PO4 (14.23 g, 67.0 mmol), Pd(dppf)C12 (1.63 g, 2.23 mmol) under N2 atmosphere and the mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 100 °C for 2 hrs. The mixture was diluted EtOAc (50 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash
chromatography (eluted with PE: EtOAc = 50: 1 to 10: 1) to give the title compound (3 g, 90% yield) as light yellow oil. LC/MS (ESI) m/z: 150 (M+H)+.
Step 2: 2-methoxy-5-propylpyridine
[0193] To a solution of 5-allyl-2-methoxypyridine (3 g, 20.1 mmol) in MeOH (30 mL) was added Pd(OH)2/C (0.28 g, 10% wt) under N2 atmosphere. After addition, the mixture was degassed under N2 atmosphere for three times and stirred under a Hz balloon at 25 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (2.74 g, 90.1% yield) as colorless oil, which was used in next step directly. LC/MS (ESI) m/z: 152 (M+H)+.
Step 3: 5-propylpyridin-2(lH)-one (4)
[0194] To a solution of 2-methoxy-5-propylpyridine (2.74 g, 18.12 mmol) in EtOH (27 mL) was added aq.HBr (27 mL, 40% wt) and the mixture was stirred at 85 °C for 16 hrs. The mixture was quenched with saturated aq.NaHCOs solution and extracted with DCM (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 10: 1 to 1 : 1) to give the title compound (723 mg, 29.1% yield) as white solid. ’H NMR (400 MHz, CDCh) 6 13.21 (s, 1H), 7.35 (dd, J= 92, 2.5 Hz, 1H), 7.14 (d, J= 22 Hz, 1H), 6.55 (d, J= 92 Hz, 1H), 2.35 (t, J= 7.6 Hz, 1H), 1.60-1.48 (m, 1H), 0.92 (t, J= 7.2 Hz, 2H). LC/MS (ESI) m/z: 138 (M+H)+.
Intermediate 16: 5-(cyclopropylmethyl)pyridin-2(lH)-one
Step 1: N'-[(lE)-cyclopropylmethylidene]-4-methylbenzene-l-sulfonohydrazide
[0195] To a solution of 4-methylbenzene-l -sulfonohydrazide (1 g, 5.4 mmol) in MeOH (10 mL) was added cyclopropanecarbaldehyde (0.40 mL, 5.4 mmol) drop-wisely at 0 °C and the mixture was stirred at 70 °C for 10 mins. The mixture was concentrated to dryness and the residue was purified by flash chromatography (0 ~ 40% EtOAc in PE) to give the title compound (1.1 g, 86.0% yield) as white solid. LC-MS (ESI) m/z 239 (M+H)+.
Step 2: 5-(cyclopropylmethyl)-2-methoxypyridine
[0196] To mixture of N'-[(lE)-cyclopropylmethylidene]-4-methylbenzene-l-sulfonohydrazide (1 g, 4.2 mmol) and (6-methoxypyri din-3 -yl)boronic acid (0.64 g, 4.2 mmol) in 1,4-dioxane (10 mL) was added K2CO3 (580 mg, 4.2 mmol) and the mixture was stirred at 110 °C for 16 hrs. The mixture was diluted with EtOAc (15 mL), washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 5% EtOAc in PE) to give 5- (cyclopropylmethyl)-2-methoxypyridine (210 mg, 30.7% yield) as colorless oil. LC-MS (ESI) m/z 164 (M+H)+. XHNMR (400 MHz, CDCk) 6 8.03 (d, J = 1.9 Hz, 1H), 7.48 (dd, J= 8.4, 1.9 Hz, 1H), 6.68 (d, J = 8.4 Hz, 1H), 3.92 (s, 3H), 2.46 (d, J = 6.9 Hz, 2H), 1.01 - 0.84 (m, 1H), 0.57 - 0.46 (m, 2H), 0.20 - 0.17 (m, 2H).
Step 3: 5-(cyclopropylmethyl)pyridin-2(lH)-one
[0197] To a mixture of 5-(cyclopropylmethyl)-2-methoxypyridine (200 mg, 1.2 mmol) in MeCN (5 mL) was added Nal (367 mg, 2.5 mmol) and TMSC1 (0.31 mL, 2.5 mmol) and the reaction mixture was stirred at 70 °C for 16 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and was concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give 5-(cyclopropylmethyl)pyridin- 2(lH)-one (50 mg, 27.4% yield) as colorless oil. LC-MS (ESI) m/z 150 (M+H)+.
Intermediate 17: 5-(cyclobutylmethyl)pyridin-2(lH)-one
intermediate 17
[0198] The title compound was prepared from cyclobutanecarbaldehyde using the same sequence as the synthesis of intermediate 16. LC-MS (ESI) m/z 164 (M+H)+.
Intermediate 18: 5-(cyclobutylmethyl)pyridin-2(lH)-one
[0199] The title compound was prepared from isobutyraldehyde using the same sequence as the synthesis of intermediate 16. LC-MS (ESI) m/z 152 (M+H)+.
Intermediate 19: 5-isopropylpyridin-2(lH)-one
Step 1: 2-methoxy-5-(prop-l-en-2-yl)pyridine
[0200] To a solution of 5-bromo-2-methoxypyridine (1.0 g, 5.32 mmol) and 4,4,5,5-tetramethyl- 2-(prop-l-en-2-yl)-l,3,2-dioxaborolane (1.34 g, 7.98 mmol) in 1,4-dioxane (10 ml) and water (2 mL) were added K2CO3 (1.47 g, 10.64 mmol), Pd(PPh3)4 (0.61 g, 0.53 mmol) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 100 °C for 16 hrs. The mixture was diluted with water and extracted with EtOAc (2 x 15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 200: 1 to 20: 1) to give the title compound (600 mg, 75.6% yield) as colorless oil. LC/MS (ESI) m/z: 150 (M+H)+. ’H NMR (400 MHz, CDCh) 6 8.25 (d, J = 2.4 Hz, 1H), 7.69 (dd, J= 8.6, 2.6 Hz, 1H), 6.71 (dd, J= 8.6, 0.6 Hz, 1H), 5.29 (s, 1H), 5.05-5.01 (m, 1H), 3.94 (s, 1H), 2.13 (d, J = 0.5 Hz, 1H).
Step 2: 5-isopropyl-2-methoxypyridine
[0201] To a solution of 2-methoxy-5-(prop-l-en-2-yl)pyridine (600 mg, 4.02 mmol ) in MeOH (6 mL) was added Pd(OH)2 (50 mg, 10% wt) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at 25 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (290 mg, 47.7% yield) as colorless oil, which was used in next step directly. TH NMR (400 MHz, CD3OD) 8 7.95 (d, J= 2.4 Hz, 1H), 7.59 (dd, J= 8.6, 2.5 Hz, 1H), 6.74 (d, J= 8.6 Hz, 1H), 3.87 (s, 3H), 2.93 - 2.85 (m, 1H), 1.24 (d, J= 6.9 Hz, 6H). LC/MS (ESI) m/z: 152 (M+H)+.
Step 3: 5-isopropylpyridin-2(lH)-one
[0202] To a solution of 5-isopropyl-2-methoxypyridine (150 mg, 0.99 mmol) in EtOH (1.5 mL) was added aq.HBr (1.5 mL, 40% wt) under N2 atmosphere and the mixture was stirred at 85 °C for 16 hrs. The mixture was quenched with saturated aq.NaHCCh solution and extracted with DCM (3 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (115 mg, 84.5% yield) as white solid. LC/MS (ESI) m/z: 138 (M+H)+.
Intermediate 20: 5-cyclobutylpyridin-2(lH)-one
Step 1: l-(6-methoxypyridin-3-yl)cyclobutan-l-ol
[0203] To a stirred solution of 5-bromo-2-methoxypyridine (1.38 mL, 10.6 mmol) in dry THF (25 mL) was added n-BuLi (5.5 mL, 13.8 mmol) drop-wisely at -78 °C. After stirring at this temperature for 30 mins, cyclobutanone (1.2 mL, 15.9 mmol) was added and the resulting mixture was stirred at -78 °C for 30 mins and r.t. for 30 mins. The mixture was quenched with ice-water and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness, the residue was purified by flash chromatography (PE: EtOAc= 10: 1) to give the title compound (1.5 g, 78.6% yield). LC/MS (ESI) m/z: 180 (M+H)+. 'H NMR (400 MHz, CDCh) 6 8.29 (d, J= 2.2 Hz, 1H), 7.72 (dd, J= 8.6,
2.6 Hz, 1H), 6.76 (dd, J= 8.6, 0.6 Hz, 1H), 3.94 (s, 3H), 2.62 - 2.46 (m, 2H), 2.41 - 2.32 (m, 2H), 2.08 - 1.94 (m, 2H), 1.69 - 1.59 (m, 2H).
Step 2: 5-cyclobutyl-2-methoxypyridine
[0204] To a solution of l-(6-methoxypyri din-3 -yl)cy cl obutan-l-ol (1 g, 5.5 mmol) in MeOH (3 mL) was added conc.^SCU (1 mL) followed by Pd/C (80 mg, 10% wt) at 0 °C, the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at r.t. for 1 hr. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 10: 1 to 5: 1) to give the title compound (300 mg, 32.9% yield) as light yellow oil. LC/MS (ESI) (m/z): 164 (M+H)+. ’H NMR (400 MHz, CDCh) 6 7.98 (t, J= 4.4 Hz, 1H), 7.47 (dd, J= 8.5, 2.5 Hz, 1H), 6.69 (d, J= 8.5 Hz, 1H), 3.91 (s, 3H), 3.46 (dd, J= 17.4,
8.7 Hz, 1H), 2.40 - 2.28 (m, 2H), 2.16 - 2.02 (m, 3H), 1.91 - 1.82 (m, 1H).
Step 3: 5-cyclobutylpyridin-2-ol
[0205] To a solution of 5-cyclobutyl-2-methoxypyridine (100 mg, 0.6 mmol ) in EtOH (5 mL) was added aq.HBr (2 mL, 48% wt) and the mixture stirred at 70 °C under N2 atmosphere for 16 hrs. The mixture was poured into ice-cooled saturated aq.NaHCOs solution and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness to give the title compound (70 mg, 76.5% yield). LC/MS (ESI) (m/z): 150 (M+H)+. ’H NMR (400 MHz, CDCh) 6 12.76 (s, 1H), 7.42 (dd, J= 9.3, 2.4 Hz, 1H), 7.14 (d, J = 1.8 Hz, 1H), 6.56 (d, J = 9.3 Hz, 1H), 3.34 - 3.23 (dt, J = 17.2, 8.7 Hz, 1H), 2.27 - 2.23 (m , 2H), 2.06 - 1.92 (m, 3H), 1.89 - 1.76 (m, 1H).
Intermediate 21: 5-cyclopropyl-4-methylpyridin-2(lH)-one
Step 1: 5-cyclopropyl-2-methoxy-4-methylpyridine
[0206] To a solution of 5-bromo-2-methoxy-4-methylpyridine (2 g, 9.90 mmol) and cyclopropylboronic acid (1.11 g, 12.87 mmol) in toluene (30 mL) and water (3 mL) were added K3PO4 (6.30 g, 29.67 mmol), tricyclohexyl phosphine (0.28 g, 0.99 mmol), Pd(OAc)2 (0.11 g, 0.50 mmol) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 100 °C for 16 hrs. The mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 200: 1 to 10: 1) to give the title compound (1.42 g, 88.1% yield) as yellow oil. LC/MS (ESI) m/z: 164 (M+H)+.
Step 2: 5-cyclopropyl-4-methylpyridin-2(lH)-one (3)
[0207] To a solution of 5-cyclopropyl-2-methoxy-4-methylpyridine (1 g, 6.12 mmol) in CEECN (10 mL) were added Nal (1.84 g, 12.25 mmol), TMSC1 (1.33 g, 12.25 mmol). The mixture was stirred at 70 °C overnight. The mixture was quenched with saturated aq.NaHCOs solution and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 1 : 1) to give the title compound (525 mg, 57.4% yield) as brown solid. 'H-NMR (400 MHz, DMSO-tL) 8 10.96 (s, 1H), 6.67 (s, 1H), 5.91 (s, 1H), 1.97 (d, = 0.6 Hz, 1H), 1.38-1.27 (m, 1H), 0.56-0.46 (m, 1H), 0.24-0.16 (m, 1H). LC/MS (ESI) m/z: 150 (M+H)+.
Intermediate 22: 4-cyclopropyl-5-methylpyridin-2(lH)-one
Step 1: 2-chloro-4-cyclopropyl-5-methylpyridine
[0208] To a mixture of 4-bromo-2-chloro-5-methylpyridine (700 mg, 3.39 mmol), K3PO4 (2.15 g, 10.17 mmol) and cyclopropylboronic acid (349 mg, 4.07 mmol) in 1,4-dioxane (25 mL) was added Pd(OAc)2 (38 mg, 0.17 mmol) and Tricyclohexyl phosphine (95 mg, 0.34 mmol) under N2 atmosphere and the mixture was stirred at 110 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL) and filtered. The filtrate was concentrated to dryness and the residue was purified by flash chromatography (silica gel, 0-100% EtOAc in PE) to the title compoud (420 mg, 73.9% yield) as colorless oil. LC/MS (ESI) m/z: 168(M+H)+.
Step 2: 4-cyclopropyl-5-methyl-2-[2-(trimethylsilyl)ethoxy] pyridine
[0209] To a solution of 2-chloro-4-cyclopropyl-5-methylpyridine (250 mg, 1.49 mmol) in toluene (5 mL) was added 2-(trimethylsilyl)ethan-l-ol (2.1 mL, 14.91 mmol), CS2CO3 (1.46 g, 4.47 mmol), Pd(OAc)2 (33 mg, 0.15 mmol), t-BuPhos (89 mg, 0.15 mmol), the mixture was degassed under N2 for three times and stirred at 110 °C for 16 hrs. The reaction mixture was concentrated to dryness and the residue was purified by flash chromatography (silica gel, 0-30% EtOAc in PE) to give the title compound (201 mg, 54.0% yield) as light yellow oil. LC/MS (ESI) m/z: 250(M+H)+.
Step 3: 4-cyclopropyl-5-methylpyridin-2-ol
[0210] To a solution of 4-cyclopropyl-5-methyl-2-[2-(trimethylsilyl)ethoxy]pyridine (200 mg, 0.80 mmol) in THF (3 mL) was added TBAF (418 mg, 1.60 mmol) and the mixture was stirred at 25 °C for 3 hrs. The reaction mixture was diluted with EtOAc (10 mL) and washed with saturated water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-20% MeOH in DCM) to give the title compound (56 mg, 46.8% yield) as white solid. LC/MS (ESI) m/z: 150 (M+H)+.1H NMR (400 MHz, DMSO-cT) 6 11.12 (s, 1H), 7.08 (s, 1H), 5.83 (s, 1H), 2.08 (d, J = 0.8 Hz, 3H), 1.80 - 1.72 (m, 1H), 0.97 - 0.91 (m, 2H), 0.68 - 0.62 (m, 2H).
Intermediate 23: 5-(cyclopropylethynyl)pyridin-2(lH)-one
Step 1: 5-(2-cyclopropylethynyl)-2-methoxypyridine
[0211] To a solution of 5-iodo-2-methoxypyridine (1 g, 4.26 mmol) in CH3CN (20 mL) was added TEA (1.8 mL, 12.77 mmol) followed by the addition of Bis(triphenylphosphine)palladium(II) chloride (0.17 g, 0.21 mmol) , Cui (0.16 g, 0.85 mmol) and ethynylcyclopropane (0.43 mL, 5.11 mmol) under N2 with stirring. And the mixture was stirred at r.t. for 16 hrs. The reaction mixture was filtered through a Celite pad, and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 30 % EtOAc in PE) to give the title compound (700 mg, 95.0 % yield) as white solid. LC/MS (ESI) m/z: 174 (M+H)+.
Step 2: 5-(2-cyclopropylethynyl)-l,2-dihydropyridin-2-one
[0212] To solution of 5-(2-cyclopropylethynyl)-2-methoxypyridine (500 mg, 2.89 mmol) in CH3CN (10 mL) was added Nal (865 mg, 5.78 mmol) and TMSC1 (0.74 mL, 5.773 mmol) and the reaction was stirred at 70 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL), washed
with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 5% MeOH in DCM) to give 5-(2- cyclopropylethynyl)-l,2-dihydropyridin-2-one (300 mg, 65.3 % yield) as yellow solid. LC/MS (ESI) m/z: 160 (M+H)+.
Intermediate 24: 4-(cyclopropylethynyl)pyridin-2(lH)-one
[0213] Intermediate 24 was prepared from 4-iodo-2-methoxypyridine using the same sequence that was used to synthesize intermediate 23. LC/MS (ESI) m/z: 160 (M+H)+.
Intermediate 25: 5-cyclopropoxypyridin-2(lH)-one
Intermediate 25
Step 1: 2-(benzyloxy)-5-cyclopropoxypyridine
[0214] To a mixture of 6-(benzyloxy )pyri din-3 -ol (300 mg, 1.5mmol) and bromocyclopropane (1.2 mL, 14.9 mmol) in NMP (5 mL) was added CS2CO3 (1.4 g, 4.4 mmol) and the resulting solution was stirred in an autoclave at 150 °C for 8 hrs. The mixture was cooled to r.t. and diluted with EtOAc (10 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0-50% of EtOAc in PE) to give the title compound (180 mg, 50% yield) as light yellow oil. LC/MS (ESI) m/z 242 [M+l]+.
Step 2: 5-cyclopropoxypyridin-2(lH)-one
[0215] To a solution of 2-(benzyloxy)-5-cyclopropoxypyridine (180 mg, 0.7 mmol) in MeOH (3 mL) was added Pd/C (20 mg, 10% wt) at 0 °C and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room temperature for 1 hr. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by prep.TLC (PE: EtOAc= 2: 1) to give the title compound (40 mg, 35.4% yield) as white foam-like solid. LC/MS (ESI) (m/z): 152 (M+H)+.
Intermediate 26: 5-propoxypyridin-2(lH)-one
[0216] Intermediate 26 was synthesized according the same sequence as was used for the synthesis of intermediate 25. LC/MS (ESI) (m/z): 154 (M+H)+.
Intermediate 27: 5-propoxypyridin-2(lH)-one
Intermediate 27
[0217] Intermediate 27 was synthesized according the same sequence as was used for the synthesis of intermediate 25. LC/MS (ESI) (m/z): 140 (M+H)+.
Intermediate 28: 5-(azetidin-l-yl)pyridin-2(lH)-one
iate 28
Step 1: 5-(azetidin-l-yl)-2-(benzyloxy)pyridine
[0218] To solution of 2-(benzyloxy)-5-bromopyridine (850 mg, 3.2 mmol ) in 1,4-dioxane (5 mL) was added azetidine (0.65 mL, 9.6 mmol) followed by CS2CO3 (2.1 g, 6.4 mmol), RuPhos (300 mg, 0.64 mmol) and Pd2(dba)3 (260 mg, 0.3 mmol), the mixture was degassed under N2 atmosphere for three times and stirred in CEM reactor at 100 °C for 2 hrs. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (650 mg, 84.3% yield) as yellow oil. LC-MS (ESI) m/z 241 (M+H)+.
Step 2: 5-(azetidin-l-yl)pyridin-2-ol
[0219] To solution of 5-(azetidin-l-yl)-2-(benzyloxy)pyridine (400 mg, 1.7 mmol) in MeOH (10 mL) was added Pd/C (50 mg, 10% wt). The mixture was degassed under N2 atmosphere and stirred under a H2 balloon at r.t. for 3 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (230 mg, 90% yield) as yellow solid. LC-MS (ESI) m/z 151 (M+H)+.
Intermediate 29: 5-propylpyrazin-2-ol
conc H2SO4
Intermediate 29
Step 3
Step 1: 5-allylpyrazin-2-amine
[0220] To a mixture of 5-bromopyrazin-2-amine (500 mg, 2.87 mmol) and 4,4,5,5-tetramethyl-2- (prop-2-en-l-yl)-l,3,2-dioxaborolane (0.81 mL, 4.31 mmol) in DMF (10 mL) was added CsF (1.3 g, 8.6 mmol) and Pd(dppf)C12 (430 mg, 0.57 mmol). The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 100 °C for 9 hrs. The mixture was diluted with EtOAc (10 mL) and washed with water and brine, dried and concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc = 4: 1) to give the title compound (250 mg, 64.1% yield) as yellow oil. LC/MS (ESI) (m/z): 135 (M+H)+.
Step 2: 5-propylpyrazin-2-amine
[0221] To a solution of 5-allylpyrazin-2-amine (240 mg, 1.78 mmol) in MeOH (10 mL) was added Pd/C (20 mg, 10% wt). The mixture was degassed under EE atmosphere for three times and stirred under a EE balloon at room temperature for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (200 mg, 82.1% yield) as yellow oil. LC/MS (ESI) (m/z): 138 (M+H)+.
Step 3: 5-propylpyrazin-2-ol
[0222] To a solution of NaNCh (3 g, 43.74 mmol) in con.EESCU (10 mL) was added propylpyrazin- 2-amine (1 g, 7.3 mmol) in portions at 0 °C and the mixture was stirred at 100 °C for 2 hrs. The mixture was diluted with ice water, neutralized with IM aq.NaOH solution to pH=5 and extracted with DCM (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (eluted with DCM: MeOH= 15: 1) to give the title compound (320 mg, 31.8% yield). LC/MS (ESI) (m/z): 139 [M+H]+.
Intermediate 30: 5-propylpyrimidin-2(lH)-one
[0223] To a solution of 2-chloro-5-propylpyrimidine (500 mg, 3.19 mmol) in EtOH (5 mL) was added con.HCl (5 mL) at 0 °C and the mixture was stirred under N2 atmosphere at 100 °C for 16 hrs. The mixture was diluted with ice water (10 mL), neutralized with saturated aq.NaHCOs solution to pH= 7 and extracted with DCM (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (eluted with DCM: MeOH= 15: 1) to give the title compound (200 mg, 45.3% yield) as yellow oil. LC/MS (ESI) m/z: 139 (M+H)+.
Intermediate 31: 6-propylpyrimidin-4(3H)-one
[0224] To a mixture of ethyl 3 -oxohexanoate (1.6 mL, 10 mmol) and formamidine acetate (1 g, 10 mmol) in MeOH (10 mL) was added MeONa (7.5 mL, 1.5 M in MeOH) drop-wisely at 0 °C and the mixture was stirred at 60 °C overnight. The reaction mixture was diluted with DCM (20 mL), washed with water, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0-100% of EtOAc in PE) to give the title compound (410 mg, 29.0% yield) as white solid. LC/MS (ESI) m/z: 139 (M+H)+.
Intermediate 32: 4-propylpyridazin-3(2H)-one
te 32
Step 1: 6-chloro-4-propylpyridazin-3(2H)-one
[0225] A solution of 3,6-dichloro-4-propylpyridazine (1.00 g, 5.23 mmol) in AcOH (10 mL) was stirred at 120 °C under N2 atmosphere for 5 hrs. The mixture was concentrated to dryness and the residue was neutralized with saturated aq.NaHCOs solution. The mixture was extracted with EtOAc (2 x 20 mL) and the combined organic layers were washed with brie, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc= 8: 1 to 5: 1) to give the title compound (550 mg, 60.9% yield) as yellow oil. LC/MS (ESI) m/z: 173 (M+H)+.
Step 2: 4-propylpyridazin-3(2H)-one
[0226] To a solution of 6-chloro-4-propylpyridazin-3(2H)-one (500 mg, 2.90 mmol) in EtOAc (5 mL) was added TEA (0.05 mL, 0.360 mmol) and Pd/C (60 mg, 10% wt) and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at 0 °C for 3 hrs. The reaction was filtered and the filtrate was concentrated to dryness. The residue was purified by column chromatography (PE: EtOAc = 5: 1 to 1 : 1) to give the title compound (75 mg, 18.7% yield) as off-white solid. LC/MS (ESI) m/z: 139 (M+H)+.
Intermediate 33: 6-propylpyridazin-3-ol
Step 1: 3-allyl-6-chloropyridazine
[0227] To a mixture of 2-allyl-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (705 mg, 4.2 mmol) and 3-chloro-6-iodopyridazine (1 g, 4.2 mmol) in 1,4-dioxane (10 mL) and water (2 mL) were added K2CO3 (1.74 g, 12.582 mmol) and Pd(dppf)C12 (153.44 mg, 0.210 mmol) under N2 atmosphere. Then the mixture reaction was stirred at 75 °C for 16 hrs. The mixture was diluted with water and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 5 : 1) to give the title compound (130 mg, 20.3% yield) as yellow oil. LC/MS (ESI) (m/z): 155 (M+H)+.
Step 2: 6-allylpyridazin-3-ol
[0228] A solution of 3-allyl-6-chloropyridazin (130 mg, 0.85 mmol) in AcOH (6 mL) was stirred at 120 °C for 2 hrs. The mixture reaction was concentrated to dryness and the residue was purified by chromatography on silica gel (PE: EtOAc= 3: 1) to give the title compound (70 mg, 61.3% yield) as yellow solid. LC/MS (ESI) (m/z): 137 (M+H)+.
Step 3: 6-propylpyridazin-3-ol
[0229] To a solution of 6-allylpyridazin-3-ol (70 mg, 0.459 mmol) in MeOH (3 mL) was added Pd/C (20 mg, 10% wt) at 0 °C, the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room temperature for 2 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (32 mg, 51.2% yield) as yellow solid. LC/MS (ESI) (m/z): 139 (M+H)+.
Intermediate 34: 6-(cyclopropylmethyl)pyridazin-3-ol
Intermediate 34
Step 1: dimethyl (3-cyclopropyl-2-oxopropyl)phosphonate
[0230] To a solution of dimethyl methylphosphonate (652 mg, 5.25 mmol) in THF (5 mL) was added n-BuLi (2.62 mL, 5.25 mmol, 2M in THF) drop-wisely at -70 °C and the mixture was stirred at this temperature for 15 mins. A solution of methyl 2-cyclopropylacetate (300 mg, 2.62 mmol) in THF (3 mL) was added to the above mixture at -70 °C and the resulting mixture was stirred at - 70 °C for 1 hr. The reaction mixture was quenched with saturated aq.NH4Cl solution at 0 °C and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (460 mg, 84.9% yield) as yellow solid. LC/MS (ESI) m/z: 207 (M+H)+.
Step 2: ethyl (2Z)-5-cyclopropyl-4-oxopent-2-enoate
[0231] To a solution of dimethyl (3-cyclopropyl-2-oxopropyl)phosphonate (460 mg, 2.23 mmol) in t-BuOH (5 mL) was added t-BuOK (250 mg, 2.23 mmol), ethyl 2-oxoacetate (0.22 mL, 2.23 mmol), and then the mixture was stirred at 25 °C for 16 hrs. The reaction mixture was diluted with EtOAc (10 mL) and washed with saturated aq.TMLCl solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-5% EtOAc in PE) to give the title compound (81 mg, 19.9% yield) as yellow oil. LC/MS (ESI) m/z: 183 (M+H)+. 'H NMR (400 MHz, CDCh) 6 6.55 (d, J = 12.1 Hz, 1H), 6.02 (d, J= 12.1 Hz, 1H), 4.21 (q, = 7.2 Hz, 2H), 2.52 (d, = 7.0 Hz, 2H), 1.29 (dd, = 9.4, 4.8 Hz, 3H), 1.01 (dd, J= 13.9, 6.1 Hz, 1H), 0.59 (q, J= 5.3 Hz, 2H), 0.17 (q, J= 5.0 Hz, 2H).
Step 3: 6-(cyclopropylmethyl)pyridazin-3-ol
[0232] To a solution of methyl (2Z)-5-cyclopropyl-4-oxopent-2-enoate (80 mg, 0.47 mmol) in EtOH (6 mL) and H2O (2 mL) was added hydrazine hydrate (0.1 mL), AcOH (2 mL), and the mixture was stirred at 100 °C for 16 hrs. The reaction mixture was diluted with EtOAc (5 mL) and
washed with saturated aq.NELCl solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-10% MeOH in DCM) to give the title compound (32 mg, 44.8% yield) as white solid. LC/MS (ESI) m/z: 151 (M+H)+. 'H NMR (400 MHz, DMSO-PL) 8 12.55 (s, 1H), 7.22 (d, J= 9.7 Hz, 1H), 6.63 (d, J= 9.7 Hz, 1H), 2.22 (d, J= 7.0 Hz, 2H), 0.80 - 0.70 (m, 1H), 0.27 (dt, J= 7.7, 4.9 Hz, 2H), - 0.01 (q, J = 4.9 Hz, 2H).
Intermediate 35: 5-(lH-pyrazol-l-yl)pyridin-2(lH)-one
5
Step 1: 2-(benzyloxy)-5-(lH-pyrazol-l-yl)pyridine
[0233] To a mixture of 2-(benzyloxy)-5-bromopyridine (1 g, 3.79 mmol) and IH-pyrazole (392 mg, 5.68 mmol) in DMSO (10 mL) were added Cui (145 mg, 0.76 mmol), L-Proline (87 mg, 0.757 mmol) and K2CO3 (1047 mg, 7.57 mmol) under N2 atmosphere and the mixture was stirred under N2 atmosphere at 120 °C for 16 hrs. The mixture was diluted with water and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 5: 1) to give the title compound (350 mg, 36.8% yield) as white solid. LC/MS (ESI) (m/z): 252 (M+H)+.
Step 2: 5-(lH-pyrazol-l-yl)pyridin-2-ol
[0234] To a solution of 2-(benzyloxy)-5-(lH-pyrazol-l-yl)pyridine(450 mg, 1.791 mmol) in MeOH (10 mL) was added Pd/C (45 mg, 10% wt) and the mixture was degassed udner N2 atmosphere for three times and stirred under H2 balloon at r.t. for 3 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give he title compound (290 mg, 100.5% yield) as a colorless oil. LC/MS (ESI) m/z: 162 (M+H)+.
Intermediate 36: (R)-5-(cyclopropylmethyl)-l-methylimidazolidin-2-one
Step 7 Step 8 7 8 intermediate 36
Step 1: (R)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoic acid
[0235] To a solution of (2R)-2-amino-3-cyclopropylpropanoic acid (6 g, 46.4 mmol) in THF (60 mL) and water (60 mL) were added NaHCOs (11.1 g, 139.2 mmol) and di-tert-butyl decarbonate (12.9 mL, 60.4 mmol) at 0 °C and the mixture was stirred at room temperature for 16 hrs. The reaction mixture was diluted with water and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (DCM: MeOH = 10: 1) to give the title compound (10 g, 93.9% yield) as yellow oil. ’H NMR (400 MHz, CDCh) 6 6.04 (s, 1H), 5.30 (d, J= 7.7 Hz, 1H), 4.35 (d, J= 6.0 Hz, 1H), 1.68- 1.65 (m, 2H), 1.43-1.42 (m, 9H), 0.73-0.74 (m, 1H), 0.47-0.46 (m, 2H), 0.10-0.12 (m, 2H). LC/MS (ESI) (m/z): 174 (M+H-56)+.
Step 2: (R)-tert-butyl (l-cyclopropyl-3-hydroxypropan-2-yl)carbamate
[0236] To a solution of(R)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropanoic acid (6 g, 17.4 mmol) in THF (50 mL) was added BH3-THF complex (52.3 mL, 52.3 mmol, IM in THF) drop-wisely at 0 °C and the mixture was stirred at room temperature for 16 hrs. The reaction was quenched with MeOH at 0 °C and concentrated to dryness. The residue was purified by chromatography on silica gel (DCM: MeOH = 10: 1) to give the title compound (2 g, 35.5% yield) as yellow oil. LC/MS (ESI) (m/z): 160 (M+H-56)+.
Step 3: (R)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropyl methanesulfonate
[0237] To a solution of (R)-tert-butyl (l-cyclopropyl-3-hydroxypropan-2-yl)carbamate (2.0 g, 9.3 mmol) in DCM (30 mL) were added TEA (3.9 mL, 27.9 mmol) followed by drop-wise addition of
MsCl (1.44 mL, 18.6 mmol) at 0 °C and the mixture was stirred at room temperature for 16 hrs. The mixture was diluted with water (10 mL) and extracted with DCM (2 x 15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 5: 1) to give the title compound (2.0 g, 73.4% yield) as yellow oil. LC/MS (ESI) (m/z): 238 (M+H-56)+.
Step 4: (R)-tert-butyl (l-azido-3-cyclopropylpropan-2-yl)carbamate
[0238] To a solution of (R)-2-((tert-butoxycarbonyl)amino)-3-cyclopropylpropyl methanesulfonate (1.5 g, 5.1 mmol) in DMSO (20 mL) was added NaNs (1.0 g, 15.3 mmol) and the mixture was stirred at 100 °C for 16 hrs. The reaction mixture was diluted with water (10 mL) and extracted with EtOAc (2 x 15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 5: 1) to give the title compound (525 mg, 42.7% yield) as yellow oil. ’H NMR (400 MHz, CDCh) 6 4.64 (d, J= 5.2 Hz, 1H), 3.82 (s, 1H), 3.54-3.45 (m, 2H), 1.63 (s, 1H), 1.45 (s, 10H), 0.71-0.64 (m, 1H), 0.52-0.47 (m, 2H), 0.11- 0.08 (m, 2H).
Step 5: (R)-tert-butyl (l-azido-3-cyclopropylpropan-2-yl)(methyl)carbamate
[0239] To a solution of (R)-tert-butyl (l-azido-3-cyclopropylpropan-2-yl)carbamate (525 mg, 2.19 mmol) in DMF (10 mL) was added NaH (114 mg, 2.84 mmol, 60% dispersion in mineral oil) in portions at 0 °C and the mixture was stirred at 0 °C for 1 hr. Then Mel (0.33 mL, 4.37 mmol) was added and the mixture was stirred at room temperature for 16 hrs. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE : EtOAc= 5: 1) to give the title compound (480 mg, yield 86.4%) as white solid. ’H NMR (400 MHz, CDCh) 6 4.21 (s, 1H), 3.52-3.22 (m, 2H), 2.78 (s, 3H), 1.62-1.54 (m, 1H), 1.48 (s, 9H), 1.33-1.26 (m, 1H), 0.68-0.58 (m, 1H), 0.48-0.46 (m, 2H), 0.1-0.03 (m, 2H). LC/MS (ESI) (m/z): 199 (M+H-56)+.
Step 6: (R)-tert-butyl (l-amino-3-cyclopropylpropan-2-yl)(methyl)carbamate
[0240] To a solution of (R)-tert-butyl (l-azido-3-cyclopropylpropan-2-yl)(methyl)carbamate (480 mg, 1.89 mmol) in MeOH (6 mL) was added Pd/C (80 mg, 10% wt) at 0 °C and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room temperature for 2 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (230 mg, 53.4% yield) as yellow solid. LC/MS (ESI) (m/z): 229 (M+H)+.
Sytep 7: (R)-3-cyclopropyl-N2-methylpropane-l,2-diamine
[0241] To a solution of (R)-tert-butyl (l-amino-3-cyclopropylpropan-2-yl)(methyl)carbamate (230 mg, 1.0 mmol) in DCM (4 mL) was added TFA (4 mL) at 0 °C and the reaction mixture was stirred at room temperature for 2 hrs. The reaction mixture was concentrated under reduced pressure to dryness to give the title compound (120 mg, 92.9% yield) as yellow oil. LC/MS (ESI) (m/z): 129 (M+H)+.
Step 8: (S)-5-(cyclopropylmethyl)-l-methylimidazolidin-2-one
[0242] To a solution of (R)-3-cyclopropyl-N2-methylpropane-l,2-diamine (120 mg, 0.94 mmol) in DCM (5 mL) were added TEA (0.39 mL, 2.8 mmol) and CDI (152 mg, 0.94 mmol) and the mixture was stirred at room temperature for 16 hrs. The reaction mixture was diluted with water (5 mL) and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 1 : 2) to give the title compound (120 mg, 82.7% yield) as white solid. LC/MS (ESI) (m/z): 155 (M+H)+. 'H-NMR (400 MHz, CDCh) 6 4.57 (s, 1H), 3.64 - 3.53 (m, 2H), 3.22 - 3.18 (m, 1H), 2.75 (s, 3H), 1.65 - 1.50 (m, 2H), 0.69 - 0.59 (m, 1H), 0.52 - 0.50 (m, 2H), 0.12 - 0.07 (m, 2H).
Intermediate 37: (S)-5-(cyclopropylmethyl)-l-methylimidazolidin-2-one
intermediate 37
[0243] Intermediate 37 was prepared from (S)-2-amino-3 -cyclopropylpropanoic acid using the same synthetic sequence that was used to synthesize intermediate36. LC/MS (ESI) (m/z): 155 (M+H)+.
Intermediate 38: l-(cyclopropylmethyl)-l,3-dihydro-2H-imidazol-2-one
1 intermediate 38
[0244] To a solution of l-methyl-2,3-dihydro-lH-imidazol-2-one (1 g, 10.2 mmol) in DMF (10 mL) was added NaH (410 mg, 10.2 mmol, 60% dispersion in mineral oil) in portions at 0 °C and the mixture was stirred at this temperature for 30 min. (Bromomethyl)cyclopropane (1.2 mL, 12.2 mmol) was added to the mixture and the resulting mixture was stirred at r.t. for 16 hrs. The mixture was diluted with EtOAc (20 mL), washed with saturated aq.NTLCl solution and brine, dried over
anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 6: 1) to give the title compound (450 mg, 31.9% yield) as colorless oil. LC/MS (ESI) (m/z): 139 (M+H)+. ’H NMR (400 MHz, CDCh) 6 10.34 (s, 1H), 6.35 - 6.22 (m, 2H), 3.52 - 3.45 (m, 2H), 1.11 (s, 1H), 0.62 - 0.53 (m, 2H), 0.33 (t, J = 5.3 Hz, 2H).
Intermediate 39: l-isobutyl-l,3-dihydro-2H-imidazol-2-one
intermediate 39
[0245] Intermediate 39 was prepared from l-methyl-2,3-dihydro-lH-imidazol-2-one and 1- bromo-2-methylpropane according to the synthesis of intermediate 38. LC/MS (ESI) (m/z): 141 (M+H)+.
Intermediate 40: l-(sec-butyl)-l,3-dihydro-2H-imidazol-2-one
intermediate 40
[0246] Intermediate 40 was prepared from l-methyl-2,3-dihydro-lH-imidazol-2-one and 2- bromobutane according to the synthesis of intermediate 38. LC/MS (ESI) (m/z): 141 (M+H)+.
Intermediate 41: 4-chloro-6-(lH-pyrazol-l-yl)pyrimidine
intermediate 41
[0247] To the mixture of 4,6-dichloropyrimidine (1 g, 6.71 mmol) and IH-pyrazole (457 mg, 6.71 mmol) in DMF (20 mL) was added CS2CO3 (4.37 g, 13.4 mmol) and the mixture was stirred at r.t. for 18 hrs. The mixture was diluted with EtOAc (40 mL) and the mixture was washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was triturated with EtOAc (10 mL) and filtered. The filter cake was dried under vacuum to give the title compound (660 mg, 54.4% yield) as white solid. LC/MS (ESI) m/z: 181 (M+H)+. 'H NMR (400 MHz, CDCh) 8 8.79-8.79 (d, J = 0.8 Hz, 1H), 8.55-8.57 (dd, J = 2.7, 0.5 Hz, 1H), 7.97-7.98 (d, J = 1.0 Hz, 1H), 7.81 (d, J = 1.0 Hz, 1H), 6.53-6.54 (dd, J = 2.7, 1.6 Hz, 1H).
Intermediate 42 : 2-chloro-4-cyclobutylpyrimidine
[0248] To a mixture of 2-chloropyrimidine (3 g, 26.2 mmol) and cyclobutanecarboxylic acid (2.3 mL, 23.6 mmol) in DCM (15 mL) and water (15 mL) was added AgNOs (890 mg, 5.2 mmol), followed by in portions addition of (NH4)2S20s (6.0 g, 26.2 mmol) at room temperature and the mixture was stirred at 25 °C for 16 hrs. The mixture was diluted with DCM (50 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 5: 1 to 1 : 1) to give the title compound (2.2 g, 49.8% yield) as colorless oil. LC/MS (ESI) m/z: 169 (M+H)+. ’H-NMR (400 MHz, CDCh) 6 8.49 (d, J= 5.2 Hz, 1H), 7.11 (d, J= 5.2 Hz, 1H), 3.70-3.53 (m, 1H), 2.41-2.30 (m, 4H), 2.15-2.03 (m, 1H), 1.99-1.92(m, 1H).
Intermediate 43: 2-chloro-4-isopropylpyrimidine
intermediate 43
[0249] Intermediate 43 was prepared from 2-chloropyrimidine and isobutyric acid using the same synthetic method as intermediate 42. LC/MS (ESI) m/z: 157 (M+H)+ 1HNMR (400 MHz, CD3OD) 6 8.52 (d, J= 5.1 Hz, 1H), 7.17 (d, J= 5.1 Hz, 1H), 3.06 - 2.99 (m, 1H), 1.32 (d, J= 7.0 Hz, 6H).
Intermediate 44: 2-chloro-4-cyclopropylpyrimidine
intermediate 44
[0250] Intermediate 44 was prepared from 2-chloropyrimidine and cyclopropanecarboxylic acid using the same synthetic method as intermediate 42. LC/MS (ESI) m/z: 155 (M+H)+.
Intermediate 45: 4-chloro-6-cyclobutylpyrimidine
Step 1: 6-propyl-3,4-dihydropyrimidin-4-one
[0251] To a solution of methyl 3-cyclobutyl-3-oxopropanoate (2 g, 12.81 mmol) and formamidine acetate salt (1.33 g, 19.98 mmol) in MeOH (30 mL) was added 5N MeONa/MeOH solution (7.7 mL, 38.5 mmol) drop-wisely at 0 °C. After the addition, the mixture was stirred at 70 °C for 4 hrs. After cooling to 0 °C, the reaction was filtered and was treated with DCM (100 mL) and water (100 mL), the organic layer was separated and the aqueous layer was extracted with DCM (50 mL). The combined organic was concentrated to dryness and the residue was purified by flash chromatography (0-80% of EtOAc in PE) to give the title compound (400 mg, 29.0% yield) as white solid. LC/MS (ESI) m/z: 151 (M+H)+.
Step 2: 4-chloro-6-cyclobutylpyrimidine
[0252] A stirred solution of 6-cyclobutyl-3,4-dihydropyrimidin-4-one (100 mg, 0.666 mmol ) in POCh (2 mL) was stirred at 120 °C for 2 hrs. The solution was concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0-10% of EtOAc in PE) to give the title compound (70 mg, 62.3% yield) as light yellow oil. LC/MS (ESI) m/z: 169 (M+H)+. XH NMR (400 MHz, CDCh) 6 8.91 (s, 1H), 7.20 (s, 1H), 3.63 - 3.59 (m, 1H), 2.40-2.30 (m, 4H), 2.12-2.07 (m, 1H), 1.96-1.93 (m, 1H).
Intermediate 46: 3-chloro-5-cyclopropyl-l,2,4-oxadiazole
intermediate 46
Step 1: N-cyanocyclopropanecarboxamide
[0253] To a solution of sodium hydrogen cyanamide (1.25 g, 19.51 mmol) in THF (10 mL) was added cyclopropanecarbonyl chloride (1.02 g, 9.76 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at 25 °C for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in H2O (10 mL). The mixture was washed with EtOAc (2 x 3 mL), acidified with IN aq.HCl to pH~2 and extracted with DCM (3 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (564 mg, 52.5% yield) as colorless oil, which was used in next step directly.
Step 2: 5-cyclopropyl-l,2,4-oxadiazol-3-amine
[0254] To a mixture of N-cyanocyclopropanecarboxamide (525 mg, 4.77 mmol) and hydroxylamine hydrochloride (497.0 mg, 7.15 mmol) in EtOH (6 mL) was added pyridine (1.51 g, 19.07 mmol) under N2 atmosphere and the mixture was stirred at 25 °C for 16 hrs. The mixture was diluted with water (10 mL) and extracted with DCM (3 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness give the title compound (429 mg, 71.9% yield) as white solid, which was used in next step directly. LC/MS (ESI) m/z: 126 (M+H)+ 1H NMR (400 MHz, CDCh) 6 4.28 (s, 1H), 2.05 (tt, J= 7.0, 6.0 Hz, 1H), 1.19-1.12 (m, 2H).
Step 3: 3-chloro-5-cyclopropyl-l,2,4-oxadiazole
[0255] To a solution of 5-cyclopropyl-l,2,4-oxadiazol-3-amine (200 mg, 1.60 mmol) in aq.HCl (2 mL, 36% wt) was added dropwise a solution of NaNCh (276 mg, 4.00 mmol) in water (2 mL) and the mixture was stirred at 0 °C for 2 hrs. The mixture was diluted with water and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 200: 1 to 20: 1) to give the title compound (78 mg, 33.8% yield) as yellow oil. XH NMR (400 MHz, CDCh) 6 2.24-2.15 (m, 1H), 1.34-1.25 (m, 5H).
Intermediate 47 : 3-chloro-5-(cyclopropylmethyl)-l,2,4-oxadiazole
intermediate 47
[0256] The title compound was prepared from 2-cyclopropylacetyl chloride using the same procedure as intermediate 46. LC/MS (ESI) m/z: 159 (M+H)+.
Intermediate 48: 3-chloro-5-cyclobutyl-l,2,4-oxadiazole
[0257] The title compound was prepared from cyclobutanecarbonyl chloride using the same procedure as intermediate 46. LC/MS (ESI) m/z: 159 (M+H)+.
Intermediate 49: 5-bromo-l-propyl-lH-l,2,4-triazole
intermediate 49
[0258] To a mixture of 3-bromo-4H-l,2,4-triazole (1 g, 6.76 mmol), 1-iodopropane (1.0 mL, 10.13 mmol) and TBAF (10 mg, cat.) in toluene (10 mL) was added a solution of KOH (750 mg, 13.5 mmol) in water (2 mL) and the mixture was stirred at 60 °C for 16 hrs. The mixture was diluted with water (10 mL) and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (eluted with PE: EtOAc= 6: 1) to give the title compound (400 mg, 31.3% yield) as yellow oil. LC/MS (ESI) m/z: 190/192 (M+H)+.1H-NMR (400 MHz, CDCh) 6 7.89 (s, 1H), 4.14 (t, J= 2.4 Hz, 2H),1.91 (m, 2H),0.95 (t, J= 2.4 Hz, 2H).
Intermediate 50: 5-bromo-l-(cyclopropylmethyl)-lH-l,2,4-triazole
intermediate 50
[0259] The title compound was prepare from 3-bromo-4H-l,2,4-triazole and (bromomethyl)cyclopropane using the same procedure as intermediate 49. LC/MS (ESI) m/z: 202/204 (M+H)+.
Intermediate 51: 5-bromo-l-isobutyl-lH-l,2,4-triazole
intermediate 51
[0260] The title compound was prepare from 3-bromo-4H-l,2,4-triazole and l-iodo-2- methylpropane using the same procedure as intermediate 49. LC/MS (ESI) m/z: 204/206 (M+H)+. 'H-NMR (400 MHz, CDCh) 6 7.89 (s, 1H), 3.97 (d, J= 7.2 Hz, 2H), 2.35-2.86 (m, 1H), 0.95 (d, J= 6.8 Hz, 6H).
Example 1 : (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((3-methyl-2-oxo-5-propylpyridin- l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate
[0261] To a solution of methyl (S)-2-(5,5-difluoro-l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-methylpyridin-3 -yl)piperi din-3 -yl)acetate (40 mg, 0.1 mmol) in DCM (1 mL) was added TEA (20 mg, 0.2 mmol) followed by MsCl (17 mg, 0.15 mmol) at 0 °C and the miture was stirred at this temperature for 2 hrs. The mixture was diuted with DCM (2 mL), washed with saturated aq.NaHCCh solution and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (43 mg, 91% yield) as light yellow solid, which was directly used in the next reaction without purification. LC/MS (ESI) (m/z): 474 (M+H)+.
Step 2: methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((3-methyl-2-oxo-5- propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate
[0262] To a mixture of methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5- (((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (43 mg, 0.091 mmol) and 3-methyl-5-propyl-l,2-dihydropyridin-2-one (16.5 mg, 0.11 mmol) in toluene (3 mL) and water (1 mL) were added K2CO3 (25 mg, 0.182 mmol) and TBAF (3 mg, cat. ammount) and the reaction mixture was stirred at 100 °C for 16 hrs. The reaction mixture was diluted with water (3 mL) and extracted with EtOAc (2 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (35 mg, 72.9% yield) as light yellow solid. LC/MS (ESI) (m/z): 529 (M+H)+.
Step 3: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((3-methyl-2-oxo-5-propylpyridin- l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
[0263] To a solution of methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((3-methyl-2-oxo- 5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate
(35 mg, 0.066 mmol) in THF (1 mL) and methanol (2 mL) was added a solution of LiOH (15.8 mg, 0.66 mmol) in water (1 mL) at 0 °C. After stirring at room temperature for 2 hrs, the reaction mixture was concentrated to dryness and the residue was dissolved in water (3 mL). The mixture was washed with MTBE twice and the aqueous layer was acidified with IN aq.HCl to pH~2 and extracted with EtOAc (2 x 2 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 10-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (22 mg, 64.6% yield) as white solid. LC/MS (ESI) (m/z): 515 (M+H)+. ’H NMR (400 MHz, DMSO-tL) 8 7.82 (d, = 8.3 Hz, 1H), 7.62 (d, J= 1.7 Hz, 1H), 7.55 (d, J= 8.4 Hz, 1H), 7.17-7.16 (m, 1H), 5.56 (s, 2H), 4.23 (s, 3H), 3.20-3.04 (m, 4H), 2.60-2.55 (m, 4H), 2.39-2.27 (m, 4H), 2.15 (t, J= 7.4 Hz, 2H), 1.95 (s, 3H), 1.84-1.68 (m, 1H), 1.35-1.26 (m, 2H), 0.71 (t, J= 7.3 Hz, 3H).
Example 2: (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-3-methyl-2-oxopyridin-l(2H)-yl)methyl)- l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: 3-bromo-6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridine
[0264] To a solution of (4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methanol (500 mg, 1.76 mmol) in DCM (10 mL) was added PBrs (717 mg, 2.65 mmol) drop- wisely at 0 °C and the mixture was stirred at 0 °C to r.t. for 3 hrs. The mixture was diluted with
DCM (10 mL), washed with ice-cooled saturated aq.NaHCCh solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give crude product, which was purified by flash chromatography (silica gel, 0-30% EtOAc in PE) to give the title compound (510 mg, 83.7% yield) as white solid. LC/MS (ESI) m/z: 347 (M+H)+.
Step 2: l-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-4- (cyclopropylmethyl)-3-methylpyridin-2(lH)-one
[0265] To a mixture of 3-bromo-6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridine (200 mg, 0.58 mmol) and 4-(cy cl opropylmethyl)-3 -methyl- 1,2-dihydropyri din-2- one (136 mg, 0.83 mmol) in toluene (5 mL) and H2O (1 mL) was added K2CO3 (230 mg, 1.66 mmol) and TBAF (lOmg, cat.) and the mixture was stirred at 100 °C for 3 hrs. The reaction mixture was diluted with EtOAc (5 mL), washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-56% EtOAc in PE) to give the title compound (220 mg, 88.9% yield) as white solid. LC/MS (ESI) m/z: 428/430 (M+H)+.
Step 3: methyl (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-3-methyl-2-oxopyridin-l(2H)- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetate
[0266] To a mixture of l-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl)-4-(cyclopropylmethyl)-3-methylpyridin-2(lH)-one (78 mg, 0.18 mmol), methyl 2- [(3S)-5,5-difluoropiperidin-3-yl]acetate (35 mg, 0.18 mmol), CS2CO3 (177 mg, 0.54 mmol) and Ru-phos (17 mg, 0.036 mmol) in 1,4-dioxane (2 mL) was added Ru-phos-Pd-G3 (30 mg, 0.036 mmol). Then the mixture was degassed under N2 atmosphere for three times and stirred at 110 °C under N2 atmosphere for 16 hrs. The reaction mixture was poured into ice-water and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-50% EtOAc in PE) to give the title compound (35 mg, 35.5% yield) as yellow solid. LC/MS (ESI) m/z: 541 (M+H)+.
Step 4: (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-3-methyl-2-oxopyridin-l(2H)-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0267] To a solution of methyl (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-3-methyl-2-oxopyridin- l(2H)-yl)methyl)-l -methyl- 1H- 1,2, 3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetate (35 mg, 0.065 mmol) in MeOH (1 mL), H2O (1 mL), THF (4 mL) was added LiOH (50 mg, 2.1 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was acidified with IN aq.HCl to pH~3 and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue
was purified by prep.HPLC (C18, 10-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (15 mg, 43.8% yield) as white solid. LC/MS (ESI) m/z: 527 (M+H)+. 'H N R (400 MHz, CD3OD) 8 7.83 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 7.1 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 6.30 (d, J = 7.2 Hz, 1H), 5.73 (s, 2H), 4.21 (s, 3H), 3.28 - 3.23 (m, 2H), 3.15 - 3.00 (m, 1H), 2.62 - 2.56 (m, 1H), 2.59 (s, 3H), 2.54 - 2.48 (m, 1H), 2.43 - 2.39 (m, 4H), 2.36 - 2.26 (m, 1H), 2.04 (s, 3H), 1.81 - 1.64 (m, 1H), 0.90 - 0.87 (m, 1H), 0.52 - 0.46 (m, 2H), 0.18 - 0.14 (m, 2H).
The examples in the following table were prepared by the indicated method using analogous reactants.
Example 43: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((4-oxo-3-propylpyridin-l(4H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: 4-(benzyloxy)-3-bromopyridine
[0268] To a solution of 3-bromopyridin-4-ol (0.13 mL, 1.16 mmol) in DMF (2 mL) was added NaH (92 mg, 2.30 mmol, 60% dispersion in mineral oil) in portions at 0 °C under N2 atmosphere and the reaction was stirred at 0 °C for 20 min. BnBr (0.21 mL, 1.76 mmol) was added to the above mixture and the resulting mixture was stirred at 25 °C for 16 hrs. The reaction was quenched with water (20 mL) at 0 °C and the mixture was extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with water and brine, dried over Na2SO4, filtered and concentrated to
dryness. The residue was purified by column chromatography (PE: EtOAc= 50: 1 to 20: 1) to give the title compound (300 mg, 98.6% yield) as light yellow solid. LC/MS (ESI) m/z: 264 (M+H)+.
Step 2: 3-allyl-4-(benzyloxy) pyridine
[0269] To a mixture of 4-(benzyloxy)-3 -bromopyridine (300 mg, 1.14 mmol), Tibutyl(vinyl)tin (0.53 mL, 1.71 mmol) and LiCl (121 mg, 2.85 mmol) was added Pd(PPh3)4 (132 mg, 0.114 mmol) under N2 atmosphere. After addition, the mixture was degassed under N2 atmosphere at 100 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL), washed with saturated aq.KF solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography (DCM: MeOH = 50: 1 to 20: 1) to give the title compound 3 (205 mg, 80.2% yield) as yellow oil. LC/MS (ESI) m/z: 226 (M+H)+.
Step 3: 3-propylpyridin-4-ol
[0270] To a solution of 3-allyl-4-(benzyloxy)pyridine (150 mg, 0.67 mmol) in MeOH (3 mL) was added Pd(OH)2/C (20 mg, 10% wt) at 25 °C under N2 atmosphere and the mixture was degassed under N2 atmosphere for three times, stirred under a H2 balloon at 25 °C for 5 hrs. The mixture was filtered and the filter cake was washed with MeOH (2 x 5 mL). The filtrate was concentrated to dryness and the residue was purified by column chromatography (DCM: MeOH = 20: 1 to 10: 1) to give compound 4 (50 mg, 54.7% yield) as colorless oil. LC/MS (ESI) m/z: 138 (M+H)+.
Step 4: methyl (R)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((4-oxo-3-propylpyridin- l(4H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate
[0271] To a mixture of 3-propylpyridin-4-ol (15.7 mg, 0.114 mmol) and methyl (S)-2-(5,5- difluoro-l-(2-methyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4- yl)pyri din-3 -yl)piperi din-3 -yl)acetate (36 mg, 0.076 mmol) in toluene (2 mL) and H2O (1 mL) was added K2CO3 (31.5 mg, 0.23 mmol) followed by TBAF (2 mg, 0.008 mmol) and the reaction mixture was heated to 80 °C for 16 hrs. The mixture was diluted with EtOAc (3 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (50 mg, 100% yield) as yellow solid, which was used in next reaction directly. LC/MS (ESI) m/z: 515 (M+H)+.
Step 5: (R)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((4-oxo-3-propylpyridin-l(4H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
[0272] To a solution of methyl (R)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((4-oxo-3- propylpyridin-l(4H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (50 mg, 0.097 mmol) in THF (2 mL), MeOH (0.50 mL) and water (0.5 mL) was added LiOH.ftO (42 mg, 1.00 mmol) at 25 °C and the mixture was stirred at 25 °C for 16 hrs. The reaction was concentrated
to dryness and the residue was diluted with water (5 mL). The mixture was basified with IN aq.NaOH to pH~14 and washed with EtOAc (2 x 2mL). The aqueous layer was acidified with IN aq.HCl to pH~3 and extracted with DCM (2 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (5.2 mg, 10.7%) as white solid. LC/MS (ESI) m/z: 501 (M+H)+. ’H NMR (400 MHz, DMSO) 8 7.90 (d, J = 8.3 Hz, 1H), 7.84 - 7.75 (m, 2H),
7.59 (d, J= 8.4 Hz, 1H), 6.03 (d, J= 13 Hz, 1H), 5.69 (s, 2H), 4.10 (s, 3H), 3.21 - 3.07 (m, 3H),
2.59 - 2.56 (m, 1H), 2.52 (s, 3H), 2.40 - 2.25 (m, 4H), 2.22 - 2.15 (m, 2H), 2.03 - 1.95 (m, 1H), 1.80 - 1.73 (m, 1H), 1.40 - 1.31 (m, 2H), 0.78 (t, J = 7.4 Hz, 3H).
Example 44: 2-[5,5-difluoro-l-(2-methyl-6-{l-methyl-5-[2-(6-oxo-5-propyl-l,6- dihydropyridazin-l-yl)ethyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)piperidin-3-yl]acetic acid
Step 1: 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]acetonitrile
[0273] To a solution of 3-bromo-6-[5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl]-2- methylpyridine (1.1 g, 3.18 mmol) in CH3CN (10 mL) was added NaCN (260 mg, 5.31 mmol) in DMSO (10 mL) and the reaction mixture was stirred at r.t. for 30 min, then was partitioned between EtOAc and water. The aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic extracts were concentrated washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0% to 100% EtOAc in PE) to give the title compound (680 mg, 73.2 % yield) as white solid. XH NMR (400 MHz, CDCh) 6 7.92 (q, J= 8.4 Hz, 2H), 4.64 (s, 2H), 4.19 (s, 3H), 2.69 (s, 3H), 1.66 (s, 2H).
Step 2: 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]acetic acid
[0274] To a solution of 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]acetonitrile (630 mg, 2.16 mmol) in ethanol (10 mL) and H2O (10 mL) was added KOH (483 mg, 8.63 mmol) and the resulting mixture was refluxed for 16 hrs. The ethanol was removed under reduced pressure, and then the solution was cooled to below 10° C and acidified with concentrated aq.HCl to pH~l. The mixture was extracted with EtOAc (2 x 10 mL) and the combined organic extracts were concentrated washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (680 mg , 101.4 % yield) as white solid. LC/MS (ESI) m/z: 312/314 (M+H) +.
Step 3: 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]ethan-l-ol
[0275] To a mixture of 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]acetic acid (450 mg, 1.45 mmol) in THF was added BH3.THF complex (4.3 mL, 1 M in THF) drop-wisely at 0 °C and the mixture was stirred at r.t. for 6 hrs. The reaction mixture was quenched by drop-wise addition of MeOH (5 mL) at 0 °C and the resulting mixture was concentrated to dryness to give the title compound (250 mg, 58.2 % yield) as white solid. LC/MS (ESI) m/z: 298/300 (M+H)+.
Step 4: 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]ethyl methanesulfonate
[0276] To a stirred solution of 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]ethan-l-ol (250 mg, 0.84 mmol) in DCM (10 mL) was added MsCl (0.1 mL, 1.26 mmol) and TEA (0.35 mL, 2.52 mmol) at 0 °C under N2 atmosphere. After stirring at r.t. for 3 hrs, the reaction mixture was quenched with H2O (10 mL), extracted with DCM (2x 10 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc= 9: 1 to 4: 1) to give the title compound (270 mg, 85.5 % yield) as yellow solid. LC/MS (ESI) m/z: 376/378 (M+H)+.
Step 5: 2-{2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]ethyl}-4- propyl-2,3-dihydropyridazin-3-one
[0277] To a solution of 2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]ethyl methanesulfonate (120 mg, 0.32 mmol) and 4-propyl-2,3-dihydropyridazin-3-one (66 mg, 0.48 mmol) in toluene (2 mL) was added K2CO3 (132 mg, 0.96 mmol) in H2O (2 mL) followed by TBAF (8 mg, 0.03 mmol) and the mixture was stirred at 100 °C for 16 hrs. The reaction mixture diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~25 % EtOAc
in PE) to give the title compound (40 mg, 30.0 % yield) as brown solid. LC/MS (ESI) m/z: 418/420 (M+H)+.
Step 6: methyl 2-[(3R)-5,5-difluoro-l-(2-methyl-6-{l-methyl-5-[2-(6-oxo-5-propyl-l,6- dihydropyridazin-l-yl)ethyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)piperidin-3-yl]acetate
[0278] To mixture of 2-{2-[4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]ethyl}-4-propyl-2,3-dihydropyridazin-3-one (40 mg, 0.10 mmol) and methyl 2-[(3R)-5,5- difluoropiperidin-3-yl]acetate (22 mg, 0.12 mmol) in toluene (2 mL) were added CS2CO3 (62 mg, 0.19 mmol) followed by the addition of BINAP (6 mg, 0.01 mmol ) and Pd(OAc)2 (2 mg, 0.01 mmol) under N2 atmosphere. The reaction was degassed under N2 atmosphere for three times and stirred at 110 °C in a CEM microwave reactor for 2 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 55% EtOAc in PE) to give the title compound (10 mg, 19.7 % yield) as yellow solid. LC/MS (ESI) m/z: 531 (M+H)+.
Step 7: 2-[5,5-difluoro-l-(2-methyl-6-{l-methyl-5-[2-(6-oxo-5-propyl-l,6-dihydropyridazin-
1-yl)ethyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)piperidin-3-yl]acetic acid
[0279] To a solution of methyl 2-[5,5-difluoro-l-(2-methyl-6-{ l-methyl-5-[2-(6-oxo-5-propyl- l,6-dihydropyridazin-l-yl)ethyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)piperidin-3-yl]acetate (10 mg, 0.02 mmol) in THF (5 mL) and MeOH (1 mL) was added a solution of LiOH (8 mg, 0.2 mmol) in H2O (1 mL). The mixture was stirred at r.t. for 2 hrs. The mixture was acidified with IN aq.HCl to pH~3 and extracted with DCM (2 x 2 mL). The combined organic layers were washd with brine and concentrated to dryness. The residue was purified by prep.HPLC (Cl 8, 0 ~ 90 % acetonitrile in H2O with 0.1% formic acid) to give 2-[5,5-difhioro-l-(2-methyl-6-{ l-methyl-5-[2-(6-oxo-5- propyl- 1 ,6-dihydropyridazin- 1 -yl)ethyl]- 1H- 1 ,2,3 -tri azol -4-yl Jpyri din-3 -yl)piperi din-3 -yl]acetic acid (2.2 mg, 22.6 % yield) as white solid. LC/MS (ESI) m/z: 517 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.65 (d, J= 8.3 Hz, 1H), 7.57 (d, J= 4.2 Hz, 1H), 7.44 (d, J= 8.3 Hz, 1H), 6.99 (d, J= 4.2 Hz, 1H), 4.61 (s, 3H), 4.50 (t, J= 13 Hz, 2H), 4.06 (s, 3H), 3.78 (t, J = 6.6 Hz, 2H), 3.14 - 2.99 (m, 1H), 2.56 (s, 3H), 2.54 - 2.47 (m, 1H), 2.42 - 2.35 (m, 4H), 2.34 - 2.25 (m, 1H), 1.83 - 1.64 (m, 1H), 1.57 - 1.45 (m, 2H), 0.92 (t, J= 1A Hz, 3H).
Example 45 and 46: 2-((3R,5R) or (3S,5S)-l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin- l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetic acid and
2-((3S,5S) or (3R,5R)-l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetic acid
Step 1: Cis-methyl 5-hydroxypiperidine-3-carboxylate
[0280] To a solution of cis-l-benzyl 3-methyl 5-hydroxypiperidine-l,3-dicarboxylate (8 g, 27.3 mmol) in EtOAc (100 mL) was added Pd/C (1 g, 10% wt) and the mixture was degassed under N2 atmosphere for three times, stirred under a H2 balloon at room temperature for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (4.3 g, 99% yield) as colorless oil. LC/MS (ESI) m/z: 160 (M+l)+.
Step 2: Cis-methyl l-benzyl-5-hydroxypiperidine-3-carboxylate
[0281] To a mixture of cis-methyl 5-hydroxypiperidine-3-carboxylate (4.3 g, 27.0 mmol) and K2CO3 (7.5 g, 54.1 mmol) in DMF (50 mL) was added BnBr (7.4 g, 40.5 mmol) and the mixture was stirred at r.t. for 2 hrs. The mixture was diluted with EtOAc (100 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0- 100%, EtOAc in PE) to give the title compound (3.85 g, 57.2% yield) as yellow oil. LC/MS (ESI) m/z: 250 (M+l)+.
Step 3: Trans-methyl l-benzyl-5-fluoropiperidine-3-carboxylate
[0282] To a mixture of cis-methyl l-benzyl-5-hydroxypiperidine-3-carboxylate (3.85 g, 15.4 mmol) in DCM (50 mL) was added DAST (4.1 mL, 30.9 mmol) drop-wisely at -78 °C and the mixture was stirred at -78 °C to r.t. for 16 hrs. The mixture was quenched with saturated
aq.NaHCCh solution at 0 °C and extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0- 100%, EtOAc in PE) to give the title compound (3.2 g, 82.5% yield) as yellow oil. LC/MS (ESI) m/z: 252 (M+l)+.
Step 4: Trans-methyl 5-fluoropiperidine-3-carboxylate
[0283] To a mixture of trans-methyl l-benzyl-5-fluoropiperidine-3-carboxylate (3.2 g, 12.7 mmol) in MeOH (50 mL) was added Pd(OH)2 (400 mg, 10% wt) and AcOH (3 drops) and the mixture was degassed under N2 for three times and stirred under a H2 balloon at r.t. for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (2.5 g, 100% yield) as colorless oil. LC/MS (ESI) m/z: 162 (M+l)+.
Step 5: Trans-l-benzyl 3-methyl 5-fluoropiperidine-l,3-dicarboxylate
[0284] To a mixture of trans-methyl 5-fluoropiperidine-3-carboxylate (2.5 g, 15.5 mmol) in THF (30 mL) and saturated aq.NaHCCh solution (15 mL) was added CbzCl (5.27 g, 31.0 mmol) drop- wisely at 0 °C and the mixture was stirred at r.t. for 16 hrs. The mixture was extracted with EtOAc (2 x 20 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0-50%, EtOAc in PE) to give the title compound (3.7 g, 80.8% yield) as yellow oil. LC/MS (ESI) m/z: 296 (M+l)+.
Step 6: Trans-l-((benzyloxy)carbonyl)-5-fluoropiperidine-3-carboxylic acid
[0285] To a solution of trans-l-benzyl 3-methyl 5-fluoropiperidine-l,3-dicarboxylate (3.7 g, 12.5 mmol) in MeOH (40 mL), THF (20 mL) and H2O (20 mL) was added LiOHH2O (2.63 g, 62.6 mmol) and the mixture was stirred at r.t. for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (50 mL), washed with EtOAc (2 x 10 mL). The aqueous layer was acidified with IN aq.HCl to pH~4 and extracted with DCM (3 x 30mL). The combined organic layers were washed brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (3.1 g, 88% yield) as white solid. LC/MS (ESI) m/z: 282 (M+l)+.
Step 7: Trans-benzyl 3-(chlorocarbonyl)-5-fluoropiperidine-l-carboxylate
[0286] To a solution of l-[(benzyloxy)carbonyl]-5-fluoropiperidine-3-carboxylic acid (3.1 g, 11.0 mmol) and DMF (0.085 mL, 1.10 mmol) in DCM (31 mL) was added Oxalyl chloride (2.80 g, 22.0 mmol) drop-wisely at 0 °C and the mixture was stirred at r.t. for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in THF (40 mL). A solution of TMSCHN2 (16.5 mL, 2M in toluene) was added to the above mixture and the mixture was stirred at r.t. for 16 hrs. The reaction mixture was quenched with AcOH (6 mL) and concentrated to dryness to give a yellow residue. The residue was dissolved in MeOH (50 mL) and FsCCOOAg (0.48 g, 2.16 mmol)
and TEA (6 mL) were added. The reaction mixture was sonicated with ultrasound at room temperature for 1 hr. The mixture was concentrated to dryness and the residue was purified by flash chromatography (silica gel (40g), 0-100%, EtOAc in PE) to give the title compound (2.0 g, 60% yield) as yellow oil. LC/MS (ESI) m/z: 310 (M+l)+.
Step 8: Trans-methyl 2-(5-fluoropiperidin-3-yl)acetate
[0287] To a mixture of trans-benzyl 3-fluoro-5-(2-methoxy-2-oxoethyl)piperidine-l-carboxylate (2 g, 6.46 mmol) in EtOAc (50 mL) was added Pd/C (200 mg, 10% wt), the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at r.t. for 2 hrs. The reaction mixture was filtered and the filtrate was concentrated to dryness to give the title compound (1.1 g, yield 97%) as off-white solid. LC/MS (ESI) m/z: 176 (M+l)+.
Step 9: Trans-methyl 2-(l-(2-ethyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetate
[0288] To a mixture of 3-bromo-2-ethyl-6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3-triazol- 4-yl}pyridine(600 mg, 1.57 mmol ), trans-methyl 2-(5-fluoropiperidin-3-yl)acetate (276 mg, 1.58 mmol ), Ru-phos (147 mg, 0.315 mmol) and CS2CO3 (1.0 mg, 3.14 mmol) in 1,4-dioxane (15 mL) was added Pd2(dba)3 (216 mg, 0.236 mmol) under N2 atmosphere, the mixture was degassed under N2 for three times and stirred at 120 °C for 3 hrs. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0- 40% EtOAc in PE) to give the title compound (430 mg, 57.5% yield) as yellow solid. LC/MS (ESI) m/z: 476 (M+l)+.
Step 10: Methyl 2-((3S,5S) or (3R,5R)-l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetate (14-P1) & methyl 2-((3R,5R) or (3S,5S)-l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetate (14-P2)
[0289] To a mixture of methyl 2-[l-(2-ethyl-6-{ l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3- triazol-4-yl}pyridin-3-yl)-5-fluoropiperidin-3-yl]acetate (430 mg, 0.904 mmol) in MeOH (10 mL) was added PPTS (454 mg, 1.81 mmol). After stirred at 50 °C for 16 hrs, the mixture was poured into saturated aq.NFLCl solution and extracted with EtOAc (3 x 10 mL). The combined organic phase was washed brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cis, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the racemic product, which was purified by chiral SFC to give compoiund 14-P1 (peak 1, retention time: 5.48 min) (64 mg, yield 18%) and 14-P2 (peak 2, retention time: 5.83 min) (92 mg, yield 26%) as white solid. LC/MS (ESI) m/z: 392.5 (M+l)+. SFC condition: Column: ChiralPak OJ, 250x21.2 mm I.D., 5 pm; Mobile phase: A for CO2 and B for Methanol (0.1% NH4OH); Gradient: B 40%; Flow rate: 50 mL /min; Column temperature: 35 °C.
Step 11: methyl 2-((3S,5S) or (3R,5R)-l-(2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy) methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetate
[0290] To a mixture of compound 14-P1 (64 mg, 0.16 mmol) and TEA (0.07 mL, 0.510 mmol) in DCM (3 mL) was added MsCl (0.025 mL, 0.33 mmol) at 0 °C. After stirring at 0 °C for 1 hr, the reaction mixture was diluted with DCM (5 mL), washed with saturated aq.NaHCCh solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (76 mg, 99% yield) as yellow solid. LC/MS (ESI) m/z: 470 (M+l)+.
Step 12: methyl 2-((3S,5S) or (3R,5R)-l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin- l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetate
[0291] To a mixture of compound 15 (35 mg, 0.075 mmol) and K2CO3 (21 mg, 0.151 mmol) in toluene (2 mL) and H2O (0.4 mL) was added 5-propyl-l,2-dihydropyridin-2-one (12 mg, 0.089 mmol). After stirring at 100 °C for 2 hrs, the reaction mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to give the title compound (38 mg, 99.8% yield) as yellow solid. LC/MS (ESI) m/z: 511 (M+l)+.
Step 13: 2-((3S,5S) or (3R,5R)-l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetic acid
[0292] To a solution of compound 16 (38 mg, 0.074 mmol) in THF (2 mL), H2O (0.5 mL) and MeOH (0.5 mL) was added LiOHELO (31 mg, 0.740 mmol). After stirring at r.t. for 16 hrs, the reaction mixture was acidified with IN aq.HCl to pH~6 and extracted with DCM (3 x 5 mL). The combined organic layers were washed brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cis, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (8.5 mg, 23% yield) as white solid. LC/MS (ESI) m/z: 497 (M+l)nHNMR (400 MHz, CD3OD) 8 7.88 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 1.7 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.38 (dd, J = 9.3, 2.4 Hz, 1H), 6.52 (d, J = 9.2 Hz, 1H), 5.87 (s, 2H), 4.82 - 4.63 (m, 1H), 4.16 (s, 3H), 3.21 - 3.12 (m, 1H), 3.02 - 2.90 (m, 2H), 2.89 - 2.79 (m, 1H), 2.54 - 2.40 (m, 3H), 2.39 - 2.27 (m, 2H), 2.21 (t, J = 7.5 Hz, 2H), 1.48 - 1.28 (m, 7H), 0.76 (t, J = 7.3 Hz, 3H).
Example 46: 2-((3R,5R) or (33,5S)-l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5-fluoropiperidin-3-yl)acetic acid
[0293] The title compound was prepared from compound 14-P2 as the same sequence for the synthesis of example 45. LC/MS (ESI) m/z: 497 (M+l)+. 'H NMR (400 MHz,CD3OD) 8 7.88 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 2.0 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.38 (dd, J = 9.3, 2.5 Hz, 1H), 6.52 (d, J = 9.2 Hz, 1H), 5.87 (s, 2H), 4.73 (d, J = 4.6 Hz, 1H), 4.16 (s, 3H), 3.33 (s, 1H), 3.20 - 3.14 (m, 1H), 3.01 - 2.90 (m, 2H), 2.88 - 2.81 (m, 1H), 2.54 - 2.40 (m, 3H), 2.39 - 2.26 (m, 2H),
2.21 (t, J = 7.6 Hz, 2H), 1.50 - 1.40 (m, 1H), 1.39 - 1.33 (m, 2H), 1.31 (t, J = 7.5 Hz, 3H), 0.76 (t, J = 7.3 Hz, 3H).
Example 47 : 2-(l-(4-fluoro-2-methyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: 6-bromo-3-fluoro-2-methylpyridine 1-oxide
[0294] To solution of 6-bromo-3-fluoro-2-methylpyridine (10 g, 52.6 mmol) in TFA (100 mL) was added H2O2 (40 mL, 353 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at 70 °C for 20 hrs. The reaction was cooled to 0 °C and quenched with saturated aq.Na2S2Ch solution. The mixture was extracted with EtOAc (3 x 100 mL) and the combined organic layers were washed with saturated aq.NaHCCh solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc = 10: 1 to 0: 1) to give the title compound (8.2 g, 75.6% yield) as yellow solid.
Step 2: 6-bromo-3-fluoro-2-methyl-4-nitropyridine 1-oxide
[0295] To a solution of 6-bromo-3-fluoro-2-methylpyridine 1-oxide (7 g, 34.0 mmol) in conc.H2SO4 (70 mL, 731 mmol) was added KNO3 (1.96 g, 19.4 mmol) in portions at 0 °C and the mixture was stirred at 120 °C for 6 hrs. The reaction mixture was poured into ice-water and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with saturated aq.NaHCOs solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The
residue was recrystallized in EtOAc to give the title compound (2.57 g, 30.1% yield) as yellow solid. LC/MS (ESI) m/z: 251 (M+H)+.
Step 3: 6-bromo-3-(3-(2-ethoxy-2-oxoethyl)piperidin-l-yl)-2-methyl-4-nitropyridine 1-oxide [0296] To a solution of 6-bromo-3-fluoro-2-methyl-4-nitropyridine 1-oxide (1.2 g, 4.78 mmol) in THF (5 mL) was added TEA (0.7 mL, 5.04 mmol) and a solution of ethyl 2-(piperi din-3 -yl)acetate (0.9 g, 5.26 mmol) in THF (5 mL) at 0 °C and the reaction was stirred at 25 °C for 24 hrs. The mixture was diluted with EtOAc (20 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc= 10: 1 to 3: 1) to give the title compound (1.55 g, 82.8% yield) as red solid. LC/MS (ESI) m/z: 402 (M+H)+.
Step 4: ethyl 2-(l-(6-bromo-2-methyl-4-nitropyridin-3-yl)piperidin-3-yl)acetate
[0297] To a solution of 6-bromo-3-(3-(2-ethoxy-2-oxoethyl)piperidin-l-yl)-2-methyl-4- nitropyridine 1-oxide (1.55 g, 4.13 mmol ) in DCM (15 mL) was added a solution of PBn (0.91 mL, 9.63 mmol) in DCM (2 mL) at 0 °C under N2 atmosphere and the mixture was stirred at 16 °C for 3 hrs. The reaction was poured into ice-cooled saturated aq.NaHCCh solution and extracted with DCM (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc = 30: 1 to 10: 1) to give the title compound (1.52 g, 93.9% yield) as red oil. LC/MS (ESI) m/z: 386 (M+H)+.
Step 5: ethyl 2-(l-(6-bromo-4-fluoro-2-methylpyridin-3-yl)piperidin-3-yl)acetate
[0298] To solution of ethyl 2-(l-(6-bromo-2-methyl-4-nitropyridin-3-yl)piperidin-3-yl)acetate (1.5 g, 3.88 mmol) in DMSO (15 mL) was added KF (1.13 g, 19.4 mmol) and the reaction mixture was stirred at 140 °C under N2 atmosphere for 3 hrs. The mixture was poured into ice-water and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc = 20: 1 to 10: 1) to give the title compound (700 mg, 50.2% yield) as yellow solid. LC/MS (ESI) m/z: 359 (M+H)+.
Step 6: ethyl 2-(l-(4-fluoro-6-(3-hydroxyprop-l-yn-l-yl)-2-methylpyridin-3-yl)piperidin-3- yl)acetate
[0299] To a mixture of ethyl 2-(l-(6-bromo-4-fluoro-2-methylpyri din-3 -yl)piperi din-3 -yl)acetate (830 mg, 2.31 mmol) and TEA (0.96 mL, 6.93 mmol) in MeCN (8 mL) were added Cui (10 mg, 0.046 mmol) and Pd(PPh3)2Ch (32.4 mg, 0.046 mmol) at 16 °C under N2 atmosphere. Then prop- 2-yn-l-ol (0.27 mL, 4.62 mmol) was added and the resulting mixture was degassed under N2
atmosphere for three times and stirred at 25 °C for 22 hrs. The mixture was diluted with EtOAc (20 mL) and filtered. The filtrate was concentrated to dryness and the residue was purified by silica gel chromatography (PE: EtOAc= 10: 1 to 1 : 1) to give the title compound (430 mg, 55.7% yield) as yellow oil. LC/MS (ESI) m/z: 335 (M+H)+.
Step 7: ethyl 2-(l-(4-fluoro-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridin-3-yl)piperidin-3-yl)acetate
[0300] To a solution of ethyl 2-(l-(4-fluoro-6-(3 -hydroxyprop- l-yn-l-yl)-2-m ethylpyri din-3 - yl)piperi din-3 -yl)acetate (430 mg, 1.29 mmol) in 1,4-dioxane (10 mL) were added TMSCH2N3 (332mg, 2.57 mmol), Cp*RuCl(PPh3)2 (51 mg, 0.064 mmol) and cuprous iodide (12.25 mg, 0.064 mmol) under N2 atmosphere. The mixture reaction was degassed under N2 atmosphere for three times and stirred at 50 °C under N2 atmosphere for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in THF (10 mL) and TBAF (336 mg, 1.29 mmol) was added. The mixture was stirred at room temperature for 1 hr. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (DCM: EtOAc= 6: 1) to give the title compound (200 mg, 39.7% yield) as yellow solid. LC/MS (ESI) (m/z): 392 (M+H)+.
Step 8: ethyl 2-(l-(4-fluoro-2-methyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate
[0301] To a solution of ethyl 2-(l-(4-fluoro-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)-2-methylpyridin-3 -yl)piperi din-3 -yl)acetate (200 mg, 0.511 mmol) in DCM (10 mL) were added TEA (0.213 mL, 1.53mmol) and MsCl (0.079 mL, 1.02 mmol) at 0 °C and the mixture was stirred at room temperature for 1 hr. The mixture was diluted with water and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the title compound (210 mg, 87.5% yield) as yellow solid. LC/MS (ESI) (m/z): 470 (M+H)+.
Step 9: ethyl 2-(l-(4-fluoro-2-methyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate
[0302] To a mixture of ethyl 2-(l-(4-fluoro-2-methyl-6-(l-methyl-5-
(((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (135 mg, 0.29 mmol) and 5-propyl-l,2-dihydropyridin-2-one (59 mg, 0.43 mmol) in toluene (4 mL) and H2O (1 mL) were added K2CO3 (80 mg, 0.57 mmol) and TBAF (7.5 mg, 0.03 mmol) under N2 atmosphere and the mixture was stirred at 70 °C for 3 hrs. The reaction mixture was diluted with water and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was
purified by silica gel chromatography (PE: EtOAc= 5: 1 to 2: 1) to give the title compound (70 mg, 47.7% yield) as yellow oil. LC/MS (ESI) (m/z): 511 (M+H)+.
Step 10: 2-(l-(4-fluoro-2-methyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
[0303] To a solution of ethyl 2-(l-(4-fluoro-2-methyl-6-(l-methyl-5-((2-oxo-5-propylpyridin- l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (50 mg, 0.098 mmol) in THF (2 mL) and MeOH (3 mL) was added a solution of Li OH (23.5 mg, 0.98 mmol) in water (1 mL) at 0 °C and the mixture was stirred at room temperature for 1 hr. The mixture was concentrated to 1/5 volume, diluted with water and washed with ethyl acetate twice. The aqueous layer was acidified with IN aq.HCl to pH~3 and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by prep-HPLC (Cl 8, 25-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (10 mg, 21.2% yield) as white solid. LC/MS (ESI) m/z: 483 (M+H)+. XH NMR (400 MHz, CD3OD) 87.83 (d, = 2.1 Hz, 1H), 7.60 (d, J= 13.0 Hz, 1H), 7.38 (dd, J = 9.2, 2.5 Hz, 1H), 6.47 (d, J= 92 Hz, 1H), 5.72 (s, 2H), 4.23 (s, 3H), 3.14 (t, J= 11.7 Hz, 2H), 3.06-3.03 (m, 2H), 2.63 (s, 3H), 2.31-2.26 (m, 4H), 1.96-1.90 (m, 1H), 1.84 (d, J= 12.9 Hz, 2H), 1.51-1.36 (m, 4H), 0.80 (t, J= 13 Hz, 3H).
Example 48: 2-(l-(2-ethyl-4-fluoro-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: 6-bromo-2-ethyl-3-fluoropyridine
[0304] To a mixture of 6-bromo-3-fluoro-2-methylpyridine (7.9 g, 41.6 mmol) and DMPU (6.5 mL, 54.1 mmol) in THF (80 mL) was added LDA (27 mL, 54.1 mmol, 2M in THF) drop-wisely at -70 °C under N2 atmosphere and the mixture was stirred at -70 °C for 1 hr. Mel (3.37 mL, 54.1 mmol) was added to the above mixture and the resulting mixture was stirred at -70 °C for 3 hrs and r.t. for 16 hrs. The reaction was quenched with saturated aq.NBLiCl solution and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (eluted with PE) to give the title compound (2 g, 21.2% yield) as colorless oil. LC/MS (ESI) m/z: 204/206 (M+H)+.
Step 2: 6-bromo-2-ethyl-3-fluoropyridine 1-oxide
[0305] To a solution of 6-bromo-2-ethyl-3-fluoropyridine (2 g, 10.5 mmol) in TFA (20 mL) was added H2O2 (8 mL, 70.6 mmol) and the mixture was stirred at 70 °C under N2 atmosphere for 16 hrs. The reaction was cooled to 0 °C and quenched with saturated aq.Na2S2Ch solution. The mixture was extracted with EtOAc (3 x 50 mL) and the combined organic layers were washed saturated aq.NaHCOs solution and brine (50 mL), dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography (PE: EtOAc = 10: l to 5: l) to give the title compound (1.5 g, 65.0% yield) as yellow solid. LC/MS (ESI) m/z: 220/222 (M+H)+.
Step 3: 6-bromo-2-ethyl-3-fluoro-4-nitropyridine 1-oxide
[0306] To a solution of 6-bromo-2-ethyl-3-fluoropyridine 1-oxide (5.0 g, 22.7 mmol) in conc.H2SO4 (50 mL) was added KNO3 (9.19 g, 90.9 mmol) in portions at 0 °C and the mixture was stirred at 120 °C for 4 hrs. The mixture was poured into ice-water and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with saturated aq.NaHCOs solution and brine (20 mL), dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc= 5: 1 to 3: 1) to give the title compound (380 mg, 6.31% yield) as yellow solid. LC/MS (ESI) m/z: 265/267 (M+H)+.
Step 4: 6-bromo-3-(3-(2-ethoxy-2-oxoethyl)piperidin-l-yl)-2-ethyl-4-nitropyridine 1-oxide
[0307] To a solution of 6-bromo-2-ethyl-3-fluoro-4-nitropyridine 1-oxide (380 mg, 1.43 mmol) and ethyl 2-(piperi din-3 -yl)acetate (318 mg, 1.86 mmol) in THF ( 5 mL) was added TEA (0.60 mL, 4.30 mmol) and the mixture was stirred at 25 °C for 4 hrs. The mixture was concentrated to dryness and the residue was purified by silica gel chromatography (PE: EtOAc = 10: 1 to 3: 1) to give the title compound (480 mg, 80.4% yield) as yellow oil. LC/MS (ESI) m/z: 416/418 (M+H)+.
Step 5: ethyl 2-(l-(6-bromo-2-ethyl-4-nitropyridin-3-yl)piperidin-3-yl)acetate
[0308] To a solution of 6-bromo-3-(3-(2-ethoxy-2-oxoethyl)piperidin-l-yl)-2-ethyl-4- nitropyridine 1 -oxide (480 mg, 1.15 mmol) in DCM (5 mL) was added a solution of PBrs (0.11 mL, 1.15 mmol) in DCM (1 mL) at 0 °C under N2 atmosphere and the mixture was stirred at r.t. for 5 hrs. The reaction mixture was poured into ice-cooled saturated aq.NaHCCh solution and extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc = 30: 1 to 20: 1) to give the title compound (435 mg, 94.3% yield) as yellow solid. LC/MS (ESI) m/z: 400/402 (M+H)+.
Step 6: ethyl 2-(l-(6-bromo-2-ethyl-4-fluoropyridin-3-yl)piperidin-3-yl)acetate
[0309] To a solution of ethyl 2-(l-(6-bromo-2-ethyl-4-nitropyridin-3-yl)piperidin-3-yl)acetate (435 mg, 1.09 mmol) in DMF (5 mL) was added TBAF (5.43 mL, 5.43 mmol, IM in THF) and the reaction was stirred at 50 °C for 1 hr. The mixture was poured into ice-water and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc = 30: 1 to 20: 1) to give the title compound (220 mg, 54.2% yield) as yellow solid. LC/MS (ESI) m/z: 373/375 (M+H)+.
Step 7: ethyl 2-(l-(2-ethyl-4-fluoro-6-(3-hydroxyprop-l-yn-l-yl)pyridin-3-yl)piperidin-3- yl)acetate
[0310] To a mixture of ethyl 2-(l-(6-bromo-2-ethyl-4-fluoropyri din-3 -yl)piperi din-3 -yl)acetate (220 mg, 0.59 mmol) and prop-2-yn-l-ol (0.10 mL, 1.77 mmol) in CEECN (5 mL) was added TEA (0.25 mL, 1.77 mmol), Pd(PPh3)2C12 (41.4 mg, 0.059 mmol) and Cui (11.2 mg, 0.059 mmol) at 0 °C under N2 atmosphere and the mixture was stirred under N2 atmosphere at 25 °C for 16 hrs. The mixture was concentrated to dryness and the residue was purified by silica gel chromatography (PE: EtOAc = 10: 1 to 2: 1) to give the title compound (167 mg, 81.3% yield) as yellow solid. LC/MS (ESI) m/z: 349 (M+H)+.
Step 8: ethyl 2-(l-(2-ethyl-4-fluoro-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)piperidin-3-yl)acetate
[0311] To a mixture of ethyl 2-(l-(2-ethyl-4-fluoro-6-(3-hydroxyprop-l-yn-l-yl)pyridin-3- yl)piperi din-3 -yl)acetate (167 mg, 0.48 mmol) and TMSCH2N3 (0.14 mL, 0.96 mmol) in 1,4- dioxane (3 mL) were added Cp*RuCl(PPh3)2 (38 mg, 0.05 mmol) and Cui (9.1 mg, 0.05 mmol) under N2 atmosphere. The reaction mixture was degassed and stirred under N2 atmosphere at 50 °C for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in THF (10 mL) followed by the addition of TBAF (1.5 mL, 3 mmol, 2M in THF). The mixture was diluted
with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (DCM: EtOAc = 100: 0 to 1 : 1) to give the title compound (100 mg, 51.4% yield) as yellow oil. LC/MS (ESI) m/z: 406 (M+H)+.
Step 9: ethyl 2-(l-(2-ethyl-4-fluoro-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate
[0312] To a solution of ethyl 2-(l-(2-ethyl-4-fluoro-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol -4-yl)pyri din-3 -yl)piperi din-3 -yl)acetate (40 mg, 0.099 mmol) in DCM (2 mL) was added TEA (0.10 mL, 0.719 mmol) and MsCl (0.05 mL, 0.646 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at r.t. for 30 min. The mixture was diluted with DCM (5 mL) and washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (50 mg, 100% yield), which was directly used to next step directly. LC/MS (ESI) m/z: 484 (M+H)+.
Step 10: 2-(l-(2-ethyl-4-fluoro-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-
1.2.3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
[0313] The title compound was prepared as the procedure described for the synthesis of Example 47. LC/MS (ESI) m/z: 497 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.69 - 7.62 (m, 2H), 7.48 - 7.30 (m, 1H), 6.53 - 6.49 (d, J = 9.2 Hz, 1H), 5.84 (s, 2H), 4.16 (s, 3H), 3.21 - 3.13 (m, 2H), 3.06 - 2.98 (m, 4H), 2.31 - 2.28 (d, J = 7.0 Hz, 2H), 2.21 - 2.26 (m, 2H), 1.98 - 1.88 (m, 1H), 1.80-1.86 (m, 2H)„ 1.51 - 1.36 (m, 4H), 1.32 - 1.26 (m, 3H), 0.80 - 0.75 (m, 3H).
Example 49: (S)-2-(l-(2-cyano-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-
1.2.3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: 3,6-dibromopicolinoyl chloride
[0314] A solution of 3,6-dibromopicolinic acid (1 g, 3.56 mmol) in SOCh (10 mL) was stirred at 85 °C for 3 hrs. The reaction mixture was concentrated to dryness to give the title compound (1.0 g, 95.0% yield) as yellow oil, which was directly used in the next step.
Step 2: 3,6-dibromopicolinamide
[0315] To a solution of 3,6-dibromopyridine-2-carbonyl chloride (1 g, 3.34 mmol) in DCM (10 mL) was added drop-wisely NH4OH (10 mL) at 0 °C and the mixture was stirred at 0 °C for 1 hr. The mixture was poured into ice water and extracted with DCM (2 x 10 mL). The combined organic layers were washed with brine, dried with anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (900 mg, 90% yield). XHNMR (400 MHz, CDCh) d 7.88 (d, J= 8.4Hz, 1H), 7.45 (d, J= 8.4Hz, 1H), 5.59 (s, 2H). LC/MS (ESI) m/z: 281 (M+H)+.
Step 3: 3,6-dibromopicolinonitrile
[0316] To a solution of 3,6-dibromopicolinamide (900 mg, 3.21 mmol) in DCM (10 mL) was added pyridine (1.3 mL, 16 mmol), followed by TFAA (1.25 mL, 9 mmol) at 0 °C and the mixture was stirred at this temperature for 1 hr. The mixture was poured into ice water and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried with anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (eluted with PE: EtOAc = 30: 1 to 5: 1) to give the title compound (650 mg, 77.2% yield) as white solid. ’H NMR (400 MHz, CDCh) 6 7.85 (d, J= 8.4 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H).
Step 3: 3-bromo-6-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-l-yn-l-yl)picolinonitrile
[0317] To a mixture of 3,6-dibromopicolinonitrile (2.3 g, 8.7 mmol ) and 2-(prop-2-yn-l- yloxy)oxane (1.5 g, 10.54 mmol) in MeCN (20 mL) was added TEA (3.7 mL, 26.34 mmol), Cui (84 mg, 0.44 mmol) and Pd(PPh3)2Ch (310 mg, 0.44 mmol ). The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at room temperature for 16 hrs. The mixture was diluted with ice water and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 2: 1) to give the title compound (2.2 g, 54.4% yield) as yellow solid. ’H NMR (400 MHz, CDCh) 6 7.97 (d, J= 8.4 Hz, 1H), 7.48 (d, J = 8.4 Hz, 1H), 4.86 (t, J= 3.2 Hz, 1H), 4.50 (q, J = 16.4 Hz, 2H), 3.93-3.81 (m, 1H), 3.62-3.51 (m, 1H), 1.91-1.72 (m, 2H), 1.75- 1.60 (m, 3H). LC (ESI) m/z: 238 (M+H-84)+.
Step 4: 3-bromo-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3-triazol-4- yl)picolinonitrile
[0318] To a solution of 3-bromo-6-(3-((tetrahydro-2H-pyran-2-yl)oxy)prop-l-yn-l- yl)picolinonitrile (2.2 g, 6.85 mmol) in 1,4-dioxane (5 mL) were added
(azidomethyl)trimethylsilane (1.1 g, 8.22 mmol), Cui (65 mg, 0.34 mmol), Cp*RuCl(PPh3)2 (270 mg, 0.34 mmol). The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 50 °C for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in THF (10 mL). TBAF (1.8 g, 13.7 mmol) was added to the above mixture and the resulting mixture was stirred at 0 °C for 10 min. The mixture was diluted with EtOAc (5 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give crude product, which was purified by flash chromatography (PE: EtOAc = 4: 1) to give the title compound (1.6 g, 51.8% yield) as white solid. LC/MS (ESI) (m/z): 294 (M+H-84)+.
Step 6: methyl 2-((3S)-l-(2-cyano-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0319] To a mixture of 3-bromo-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH- l,2,3-triazol-4-yl)picolinonitrile (80 mg, 0.21 mmol) and methyl (S)-2-(5,5-difluoropiperidin-3- yl)acetate (40.9 mg, 0.21 mmol) in 1,4-dioxane (7.5 mL) were added CS2CO3 (137.8 mg, 0.42 mmol) , Ru-Phos Pd G3 (35 mg, 0.04 mmol), Ru-phos (20 mg, 0.04 mmol) under N2 atmosphere. The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 110 °C overnight. The mixture was diluted with EtOAc (5 mL) and washed with water, brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 2: 1) to give the title compound (70 mg, 67.5% yield) as yellow solid. LC/MS (ESI) m/z: 491 (M+H)+.
Step 7: methyl (S)-2-(l-(2-cyano-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0320] To a solution of methyl 2-((3S)-l-(2-cyano-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (70 mg, 0.14 mmol) in MeOH (5 mL) was added PPTS (72 mg, 0.28 mmol) and the mixture was stirred at 50 °C for 16 hrs. The mixture was concentrated to dryness and the residue was purified by chromatography on silica gel (eluted with PE: EtOAc= 1 : 1) to give the title compound (55 mg, 94.8% yield) as yellow solid. LC/MS (ESI) m/z: 407 (M+H)+.
Step 8: methyl (S)-2-(l-(2-cyano-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0321] To a solution of methyl (S)-2-(l-(2-cyano-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (60 mg, 0.15 mmol ) in DCM (2 mL) was added TEA (0.06 mL, 0.44 mmol), followed by MsCl (25 mg, 0.22 mmol ) at 0 °C and the reaction mixture was stirred at 0 °C for 1 hr. The mixture was diluted with ice water and extracted with DCM (2 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous
Na2SO4, filtered and concentrated to dryness give the title compound (65 mg, 90.8% yield) as yellow solid. LC/MS (ESI) m/z: 485 (M+H)+.
Step 9: methyl (S)-2-(l-(2-cyano-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0322] To a mixture of methyl (S)-2-(l-(2-cyano-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (70 mg, 0.14 mmol) and 5- propylpyridin-2(lH)-one (20 mg, 0.14 mmol) in toluene (5 mL) and water (1 mL) was added K2CO3 (40 mg, 0.29 mmol) and TBAF (3.4 mg, cat.) and the mixture was stirred at 110 °C for 1.5 hrs. The reaction mixture was diluted with EtOAc (5 mL) and washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (65 mg, 88.4% yield) as yellow solid. LC/MS (ESI) m/z: 526 (M+H)+.
Step 10: (S)-2-(l-(2-cyano-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-
1.2.3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid (12)
[0323] To a solution of methyl (S)-2-(l-(2-cyano-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (35 mg, 0.067 mmol) in MeOH (1 mL), water (1 mL) and THF (4 mL) was added LiOH (28 mg, 0.67 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was acidified with IM aq.HCl and extracted with EtOAc (3 x 3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (20 mg, 58.7% yield) as white solid. TH NMR (400 MHz, CD3OD) 6 8.21 (d, J = 9.2 Hz, 1H), 7.91 (d, J= 2.0 Hz, 1H), 7.80 (d, J= 9.2 Hz, 1H), 7.39 (dd, J= 9.2, 2.0 Hz, 1H), 6.41 (d, = 9.2 Hz, 1H), 5.55 (s, 2H), 4.31 (s, 3H), 3.98-3.74 (m, 2H), 3.57-3.32 (m, 4H), 3.03-2.91 (m, 1H), 2.59-2.32 (m, 6H), 1.90-1.74 (m, 6H), 1.55-1.45 (m, 1H), 0.88 (t, J= 7.2, 3H). LC/MS (ESI) m/z: 512 (M+H)+.
Example 50: (R)-2-(l-(2-cyano-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-
1.2.3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
[0324] The title compound was prepared as the procedure described for the synthesis of example 49. LC/MS (ESI) m/z: 476 (M+H)+. ’H NMR (400 MHz, CD3OD) 5 8.17 - 8.14 (d, J = 8.9 Hz, 1H), 7.91 (s, 1H), 7.71 - 7.68 (d, J = 9.0 Hz, 1H), 7.41 - 7.37 (m, 1H), 6.42 - 6.39 (d, J = 9.2 Hz, 1H), 5.54 (s, 2H), 4.30 (s, 3H), 3.77 - 3.65 (m, 2H), 3.02 - 2.96 (m, 1H), 2.81 - 2.74 (m, 1H), 2.46 - 2.39 (m, 3H), 2.27 - 2.24 (m, 2H), 1.99 - 1.81 (m, 3H), 1.59 - 1.46 (m, 3H), 0.89 - 0.85 (m, 3H).
Example 51: (S)-2-(l-(2-cyano-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- 1 ,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
[0325] The title compound was prepared as the procedure described for the synthesis of example 49. LC/MS (ESI) m/z: 476 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 8.21 (d, J= 92 Hz, 1H), 7.91 (d, J= 2.0 Hz, 1H), 7.80 (d, J= 92 Hz, 1H), 7.39 (dd, J= 9.2, 2.0 Hz, 1H), 6.41 (d, J = 92 Hz, 1H), 5.55 (s, 2H), 4.31 (s, 3H), 3.98 - 3.74 (m, 2H), 3.57 - 3.32 (m, 4H), 3.03 - 2.91 (m, 1H), 2.59 - 2.32 (m, 6H), 1.90 - 1.74 (m, 6H), 1.55 - 1.45 (m, 1H), 0.88 (t, J= 12, 3H).
Example 52 and 53: (R) or (S)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetic aci and (S) or (R)-2- (l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetic acid
Step 1: (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methanesulfonate
[0326] To a solution of (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methanol (1 g, 2.91 mmol) in DCM (10 mL) were added TEA (590 mg, 5.8 mmol) followed by drop-wise addition of MsCl (0.40 g, 3.49 mmol) at 0 °C, and the mixture was stirred at 0 °C for 2 hrs. The mixture was quenched with saturated aq.NaHCCh solution and extracted with DCM (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (1.27 g, 103.5% yield) as yellow oil, which was used in next step directly. LC/MS (ESI) m/z: 423 (M+H)+.
Step 2: l-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-5- propylpyridin-2(lH)-one
[0327] To a mixture of (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methanesulfonate (1.27 g, 3.01 mmol) and 5-propylpyridin-2(lH)-one (0.54 g, 3.91 mmol) in toluene (15 mL) and water (3 mL) were added K2CO3 (1.25 g, 9.02 mmol), TBAF (80 mg, 0.30 mmol) and the mixture was stirred at 100 °C for 16 hrs. The mixture was diluted EtOAc (20 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 20: 1 to 1 : 1) to give the title compound (1.06 g, 76.1% yield) as yellow solid. LC/MS (ESI) m/z: 464 (M+H)+.
Step 3: ethyl (R)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetate and ethyl (S)-2-(l-(2-ethyl-6-(l- methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-2- oxopiperidin-3-yl)acetate
[0328] To a mixture of l-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl)-5-propylpyridin-2(lH)-one (120 mg, 0.26 mmol) and ethyl 2-(2-oxopiperi din-3 - yl)acetate (48 mg, 0.26 mmol) in 1,4-di oxane (3 mL) was added CS2CO3 (253 mg, 0.78 mmol), Ni,N2-dimethylethane-l,2-diamine (2.3 mg, 0.026 mmol), Cui (9.9 mg, 0.052 mmol) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 110 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chiral SFC to give arbitrarily assigned: ethyl (R)-2-(l-(2-ethyl-6-(l- methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-2- oxopiperi din-3 -yl)acetate (Peak 1, retention time: 6.782 min) (37 mg, yield 27.4%) and ethyl (S)- 2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4- yl)pyri din-3 -yl)-2-oxopiperi din-3 -yl)acetate (Peak 2, retention time: 7.367 min) (37 mg, yield 27.4%) as white solid. LC/MS (ESI) m/z: 521 (M+H)+. SFC Instrument: Waters Thar 80 preparative SFC, Column: ChiralPak IA, 250x21.2mm I.D., 5pm, Mobile phase: A for CO2 and B
for MEOH+0.1%NH3H2O, Gradient: B 35%, Flow rate: 50mL /min, Column temperature: 35 °C, Wavelength: 220nm.
Step 4: (R) or (S)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetic acid
[0329] To a solution of ethyl (R)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetate (37 mg, 0.071 mmol) in THF (2 mL), MeOH (0.5 mL) and water (0.5 mL) was added lithium hydroxide monohydrate (30 mg, 0.71 mmol) and the reaction mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water. The mixture was washed with EtOAc (2 x 3 mL) and the aqueous layer was acidified with IN aq.HCl to pH = 3 and extracted with EtOAc (3 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (14.7 mg, 42.0% yield) as white solid. LC/MS (ESI) m/z: 493 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 8.03 (dd, J = 8.2, 1.9 Hz, 1H), 7.76-7.65 (m, 1H), 7.41 (dd, J= 9.3, 2.5 Hz, 1H), 6.55 (d, = 9.2 Hz, 1H), 5.91 (s, 1H), 4.14 (s, 1H), 3.82-3.46 (m, 1H), 2.88-2.68 (m, 2H), 2.27-2.22 (m, 1H), 2.15-1.96 (m, 1H), 1.47-1.36 (m, 1H), 1.31-1.25 (m, 1H), 0.79 (t, J = 7.2 Hz, 1H).
Example 53: (S) or (R)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-2-oxopiperidin-3-yl)acetic acid
[0330] The title compound was prepared according to the procedure described for the synthesis of example 53. LC/MS (ESI) m/z: 493 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 8.03 (dd, J= 8.3, 1.8 Hz, 1H), 7.77 - 7.64 (m, 2H), 7.41 (dd, J= 9.2, 2.5 Hz, 1H), 6.55 (d, J= 92 Hz, 1H), 5.91 (s, 2H), 4.14 (s, 3H), 3.81 - 3.46 (m, 2H), 2.89-2.70 (m, 5H), 2.25 (t, J = 7.6 Hz, 2H), 2.16-1.93 (m, 4H), 1.47 - 1.37 (m, 2H), 1.31 - 1.25 (m, 3H), 0.79 (t, J = 12 Hz, 3H).
Example 54 and 55: (R) or (S)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-6-oxopiperidin-3-yl)acetic acid and (S) or (R)- 2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-6-oxopiperidin-3-yl)acetic acid
Step 1: tert-butyl 3-(2-ethoxy-2-oxoethyl)piperidine-l-carboxylate
[0331] To a mixture of ethyl 2-(piperi din-3 -yl)acetate (1 g, 5.8 mmol) in DCM (25 mL) and di- tert-butyl dicarbonate (1.9 mL, 8.8 mmol) was added TEA (1.6 mL, 11.7 mmol) at 0 °C and the mixture was stirred at r.t. for 16 hrs. The mixture was concentrated to dryness and the residue was purified by flash chromatography (0 ~ 20% EtOAc in PE) to give the title compound (1.3 g, 82.3% yield) as yellow oil. LC-MS (ESI) m/z 272 (M+H)+.
Step 2: tert-butyl 5-(2-ethoxy-2-oxoethyl)-2-oxopiperidine-l-carboxylate
[0332] To solution of tert-butyl 3 -(2-ethoxy-2-oxoethyl)piperidine-l -carboxylate (1.3 g, 4.8 mmol) in EtOAc (10 mL) was added a solution of NaIO4 (5.1 g, 24.0 mmol) in H2O (10 mL) followed by Ruthenium(IV) oxide hydrate (70 mg, 0.45 mmol) at 0 °C and the reaction mixture was stirred at r.t. for 2 hrs. The reaction mixture was filtered through a celite pad and the filter cake was washed with EtOAc (2 x 5 mL). The filtrate was washed with saturated aq.Na2SO3 solution and brine, dried over anhydrous Na2SO4, filtered and was concentrated to dryness. The residue was purified by flash chromatography (0 ~ 30% EtOAc in PE) to give the title compound (1.1 g, 80.1% yield) as yellow oil. LC-MS (ESI) m/z 286 (M+H)+.
Step 3: ethyl 2-(6-oxopiperidin-3-yl)acetate
[0333] To a solution of tert-butyl 5-(2-ethoxy-2-oxoethyl)-2-oxopiperidine-l -carboxylate (1.1 g, 3.9 mmol) in 1,4-dioxane (5 mL) was added HCl/l,4-di oxane (4.8 mL, 4M) at 0 °C and the reaction mixture was stirred at r.t. for 1 hr. The mixture was concentrated to dryness and the residue was basified with saturated aq.NaHCOs solution. The mixture was extracted with EtOAc (2 x 10 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (640 mg, 89.6% yield) as yellow syrup. LC-MS (ESI) m/z 186 (M+H)+.
Step 4: ethyl (R)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-
1.2.3-triazol-4-yl)pyridin-3-yl)-6-oxopiperidin-3-yl)acetate and ethyl (S)-2-(l-(2-ethyl-6-(l- methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-6- oxopiperidin-3-yl)acetate
[0334] To a solution of l-{[4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methyl}-5-propyl-l,2-dihydropyridin-2-one (250 mg, 0.5 mmol) in 1,4-dioxane (10 mL) were added ethyl 2-(6-oxopiperidin-3-yl)acetate (150 mg, 0.8 mmol) followed by the addition of CS2CO3 (527 mg, 1.6 mmol), Cui (21 mg, 0.11 mmol) and Ni,N2-dimethylethane-l,2-diamine (15 mg, 0.11 mmol) and the reaction mixture was stirred at 120 °C forl6 hrs. The mixture was filtered through a Celite pad and the filter cake was washed with EtOAc (10 mL). The filtrate was washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) and further separated by chiral SFC to give arbitrarily assigned: ethyl 2-[(3R)-l-(2-ethyl-6-{ l-methyl-5-[(2-oxo-5-propyl- l,2-dihydropyridin-l-yl)methyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)-6-oxopiperidin-3-yl]acetate (peak 1 retention time: 4.123 min) (35 mg, 9.2% yield) and ethyl 2-[(3S)-l-(2-ethyl-6-{ l-methyl- 5-[(2-oxo-5-propyl-l,2-dihydropyridin-l-yl)methyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)-6- oxopiperi din-3 -yl]acetate (peak 2, retention time:4.669 min) (40 mg, 10.3% yield) as white solid. LC-MS (ESI) m/z 521 (M+H)+. SFC condition: Column: ChiralPak IA, 250x21.2mm I.D., 5pm; Mobile phase: A for CO2 and B for Methanol (0.1% NH4OH); Gradient: B 30%; Flow rate: 50 mL /min; Column temperature: 35 °C.
Step 5: (R) or (S)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-
1.2.3-triazol-4-yl)pyridin-3-yl)-6-oxopiperidin-3-yl)acetic acid
[0335] To solution of ethyl 2-[(3R)-l-(2-ethyl-6-{ l-methyl-5-[(2-oxo-5-propyl-l,2- dihydropyridin-l-yl)methyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl)-6-oxopiperidin-3-yl]acetate (35 mg, 0.06 mmol) in THF (4 mL) and MeOH (1 mL) was added LiOH (28 mg, 0.7 mmol) in H2O (1 mL) at 0 °C and the reaction was stirred at r.t. for 2 hrs. The mixture was concentrated to dryness and the residue was diluted with water (5 mL) and washed with EtOAc (2 x 3 mL) twice. The aqueous layer was acidified with IN aq.HCl to pH ~3 and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-HPLC (Cl 8, 0 ~ 90 % acetonitrile in H2O with 0.1 % formic acid) to give the title compound (7 mg, 21.2% yield) as white solid. LC- MS (ESI) m/z 493 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 8.06 - 8.03 (m, 1H), 7.78 - 7.71 (m, 1H), 7.66 - 7.65 (t, J= 2.6 Hz, 1H), 7.442 - 7.29 (dd, J= 9.3, 2.5 Hz, 1H), 6.55 (d, J= 9.3 Hz, 1H), 5.91 (d, J= 1.8 Hz, 2H), 4.15 (s, 3H), 3.87 - 3.41 (m, 2H), 2.81 - 2.67 (m, 3H), 2.62 - 2.49
(m, 1H), 2.45 - 2.43 (m, 2H), 2.35 - 2.32 (m, 1H), 2.26 - 2.22 (t, J= 7.5 Hz, 2H), 2.20 - 2.09 (m, 1H), 1.89 - 1.78 (m, 1H), 1.47 - 1.36 (m, 2H), 1.32 - 1.26 (q, J= 7.6 Hz, 3H), 0.80 - 0.77 (t, J= 13 Hz, 3H).
Example 55: (S) or (R)-2-(l-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-6-oxopiperidin-3-yl)acetic acid
[0336] The title compound was prepared according to the procedure described for the synthesis of Example 54. ’H NMR (400 MHz, CD3OD) 8 7.98 - 7.91 (m, 1H), 7.67 - 7.60 (m, 1H), 7.56 (t, J= 2.6 Hz, 1H), 7.34 -7.27 (m, 1H), 6.45 (d, J= 9.3 Hz, 1H), 5.81 (d, J= 1.7 Hz, 2H), 4.05 (s, 3H), 3.76 - 3.34 (m, 2H), 2.72 - 2.58 (m, 3H), 2.53 - 2.39 (m, 1H), 2.39 - 2.32 (m, 2H), 2.28 - 2.18 (m, 1H), 2.15 (t, J= 7.5 Hz, 2H), 2.06 (d, J= 13.6 Hz, 1H), 1.82 - 1.65 (m, 1H), 1.38 - 1.26 (m, 2H), 1.19 (q, J= 7.6 Hz, 3H), 0.69 (t, J= 13 Hz, 3H). LC/MS (ESI) m/z: 493 (M+H)+.
Example 56: (R)-2-(5,5-difluoro-l-(5-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)- lH-l,2,3-triazol-4-yl)pyrazin-2-yl)piperidin-3-yl)acetic acid
Step 1: 3-(5-bromopyrazin-2-yl)prop-2-yn-l-ol
[0337] To a solution of 2, 5 -dibromopyrazine (1.6 g, 6.73 mmol) and prop-2-yn-l-ol (0.38 g, 6.73 mmol) in MeCN (16 mL) were added TEA (2.0 g, 20.18 mmol), Cui (30 mg, 0.14 mmol), Pd(PPh3)2C12 (90 mg, 0.14 mmol) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 25 °C for 16 hrs. The mixture was diluted with water and extracted with EtOAc (2 x 15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (453 mg, 31.6% yield) as yellow solid. LC/MS (ESI) m/z: 213/ 215 (M+H)+.
Step 2: (4-(5-bromopyrazin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methanol
[0338] To a solution of 3-(5-bromopyrazin-2-yl)prop-2-yn-l-ol (453 mg, 2.13 mmol) and TMSCH2N3 (493.76 mg, 3.83 mmol) in 1,4-dioxane (5 mL) were added Cui (20.3 mg, 0.11
mmol), chloro(pentamethylcyclopentadienyl)bis(triphenylphosphine)ruthenium(II) (84.7 mg, 0.11 mmol) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 50 °C for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in THF (5 mL). TBAF (1 M in THF, 4.3 mL) was added and the resulting mixture was stirred at 25 °C for 1 hr. The mixture was diluted with water (10 mL) and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (205 mg, 35.7% yield) as yellow solid. LC/MS (ESI) m/z: 270/ 272 (M+H)+.
Step 3: (4-(5-bromopyrazin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methanesulfonate
[0339] To a solution of (4-(5-bromopyrazin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methanol (205 mg, 0.76 mmol) in DCM (2 mL) were added TEA (230.4 mg, 2.28 mmol) and MsCl (104.3 mg, 0.91 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at 0 °C for 2 hrs. The mixture was quenched with saturated aq.NaHCOs solution and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (295 mg, 111.6% yield) as yellow solid, which was used in next step directly. LC/MS (ESI) m/z: 348/ 350 (M+H)+.
Step 4: l-((4-(5-bromopyrazin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-5- propylpyridin-2(lH)-one
[0340] To a solution of (4-(5-bromopyrazin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methanesulfonate (295 mg, 0.85 mmol) and 5-propylpyridin-2(lH)-one (174.3 mg, 1.27 mmol ) in toluene (5 mL) and H2O (1 mL) were added K2CO3 (351 mg, 2.54 mmol), TBAF (22 mg, 0.085 mmol) at r.t. under N2 atmosphere and the mixture was stirred at 100 °C for 16 hrs. The mixture was diluted with water (10 mL) and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 20: 1 to 2: 1) to give the title compound 6 (130 mg, 39.4% yield) as yellow solid. LC/MS (ESI) m/z: 389/ 391 (M+H)+.
Step 5: methyl (S)-2-(5,5-difluoro-l-(5-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyrazin-2-yl)piperidin-3-yl)acetate
[0341] To a solution of l-((4-(5-bromopyrazin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-5- propylpyridin-2(lH)-one (30 mg, 0.077 mmol) and methyl (S)-2-(5,5-difluoropiperidin-3- yl)acetate (14.9 mg, 0.077 mmol) in 1,4-dioxane (2 mL) were added CS2CO3 (49 mg, 0.15 mmol), Ru-Phos Pd G3 (13 mg, 0.015 mmol), Ru-Phos (7.2 mg, 0.015 mmol) under N2
atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The mixture was diluted with water (10 mL) and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (30 mg, 77.6% yield) as white solid, which was used in next step directly. LC/MS (ESI) m/z: 502 (M+H)+.
Step 6: (S)-2-(5,5-difluoro-l-(5-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- 1 ,2,3-tr iazol-4-yl)pyrazin-2-yl)piperidin-3-yl)acetic acid
[0342] To a solution of methyl (S)-2-(5,5-difluoro-l-(5-(l-methyl-5-((2-oxo-5-propylpyridin- l(2H)-yl)methyl)-lH-l,2,3-triazol-4-yl)pyrazin-2-yl)piperidin-3-yl)acetate (30 mg, 0.06 mmol) in THF (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOH.ftO (25 mg, 0.60 mmol) at 25 °C. The reaction was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (5 mL). The mixture was washed with EtOAc (2 x 3 mL) and the aqueous layer was acidified with IN aq.HCl to pH = 4 and extracted with EtOAc (3 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (3.6 mg, 12.3% yield) as white solid. LC/MS (ESI) m/z: 488 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 8.68 (s, 1H), 8.41 (s, 1H), 7.71 (d, J= 2.4 Hz, 1H), 7.37 (dd, J= 12.0, 2.6 Hz, 1H), 6.43 (d, J= 9.6 Hz, 1H), 5.60 (s, 2H), 4.25 (s, 4H), 3.29 - 3.19 (m, 3H), 3.02- 2.91 (m, 1H), 2.40 - 2.27 (m, 7H), 1.91 - 1.75 (m, 1H), 1.49 - 1.40 (m, 2H), 0.86 - 0.78 (m, 3H).
Example 57: 2-(l-(5-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol- 4-yl)pyrazin-2-yl)piperidin-3-yl)acetic acid
Example 57
[0343] The title compound was prepared according to the procedure described for the synthesis of example 56. LC/MS (ESI) m/z: 452 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 8.63 (d, J= 1.2 Hz, 1H), 8.30 (s, 1H), 7.70 (d, J= 2.0 Hz, 1H), 7.35 (dd, J= 9.2 Hz, d, J= 2.8 Hz, 1H), 6.44 (d, J = 9.2 Hz, 1H), 5.59 (s, 2H), 4.47 - 4.41 (m, 2H), 4.24 (s, 3H), 3.02 - 2.95 (m, 2H), 2.34 - 2.24 (m,
4H), 2.11 - 2.02 (m, 1H), 1.93 - 1.84 (m, 2H), 1.51-1.40 (m, 2H), 1.36 - 1.24 (m, 2H), 0.83 (d, J = 7.2 Hz, 3H).
Example 58: 2-[(3R)-l-(6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l-yl)methyl]- lH-l,2,3-triazol-4-yl}-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl]acetic acid
Step 1: 3,6-dibromo-2-(trifluoromethyl)pyridine
[0344] To a solution of 5-bromo-6-(trifluoromethyl)pyridin-2-amine (1.01 g, 4.14 mmol) in aq. HBr (1.34 g, 16.59 mmol, 40% wt) was added Bn (0.59 mL, 11.61 mmol), NaNCh (0.72 g, 10.37 mmol) in water (10 mL) at 0 °C, and the mixture was stirred at 0 °C for 1 hr. The reaction mixture was diluted with EtOAc (20 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-10% EtOAc in PE) to give the title compound (720 mg, 56.9% yield) as white solid. ’H NMR (400 MHz, DMSO) 8 8.34 (d, J= 8.4 Hz, 1H), 7.95 (d, J= 8.4 Hz, 1H).
Step 2: 3-bromo-6-[3-(oxan-2-yloxy)prop-l-yn-l-yl]-2-(trifluoromethyl)pyridine
[0345] To a solution of 3,6-dibromo-2-(trifhioromethyl)pyridine (720 mg, 2.36 mmol) in acetonitrile (10 mL) was added 2-(prop-2-yn-l-yloxy)oxane (397 mg, 2.83 mmol), Cui (22 mg, 0.11 mmol), triethylamine (0.98 mL, 7.08 mmol), Pd(PPh3)2Ch (83 mg, 0.11 mmol), and the mixture was degassed under N2 for 3 times and stirred at 25 °C for 16 hrs. The reaction mixture was concentrated to dryness and the residue was purified by flash chromatography (silica gel, 0- 20% EtOAc in PE) to give the title compound (696 mg, 80.9% yield) as yellow oil. LC/MS (ESI)
m/z: 364 (M+H)+. XH NMR (400 MHz, DMSO-tL) 6 8.42 (d, J= 8.4 Hz, 1H), 7.78 (d, J= 8.3 Hz, 1H), 4.82 (d, J= 3.2 Hz, 1H), 4.59 - 4.43 (m, 2H), 3.81 - 3.72 (m, 1H), 3.53 - 3.46 (m, 1H), 1.74 - 1.63 (m, 2H), 1.56 - 1.47 (m, 4H).
Step 3: 3-bromo-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3-triazol-4- yl)-2-(trifluoromethyl)pyridine
[0346] To a solution of 3-bromo-6-[3-(oxan-2-yloxy)prop-l-yn-l-yl]-2-(trifluoromethyl)pyridine (696 mg, 1.91 mmol) in 1,4-di oxane (7 mL) was added TMSCH2N3 (246 mg, 1.91 mmol), Cui (18 mg, 0.096 mmol), pentamethylcyclopentadienylbis(triphenylphosphine)ruthenium(II) chloride (76 mg, 0.096 mmol), and the mixture was degassed under N2 for three times and stirred at 50 °C for 16 hrs. Then the reaction mixture was concentrated to dryness and the residue was dissolved in THF (7 mL). TBAF (1.49 g, 5.73 mmol) was added to the mixture and the resulting mixture was stirred at r.t. for 1 hr. The mixture was diluted with EtOAc (10 mL), washed with saturated aq.NH-tCl solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-60% EtOAc in PE) to give the title compound (306 mg, 38.0% yield) as white solid. ’H NMR (400 MHz, DMSO ;) 6 8.52 (d, J= 8.5 Hz, 1H), 8.30 (d, J= 8.5 Hz, 1H), 5.36 (d, J= 12.5 Hz, 1H), 5.19 (d, J= 12.5 Hz, 1H), 4.77 - 4.72 (m, 1H), 4.18 (s, 3H), 3.77 - 3.68 (m, 1H), 3.46 - 3.41 (m, 1H), 1.73 - 1.61 (m, 2H), 1.57 - 1.44 (m, 4H).
Step 4: ethyl 2-((3R)-l-(6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3- triazol-4-yl)-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)acetate
[0347] To a solution of 3-bromo-6-{ l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3-triazol-4-yl}- 2-(trifluoromethyl)pyridine (180 mg, 0.42 mmol) in 1,4-dioxane (5 mL) was added CS2CO3 (417 mg, 1.28 mmol), ethyl 2-[(3R)-piperidin-3-yl]acetate (73 mg, 0.42 mmol), RuPhos Pd G3 (71 mg, 0.085 mmol), RuPhos (40 mg, 0.085 mmol) and the mixture was degassed under N2 for 3 times and stirred at 120 °C for 16 hrs. The reaction mixture was diluted with EtOAc (10 mL) and washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-60% EtOAc in PE) to give the title compound (125 mg, 57.2% yield) as yellow solid. LC/MS (ESI) m/z: 512 (M+H)+.
Step 5: ethyl (R)-2-(l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- (trifluoromethyl)pyridin-3-yl)piperidin-3-yl)acetate
[0348] To a solution of ethyl 2-[(3S)-l-(6-{ l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3-triazol- 4-yl}-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl]acetate (125 mg, 0.24 mmol) in MeOH (5 mL) was added PPTS (184 mg, 0.73 mmol) and the mixture was stirred at 60 °C for 2 hrs. The reaction mixture was concentrated to dryness and the residue was diluted with DCM (10 mL),
washed with saturated aq. NH4CI solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-80% EtOAc in PE) to give the title compound (102 mg, 97.7% yield) as yellow solid. LC/MS (ESI) m/z: 428 (M+H)+.
Step 6: ethyl (R)-2-(l-(6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)-2- (trifluoromethyl)pyridin-3-yl)piperidin-3-yl)acetate
[0349] To a solution of ethyl 2-[(3R)-l-{6-[5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl]- 2-(trifluoromethyl)pyridin-3-yl}piperidin-3-yl]acetate (50 mg, 0.11 mmol) in DCM (3 mL) was added TEA (0.081 mL, 0.58 mmol), MsCl (0.011 mL, 0.14 mmol), and then the mixture was stirred at 0 °C for 30 mins. The reaction mixture was diluted with DCM (5 mL) and washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to the title compound (62 mg, 94.4% yield) as yellow oil. LC/MS (ESI) m/z: 506 (M+H)+.
Step 7: ethyl 2-[(3R)-l-(6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l-yl)methyl]- lH-l,2,3-triazol-4-yl}-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl]acetate
[0350] To a solution of ethyl 2-[(3S)-l-(6-{5-[(methanesulfonyloxy)methyl]-l-methyl-lH-l,2,3- triazol-4-yl}-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl]acetate (62 mg, 0.12 mmol) in toluene (5 mL) and water (1 mL) was added 5-propyl-l,2-dihydropyridin-2-one (34 mg, 0.24 mmol), K2CO3 (51 mg, 0.36 mmol), and then the mixture was stirred at 110 °C for 16 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (71 mg, 95.1% yield) as yellow solid. LC/MS (ESI) m/z: 547 (M+H)+.
Step 8: 2-[(3R)-l-(6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l-yl)methyl]-lH- l,2,3-triazol-4-yl}-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl]acetic acid
[0351] To a solution of ethyl 2-[(3R)-l-(6-{ l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l- yl)methyl]-lH-l,2,3-triazol-4-yl}-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl]acetate (69 mg, 0.12 mmol) in THF (2 mL) was added MeOH (0.5 mL), water (0.5 mL), LiOH (30 mg, 1.26 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was acidified with IN aq.HCl and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep.HPLC to give the title compound (28 mg, 42.8% yield) as white solid. LC/MS (ESI) m/z: 519 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 8.27 (d, J= 8.6 Hz, 1H), 8.01 (d, J= 8.6 Hz, 1H), 7.73 (d, J= 2.1 Hz, 1H), 7.40 - 7.35 (m, 1H), 6.49 (d, J= 9.2 Hz, 1H), 5.76 (s, 2H), 4.22 (s, 3H), 3.23 - 3.18 (m, 1H), 3.11 - 3.05 (m, 1H), 2.88 - 2.80 (m, 1H), 2.66 - 2.59 (m, 1H), 2.35 - 2.28
(m, 2H), 2.27 - 2.19 (m, 3H), 1.94 - 1.72 (m, 3H), 1.43 - 1.33 (m, 2H), 1.31 - 1.20 (m, 1H), 0.76 (t, J= 7.3 Hz, 3H).
Example 59: (R)-2-(l-(6-(5-((5-cyclopropyl-2-oxopyridin-l(2H)-yl)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-(trifluoromethyl)pyridin-3-yl)piperidin-3-yl)acetic acid
The title compound was prepared according to the procedure described for the synthesis of example 58. LC/MS (ESI) m/z: 519 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 8.29 (d, J= 8.5 Hz, 1H), 8.04 (d, J= 8.7 Hz, 1H), 7.74 - 7.71 (m, 1H), 7.31 - 7.26 (m, 1H), 6.49 (d, J= 9.3 Hz, 1H), 5.79 (s, 2H), 4.22 (s, 3H), 3.26 - 3.22 (m, 1H), 3.16 - 3.10 (m, 1H), 2.90 - 2.84 (m, 1H), 2.68 - 2.62 (m, 1H), 2.35 - 2.30 (m, 2H), 2.28 - 2.21 (m, 1H), 1.96 - 1.89 (m, 1H), 1.85 - 1.76 (m, 2H), 1.64 - 1.56 (m, 1H), 1.33 - 1.24 (m, 1H), 0.80 - 0.74 (m, 2H), 0.37 - 0.31 (m, 2H).
Example 60: (R)-2-(l-(2-(difluoromethyl)-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: 3,6-dibromopicolinaldehyde
[0352] To a solution of 3, 6-dibromo-2-m ethylpyridine (2 g, 7.9 mmol) in 1,4-dioxane (20 mL) was added SeCh (3.54 g, 31.9 mmol) and H2O (0.5 mL) the mixture was stirred at 120 °C for 16
hrs. The mixture was diluted with ice water (10 mL) and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 10: 1) to give the title compound (1.2 g, 56.8% yield) as white solid. LC/MS (ESI) (m/z): 266 (M+H)+. XH NMR (400 MHz, CDCh) 6 10.09 (s, 1H), 7.87 (d, J= 8.4 Hz, 1H), 7.54 (d, J= 8.4 Hz, 1H).
Step 2: 3,6-dibromo-2-(difluoromethyl)pyridine
[0353] To a solution of 3,6-dibromopyridine-2-carbaldehyde (500 mg, 1.8 mmol) in DCM (10 mL) was added DAST (0.6 mL, 4.7 mmol) at 0 °C and the mixture was stirred at 25 °C for 1 hr. The mixture was diluted with DCM (10 mL) and washed with saturated aq.NaHCOs solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 10: 1) to give the title compound (400 mg, 73.8% yield) as white solid. LC/MS (ESI) (m/z): 288 (M+H)+ 1H NMR (400 MHz, CDCh) 6 7.81 (d, J= 8.4 Hz, 1H), 7.49 (d, J= 8.4 Hz, 1H), 6.80 (t, J= 53.6 Hz, 1H)
Step 3: 3-bromo-2-(difluoromethyl)-6-[3-(oxan-2 yloxy)prop-l-yn-l-yl]pyridine
[0354] To a mixture of 3,6-dibromo-2-(difluoromethyl)pyridine (400 mg, 1.3 mmol) and (prop- 2-yn-l-yloxy)tetrahydro-2H-pyran (195 mg, 1.3 mmol) in MeCN (10 mL) was added TEA (423 mg, 4.1 mmol), Cui (13.2 mg, 0.07 mmol) and Pd(PPh3)2Ch (49 mg, 0.07 mmol). The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at r.t. overnight. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 2: 1) to give the title compound (400 mg, 82.9% yield) as yellow solid. XH NMR (400 MHz, CDCh) 6 7.92 (s, 1H), 7.40 (t, J= 7.8 Hz, 1H), 6.82 (s, 1H), 4.87 (t, J= 3.3 Hz, 1H), 4.50 (d, J= 11.6 Hz, 2H), 3.89 - 3.80 (m, 1H), 3.59 - 3.52 (m, 1H), 1.88 - 1.58 (m, 6H).
Step 4: 3-bromo-2-(difluoromethyl)-6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3-triazol- 4-yl}pyridine
[0355] To a solution of 3-bromo-2-(difluoromethyl)-6-[3-(oxan-2-yloxy)prop-l-yn-l-yl]pyridine (1.5 g, 4.3 mmol) in 1,4-dioxane (10 mL) were added (azidomethyl)trimethylsilane (0.56 g, 4.3 mmol), Cui (0.007 mL, 0.2 mmol) , Cp*RuCl(PPh3)2 (0.17 g, 0.2 mmol). The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 50 °C for 16 hrs. The mixture was concentrated to dryness and the residue was dissolved in THF (10 mL). TBAF (1.8 g, 13.7 mmol) was added to the above mixture and the resulting mixture was stirred at 0 °C for 10 mins. The mixture was diluted with EtOAc (10 mL) and washed with water, brine,
dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 4: 1) to give the title compound (1.25 g, 71.5% yield) as white solid. LC/MS (ESI) (m/z): 403 (M+H)+ 1H NMR (400 MHz, CDCh) 6 8.21 (d, J= 8.5 Hz, 1H), 8.00 (t, J= 10.1 Hz, 1H), 7.06 - 6.79 (m, 1H), 5.38 - 5.25 (m, 2H), 4.76 (t, J = 3.4 Hz, 1H), 4.17 (s, 3H), 3.88 - 3.75 (m, 1H), 3.51 (dd, J= 10.9, 4.9 Hz, 1H), 1.83 - 1.68 (m, 3H), 1.51 (d, J = 4.9 Hz, 2H).
Step 5: ethyl 2-[(3R)-l-[2-(difluoromethyl)-6-{l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3- triazol-4-yl}pyridin-3-yl] piperidin-3-yl] acetate
[0356] To a mixture of 3-bromo-2-(difluoromethyl)-6-{ l-methyl-5-[(oxan-2-yloxy)methyl]-lH-
1.2.3-triazol-4-yl}pyridine(100 mg, 0.24 mmol) and ethyl 2-[(3R)-piperidin-3-yl]acetate (42 mg, 0.248 mmol) in 1,4-dioxane (7.5 mL) were added CS2CO3 (242 mg, 0.74 mmol) , Ru-Phos Pd G3 (42 mg, 0.04 mmol), Ru-phos (23 mg, 0.04 mmol) under N2 atmosphere. The mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 4: 1) to give the title compound (100 mg, 81.6% yield). LC/MS (ESI) m/z: 494 (M+H)+.
Step 6: ethyl (S)-2-(l-(2-cyano-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate
[0357] To a solution of ethyl give ethyl 2-[(3R)-l-[2-(difluoromethyl)-6-{ l-methyl-5-[(oxan-2- yloxy)methyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl]piperidin-3-yl]acetate (80 mg, 0.162 mmol) in MeOH (10 mL) was added PPTS (203 mg, 0.810 mmol) and the mixture was stirred at 50 °C for 16 hrs. The mixture was concentrated to dryness and the residue was purified by chromatography on silica gel (eluted with PE: EtOAc= 1 : 1) to give the title compound (65 mg, 97% yield). LC/MS (ESI) m/z: 410 (M+H)+.
Step 7: ethyl (S)-2-(l-(2-cyano-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate
[0358] To a solution of ethyl 2-[(3R)-l-[2-(difluoromethyl)-6-[5-(hydroxymethyl)-l -methyl- 1H-
1.2.3-triazol-4-yl]pyridin-3-yl]piperidin-3-yl]acetate (65 mg, 0.159 mmol) in DCM (10 mL) was added TEA (0.1 mL, 0.4 mmol) followed by MsCl (0.1 mL, 0.2 mmol) at 0 °C and the reaction mixture was stirred at 0 °C for 1 hr. The mixture was diluted with ice water and extracted with DCM (2 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness give the title compound (70 mg, 90% yield) as yellow solid. LC/MS (ESI) m/z: 488 (M+H)+.
Step 8: [(3R)-l-[2-(difluoromethyl)-6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l- yl)methyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl]piperidin-3-yl]acetate
[0359] To a mixture of 2-{4-[6-(difluoromethyl)-5-[(3R)-3-(2-ethoxy-2-oxoethyl)piperidin-l- yl]pyridin-2-yl]-l-methyl-lH-l,2,3-triazol-5-yl}ethane-l-sulfonic acid (60 mg, 0.1 mmol) and 5- propylpyridin-2-ol (17 mg, 0.1 mmol) in toluene (5 mL) and water (1 mL) was added K2CO3 (51 mg, 0.3 mmol) and TBAF (0.6 mg, 0.002 mmol) and the mixture was stirred at 110 °C for 1.5 hrs. The reaction mixture was diluted with EtOAc (5 mL) and washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (60 mg, 92.2% yield) as yellow solid. LC/MS (ESI) m/z: 529 (M+H)+.
Step 9: 2-[(3R)-l-[2-(difluoromethyl)-6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l- yl)methyl]-lH-l,2,3-triazol-4-yl}pyridin-3-yl]piperidin-3-yl]acetic acid
[0360] To a solution of 2-{4-[6-(difluoromethyl)-5-[(3R)-3-(2-ethoxy-2-oxoethyl)piperidin-l- yl]pyridin-2-yl]-l-methyl-lH-l,2,3-triazol-5-yl}ethane-l-sulfonic acid (65 mg, 0.13 mmol) in MeOH (1 mL), water (1 mL) and THF (4 mL) was added LiOH (5.5 mg, 0.13 mmol) and the mixture was stirred at 25 °C for 1.5 hrs. The reaction mixture was acidified with IM aq.HCl to pH=4 and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep- HPLC to give the title compound (30 mg, 44.9% yield) as white solid. LC/MS (ESI) m/z: 501 (M+H)+. XH NMR (400 MHz, CD3OD) 8 8.15 (d, J = 8.7 Hz, 1H), 8.00 (d, J= 2.0 Hz, 1H), 7.84 (d, J= 8.6 Hz, 1H), 7.37 (dd, J= 9.2, 2.4 Hz, 1H), 7.20 (t, J= 54.4 Hz, 1H), 6.48 (d, J= 9.2 Hz, 1H), 5.78 (s, 2H), 4.26 (s, 3H), 3.23 (d, J= 11.5 Hz, 1H), 3.12 (d, J= 10.8 Hz, 1H), 2.89 - 2.79 (m, 1H), 2.65 - 2.57 (m, 1H), 2.25 (dd, J= 20.7, 13.4 Hz, 5H), 1.96 - 1.80 (m, 3H), 1.37 (dd, J= 14.9, 7.4 Hz, 2H), 1.31 - 1.22 (m, 1H), 0.75 (t, J= 7.3 Hz, 3H).
Example 61: 2-((S)-l-(6-(5-(((S)-4-(cyclopropylmethyl)-3-methyl-2-oxoimidazolidin-l- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetic acid
Example 61
Step 1: (4S)-l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]methyl}-4- (cyclopropylmethyl)-3-methylimidazolidin-2-one
[0361] To a mixture of 3-bromo-6-[5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl]-2- ethylpyridine (140 mg, 0.39 mmol) and (5S)-5-(cyclopropylmethyl)-l-methylimidazolidin-2-one (90 mg, 0.58 mmol) in DMF (10 mL) was added NaH (47 mg, 1.17 mmol, 60% dispersion in mineral oil) at 0 °C and the mixture was stirred at r.t for 16 hrs. The reaction mixture was quenched with ice-water and the mixture was extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 35 % EtOAc in PE) to give the title compound (90 mg, 53.4% yield) as white solid. LC/MS (ESI) m/z: 434/436 (M+H)+.
Step 2: methyl 2-[(3S)-l-[6-(5-{[(4S)-4-(cyclopropylmethyl)-3-methyl-2-oxoimidazolidin-l- yl]methyl}-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3- yl] acetate
[0362] To a mixture of (4S)-l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methyl}-4-(cyclopropylmethyl)-3-methylimidazolidin-2-one (45 mg, 0.10 mmol) and methyl 2-[(3S)-5,5-difluoropiperidin-3-yl]acetate (30 mg, 0.16 mmol) in 1,4-dioxane (5 mL) was added CS2CO3 (104 mg 0.32 mmol) and Pd2(dba)3 (9 mg, 0.01 mmol) and RuPhos (5 mg, 0.01 mmol) under N2 atmosphere and the mixture was stirred at 110 °C for 16 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 50% EtOAc in PE) to give the title compound (22 mg, 40.3% yield) as yellow solid. LC/MS (ESI) m/z: 546 (M+H)+.
Step 3: 2-[(3S)-l-[6-(5-{[(4S)-4-(cyclopropylmethyl)-3-methyl-2-oxoimidazolidin-l- yl]methyl}-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3- yl] acetic acid
[0363] To a solution of methyl 2-[(3R)-l-[6-(5-{[(4S)-4-(cyclopropylmethyl)-3-methyl-2- oxoimidazolidin- 1 -yl]methyl } - 1 -methyl- 1H- 1 ,2,3 -tri azol-4-yl)-2-ethylpyri din-3 -y 1 ] - 5 , 5 - difluoropiperi din-3 -yl]acetate (22 mg, 0.04 mmol) in THF (5 mL) and MeOH (1 mL) was added a solution of LiOH (4 mg 0.18 mmol) in H2O (1 mL) and the mixture was stirred at r.t. for 3 hrs. The mixture was acidified with IN aq.HCl to pH~4 and extracted with DCM (3 x 3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-HPLC (C18, 0 ~ 90 % acetonitrile in H2O with 0.1% HCOOH) to give the title compound (11 mg, 50.9% yield) as white solid. TH NMR (400 MHz, CD3OD) 8 7.87 (d, J= 8.3 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H), 5.13 (s, 2H), 4.11 (s, 3H), 3.54 - 3.47 (m, 1H), 3.41 (t, J = 8.8 Hz, 1H), 3.22 (d, J= 10.1 Hz, 2H), 3.10 - 2.93 (m, 4H), 2.76 (s, 3H), 2.63 - 2.48 (m, 2H), 2.38 - 2.23 (m, 3H), 1.95 (s, 3H), 1.77 - 1.62 (m, 1H), 1.46 - 1.30 (m, 6H), 0.54 - 0.42 (m, 1H), 0.40 - 0.29 (m, 2H). LC/MS (ESI) m/z: 532 (M+H)+.
The examples in the following table were prepared by using method analogous to the examples as indicated in the method column in the table.
Example 65: 2-((S)-l-(6-(5-(((S)-4-(cyclopropylmethyl)-2-oxoimidazolidin-l-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: tert-butyl (S)-(l-amino-3-cyclopropylpropan-2-yl)carbamate
[0364] To a solution of tert-butyl (S)-(l-azido-3-cyclopropylpropan-2-yl)carbamate (580 mg, 2.4 mmol) in MeOH (8 mL) was added Pd/C (100 mg, 5% wt) at 0 °C and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room temperature for 2 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (500 mg, 96.6% yield) as yellow solid. LC/MS (ESI) (m/z): 215 (M+H)+.
Step 2: 4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazole-5-carbaldehyde
[0365] To a solution of oxalyl chloride (0.15 mL, 1.74 mmol) in DCM (10 mL) was added a solution of DMSO (0.19 mL, 2.6 mmol) in DCM (2 mL) at -78 °C. After stirring for 20 minutes, a solution of (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methanol (300 mg, 0.87 mmol) in DCM (5 mL) was added and the mixture was stirred at -78 °C for 2 hrs. TEA (0.47 mL, 3.4 mmol) was added drop-wisely at -78 °C and the resulting mixture was stirred from -78 °C to r.t. for 2 hrs. The mixture was diluted with DCM (5 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 3: 1) to give the title compound (170 mg, 57.0% yield) as white solid. LC/MS (ESI) (m/z): 343 (M+H)+.
Step 3: tert-butyl (S)-(l-cyclopropyl-3-(((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3- triazol-5-yl)methyl)amino)propan-2-yl)carbamate
[0366] To a mixture of 4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazole-5- carbaldehyde (173 mg, 0.51 mmol) and tert-butyl (S)-(l-amino-3-cyclopropylpropan-2- yl)carbamate (108 mg, 0.5 mmol) in DCE (5 mL) was added sodium triacetoxyborohydride (160
mg, 0.76 mmol) and the reaction was stirred at room temperature under N2 atmosphere for 4 hrs. The reaction mixture was quenched with saturated aq.NaHCOs solution (5 mL) and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 2: 1) to give the title compound (160 mg, 58.6% yield) as white solid. LC/MS (ESI) (m/z): 541 (M+H)+.
Step 4: (S)-3-cyclopropyl-Nl-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl)propane-l,2-diamine TEA salt
[0367] To a solution of tert-butyl (S)-(l-cyclopropyl-3-(((4-(6-ethyl-5-iodopyridin-2-yl)-l- methyl-lH-l,2,3-triazol-5-yl)methyl)amino)propan-2-yl)carbamate (160 mg, 0.3 mmol) in DCM (5 mL) was added TFA (5 mL, 67.3 mmol) at 0 °C and the reaction mixture was stirred at room temperature for 2 hrs. The reaction mixture was concentrated under reduced pressure to give the title compound (160 mg, yield 100%) as yellow oil, which was directly used in the next step. LC/MS (ESI) (m/z): 441 (M+H)+.
Step 5: (S)-4-(cyclopropylmethyl)-l-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3- triazol-5-yl)methyl)imidazolidin-2-one
[0368] To a solution of (S)-3-cyclopropyl-Nl-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH- l,2,3-triazol-5-yl)methyl)propane-l,2-diamine TFA salt (160 mg, 0.34 mmol) in DCM (6 mL) were added TEA (0.13 mL, 0.91 mmol) and CDI (49.3 mg, 0.3 mmol) and the mixture was stirred at room temperature for 16 hrs. The reaction mixture was washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 3: 1) to give the title compound (110 mg, 77.5% yield) as white solid. LC/MS (ESI) (m/z): 467 (M+H)+.
Step 6: methyl 2-((S)-l-(6-(5-(((S)-4-(cyclopropylmethyl)-2-oxoimidazolidin-l-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0369] To a mixture of (S)-4-(cyclopropylmethyl)-l-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl- lH-l,2,3-triazol-5-yl)methyl)imidazolidin-2-one (30 mg, 0.064 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3 -yl)acetate (12.4 mg, 0.064 mmol) in 1,4-dioxane (2 mL) were added CS2CO3 (42 mg, 0.128 mmol), RuPhos (15 mg, 0.032 mmol) and RuPhos Pd G3 (15 mg, 0.064 mmol) under N2 atmosphere and the mixture reaction was stirred at 100 °C under N2 atmosphere for 16 hrs. The reaction mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep.TLC (PE: EtOAc= 2: 1) to give the title compound (15 mg, 43.9% yield) as yellow solid. LC/MS (ESI) (m/z): 532 (M+H)+.
Step 7: 2-((S)-l-(6-(5-(((S)-4-(cyclopropylmethyl)-2-oxoimidazolidin-l-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0370] To a solution of methyl 2-((S)-l-(6-(5-(((S)-4-(cyclopropylmethyl)-2-oxoimidazolidin-l- yl)methyl)-l -methyl-lH- 1,2, 3-tri azol -4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetate (15 mg, 0.028 mmol) in THF (1 mL) and MeOH (2 mL) was added a solution of LiOH (6.7 mg, 0.28 mmol) in water (1 mL) at 0 °C. After stirring at room temperature for 2 hrs, the reaction mixture was concentrated to dryness and the residue was dissolved in water (3 mL). The mixture was washed with EtOAc twice and the aqueous layer was acidified with IN aq.HCl to pH~2 and extracted with EtOAc (2 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 25-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (4.3 mg, 29.6% yield) as white solid. LC/MS (ESI) (m/z): 518 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.88 (d, J= 8.4 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H), 5.12 (s, 2H), 4.12 (s, 3H), 3.72-3.65 (m, 1H), 3.44 (t, J= 8.9 Hz, 1H), 3.26-3.21 (m, 2H), 3.13-3.07 (m, 1H), 3.06-3.02 (m, 1H), 3.0-2.94 (m, 2H), 2.61 (t, J= 10.3 Hz, 1H), 2.55-2.46 (m, 1H), 2.41-2.39 (m, 2H), 2.33-2.25 (m, 1H), 1.81-1.67 (m, 1H), 1.42-1.22 (m, 8H), 0.61-0.55 (m, 1H), 0.38-0.36 (m, 2H).
Example 66: 2-[(3R)-l-[2-ethyl-6-(l-methyl-5-{[3-methyl-4-(2-methylpropyl)-2-oxo-2,3- dihydro-lH-imidazol-l-yl]methyl}-lH-l,2,3-triazol-4-yl)pyridin-3-yl]-5,5-difluoropiperidin- 3-yl] acetic acid
Step 1: methyl (2S)-2-amino-4-methylpentanoate hydrochloride
[0371] To a solution of L-leucine (5 g, 38.12 mmol) in MeOH (50 mL) was added sulfuroyl di chloride (6.2 mL, 76.24 mmol) and the reaction mixture was stirred at r.t. for 16 hrs. The mixture was concentrated to dryness to give the title compound (5 g, 90.3 % yield) as white solid. Step 2: (5R)-5-(2-methylpropyl)imidazolidine-2, 4-dione
[0372] To a solution of methyl (2S)-2-amino-4-methylpentanoate (4 g, 27.6 mmol) in water (50 mL) was added KOCN (2.35 g, 28.9 mmol) and the mixture was stirred at r.t. for 1 hr. The mixture was extracted with EtOAc (2 x 20 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was dissolved in 2N aq.HCl (20 mL) and the mixture was stirred at reflux for 1 hr. The mixture was extracted with EtOAc (3 x 10 mL) and the combined organic phases were dried over Na2SO4, filtered and concentrated to dryness to give the title compound (2.3 g, 53.5 % yield). LC/MS (ESI) m/z: 157 (M+H)+.
Step 3: 3-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]methyl}-5-(2- methylpropyl)imidazolidine-2, 4-dione
[0373] To a stirred mixture of 3-bromo-6-[5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl]-2- ethylpyridine (500 mg, 1.39 mmol) and 5-(2-methylpropyl)imidazolidine-2, 4-dione (434 mg, 2.78 mmol) in DMF (10 mL) was added Na2CO3 (442 mg, 4.17 mmol) in portions at r.t., and the mixture was stirred at 50 °C for 16 hrs. The reaction mixture was quenched with H2O (10 mL) and extracted with EtOAc (3 ^ 5 mL). The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography flash chromatography (silica gel, EtOAc: PE= 1 : 2) to give the title compound (200 mg, 33.1% yield) as white solid. LC/MS (ESI) m/z: 436/438 (M+H)+.
Step 4: l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]methyl}-5- hydroxy-4-(2-methylpropyl)imidazolidin-2-one
[0374] To a stirred solution of 3-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methyl}-5-(2-methylpropyl)imidazolidine-2, 4-dione (50 mg, 0.12 mmol) in THF (5 mL) was added LiAlEL (9 mg, 0.23 mmol) at 0 °C and the mixture was stirred at this temperature for 30 mins. The reaction mixture was quenched with Na2SO4.9H2O and stirred at r.t. for 10 mins. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (50 mg, 79.6% yield) as white solid. LC/MS (ESI) m/z: 438/440 (M+H)+.
Step 5: (S)-2-(N-methyl-4-nitrophenylsulfonamido)hex-5-enoic acid
[0375] To a stirred solution of l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methyl}-5-hydroxy-4-(2-methylpropyl)imidazolidin-2-one (50 mg, 0.11 mmol) in DCM (5
mL) was added TFA (0.5 mL) at r.t.. After stirring at r.t. for 3 hrs, the reaction mixture was concentrated to dryness under reduced pressure to give the title compound (50 mg, 104.3% yield) as yellow oil, which was used directly without further purification. LC/MS (ESI) m/z: 420/422 (M+H) +.
Step 6: l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]methyl}-3- methyl-4-(2-methylpropyl)-2,3-dihydro-lH-imidazol-2-one
[0376] To a stirred solution of l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methyl}-4-(2-methylpropyl)-2,3-dihydro-lH-imidazol-2-one (50 mg, 0.12 mmol) in DMF (5 mL) was added NaH (14 mg 0.36 mmol, 60% dispersion in mineral oil) in portions at 0 °C, and the mixture was stirred at this temperature for 30 mins. Mel (0.015 mL, 0.24 mmol) was added to the mixture and the resulting mixture was stirred at r.t. for 3 hrs. The reaction mixture was quenched with sat.NELCl solution and extracted with EtOAc (3 x 5 mL). The combined organic phase was washed with brine, dried over Na2SO4 and concentrated. The residue was purified by flash chromatography (silica gel, EtOAc: PE= 1 : 3) to give the title compound (50 mg, 96.8 % yield) as white solid. LC/MS (ESI) m/z: 434/436 (M+H)+.
Step 7: methyl 2-[(3R)-l-[2-ethyl-6-(l-methyl-5-{[3-methyl-4-(2-methylpropyl)-2-oxo-2,3- dihydro-lH-imidazol-l-yl]methyl}-lH-l,2,3-triazol-4-yl)pyridin-3-yl]-5,5-difluoropiperidin- 3-yl] acetate
[0377] To a solution of l-{[4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methyl}-3-methyl-4-(2-methylpropyl)-2,3-dihydro-lH-imidazol-2-one (50 mg, 0.12 mmol ) in 1,4-dioxane (5 mL) was added methyl 2-[(3R)-5,5-difluoropiperidin-3-yl]acetate (27 mg, 0.14 mmol) followed by the addition of CS2CO3 (114 mg, 0.35 mmol) and Bis(tri-tert- butylphosphine)palladium (6 mg, 0.012 mmol) under N2 atmosphere with stirring and the mixture was stirred at 100 °C for 16 hrs. The reaction mixture was filtered through a Celite pad and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 50 % EtOAc in PE) to give the title compound (28 mg, 44.4% yield) as yellow solid. LC/MS (ESI) m/z: 546 (M+H)+.
Step 8: 2-[(3R)-l-[2-ethyl-6-(l-methyl-5-{[3-methyl-4-(2-methylpropyl)-2-oxo-2,3-dihydro- lH-imidazol-l-yl]methyl}-lH-l,2,3-triazol-4-yl)pyridin-3-yl]-5,5-difluoropiperidin-3- yl] acetic acid
[0378] To a solution of methyl 2-[(3R)-l-[2-ethyl-6-(l-methyl-5-{[3-methyl-4-(2-methylpropyl)- 2-oxo-2,3-dihydro-lH-imidazol-l-yl]methyl}-lH-l,2,3-triazol-4-yl)pyridin-3-yl]-5,5- difluoropiperi din-3 -yl]acetate (28 mg, 0.051 mmol) in THF (5 mL) and MeOH (1 mL) was added LiOH (8 mg, 0.33 mmol) in H2O (1 mL) and the reaction was stirred at r.t. for 3 hrs. The mixture
was concentrated to dryness and the residue was dissolved in H2O (3 mL). The mixture was acidified with 1 N aq.HCl to pH~4 and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was was purified by perp-HPLC (Cl 8, 0 ~ 90 % acetonitrile in H2O with 0.1 % formic acid) to give the title compound (6 mg, 22% yield) as white solid. LC/MS (ESI) m/z: 532 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.90 (d, J= 8.3 Hz, 1H), 7.60 (d, J= 8.4 Hz, 1H), 6.29 (s, 1H), 5.50 (s, 2H), 4.12 (s, 3H), 3.28 - 3.21 (m, 2H), 3.19 (s, 3H), 3.17 - 3.04 (m, 1H), 2.98 (q, J= 7.5 Hz, 2H), 2.61 (t, J= 10.6 Hz, 1H), 2.57 - 2.46 (m, 1H), 2.40 (d, J= 6.9 Hz, 2H), 2.36 - 2.26 (m, 1H), 2.23 - 2.16 (m, 2H), 1.83 - 1.64 (m, 2H), 1.33 (t, J= 7.5 Hz, 3H), 0.86 (d, J= 6.6 Hz, 6H).
Example 67: Preparation of (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-3-methyl-2-oxo-2,3- dihydro-lH-imidazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)- 5,5-difluoropiperidin-3-yl)acetic acid
[0379] The title compound was prepared from (S)-2-amino-3 -cyclopropylpropanoic acid using the same synthetic sequence that was used to synthesize example 66. LC/MS (ESI) m/z: 517 (M+H)+. ’H NMR (400 MHz, DMSO-tL) 6 7.88 (d, J= 8.3 Hz, 1H), 7.58 (d, J= 8.4 Hz, 1H), 6.50 (s, 1H), 5.26 (s, 2H), 4.14 (s, 3H), 3.22 - 3.07 (m, 2H), 3.05 (s, 3H), 2.60 (d, J= 10.0 Hz, 1H), 2.55 (s, 3H), 2.39 - 2.25 (m, 4H), 2.21 (d, J= 5.9 Hz, 2H), 1.81 - 1.74 (m, 1H), 0.79 - 0.75 (m, 1H), 0.46 - 0.33 (m, 2H), 0.09 - 0.01 (m, 2H).
Example 68: (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-4-methyl-5-oxo-4,5-dihydro-lH-l,2,4- triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5- difluoropiperidin-3-yl)acetic acid
Step 1: 2-cyclopropyl-N-[(methylcarbamoyl)amino] acetamide
[0380] To a solution of 2-cyclopropylacetic acid (500 mg, 5.0 mmol) and l-amino-3 -methylurea (370 mg, 4.2 mmol) in MeCN (10 mL) was added DCC (1.03 g, 5.0 mmol) at 0 °C under N2 atmosphere. After the addition, the resulting solution was stirred at r.t. for 3 hrs. The mixture was diluted with EtOAc (10 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (560 mg, 78.6% yield) as white solid. LC/MS (ESI) m/z: 172 (M+l)+.
Step 2: 3-(cyclopropylmethyl)-4-methyl-4,5-dihydro-lH-l,2,4-triazol-5-one
[0381] A solution of 2-cyclopropyl-N-[(methylcarbamoyl)amino]acetamide (514 mg, 3.0 mmol) in aq.NaOH solution (12 mL, 24.0 mmol, 2 M in water) was stirred at 100 °C for 16 hrs. The mixture was washed with EtOAc (30 mL) and the aqueous layer was treated with IN aq.HCl to adjust pH=l. The aqueous layer was concentrated under vacuum to dryness and the residue was purified by flash chromatography (eluent: 0-50% of MeOH in H2O) to give the title compound (220 mg, 47.8% yield) as white solid. LC/MS (ESI) m/z: 154 (M+l)+.
Step 3: 3-(cyclopropylmethyl)-l-{[4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol- 5-yl]methyl}-4-methyl-4,5-dihydro-lH-l,2,4-triazol-5-one
[0382] To a mixture of 6-[5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl]-2-ethyl-3- iodopyridine(50 mg, 0.12 mmol) and K2CO3 (51 mg, 0.37 mmol) in DMF (5 mL) was added 3- (cyclopropylmethyl)-4-methyl-4,5-dihydro-lH-l,2,4-triazol-5-one (28 mg, 0.18 mmol) under N2 atmosphere. After the addition, the resulting solution was stirred at 60 °C for 3 hrs. The mixture was diluted with EtOAc (5 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluent: 0-100% of EtOAc in PE) to give the title compound (36 mg, 61.1% yield) as white solid. LC/MS (ESI) m/z: 480 (M+l)+.
Step 4: methyl (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-4-methyl-5-oxo-4,5-dihydro-lH-l,2,4- triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5- difluoropiperidin-3-yl)acetate
[0383] To a mixture of 5-(cyclopropylmethyl)-2-((4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-
1.2.3-triazol-5-yl)methyl)-4-methyl-2,4-dihydro-3H-l,2,4-triazol-3-one (36 mg, 0.075 mmol) and methyl (S)-2-(5,5-difluoropiperidin-3-yl)acetate (14.5 mg, 0.075 mmol) in 1,4-dioxane (8 mL) were added CS2CO3 (49 mg, 0.15 mmol) , Ru-Phos Pd G3 (14 mg, 0.015 mmol), Ru-phos (7 mg, 0.017 mmol) under N2 atmosphere. The mixture was degassed under N2 atmosphere for three times and stirred under N2 atmosphere at 110 °C for 16 hrs. The mixture was diluted with EtOAc (5 mL) and washed with water, brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluent: 0~ 50% of EtOAc in PE) to give the title compound (26 mg, 61.1% yield) as yellow solid. LC/MS (ESI) m/z: 545 (M+H)+.
Step 5: (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-4-methyl-5-oxo-4,5-dihydro-lH-l,2,4-triazol- l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetic acid
[0384] To a solution of (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-4-methyl-5-oxo-4,5-dihydro-lH-
1.2.4-triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5- difluoropiperi din-3 -yl)acetate (26 mg, 0.05 mmol) in MeOH (1 mL), water (1 mL) and THF (4 mL) was added LiOH (14 mg, 0.34 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was acidified with IM aq.HCl and extracted with DCM (2 x 3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (8.9 mg, 41.6% yield) as white solid. LC/MS (ESI) m/z: 531 [M+l]+. XH NMR (400 MHz, CD3OD) 8 7.83 (d, J = 8.1 Hz, 1H), 7.55 (d, J = 8.2 Hz, 1H), 5.72 (s, 2H), 4.13 (s, 3H), 3.52 - 3.45 (m, 1H), 3.25 - 3.23 (m, 1H), 3.23 (s, 3H), 3.22 - 3.19 (m, 1H), 3.13 (d, J = 1.6 Hz, 2H), 2.95 (q, J = 7.6 Hz, 2H), 2.64 - 2.54 (m, 1H), 2.53 - 2.45 (m, 1H), 2.42 (d, J = 6.9 Hz, 2H), 2.38 (dd, J = 6.7, 2.8 Hz, 2H), 1.32 (t, J = 7.5 Hz, 3H), 0.96 (m, 1H), 0.52 - 0.47 (m, 2H), 0.15 - 0.12 (m, 2H).
Example 69: 2-((R)-l-(6-(5-(((S)-5-(cyclopropylmethyl)-2-oxooxazolidin-3-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: (S)-3-cyclopropyl-2-hydroxypropanoic acid
[0385] To suspension of (S)-2-amino-3-cyclopropylpropanoic acid (5 g, 38.7 mmol) in H2O (30 mL) was added 2N H2SO4 (22 mL, 44 mmol) and the mixture was cooled to 0 °C. To the above mixture, 2N aq.NaNCh solution (19.5 mL, 39.0 mmol) were added drop-wisely while maintaining the internal temperature below than 5 °C. The reaction was stirred at 0 °C for 3 hrs and r.t. for 16 hrs. The reaction mixture was saturated with NaCl and extracted with EtOAc (5 x 30 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to dryness to give the title compound (2.14 g, 42.5% yield) as yellow oil.
Step 2: (S)-N-benzyl-3-cyclopropyl-2-hydroxypropanamide
[0386] To a mixture of (S)-3-cyclopropyl-2-hydroxypropanoic acid (2.14 g, 16.4 mmol), phenylmethanamine (2.16 mL, 19.7 mmol), TEA (6.86 mL, 49.3 mmol) and HOBt (3.33 g, 24.7 mmol) in DMF (20 mL) was added EDCI (4.37 mL, 24.7 mmol) at 0 °C under N2 atmosphere and the reaction was stirred at 25 °C for 2 hrs. Water (50 mL) was added and the mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography on silica (DCM: MeOH = 100: 1 to 30: 1) to give the title compound (2.6 g, 72.1% yield) as yellow oil. LC/MS (ESI) m/z: 220 (M+H)+.
Step 3: (S)-l-(benzylamino)-3-cyclopropylpropan-2-ol
[0387] To suspension of LiAlEL (1.35 g, 35.6 mmol) in THF (10 mL) was added solution of (S)- N-benzyl-3-cyclopropyl-2-hydroxypropanamide (2.6 g, 11.8 mmol) in THF (10 mL) drop-wisely
at 0 °C under N2 atmosphere and the mixture was stirred at 70 °C for 16 hrs. The reaction was cooled to 0 °C and quenched with 1.5 mL water, 1.5 mL 15% NaOH solution and 4.5 mL water. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by column chromatography on silica (DCM: MeOH = 100: 1 to 20: 1) to give the title compound (1.53 g, 62.8% yield) as yellow solid. LC/MS (ESI) m/z: 206 (M+H)+.
Step 4: (S)-3-benzyl-5-(cyclopropylmethyl)oxazolidin-2-one
[0388] To a solution of (S)-l-(benzylamino)-3-cyclopropylpropan-2-ol (1.5 g, 7.31 mmol) in CH3CN (15 mL) were added TEA (1.05 mL, 7.55 mmol) and N,N’-disuccinimidyl carbonate (1.87 g, 7.30 mmol) at 0 °C and the mixture was stirred at 25 °C for 16 hrs. The reaction mixture concentrated to dryness and the residue was purified by column chromatography on silica (DCM: MeOH= 100: 1 to 50: 1) to give the title compound (1.3 g, 76.9% yield) as yellow oil. LC/MS (ESI) m/z: 232 (M+H)+.
Step 5: (S)-l-amino-3-cyclopropylpropan-2-ol
[0389] To a solution of (S)-3-benzyl-5-(cyclopropylmethyl)oxazolidin-2-one (900 mg, 3.89 mmol) in MeOH (7 mL) was added Pd/C (100 mg, 10% wt) at 25 °C under N2 atmosphere and the mixture was stirred under a H2 balloon at 25 °C for 3 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (450 mg, 100% yield) as yellow oil. LC/MS (ESI) m/z: 116 (M+H)+.
Step 6: (S)-5-(cyclopropylmethyl)oxazolidin-2-one
[0390] To a mixture of (S)-l-amino-3-cyclopropylpropan-2-ol (450 mg, 3.9 mmol) and TEA (1.21 mL, 8.7 mmol) in CH3CN (10 mL) was added DSC (1.2 g, 4.69 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at 25 °C for 16 hrs. The reaction was concentrated to dryness and the residue was purified by column chromatography on silica (DCM: MeOH= 100: 1 to 20: 1) to give the title compound (460 mg, 83.5% yield) as white solid. LC/MS (ESI) m/z: 142 (M+H)+.
Step 7: (S)-3-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-5- (cyclopropylmethyl)oxazolidin-2-one
[0391] To a solution of (S)-5-(cyclopropylmethyl)oxazolidin-2-one (102 mg, 0.722 mmol) in DMF (2 mL) was added NaH (44.4 mg, 1.11 mmol, 60% dispersion in mineral oil) at 0 °C under N2 atmosphere and the mixture was stirred at 0 °C for 0.5 hr. A solution of 3-bromo-6-(5- (bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridine (200 mg, 0.555 mmol) in DMF (2 mL) was added to the mixture and the resulting mixture was stirred at r.t. for 2 hrs. The mixture was quenched with saturated aq.TMLCl solution and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to
dryness. The residue was purified by column chromatography on silica gel (PE: EtOAc= 3: 1 to 1 : 1) to give the title compound (175 mg, 75.0% yield) as white solid. LC/MS (ESI) m/z: 420 (M+H)+. Step 8: methyl 2-((S)-l-(6-(5-(((S)-5-(cyclopropylmethyl)-2-oxooxazolidin-3-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0392] To a mixture of (S)-3-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl)-5-(cyclopropylmethyl)oxazolidin-2-one (130 mg, 0.309 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3 -yl)acetate (59.8 mg, 0.309 mmol) and CS2CO3 (101 mg, 0.309 mmol) in 1,4- dioxane (4 mL) was added Ru PHOS (65 mg, 0.139 mmol) and RuPhos Pd G3 (65 mg, 0.078 mmol), the mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by column chromatography on silica gel (PE: EtOAc= 3 : 1 to 1 : 1) to give the title compound (100 mg, 60.8% yield) as yellow solid. LC/MS (ESI) m/z: 543 (M+H)+.
Step 9: 2-((S)-l-(6-(5-(((S)-5-(cyclopropylmethyl)-2-oxooxazolidin-3-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0393] To a solution of methyl 2-((S)-l-(6-(5-(((S)-5-(cyclopropylmethyl)-2-oxooxazolidin-3- yl)methyl)-l -methyl-lH- 1,2, 3-tri azol -4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperi din-3- yl)acetate (100 mg, 0.188 mmol) in THF (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOHELO (150 mg, 3.58 mmol) and the mixture was stirred at 25 °C for 2 hrs. The reaction mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was washed with EtOAc (2 x 3 mL), acidified with IN aq.HCl to pH~4 and extracted with DCM (2 x 3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (11.4 mg, 11.7% yield) as white solid. LC/MS (ESI) m/z: 519 (M+H)+ 1H NMR (400 MHz, CD3OD) 8 7.89 (d, J= 8.3 Hz, 1H), 7.57 (d, J= 8.4 Hz, 1H), 5.27 - 5.11 (m, 2H), 4.58 (dt, J= 13.6, 6.6 Hz, 1H), 4.14 (s, 3H), 3.60 (t, J = 8.8 Hz, 1H), 3.26 -3.20 (m, 3H), 3.15 - 3.01 (m, 1H), 2.97 (q, J = 7.5 Hz, 2H), 2.65 - 2.55 (m, 1H), 2.52 - 2.50 (m,lH), 2.43 - 2.36 (m, 2H), 2.31 -2.29 (m, 1H), 1.81 - 1.66 (m, 1H), 1.65 -1.58 (m, 1H), 1.42 - 1.33 (m, 4H), 0.70 - 0.59 (m, 1H), 0.45 - 0.33 (m, 2H), 0.09 - 0.04 (m, 2H).
Example 70: (R)-2-(l-(6-(5-((3-(cyclopropylmethyl)-2-oxoimidazolidin-l-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: l-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-3- (cyclopropylmethyl)imidazolidin-2-one
[0394] To a solution of 3-bromo-6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridine (100 mg, 0.29 mmol) and l-(cyclopropylmethyl)imidazolidin-2-one (48.6 mg, 0.35 mmol) in DMF (2 mL) was added t-BuOK (1 M in THF, 0.58 mL, 0.58 mmol) at 0 °C under N2 and the mixture was stirred at 0 °C for 1 hr. The mixture was quenched with water and extracted with EtOAc (2 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 30: 1 to 3: 1) to give the title compound (90 mg, 76.8% yield) as white solid. LC/MS (ESI) m/z: 405/407 (M+H)+.
Step 2: methyl (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-2-oxoimidazolidin-l-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0395] To a mixture of l-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl)-3-(cyclopropylmethyl)imidazolidin-2-one (90 mg, 0.22 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3 -yl)acetate (64.4 mg, 0.33 mmol) in toluene (2 mL) were added CS2CO3 (144.7 mg, 0.44 mmol), BINAP (27.7 mg, 0.044 mmol), Pd(OAc)2 (5.0 mg, 0.022 mmol) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 100 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 10: 1 to 1 : 1) to give the title compound (95 mg, 82.7% yield) as white solid. LC/MS (ESI) m/z: 518 (M+H)+.
Step 3: (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-2-oxoimidazolidin-l-yl)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0396] To a solution of methyl (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-2-oxoimidazolidin-l- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetate (95 mg, 0.18 mmol) in THF (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOH.H2O (77 mg, 1.84 mmol) at 25 °C. The reaction was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (5 mL). The mixture was washed with EtOAc twice and the aqueous layer was acidified with IN aq.HCl to pH = 2 and
extracted with DCM (2 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (14 mg, 15.1% yield) as white solid. LC/MS (ESI) m/z: 504 (M+H)+ 1HNMR (400 MHz, CD3OD) 8 7.85 (d, J= 8.2 Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 5.06 (s, 2H), 4.12 (s, 3H), 3.46-3.38 (m, 3H), 3.37-3.34 (m, 1H), 3.28-3.22 (m, 2H), 3.11-2.96 (m, 3H), 2.58 (s, 4H), 2.54-2.44 (m, 1H), 2.42-2.33 (m, 2H), 2.33- 2.25 (m, 1H), 0.94-0.87 (m, 1H), 0.55-0.48 (m, 2H), 0.23-0.18 (m, 2H).
Example 71 : (S)-2-(5,5-difluoro-l-(6-(5-((3-isobutyl-2-oxo-2,3-dihydro-lH-imidazol-l- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: l-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl)-3- isobutyl-l,3-dihydro-2H-imidazol-2-one
[0397] To a mixture of 3-bromo-6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridine (100 mg, 0.29 mmol) and l-(2-methylpropyl)-2,3-dihydro-lH-imidazol-2-one (60 mg, 0.43 mmol) in DMF (2 mL) was added t-BuOK (0.58 mL, 0.58 mmol, IM in THF) drop- wisely at 0 °C and the mixture was stirred at 0 °C for 2 hrs. The mixture was quenched with saturated aq.NBTiCl solution and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column silica chromatography on silica (PE: EtOAc =5: 1 to 3: 1) to give the title compound (90 mg, 76.8% yield) as yellow solid. LC/MS (ESI) m/z: 406 (M+H)+.
Step 2: methyl (S)-2-(5,5-difluoro-l-(6-(5-((3-isobutyl-2-oxo-2,3-dihydro-lH-imidazol-l- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate
[0398] To the mixture of l-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl)-3-isobutyl-l,3-dihydro-2H-imidazol-2-one (40 mg, 0.10 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3 -yl)acetate (17 mg, 0.10 mmol) in toluene (2 mL) was added CS2CO3 (96 mg, 0.30 mmol), BINAP (24 mg, 0.04 mmol) and Pd(OAc)2 (9 mg, 0.04 mmol) under N2 atmosphere. The mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL) and washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography on silica (PE: EtOAc= 3: 1) to give the title compound (40 mg, 78.3% yield). LC/MS (ESI) m/z: 518 (M+H)+.
Step 3: (S)-2-(5,5-difluoro-l-(6-(5-((3-isobutyl-2-oxo-2,3-dihydro-lH-imidazol-l-yl)methyl)- l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid
[0399] To a solution of methyl (S)-2-(5,5-difluoro-l-(6-(5-((3-isobutyl-2-oxo-2,3-dihydro-lH- imidazol- 1 -yl)methyl)- 1 -methyl- 1H- 1 ,2,3 -tri azol-4-yl)-2-methylpyri din-3 -yl)piperi din-3 - yl)acetate (40 mg, 0.08mmol) in THF (2mL) and MeOH (1 mL) was added a solution of Li OH (7 mg, 0.29 mmol) in H2O (1 mL) and the mixture was stirred at r.t. for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was washed with EtOAc (2 x 3 mL), acidified with IN aq.HCl to pH~4 and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-HPLC (Cl 8, 0 ~ 90 % acetonitrile in H2O with 0.1 % formic acid) to give the title compound (20 mg, 51.4% yield) as white solid. LC/MS (ESI) m/z: 504 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.88 (d, J = 8.3 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 6.67 (d, J = 3.0 Hz, 1H), 6.40 (d, J = 3.0 Hz, 1H), 5.47 (s, 2H), 4.15 (s, 3H), 3.42 (d, J = 7.3 Hz, 2H), 3.00-3.20 (m, 2H), 2.62-2.67 (m, 1H), 2.61 (s, 3H), 2.42-2.58 (m, 2H), 2.36-2.41 (m, 2H), 2.28-2.35 (m, 1H), 1.90-2.10 (m, 1H), 1.66-1.79 (m, 1H), 0.89 (d, J = 6.7 Hz, 6H).
Example 72: (S)-2-(l-(6-(5-((3-(cyclopropylmethyl)-2-oxo-2,3-dihydro-lH-imidazol-l- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetic acid
[0400] The title compound was prepared from l-(cyclopropylmethyl)-l,3-dihydro-2H-imidazol- 2-one using the same synthetic sequence that was used to synthesize example 71. LC/MS (ESI) (m/z): 502 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.89 (d, J= 8.4 Hz, 1H), 7.55 (d, J= 8.4 Hz, 1H), 6.67 (d, J= 3.0 Hz, 1H), 6.51 (d, J= 3.0 Hz, 1H), 5.47 (s, 2H), 4.16 (s, 3H), 3.47 (d, J= 1A Hz, 2H), 3.37 - 3.31 (m, 2H), 3.14 - 3.01 (m, 1H), 2.63 - 2.55 (m, 4H), 2.53 - 2.45 (m, 1H), 2.45 - 2.36 (m, 2H), 2.35 - 2.25 (m, 1H), 1.82 - 1.63 (m, 1H), 1.14 - 1.04 (m, 1H), 0.57 - 0.50 (m, 2H), 0.32 (q, J = 4.7 Hz, 2H).
Example 73: 2-((3S)-l-(6-(5-((3-(sec-butyl)-2-oxo-2,3-dihydro-lH-imidazol-l-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0401] The title compound was prepared from 1 -(sec-butyl)- 1, 3 -dihydro-2H-imidazol-2-one using the same synthetic sequence that was used to synthesize example 71. LC/MS (ESI) m/z: 504 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.90 - 7.86 (d, J = 8.4 Hz, 1H), 7.57 - 7.53 (d, J = 8.4 Hz, 1H), 6.73 - 6.66 (d, J = 3.0 Hz, 1H), 6.49 - 6.42 (d, J = 3.0 Hz, 1H), 5.54 - 5.43 (m, 2H), 4.16 (s, 3H), 4.11 - 4.04 (m, 1H), 3.31 (s, 2H), 3.13 - 3.00 (m, 1H), 2.61 (s, 3H), 2.59 - 2.50 (d, J = 11.0 Hz, 2H), 2.35 - 2.26 (d, J = 6.8 Hz, 3H), 1.74 - 1.60 (m, 3H), 1.29 - 1.26 (d, J = 6.8 Hz, 3H), 0.83 - 0.79 (m, 3H).
Example 74: (R)-2-(l-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: ethyl (R)-2-(l-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate
[0402] To a mixture of ethyl 2-[(3R)-l-{2-ethyl-6-[5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol- 4-yl]pyridin-3-yl}piperidin-3-yl]acetate (60 mg, 0.16 mmol ) and 2-chloro-4- cyclobutylpyrimidine (34 mg, 0.2 mmol ) in THF (5 mL) was t-BuOK (0.20 mL, IM in THF) drop- wisely at 0 °C. After the addition, the mixture was stirred at r.t. for 16 hrs. The reaction mixture was diluted with EtOAc (5 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0-50% of EtOAc in PE) to give the title compound (62 mg, 77% yield) as white solid. LC-MS (ESI) m/z: 520 [M+l]+.
Step 2: (R)-2-(l-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol- 4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid
[0403] To a solution of ethyl (R)-2-(l-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate (62 mg, 0.12 mmol) in MeOH (1
mL), water (1 mL) and THF (4 mL) was added LiOH (34 mg, 1 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was acidified with IM aq.HCl to pH=3 and extracted with DCM (3 x 3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (31 mg, 55.2% yield) as white solid. LC/MS (ESI) m/z: 492 [M+l]+. XH NMR (400 MHz, CD3OD) 8 8.41 (d, J= 5.1 Hz, 1H), 7.84 (d, J= 8.0 Hz, 1H), 7.51 (d, J= 8.4 Hz, 1H), 6.98 (d, J= 5.1 Hz, 1H), 6.21 (t, J= 7.8 Hz, 2H), 4.23 (s, 3H), 3.54 - 3.47 (m, 1H), 3.17 - 3.10 (m, 1H), 3.07 - 2.97 (m, 1H), 2.84 (q, J= 7.4 Hz, 2H), 2.71 (td, J= 10.9, 2.9 Hz, 1H), 2.48 - 2.40 (m, 1H), 2.30 (d, J= 6.7 Hz, 2H), 2.25 - 2.18 (m, 5H), 2.02 (dd, J= 10.5, 7.5 Hz, 1H), 1.92 - 1.74 (m, 4H), 1.24-1.20 (t, = 72, 6.8 Hz, 3H).
The examples in the following table were prepared by using method analogous to the examples as indicated in the method column in the table.
Example 95: (R)-2-(l-(6-(5-(((4-cyclobutyl-l,3,5-triazin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: ethyl (R)-2-(l-(6-(5-(((4-chloro-6-cyclobutyl-l,3,5-triazin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate
[0404] To a solution of ethyl (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol- 4-yl)pyri din-3 -yl)piperi din-3 -yl)acetate (60 mg, 0.155 mmol) in THF (3 mL) was added NaH (12.4 mg, 0.31 mmol, 60% dispersion in mineral oil) under N2 atmosphere at 0 °C and the mixture was stirred at 0 °C for 30 mins. Then 2,4-dichloro-6-cyclobutyl-l,3,5-triazine (38 mg, 0.186
mmol) was added and the resulting mixture was stirred at 0 °C for 2 hrs. The mixture was diluted with saturated aq.NH-tCl solution and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 3: 1) to give the title compound (60 mg, 69.8% yield) as white solid. LC/MS (ESI) (m/z): 555 (M+H)+.
Step 2: ethyl (R)-2-(l-(6-(5-(((4-cyclobutyl-l,3,5-triazin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate
[0405] To a solution of ethyl (R)-2-(l-(6-(5-(((4-chloro-6-cyclobutyl-l,3,5-triazin-2- yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate
(60 mg, 0.108 mmol) in EtOAc (3 mL) were added TEA (0.075 mL, 0.540 mmol) and Pd/C (10 mg, 10% wt) at 0 °C and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room temperature for 2 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give title compound (52 mg, 92.4% yield) as yellow oil. LC/MS (ESI) (m/z): 521 (M+H)+.
Step 3: (R)-2-(l-(6-(5-(((4-cyclobutyl-l,3,5-triazin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid
[0406] To a solution of ethyl (R)-2-(l-(6-(5-(((4-cyclobutyl-l,3,5-triazin-2-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate (20 mg, 0.038 mmol) in 1,2-di chloroethane (2 mL) was added trimethyltin hydroxide (69 mg, 0.38 mmol) at room temperature. After stirring at 80 °C for 16 hrs, the mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 25-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (5.5 mg, 29% yield) as white solid. LC/MS (ESI) (m/z): 493 (M+H)+ 1H-NMR (400 MHz, CD3OD) 8 8.82 (s, 1H), 7.84-7.86 (d, J= 8.3 Hz, 1H), 7.50-7.52 (d, J= 8.4 Hz, 1H), 6.23-6.30 (m, 2H), 4.22 (s, 3H), 3.54-3.58 (m, 1H), 3.14-3.17 (d, J = 10.8 Hz, 1H), 3.02-3.05 (d, J = 11.5 Hz, 1H), 2.81-2.87 (m, 2H), 2.69-2.74 (m, 1H), 2.41-2.46 (m, 1H), 2.17-2.37 (m, 8H), 2.01-2.09 (m, 2H), 1.74-1.91 (m, 4H), 1.20-1.24 (m, 4H).
Example 96: (R)-2-(l-(6-(5-(((4-cyclobutyl-6-morpholino-l,3,5-triazin-2-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)pyridin-3- yl)piperidin-3-yl)acetic acid
[0407] To a solution of ethyl (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol- 4-yl)pyridin-3-yl)piperidin-3-yl)acetate (200 mg, 0.516 mmol) in THF (2 mL) and MeOH (6 mL) was added a solution of LiOH (16.6 mg, 0.51 mmol) in water (2 mL) at 0 °C. After stirring at room temperature for 2 hrs, the reaction mixture was concentrated to dryness and the residue was dissolved in water. The mixture was washed with EtOAc (2 x 3 mL) and the aqueous layer was acidified with IN aq.HCl to pH~2 and extracted with DCM (2 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness give the title compound (180 mg, 97% yield) as white solid. LC/MS (ESI) (m/z): 360 (M+H)+.
Step 2: allyl (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)pyridin- 3-yl)piperidin-3-yl)acetate
[0408] To a mixture of (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyri din-3 -yl)piperi din-3 -yl)acetic acid (180 mg, 0.501 mmol) and 3 -bromoprop- 1-ene (0.065 mL, 0.751 mmol) in DMF (6 mL) was added K2CO3 (138 mg, 1.002 mmol) at room temperature and the reaction mixture was stirred at 30 °C for 4 hrs. The mixture was diluted with water and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 1 : 1) to give the title compound (130 mg, 65% yield) as yellow solid. LC/MS (ESI) (m/z): 400 (M+H)+.
Step 3: allyl (R)-2-(l-(6-(5-(((4-chloro-6-cyclobutyl-l,3,5-triazin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate
[0409] To a mixture of allyl (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyri din-3 -yl)piperi din-3 -yl)acetate (130 mg, 0.325 mmol) and 2,4-dichloro-6-cyclobutyl-l,3,5-
triazine (80 mg, 0.39 mmol) in THF (6 mL) was added t-BuOK (0.65 mL, 0.65 mmol, IM in THF) under N2 atmosphere at 0 °C and the mixture was stirred at 0 °C for 2 hrs. The mixture was poured into ice-cooled saturated aq.NH-tCl solution and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried with anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 5: 1) to give the title compound (150 mg, 81.4% yield) as yellow oil. LC/MS (ESI) (m/z): 568 (M+H)+.
Step 4: (R)-2-(l-(6-(5-(((4-cyclobutyl-6-morpholino-l,3,5-triazin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid
[0410] To a solution of allyl (R)-2-(l-(6-(5-(((4-chloro-6-cyclobutyl-l,3,5-triazin-2- yl)oxy )m ethyl)- 1 -methyl- 1H- 1,2, 3 -triazol-4-yl)-2-ethylpyri din-3 -yl)piperi din-3 -yl)acetate (120 mg, 0.21 mmol) in DCM (5 mL) were added morpholine (0.037 mL, 0.423 mmol) and tetrakis(triphenylphosphine)palladium (122 mg, 0.106 mmol) under N2 atmosphere and the reaction mixture was stirred at r.t. for 2 hrs. The reaction mixture was diluted with DCM (5 mL), washed with water and brine, dried with anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 45-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (50 mg, 40.9% yield) as white solid. LC/MS (ESI) (m/z): 578 (M+H)+. TH NMR (400 MHz, CD3OD) 8 7.84-7.86 (d, J = 8.3 Hz, 1H), 7.50-7.52 (d, J= 8.4 Hz, 1H), 6.13- 6.20 (m, 2H), 4.19 (s, 3H), 3.88 (s, 2H), 3.67 (s, 2H), 3.52 (m, 4H), 3.33-3.42 (m, 1H), 3.16-3.18 (d, J= 11.1 Hz, 1H), 3.02-3.04 (d, J= 11.5 Hz, 1H), 2.84-2.89 (m, 2H), 2.70-2.76 (m, 1H), 2.42- 4.47 (m, 1H), 2.28-2.36 (m, 4H), 2.17-2.25 (m, 3H), 1.97-2.05 (m, 1H), 1.80-1.92 (m, 3H), 1.25- 1.29 (m, 4H).
Example 97: 2-[(3R)-l-{2-ethyl-6-[l-methyl-5-({[6-(lH-l,2,3-triazol-l-yl)pyrimidin-4- yl] oxy} methyl)- 1H-1 ,2, 3-triazol-4-yl] pyridin-3-yl}piperidin-3-yl] acetic acid
Step 1: prop-2-en-l-yl 2-[(3R)-l-[6-(5-{[(6-chloropyrimidin-4-yl)oxy]methyl}-l-methyl-lH- 1 ,2,3-tr iazol-4-yl)-2-ethylpyridin-3-yl] piperidin-3-yl] acetate
[0411] To a solution of prop-2-en-l-yl 2-[(3R)-l-{2-ethyl-6-[5-(hydroxymethyl)-l -methyl- 1H- l,2,3-triazol-4-yl]pyridin-3-yl}piperidin-3-yl]acetate (135 mg, 0.34 mmol) in THF (10 mL) was added t-BuOK (114 mg, 1.01 mmol) and 4,6-dichloropyrimidine (101 mg, 0.68 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at r.t. for 1 hr. The reaction mixture was quenched with ice-water (10 mL), extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with water and brine, dried over Na2SO4, filtered and evaporated to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 35 % EtOAc in PE) to give the title compound (140 mg, 80.9% yield) as white solid. LC/MS (ESI) m/z: 513 (M+H)+.
Step 2: allyl (R)-2-(l-(6-(5-(((6-(lH-l,2,3-triazol-l-yl)pyrimidin-4-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate
[0412] To a solution of prop-2-en-l-yl 2-[(3R)-l-[6-(5-{[(6-chloropyrimidin-4-yl)oxy]methyl}-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]piperidin-3-yl]acetate (140 mg, 0.27 mmol) in CEECN (3 mL) was added DBU (125 mg, 0.82 mmol) and 2H-l,2,3-triazole (94 mg, 1.37 mmol) and the mixture was stirred in a CEM microwave reactor at 105 °C for 3 hrs. The reaction mixture was evaporated to dryness and the residue was purified by prep-TLC (EtOAc: PE= 1 : 2) to give allyl (R)-2-(l-(6-(5-(((6-(lH-l,2,3-triazol-l-yl)pyrimidin-4-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol -4-yl)-2-ethylpyri din-3 -yl)piperi din-3 -yl)acetate (50 mg, 33.6% yield) (45 mg, 29% yield) as white solid. LC/MS (ESI) m/z: 545 (M+H)+.
Step 3: 2-[(3R)-l-{2-ethyl-6-[l-methyl-5-({[6-(lH-l,2,3-triazol-l-yl)pyrimidin-4- yl] oxy} methyl)- 1H-1 ,2, 3-triazol-4-yl] pyridin-3-yl} piperidin-3-yl] acetic acid
[0413] To a solution of prop-2-en-l-yl 2-[(3R)-l-{2-ethyl-6-[l-methyl-5-({[6-(lH-l,2,3-triazol- l-yl)pyrimidin-4-yl]oxy}methyl)-lH-l,2,3-triazol-4-yl]pyridin-3-yl}piperidin-3-yl]acetate (50 mg, 0.10 mmol) in DCM (3 mL) was added Pd(PPh3)4 (5 mg, 0.005 mmol) and morpholine (16 mg, 0.2 mmol) and the mixture was degassed under N2 atmosphere for three times and stirred at r.t. for 4 hrs. The reaction mixture was evaporated to dryness and the residue was purified by perp- HPLC (Cl 8, 0 ~ 90 % acetonitrile in H2O with 0.1% HCOOH) to give the title compound (12 mg, 25.9% yield) as white solid. ’H NMR (400 MHz, CD3OD) 8 8.80 (d, J= 1.3 Hz, 1H), 8.79 (d, J= 0.9 Hz, 1H), 7.91 (d, J= 1.3 Hz, 1H), 7.84 (d, J= 8.3 Hz, 1H), 7.59 (d, J= 0.9 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 6.27 (s, 2H), 4.24 (s, 3H), 3.18 - 3.12 (m, 1H), 3.07 - 2.99 (m, 1H), 2.83 (q, J= 7.5 Hz, 2H), 2.76 - 2.65 (m, 1H), 2.46 - 2.38 (m, 1H), 2.30 (d, J= 6.4 Hz, 2H), 2.24 - 2.14 (m, 1H), 1.92 - 1.72 (m, 3H), 1.23 (t, J= 7.5 Hz, 4H). LC/MS (ESI) m/z: 505 (M+H) +.
Example 98: (R)-2-(l-(6-(5-(((6-(2H-l,2,3-triazol-2-yl)pyrimidin-4-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid
Example 98
[0414] The title compound was prepared using the same procedure as example 97. LC/MS (ESI) m/z: 505 (M+H) +. ’H NMR (400 MHz, CD3OD) 8 8.76 (d, J= 0.8 Hz, 1H), 8.07 (s, 2H), 7.84 (d, J= 8.3 Hz, 1H), 7.50 (dd, J= 4.6, 3.8 Hz, 2H), 6.26 (s, 2H), 4.24 (s, 3H), 3.17 - 3.11 (m, 1H), 3.06 - 2.98 (m, 1H), 2.83 (q, J= 7.5 Hz, 2H), 2.74 - 2.66 (m, 1H), 2.48 - 2.39 (m, 1H), 2.29 (d, J= 6.7 Hz, 2H), 2.25 - 2.15 (m, 1H), 1.91 - 1.70 (m, 3H), 1.22 (t, J= 7.5 Hz, 3H).
Example 99: (S)-2-(l-(6-(5-(((6-(lH-l,2,3-triazol-l-yl)pyrimidin-4-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Example 99
[0415] The title compound was prepared from methyl (S)-2-(5,5-difluoro-l-(6-(5- (hydroxymethyl)-l-m ethyl- 1H- 1,2, 3 -tri azol-4-yl)-2-methylpyri din-3 -yl)piperi din-3 -yl)acetate using the same sequence that was synthesized example 97. 'H NMR (400 MHz, CD3OD) 6 8.79 (t, J= 1.1 Hz, 2H), 7.91 (d, J= 1.3 Hz, 1H), 7.85 (d, J= 8.3 Hz, 1H), 7.59 (d, J= 0.9 Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 6.26 - 6.18 (m, 2H), 4.24 (s, 3H), 3.27 (d, J = 13.2 Hz, 2H), 3.11 - 2.96 (m, 1H), 2.64 - 2.54 (m, 1H), 2.53 - 2.44 (m, 4H), 2.43 - 2.23 (m, 3H), 1.80 - 1.61 (m, 1H). LC/MS (ESI) m/z: 527 (M+H)+.
Example 100: (S)-2-(l-(6-(5-(((6-(lH-l,2,3-triazol-2-yl)pyrimidin-4-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0416] The title compound was prepared from methyl (S)-2-(5,5-difluoro-l-(6-(5- (hydroxymethyl)-l-m ethyl- 1H- 1,2, 3 -tri azol-4-yl)-2-methylpyri din-3 -yl)piperi din-3 -yl)acetate using the same sequence that was synthesized example 97. LC/MS (ESI) m/z: 527 (M+H)+. TH NMR (400 MHz, CD3OD) 8 8.74 (s, 1H), 8.09 (s, 2H), 7.99 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.51 (s, 1H), 6.12 (s, 2H), 4.28 (s, 3H), 3.37 (s, 2H), 3.17 - 3.09 (m, 1H), 2.70 - 2.64 (m, 1H), 2.60 (s, 3H), 2.55 - 2.47 (m, 1H), 2.42 (d, J= 7.1 Hz, 2H), 2.35 - 2.27 (m, 1H), 1.82 - 1.70 (m, 1H).
Example 101: (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyrimidin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: 2-chloro-4-(lH-pyrazol-l-yl)pyrimidine
[0417] To a solution of 2,4-dichloropyrimidine (5.0 g, 33.6 mmol) in DMF (50 mL) was added IH-pyrazole (2.28 g, 33.6 mmol) followed by K2CO3 (9.28 g, 67.1 mmol) and the reaction was stirred at r.t. for 16 hrs. The mixture was diluted with EtOAc (50 mL), washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0 ~ 5% EtOAc in PE) to give the title compound (1.2 g, 19.8% yield) as yellow solid. LC/MS (ESI) (m/z): 181 (M+H)+. XH NMR (400 MHz, CDCh) 6
8.63 (d, J = 5.5 Hz, 1H), 8.58 (d, J = 2.4 Hz, 1H), 7.86 (d, J = 5.5 Hz, 1H), 7.82 (d, J = 0.8 Hz, 1H), 6.54 (dd, J= 2.7, 1.6 Hz, 1H).
Step 2: ethyl (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyrimidin-2-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate
[0418] To a mixture of ethyl ethyl (R)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol -4-yl)pyri din-3 -yl)piperi din-3 -yl)acetate (40 mg, 0.11 mmol) and 2-chloro-4-(lH-pyrazol- l-yljpyrimidine (30 mg, 0.16 mmol) in THF (5 mL) was added t-BuOK (0.22 mL, 0.22 mmol, 1.0 M in THF) drop-wisely at 0 °C and the reaction was stirred at 0 °C for 1 hr. The mixture was quenched with saturated aq.NH4Cl solution at 0 oC and extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 60% EtOAc in PE) to give the title compound (35 mg, 59.5% yield) as yellow oil. LC/MS (ESI) (m/z): 532 (M+H)+.
Step 3: (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetic acid
[0419] To a solution of ethyl (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyrimidin-2-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)piperidin-3-yl)acetate (36 mg, 0.065 mmol) in THF (4 mL)/H20 (4 mL)/MeOH (4 mL) was added LiOH.ftO (28 mg, 0.66 mmol), and the reaction was stirred at r.t. for 2 hrs. Volatiles were removed under vacuum and the residue was diluted with H2O (5 mL). The mixture was adjusted with IN aq.HCl to pH~4. The mixture was extracted with EtOAc (3 x 5 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep- HPLC (C18, 5-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (15 mg, 45.2% yield) as white solid. LC/MS (ESI) (m/z): 504 (M+H)+. 1H NMR (400 MHz, CD3OD) 8 8.57 (d, J = 5.5 Hz, 1H), 8.34 (d, J= 2.6 Hz, 1H), 7.96 (d, J= 8.5 Hz, 1H), 7.81 - 7.74 (m, 2H), 7.61 (d, J= 5.5 Hz, 1H), 6.51 - 6.50 (m, 1H), 6.16 - 6.09 (m, 2H), 4.27 (s, 3H), 3.25 (d, J= 13.1 Hz, 3H), 3.11 (d, J= 11.0 Hz, 1H), 2.98 - 2.92 (m, 2H), 2.84 - 2.78 m, 1H), 2.56 - 2.51 (m, 1H), 2.33 - 2.31 (m, 2H), 2.27 - 2.21 (m, 1 H), 1.93 - 1.76 (m, 3H), 1.30 - 1.26 (m, 4H).
Example 102: (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyrimidin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid
[0420] The title compound was synthesized from Intermediate 2A of example 101 according to the same sequence as was used for the synthesis of example 101. LC/MS (ESI) m/z: 490 (M+H)+. 'H NMR (400 MHz, DMSO-tL) 6 8.72 (d, J = 5.5 Hz, 1H), 8.42 (d, J= 2.2 Hz, 1H), 7.93 (d, J= 1.0 Hz, 1H), 7.88 (d, J= 8.3 Hz, 1H), 7.59 (d, J= 5.5 Hz, 1H), 7.50 (d, J= 8.4 Hz, 1H), 6.57 (dd, J = 2.7, 1.6 Hz, 1H), 6.14 (s, 2H), 4.16 (s, 3H), 3.10 (d, J= 10.4 Hz, 1H), 3.02 (d, J = 11.5 Hz, 1H), 2.67 - 2.61 (m, 1H), 2.43 - 2.37 (m, 1H), 2.32 (s, 3H), 2.27 - 2.19 (m, 2H), 2.10 - 2.03 (m, 1H), 1.82 - 1.71 (m, 2H), 1.67 - 1.59 (m, 1H), 1.16 -1.08 (m, 1H).
Example 103: (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyridin-2-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: ethyl (R)-2-(l-(6-(5-(((4-iodopyridin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4- yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate
[0421] To a solution of ethyl (R)-2-(l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyri din-3 -yl)piperi din-3 -yl)acetate (200 mg, 0.53 mmol) in DMF (10 mL) was added NaH (43 mg, 1.07 mmol, 60% dispersion in mineral oil) at 0 °C and the mixture was stirred at 0 °C for 30 min. A solution of 2-fluoro-4-iodopyridine(240 mg, 1.07 mmol) in DMF (2 mL) was added drop-wisely to the above mixture and the resulting mixture was stirred at r.t. for 30 min. The mixture was quenched with saturated aq.NH-tCl solution at 0 °C and was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 45% EtOAc in PE) to give the title compound (120 mg, 38.9% yield) as yellow solid. LC/MS (ESI) (m/z): 577 (M+H)+.
Step 2: ethyl (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyridin-2-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate
[0422] To a solution of ethyl (R)-2-(l-(6-(5-(((4-iodopyridin-2-yl)oxy)methyl)-l-methyl-lH-
l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate (120 mg, 0.21 mmol) in DMSO (5 mL) was added IH-pyrazole (28 mg, 0.42 mmol) followed by K2CO3 (58 mg, 0.42 mmol), Cui (8 mg, 0.04 mmol) and N,N' -Dimethyl- 1,2-ethanediamine (4 mg, 0.04 mmol). The reaction was stirred at 120 °C for 16 hrs. The mixture was diluted with EtOAc (15 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0 ~ 40% EtOAc in PE) to give the title compound (50 mg, 46.5% yield) as yellow solid. LC/MS (ESI) m/z: 517 (M+H)+.
Step 3: (R)-2-(l-(6-(5-(((4-(lH-pyrazol-l-yl)pyridin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid
[0423] The title compounds was synthesized from compound 3 according to the same sequence as was used for the synthesis of example 101. LC/MS (ESI) m/z: 489 (M+H)+. ’H NMR (400 MHz, CD3OD) 6 8.31 (d, = 2.6 Hz, 1H), 8.18 (d, J= 5.8 Hz, 1H), 7.79 (d, J= 8.4 Hz, 1H), 7.74 (d, J= 1.6 Hz, 1H), 7.51 - 7.42 (m, 2H), 7.24 (d, J= 1.7 Hz, 1H), 6.57 - 6.44 (m, 1H), 6.03 (d, = 2.1 Hz, 2H), 4.22 (s, 3H), 3.20 (d, J= 11.0 Hz, 1H), 3.08 (d, J= 11.3 Hz, 1H), 2.75 - 2.65 (m, 1H), 2.46 (s, 3H), 2.42 (d, J= 11.2 Hz, 1H), 2.33 - 2.27 (m, 2H), 2.25 - 2.17 (m, 1H), 1.93 - 1.86 (m, 1H), 1.85 - 1.72 (m, 2H), 1.22 - 1.15 (m, 1H).
Example 104: (R)-2-(l-(6-(5-(((4-(2H-l,2,3-triazol-2-yl)pyridin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: ethyl (R)-2-(l-(6-(5-(((4-(2H-l,2,3-triazol-2-yl)pyridin-2-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate
[0424] To a solution of ethyl (R)-2-(l-(6-(5-(((4-iodopyridin-2-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate (120 mg, 0.21 mmol) in DMSO (5 mL) was added 1,2,3-1H-Triazole (29 mg, 0.42 mmol) followed by K2CO3 (58 mg, 0.42 mmol), Cui (8 mg, 0.04 mmol) and N,N' -Dimethyl- 1,2-ethanediamine (4 mg, 0.04 mmol). The reaction was stirred at 120 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 50% EtOAc in PE) to give the title compound (65 mg, 69.8% yield) as yellow solid. LC/MS (ESI) m/z: 518 (M+H)+. TH NMR (400 MHz, CDCh) 6 8.20 (d, J= 5.6 Hz, 1H), 7.87 (d, J= 8.3 Hz, 1H), 7.77 (s, 2H), 7.60
(dd, J= 5.6, 1.8 Hz, 1H), 7.40 (d, J= 1.8 Hz, 1H), 7.26 (d, J= 8.3 Hz, 1H), 6.04 (s, 2H), 4.10 (s, 3H), 4.05 - 4.03 (m, 2H), 3.02 - 2.95 (m, 1H), 2.97 (d, J= 11.4 Hz, 1H), 2.64 - 2.54 (m, 1H), 2.44 - 2.38 (m, 3H), 2.37-2.30 (m, 1H), 2.21 - 2.16 (m, 1H), 1.84 7 1.75 (m, 1H), 1.18 (dd, J= 4.7, 2.4 Hz, 3H), 1.13 - 1.05 (m, 1H).
Step 2: (R)-2-(l-(6-(5-(((4-(2H-l,2,3-triazol-2-yl)pyridin-2-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetic acid
The title compounds was synthesized according to the same sequence as was used for the synthesis of example 103. LC/MS (ESI) m/z:490 (M+H)+. XH NMR (400 MHz, CD3OD) 8 8.24 (d, J= 5.7 Hz, 1H), 7.97 (s, 2H), 7.78 (d, J= 8.3 Hz, 1H), 7.70 (dd, J= 5.7, 1.8 Hz, 1H), 7.48 (d, J= 8.3 Hz, 1H), 7.47 (d, J= 1.8 Hz, 1H), 6.06 (s, 2H), 4.22 (s, 3H), 3.22 - 3.19 (m, 1H), 3.10 - 3.05 (m, 1H), 2.73 - 2.66 (m, 1H), 2.46 (s, 3H), 2.44 - 2.40 (m, 1H), 2.32 - 2.28 (m, 2H), 2.25 - 2.18 (m, 1H), 1.93 - 1.87 (m, 1H), 1.84 - 1.72 (m, 2H), 1.26 - 1.18 (m, 1H).
Example 105: (S)-2-(l-(6-(4-(((6-(lH-pyrazol-l-yl)pyrimidin-4-yl)oxy)methyl)-3- methylisoxazol-5-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: tert-butyl (Z)-3-(methylamino)but-2-enoate
[0425] To aq.MeNTb solution (40% wt in water) (5.9 g, 190 mmol) was added tert-butyl 3- oxobutanoate (10 g, 63.2 mmol) drop-wisely at 0 °C and the mixture was stirred at r.t. for 2 hrs. The mixture was diluted with DCM (50 mL) and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (10.8 g, 99.8%
yield) as yellow oil. LC/MS (ESI) m/z: 172 (M+H)+.
Step 2: tert-butyl (E)-2-(5-bromo-6-methylpicolinoyl)-3-(methylimino)butanoate
[0426] To a mixture of 5-bromo-6-methylpicolinoyl chloride (1 g, 4.27 mmol) and tert-butyl (Z)- 3-(methylamino)but-2-enoate (0.80 g, 4.69 mmol) in THF (10 mL) was added pyridine (1.69 g, 21.3 mmol) drop-wisely at 0 °C and the mixture was stirred at r.t. for 16 hrs. The mixture was diluted EtOAc (20 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give title compound (964 mg, 61.2% yield) as yellow solid. LC/MS (ESI) m/z: 369/371 (M+H)+.
Step 3: 5-(5-bromo-6-methylpyridin-2-yl)-3-methylisoxazole-4-carboxylic acid
[0427] To a solution of tert-butyl (E)-2-(5-bromo-6-methylpicolinoyl)-3-(methylimino)butanoate (964 mg, 2.61 mmol) in EtOH (10 mL) was added hydroxylamine hydrochloride (272 mg, 3.92 mmol) and the mixture was stirred at 60 °C for 3 hrs. The mixture was diluted with water and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with DCM: MeOH = 200: 1 to 20: 1) to give the title compound (353 mg, 45.5% yield) as white solid. LC/MS (ESI) m/z: 297/299 (M+H)+.
Step 4: (5-(5-bromo-6-methylpyridin-2-yl)-3-methylisoxazol-4-yl)methanol
[0428] To a solution of 5-(5-bromo-6-methylpyridin-2-yl)-3-methylisoxazole-4-carboxylic acid (353 mg, 1.19 mmol) in THF (5 mL) was added BH3-THF (3 mL, 3 mmol, 1 M in THF) drop- wisely at 0 °C and the mixture was stirred at 60 °C for 2 hrs. The mixture was quenched with MeOH at 0 °C and concentrated to dryness. The residue was purified by flash chromatography (PE: EtOAc= 30: 1 to 3 : 1) to give the title compound (163 mg, 48.5% yield) as white solid. LC/MS (ESI) m/z: 283/285 (M+H)+.
Step 5: 5-(5-bromo-6-methylpyridin-2-yl)-3-methyl-4-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)isoxazole
[0429] To a solution of (5-(5-bromo-6-methylpyridin-2-yl)-3-methylisoxazol-4-yl)methanol (163 mg, 0.58 mmol) in DCM (3 mL) were added DHP (121 mg, 1.44 mmol), PPTS (7.2 mg, 0.029 mmol) and the mixture was stirred at r.t. for 16 hrs. The mixture was quenched with saturated aq.NaHCOs and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with DCM: MeOH= 200: 1 to 20: 1) to give the title compound (200 mg, 94.6% yield) as yellow oil. LC/MS (ESI) m/z: 367/369 (M+H)+.
Step 6: methyl 2-((3S)-5,5-difluoro-l-(2-methyl-6-(3-methyl-4-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)isoxazol-5-yl)pyridin-3-yl)piperidin-3-yl)acetate
[0430] To a mixture of 5-(5-bromo-6-methylpyridin-2-yl)-3-methyl-4-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)isoxazole (95 mg, 0.26 mmol) and methyl (S)-2-(5,5-difluoropiperidin-3-yl)acetate (50.0 mg, 0.26 mmol) in 1,4-dioxane (2 mL) were added CS2CO3 (253 mg, 0.78 mmol), Pd2(dba)3 (24 mg, 0.026 mmol), Ru-Phos (12 mg, 0.026 mmol ) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The mixture was diluted with water and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 20: 1 to 1 : 1) to give the title compound (45 mg, 36.2% yield) as yellow solid. LC/MS (ESI) m/z: 480 (M+H)+.
Step 7: methyl (S)-2-(5,5-difluoro-l-(6-(4-(hydroxymethyl)-3-methylisoxazol-5-yl)-2- methylpyridin-3-yl)piperidin-3-yl)acetate
[0431] To a solution of methyl 2-((3S)-5,5-difluoro-l-(2-methyl-6-(3-methyl-4-(((tetrahydro-2H- pyran-2-yl)oxy)methyl)isoxazol-5-yl)pyridin-3-yl)piperidin-3-yl)acetate (45 mg, 0.094 mmol) in MeOH (2 mL) was added PPTS (47 mg, 0.19 mmol) and the mixture was stirred at 60 °C for 2 hrs. The mixture was diluted with EtOAc (5 mL) and washed with saturated aq.NaHCOs solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 1 : 1) to give the title compound (30 mg, 80.9% yield) as yellow oil. LC/MS (ESI) m/z: 396 (M+H)+.
Step 8: methyl (S)-2-(l-(6-(4-(((6-(lH-pyrazol-l-yl)pyrimidin-4-yl)oxy)methyl)-3- methylisoxazol-5-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0432] To a solution of methyl (S)-2-(5,5-difluoro-l-(6-(4-(hydroxymethyl)-3-methylisoxazol-5- yl)-2-methylpyridin-3-yl)piperidin-3-yl)acetate (30 mg, 0.076 mmol) and 4-chloro-6-(lH-pyrazol- l-yl)pyrimidine (20.6 mg, 0.11 mmol) in THF (2 mL) was added t-BuOK (0.15 mL, 0.15 mmol, 1 M in THF) drop-wisely at 0 °C under N2 atmosphere and the mixture was stirred at 25 °C for 2 hrs. The mixture was quenched with water and extracted with EtOAc (3 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (30 mg, yield 73.3%) as yellow oil, which was used in next step directly. LC/MS (ESI) m/z: 540 (M+H)+.
Step 9: (S)-2-(l-(6-(4-(((6-(lH-pyrazol-l-yl)pyrimidin-4-yl)oxy)methyl)-3-methylisoxazol-5- yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0433] To a solution of methyl (S)-2-(l-(6-(4-(((6-(lH-pyrazol-l-yl)pyrimidin-4-yl)oxy)methyl)- 3-methylisoxazol-5-yl)-2-methylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (30 mg, 0.056
mmol) in THF (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOH.ftO (23.3 mg, 0.56 mmol) at 25 °C and the mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (5 mL). The mixture was washed with EtOAc (2 x 3 mL) and the aqueous layer was acidified with IN aq.HCl to pH = 4 and extracted with DCM (3 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (5 mg, 17.1% yield) as white solid. 'H NMR (400 MHz, CD3OD) 8 8.63 (s, 1H), 8.59 (d, J= 2.6 Hz, 1H), 7.76 (d, J= 1.0 Hz, 1H), 7.73 (d, = 8.2 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.27 (s, 1H), 6.54 (dd, J= 2.6, 1.7 Hz, 1H), 5.89 (s, 2H), 3.40-3.33 (m, 2H), 3.15-3.03 (m, 1H), 2.64-2.57 (m, 1H), 2.55-2.50 (m, 1H), 2.48 (s, 3H), 2.41 (s, 3H), 2.41-2.38 (m, 2H), 2.36-2.27 (m, 1H), 1.80-1.66 (m, 1H). LC/MS (ESI) m/z: 526 (M+H)+.
Example 106: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((3-oxo-4-propyl-3,4-dihydropyrazin-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
Step 1 : methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((3-oxo-4-propyl-3,4-dihydropyrazin- 2-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate
[0434] To a mixture of methyl (S)-2-(5,5-difhioro-l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol -4-yl)-2-methylpyri din-3 -yl)piperi din-3 -yl)acetate (55 mg, 0.14 mmol) and 3-chloro-l- propylpyrazin-2(lH)-one (27 mg, 0.15 mmol) in DMF (5 mL) was added t-BuOK (0.42 mL, 0.42 mmol, 1 M in THF) at 0 °C and the mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with saturated aq.NEECl solution and brine, dried over anhydrous Na2SO4 filtered and concentrated to dryness to give the title compound (70 mg, 94.2% yield). LC/MS (ESI) (m/z): 532 (M+H)+.
Step 2: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((3-oxo-4-propyl-3,4-dihydropyrazin-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
[0435] To a solution of methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((3-oxo-4-propyl- 3,4-dihydropyrazin-2-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (74 mg, 0.14 mmol) in MeOH (1 mL), water (1 mL) and THF (4 mL) was added LiOH (29 mg, 0.7 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to
dryness. The residue was diluted with water (5 mL) and washed with EtOAc (2 x 3 mL). The aqueous layer was acidified with IN aq.HCl to pH- 3 and extracted with DCM (3 x 3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (15 mg, 20.8% yield) as white solid. LC/MS (ESI) m/z: 518 (M+H)+. 'H-NMR (400 MHz, CD3OD) 8 7.83 (d, J = 8.4 Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 7.16 (d, J= 4.4 Hz, 1H), 6.92 (d, J= 4.4 Hz, 1H), 5.99 (s, 2H), 4.21 (s, 3H), 3.90 (t, J= 8.4 Hz, 2H), 3.30 - 3.24 (m, 2H), 3.14 - 3.00 (m, 1H), 2.64 - 2.51 (m, 1H), 2.47 - 2.26 (m, 7H), 1.81 - 1.62 (m, 3H), 0.94 (t, J = 7.2 Hz, 3H).
Example 107: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl-l,4-dihydropyridin-3- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: 5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one
[0436] To a solution of 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one (5 g, 35.2 mmol) in MeOH (100 mL) was added a solution of NaOH (1.41 g, 35.2 mmol) in H2O (10 mL) and the reaction was stirred at 80 °C for 30 min. (Chloromethyl)benzene (4.05 mL, 35.2 mmol) was added drop-wisely to the above mixture and the resulting mixture was stirred at 80 °C for 16 hrs. The mixture was diluted with H2O (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (800 mg, 9.8% yield) as brown yellow solid, which was directly used in the next step. LC/MS (ESI) m/z: 233 (M+H)+.
Step 2: 5-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid
[0437] To a solution of 5-(benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one (800 mg, 3.44 mmol) in acetone (50 mL) was added newly prepared Jone’s-reagent (2.6 mL, 5.2 mmol) at 0 °C and the mixture was stirred at r.t. for 1 hr. The mixture was poured into ice-water and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with saturated aq.Na2SO3 solution and
brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (850 mg, 100% yield) as yellow oil, which was directly used in the next reaction without purification. LC/MS (ESI) m/z: 247 (M+H)+.
Step 3: 5-(benzyloxy)-4-oxo-l-propyl-l,4-dihydropyridine-2-carboxylic acid
[0438] A mixture of 5-(benzyloxy)-4-oxo-4H-pyran-2-carboxylic acid (850 mg, 3.44 mmol) and propan- 1 -amine (816 mg, 13.8 mmol) in MeOH (10 mL) was stirred at r.t. for 16 hrs. The reaction mixture was concentrated to dryness and the residue was dissolved in H2O (10 mL). The mixture was acidified with 3N aq.HCl to pH~2 and filtered. The filter cake was washed with water, dried under vacuum to give the title compound (390 mg, 39.3% yield) as light yellow solid. LC/MS (ESI) m/z: 288 (M+H)+.
Step 4: 3-(benzyloxy)-l-propyl-l,4-dihydropyridin-4-one
[0439] The solution of 5-(benzyloxy)-4-oxo-l-propyl-l,4-dihydropyridine-2-carboxylic acid (250 mg, 0.87mmol) in DMF (5 mL) was stirred at 130 °C for 1 hr. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (150 mg, 70.9% yield) as yellow solid. LC/MS (ESI) m/z: 244 (M+H)+.
Step 5: 3-hydroxy-l-propylpyridin-4(lH)-one
[0440] To a solution of 3 -(benzyloxy)- 1 -propyl- l,4-dihydropyridin-4-one (150 mg, 0.62 mmol) in MeOH (3 mL) was added Pd(OH)2 (30 mg, 10% wt), the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at r.t. for 1 hr. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (90 mg, 95.3% yield) as white solid. LC/MS (ESI) (m/z): 154 (M+H)+. XH NMR (400 MHz, CDCh) 5 7.18 - 7.24 (m, 2H), 6.43 (d, J= 6.9 Hz, 1H), 3.74 - 3.80 (m, 2H), 1.89 - 1.78 (m, 2H), 0.92 - 0.98 (m, 3H).
Step 6: methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl-l,4-dihydropyridin-3- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0441] To a mixture of methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (30 mg, 0.062 mmol) and 3- hydroxy-l-propylpyridin-4(lH)-one (14 mg, 0.092 mmol) in CH3CN (1 mL) was added K2CO3 (25 mg, 0.18 mmol) and TBAI (4 mg, 0.01 mmol) and the mixture was stirred at 70 °C for 16 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (32 mg, 94.8% yield) as yellow solid. LC/MS (ESI) (m/z): 545 (M+H)+.
Step 7: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl-l,4-dihydropyridin-3- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0442] To a solution of methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l -propyl- 1,4-
dihydropyri din-3 -yl)oxy)methyl)-lH- 1,2, 3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperi din-3- yl)acetate (32 mg, 0.059 mmol) in MeOH (1 mL), water (1 mL) and THF (2 mL) was added LiOH.FbO (12 mg, 0.29 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to dryness. The residue was diluted with water (3 mL) and washed with EtOAc (2 x 3 mL). The aqueous layer was acidified with IM aq.HCl to pH ~ 3 and extracted with DCM (3 x 3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep HPLC to give the title compound (9 mg, 28.9% yield) as white solid. LC/MS (ESI) (m/z): 531 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.93 (d, J= 8.4 Hz, 1H), 7.77 (d, J= 2.1 Hz, 1H), 7.63 - 7.58 (m, 2H), 6.42 (d, J= 7.2 Hz, 1H), 6.01 - 5.82 (m, 2H), 4.22 (s, 3H), 3.71 - 3.68 (t, J= 7.2 Hz, 2H), 3.2 - 3.20 (m, 2H), 3.14 - 3.05 (m, 1H), 2.9 - 2.93 (m, 2H), 2.65 - 2.57 (m, 1H), 2.63 - 2.58 (m, 1H), 2.40 (d, J= 7.0 Hz, 2H), 2.34 - 2.25 (m, 1H), 1.80 - 1.64 (m, 1H), 1.5 - 1.49 (m, 2H), 1.33 - 1.29 (t, J = 7.5 Hz, 3H), 0.73 - 0.96 (t, J = 7.4 Hz, 3H).
Example 108: 2-[(lS)-5-(6-{5-[(5-cyclobutyl-2-oxo-l,2-dihydropyridin-l-yl)methyl]-l- methyl-lH-l,2,3-triazol-4-yl}-2-ethylpyridin-3-yl)-3,3-difluorocyclohexyl]acetic acid
Step 1: 6-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methoxy)-2- propylpyridazin-3(2H)-one
[0443] To a solution of [4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol- 5yl]methanol (150 mg, 0.5 mmol) in DMF (4 mL) was added NaH (42 mg, 1.1 mmol, 60% dispersion in mineral oil) at 0 °C and the mixture was stirred at this temperature for 30 min. 3- Chl oro-1 -propyl- l,2-dihydropyrazin-2-one (101 mg, 0.6 mmol) was added to the above mixture and the resulting mixture was stirred at r.t. for 1.5 hrs. The reaction was quenched with saturated aq.NH4Cl solution and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 4: 1) to give the title compound (120
mg, 54.0% yield) as off-white solid. LC/MS (ESI) (m/z): 420 (M+H)+.
Step 2: methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((6-oxo-l-propyl-l,6- dihydropyridazin-3-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate
[0444] To a solution of 6-((4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methoxy)-2-propylpyridazin-3(2H)-one (120 mg, 0.28 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3 -yl)acetate (55 mg, 0.28 mmol) in toluene (3 mL) were added CS2CO3 (234 mg, 0.71 mmol), BINAP (35.7 mg, 0.05 mmol), Pd(OAc)2 (6.4 mg, 0.028 mmol) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 100 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 10: 1 to 1 : 1) to give the title compound (100 mg, 67.2% yield) as white solid. LC/MS (ESI) m/z: 534 (M+H)+.
Step 3: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((6-oxo-l-propyl-l,6 dihydropyridazin-3-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetic acid
[0445] To a solution of (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-(((6-oxo-l-propyl-l,6- dihydropyridazin-3-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (50 mg, 0.094 mmol ) in THF (2 mL), MeOH (1 mL) and water (1 mL) was added LiOH.EBO (40 mg, 0.1 mmol) and the mixture was stirred at 25 °C for 3 hrs. The reaction mixture was acidified with IM aq.HCl to pH~4 and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (15 mg, 30.8% yield) as white solid. LC/MS (ESI) m/z: 518 (M+H)+. 'H NMR (400 MHz, CD3OD) 8 7.86 (d, J= 8.3 Hz, 1H), 7.55 (d, J= 8.4 Hz, 1H), 7.16 (d, J= 9.7 Hz, 1H), 6.94 (d, J= 9.7 Hz, 1H), 5.97 (s, 2H), 4.19 (s, 3H), 3.79 - 3.72 (m, 2H), 3.30 - 3.25 (m, 2H), 3.14 - 3.03 (m, 1H), 2.60 (t, J= 10.5 Hz, 1H), 2.52 (s, 3H), 2.51 - 2.42 (m, 1H), 2.39 (d, = 6.5 Hz, 2H), 2.30 (s, 1H), 1.82 - 1.66 (m, 1H), 1.65 - 1.55 (m, 2H), 0.83 (t, J = 7.4 Hz, 3H).
Example 109: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((5-oxo-2-propyl-2,5-dihydropyridazin-4- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: 3,5-dichloro-4-methoxypyridazine
[0446] To a solution of 3,4,5-trichloropyridazine (5 g, 27.26 mmol) in MeOH (50 mL) was added MeONa/MeOH solution (5.5 mL, 5 M) drop-wisely at -10 °C and the mixture was stirred at 0 °C for 1 hr. The mixture was concentrated to dryness and the residue was dissolved in H2O (50 mL). The mixture was extracted with DCM (2 x 30 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography (PE: EtOAc= 20: 1) to give the title compound (1.5 g, 30.7% yield) as yellow solid. LC/MS (ESI) m/z: 179 (M+H)+. 1HNMR (400 MHz, CDCh) 69.01 (s, 1H), 4.15 (s, 3H).
Step 2: 3-chloro-4,5-dimethoxypyridazine
[0447] To a solution of 3,5-dichloro-4-methoxypyridazine (2.8 g, 15.64 mmol) in MeOH (30 mL) was MeONa/MeOH solution (3.2 mL, 16 mmol, 5 M) drop-wisely at r.t. and the mixture was stirred at 80 °C for 1 hr. The mixture was concentrated to dryness and the residue was dissolved in H2O (50 mL). The mixture was extracted with DCM (2 x 30 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography (PE: EtOAc= 10: 1) to give the title compound (1.6 g, 58.6% yield) as yellow solid. LC/MS (ESI) m/z: 175 (M+H)+.
Step 3: 4,5-dimethoxypyridazine
[0448] To a solution of 3-chloro-4,5-dimethoxypyridazine (600 mg, 3.44 mmol) in EtOAc (20 mL) were added TEA (695 mg, 6.87 mmol) and Pd(OH)2/C (48 mg, 0.03 mmol, 10% wt) and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at 25
°C for 1 hr. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (210 mg, 43.6% yield) as white solid. LC/MS (ESI) m/z: 141 (M+H)+. XH NMR (400 MHz, CDCh) 6 8.78 (s, 2H), 3.96 (s, 6H).
Step 4: 5-methoxy-l-propyl-l,4-dihydropyridazin-4-one
[0449] To a solution of 4,5-dimethoxypyridazine (200 mg, 1.43 mmol) in acetone (5mL) was added 1 -iodopropane (485 mg, 2.85 mmol) and the mixture was stirred at 50 °C for 18 hrs. The mixture was concentrated to dryness and the residue was purified by silica gel column chromatography (PE: EtOAc= 3 : 1) to give the title compound (80 mg, 33.3% yield). LC/MS (ESI) (m/z): 169 (M+H)+. ’H NMR (400 MHz, CDCh) 6 7.86 (s, 1H), 7.42 (s, 1H), 3.93-3.98 (m, 2H), 3.80 (s, 3H), 1.81-1.89 (m, 2H), 0.87-0.93 (m, 3H).
Step 5: 5-hydroxy-l-propyl-l,4-dihydropyridazin-4-one
[0450] To a solution of 5-methoxy-l-propyl-l,4-dihydropyridazin-4-one (80 mg, 0.48 mmol) in DCM (3 mL) was BBn (0.18 mL, 1.90 mmol) drop-wisely at 0 °C and the mixture was stirred at r.t. for 2 hrs. The mixture was quenched with MeOH at 0 °C and poured into ice-cooled saturated aq.NaHCCh solution. The mixture was extracted with DCM (2 x 5 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc= 1 : 1) to give the title compound (30 mg, 40.9% yield) as yellow solid. LC/MS (ESI) m/z: 155 (M+H)+.
Step 6: methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((5-oxo-2-propyl-2,5-dihydropyridazin-4- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0451] To the mixture of 5-hydroxy-l-propyl-l,4-dihydropyridazin-4-one (14 mg, 0.09 mmol) and methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (30 mg, 0.06 mmol) in MeCN (3 mL) was added K2CO3 (25 mg, 0.18 mmol) and TBAI (5 mg, 0.01 mmol) and the mixture was stirred at 70 °C for 1 6 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (PE: EtOAc= 5: 1 to 1 : 1) to give the title compound (20 mg, 59.7% yield) as yellow solid. LC/MS (ESI) m/z: 546 (M+H)+.
Step 7 : (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((5-oxo-2-propyl-2,5-dihydropyridazin-4- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0452] To a solution of methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((5-oxo-2-propyl-2,5- dihydropyridazin-4-yl)oxy)methyl)-lH- 1,2, 3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperi din-3- yl)acetate (20 mg, 0.037 mmol) in THF (1 mL) and MeOH (1 mL) was added a solution of LiOH
(15 mg , 0.37 mmol) in H2O (0.5 mL), and the mixture was stirred at r.t. for 2 hrs. The mixture was acidified with IN aq.HCl to pH~4 and extracted with DCM (2 x 3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-HPLC (C18, 0 ~ 90% acetonitrile in H2O with 0.1% HCOOH) to give the title compound (9 mg, 46.2% yield) as white solid. LC/MS (ESI) m/z: 532 (M+H)+. TH NMR (400 MHz, CD3OD) 8 8.54 (s, 1H), 7.94 (d, J= 9.5 Hz, 2H), 7.61 (d, J= 8.4 Hz, 1H), 6.04 - 5.94 (m, 2H), 4.22 (s, 3H), 3.91 - 3.96 (t, J= 7.1 Hz, 2H), 3.25 - 3.22 (m, 2H), 3.14 - 3.05 (m, 1H), 2.99 - 2.92 (q, J= 7.7 Hz, 2H), 2.63 - 2.58 (t, J= 10.8 Hz, 1H), 2.53 - 2.50 (m, 1H), 2.41 - 2.39 (m, 2H), 2.31 - 2.26 (m, 1H), 1.80 - 1.63 (m, 3H), 1.26 - 1.32 (t, J = 7.5 Hz, 3H), 0.72 - 0.78 (t, J = 7.4 Hz, 3H).
Example 110: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-methyl-3-oxo-6-propyl-3,4-dihydropyrazin-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: N-(l-hydroxypentan-2-yl)-N'-methylethanediamide
[0453] To a solution of 2-aminopentan-l-ol (1.21 g, 11.63 mmol) in toluene (15 mL) and EtOAc was added ethyl (methylcarbamoyl)formate (1.67 g, 12.79 mmol), and the mixture was stirred at 90 °C for 16 hrs. The reaction mixture was concentrated to dryness and the solid was washed with PE, dried under vacuum to give the title compound (2.06 g, 94.1% yield) as white solid. LC/MS (ESI) m/z: 189 (M+H)+.
Step 2: N'-methyl-N-(l-oxopentan-2-yl)ethanediamide
[0454] To a solution of N-(l-hydroxypentan-2-yl)-N'-methylethanediamide (400 mg, 2.12 mmol) in DCM (15 mL) was added Dess-Martin periodinane (900 mg, 2.12 mmol) and the mixture was stirred at r.t. for 3 hrs. The mixture was washed with saturated aq.NaHCOs solution and brine, dried overNa2SO4, filtered and concentrated to dryness to give the title compound (405 mg, 81.9% yield) as white solid. LC/MS (ESI) m/z: 187 (M+H)+.
Step 3: 3-hydroxy-l-methyl-5-propyl-l,2-dihydropyrazin-2-one
[0455] To a solution of N'-methyl-N-(l-oxopentan-2-yl)ethanediamide (405 mg, 2.14 mmol) in AcOH (5 mL) was added conc.HCl (0.5 mL) and the mixture was stirred at 100 °C for 1 hr. The reaction mixture was concentrated to dryness and the residue was purified by flash chromatography (silica gel, 0-15% MeOH in DCM) to give the title compound (121 mg, 33.5% yield) as yellow solid. LC/MS (ESI) m/z: 169 (M+H)+. XH NMR (400 MHz, DMSO-tL) 8 11.25 (s, 1H), 6.29 (s, 1H), 3.23 (s, 3H), 2.16 (t, J = 7.4 Hz, 2H), 1.49 (dt, J = 14.5, 7.3 Hz, 2H), 0.86 (t, J = 7.3 Hz, 3H). Step 4: 3-{[4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl]methoxy}-l- methyl-5-propyl-l,2-dihydropyrazin-2-one
[0456] To a solution of (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methanesulfonate (207 mg, 0.49 mmol) in DMF (5 mL) was added 3-hydroxy-l-methyl-5-propyl- l,2-dihydropyrazin-2-one (115 mg, 0.68 mmol), K2CO3 (203 mg, 1.47 mmol) and the mixture was stirred at 60 °C for 2 hrs. The reaction mixture was diluted with EtOAc (10 mL), washed with saturated aq.NH-tCl solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-100% EtOAc in PE) to give the title compound (58 mg, 23.9% yield) as white solid. LC/MS (ESI) m/z: 495 (M+H)+.
Step 5: methyl 2-[(3S)-l-[2-ethyl-6-(l-methyl-5-{[(4-methyl-3-oxo-6-propyl-3,4- dihydropyrazin-2-yl)oxy]methyl}-lH-l,2,3-triazol-4-yl)pyridin-3-yl]-5,5-difluoropiperidin- 3-yl] acetate
[0457] To a solution of 3-{[4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl]methoxy}-l-methyl-5-propyl-l,2-dihydropyrazin-2-one (58 mg, 0.12 mmol) in 1,4-dioxane (2 mL) was added CS2CO3 (118 mg, 0.36 mmol), methyl 2-[(3S)-5,5-difluoropiperidin-3-yl]acetate (23 mg, 0.12 mmol), Ruphos-Pd-G3 (30 mg, 0.036 mmol), RuPhos (11 mg, 0.024 mmol) and the mixture was degassed under N2 for 3 times and stirred at 110 °C for 16 hrs. The reaction mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (75 mg, 88.3% yield) as yellow solid, which was directly used to the next reaction without purification. LC/MS (ESI) m/z: 560 (M+H)+.
Step 6: 2-[(3S)-l-[2-ethyl-6-(l-methyl-5-{[(4-methyl-3-oxo-6-propyl-3,4-dihydropyrazin-2- yl)oxy]methyl}-lH-l,2,3-triazol-4-yl)pyridin-3-yl]-5,5-difluoropiperidin-3-yl]acetic acid
[0458] To a solution of methyl 2-[(3S)-l-[2-ethyl-6-(l-methyl-5-{[(4-methyl-3-oxo-6-propyl-3,4- dihydropyrazin-2-yl)oxy]methyl}-lH- 1,2, 3-triazol-4-yl)pyridin-3-yl]-5,5-difluoropiperi din-3- yl]acetate (75 mg, 0.11 mmol) in THF (2 mL), MeOH (0.5 mL), H2O (1 mL) was added LiOH (26 mg, 1.07 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was washed
with MTBE (3 x 5 mL), acidified with IN aq.HCl to pH~3 and extracted with DCM (3 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep.HPLC to give the title compound (18 mg, 30% yield) as white solid. LC/MS (ESI) m/z: 546 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.86 (d, J= 8.3 Hz, 1H), 7.56 (d, J= 8.4 Hz, 1H), 6.94 (s, 1H), 6.12 (s, 2H), 4.21 (s, 3H), 3.48 (s, 3H), 3.22 (d, J= 10.2 Hz, 2H), 3.07 (dd, J= 24.7, 9.4 Hz, 1H), 2.89 (q, J= 7.4 Hz, 2H), 2.59 (t, J = 10.5 Hz, 1H), 2.54 - 2.46 (m, 1H), 2.36 (d, J= 7.0 Hz, 2H), 2.34 - 2.27 (m, 1H), 2.26 - 2.22 (m, 2H), 1.71 (dt, = 24.4, 15.7 Hz, 1H), 1.46 (dt, J= 13.8, 6.9 Hz, 2H), 1.27 (t, J = 7.5 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H).
Example 111: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl-l,4-dihydropyridazin-3- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: 5-chloro-3,4-dimethoxypyridazine
[0459] To a solution of 3,5-dichloro-4-methoxypyridazine (3.2 g, 17.9 mmol) in MeOH (20 mL) was added sodium methoxide solution (30% in methanol) (3.22 g, 17.9 mmol) at room temperature under N2 atmosphere and the reaction was stirred at 90 °C for 3 hrs. The mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc = 10: 1) to give the title compound (0.74 g, 23.7% yield) as white solid. LCMS (ESI) m/z: 175 (M+H)+.
Step 2: 3,4-dimethoxypyridazine
[0460] To a solution of 5-chloro-3,4-dimethoxypyridazine (740 mg, 4.24 mmol) in EtOAc (10 mL) was added TEA (1.18 mL, 8.4 mmol) and Pd(OH)2/C (120 mg, 10% wt) at 0 °C and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at room
temperature for 4 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (500 mg, 84.2% yield) as white solid. LC/MS (ESI) (m/z): 141 (M+H)+.
Step 3: 3-methoxy-l-propylpyridazin-4(lH)-one
[0461] To a solution of 3,4-dimethoxypyridazine (500 mg, 3.57 mmol) in acetone (10 mL) was added 1-iodopropane (0.52 mL, 5.35 mmol) at room temperature and the reaction mixture was stirred at 50 °C for 16 hrs. The mixture was diluted with water (5 mL) and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to dryness. The residue was purified by chromatography on silica gel (PE: EtOAc= 20: 1) to give the title compound (80 mg, 13.3% yield) as white solid. LC/MS (ESI) (m/z): 169 (M+H)+.
Step 4: 3-hydroxy-l-propylpyridazin-4(lH)-one
[0462] To a solution of 3-methoxy-l-propylpyridazin-4(lH)-one (80 mg, 0.476 mmol) in DCM (5 mL) was added BBn (0.135 mL, 1.43 mmol) at 0 °C and the mixture was stirred at r.t. for 1 hr. The reaction was quenched with MeOH at 0 °C and the mixture was basified with saturated aq.NaHCO3 solution. The mixture was extracted with DCM (2 x 5 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (30 mg, 40.9% yield) as yellow solid. LC/MS (ESI) (m/z): 155 (M+H)+. Step 5: methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl-l,4-dihydropyridazin-3- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0463] To a mixture of methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (30 mg, 0.062 mmol) and 3- hydroxy-l-propylpyridazin-4(lH)-one (14.3 mg, 0.093 mmol) in CEECN (2 mL) were added K2CO3 (17 mg, 0.124 mmol) and TBAI (2.3 mg, 0.006 mmol) and the mixture reaction was stirred at 70 °C under N2 atmosphere for 16 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give crude product, which was purified by prep.TLC (PE: EtOAc= 2: 1) to give the title compound (15 mg, 44% yield) as yellow oil. LC/MS (ESI) (m/z): 546 (M+H)+.
Step 6: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l-propyl-l,4-dihydropyridazin-3- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0464] To a solution of methyl (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((4-oxo-l -propyl- 1,4- dihydropyridazin-3-yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3- yl)acetate (10 mg, 0.018 mmol) in THF (0.5 mL) and MeOH (1 mL) was added a solution of LiOH (4.3 mg, 0.18 mmol) in water (0.5 mL) at 0 °C. After stirring at room temperature for 2 hrs, the
reaction mixture was acidified with IN aq.HCl to pH~3 and extracted with DCM (2 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 25-95 %, MeCN in H2O with 0.1% HCOOH) to give the title compound (1.4 mg, 14.4% yield) as white solid. LC/MS (ESI) (m/z): 532 (M+H)+. XH NMR (400 MHz, CD3OD) 8 8.19 (d, J= 7.1 Hz, 1H), 7.90 (d, J= 8.3 Hz, 1H), 7.58 (d, J= 8.3 Hz, 1H), 6.41 (d, J= 7.0 Hz, 1H), 6.12 (s, 2H), 4.21 (s, 3H), 3.83 (t, J= 7.0 Hz, 2H), 3.23 (d, J = 11.8 Hz, 2H), 3.13 - 3.03 (m, 1H), 2.94-2.89 (m, 2H), 2.60 (t, J= 10.7 Hz, 1H), 2.54 - 2.47 (m, 1H), 2.39 - 2.38 (m, 2H), 2.32 - 2.25 (m, 1H), 1.73 - 1.67 (m, 3H), 1.36 - 1.30 (m, 3H), 0.83 (t, J= 7.4 Hz, 3H).
Example 112: (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-triazin-3-yl)amino)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: methyl (Z)-carbamohydrazonothioate hydroiodide
[0465] To a solution of aminothiourea (5 g, 54.9 mmol) in EtOH (30 mL) was added Mel (4.1 mL, 65.8 mmol). After stirring at 75 °C for 16 hrs, the reaction mixture was cooled to 0 °C and filtered. Then filter cake was concentrated to dryness to give the title compound (4.2 g, 72.8% yield) as white solid, which was directly used in the next reaction without purification.
Step 2: 5-cyclopropyl-3-(methylthio)-l,2,4-triazine
[0466] To a solution of methyl (Z)-carbamohydrazonothioate hydroiodide (4 g, 38.0 mmol) in EtOH (80 mL) was added 2-cyclopropyl-2-oxoacetaldehyde (5.6 g, 57.05 mmol). After stirring at 75 °C for 16 hrs, the reaction mixture was poured into ice-water and extracted with DCM (3 x 50
mL). The combined organic layers were washed brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-50% EtOAc in PE) to give the title compound (2.8 g, 44% yield) as yellow oil. LC/MS (ESI) m/z: 168 (M+H)+.
Step 3: 5-cyclopropyl-3-(methylsulfonyl)-l,2,4-triazine
[0467] To a solution of 5-cyclopropyl-3-(methylthio)-l,2,4-triazine (2.6 g, 15.5 mmol) in DCM (40 mL) was added m-CPBA (8.05 g, 46.6 mmol) at 0 °C. After stirring at r.t. for 1 hr, the reaction mixture was quenched with saturated aq.Na2S2Ch solution and extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was triturated with EtOAc and the slurry was filtered. The filter cake was dried under vacuum to give the title compound (1.3 g, 42% yield) as yellow solid. LC/MS (ESI) m/z: 200 (M+H)+.
Step 4: methyl (R)-2-(l-(6-(5-(azidomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin- 3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0468] To a solution of methyl 2-[(3R)-l-(2-ethyl-6-{5-[(methanesulfonyloxy)methyl]-l-methyl- lH-l,2,3-triazol-4-yl}pyridin-3-yl)-5,5-difluoropiperidin-3-yl]acetate (40 mg, 0.082 mmol) in DMF (3 mL) was added NaNs (20 mg, 0.41 mmol). After stirring at 60 °C for 2 hrs, the reaction mixture was poured into water and extracted with EtOAc (3 x 5 mL). The combined organic phases were washed brine, dried over Na2SO4, filtered and concentrated to give the title compound (31 mg, 96.3% yield) as yellow oil, which was directly used in the next reaction without purification.
Step 5: methyl (R)-2-(l-(6-(5-(aminomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin- 3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0469] To a solution of methyl (R)-2-(l-(6-(5-(azidomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (31 mg, 0.079 mmol) in THF (2 mL) and water (0.2 mL) was added PPhs (103 mg, 0.4 mmol). After stirring at r.t. for 16 hrs, the reaction mixture was concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0 - 50%, MeOH in DCM) to give the title compound (31 mg, 96% yield) as yellow solid. LC/MS (ESI) m/z: 409 (M+l)+.
Step 6: methyl (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-triazin-3-yl)amino)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0470] To a solution of methyl (R)-2-(l-(6-(5-(aminomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (31 mg, 0.076 mmol) and DIPEA (29 mg, 0.23 mmol) in NMP (2 mL) was added 5-cyclopropyl-3-(methylsulfonyl)-l,2,4-triazine (30 mg, 0.15 mmol). After stirring at 100 °C for 2 hrs, the reaction mixture was poured into water and
extracted with EtOAc (3 x 5 mL). The combined organic phases were washed brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-100% EtOAc in PE) to give the title compound (20 mg, 50% yield) as yellow solid. LC/MS (ESI) m/z: 528 (M+l)+.
Step 8: (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-triazin-3-yl)amino)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0471] To a solution of methyl (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-triazin-3-yl)amino)methyl)- l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (20 mg, 0.038 mmol) in THF (2 mL), water (0.5 mL) and MeOH (0.5 mL) was added LiOH (8 mg, 0.19 mmol). After stirring at r.t. for 2 hrs, the reaction mixture was poured into water and washed with MTBE (3 x 2 mL). The aqueous layer was acidified with IN aq.HCl to pH~4 and extracted with DCM (3 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 10- 95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (3 mg, 15.4% yield) as white solid. LC/MS (ESI) m/z: 514 (M+l)+. XH NMR (400 MHz, CD3OD) 8 8.50 (s, 1H), 7.90 (d, J = 8.4 Hz, 1H), 7.61 (d, J= 8.4 Hz, 1H), 5.10 (d, J= 2.2 Hz, 2H), 4.22 (s, 3H), 3.28 - 3.20 (m, 2H), 3.15 - 3.05 (m, 1H), 3.03 - 2.96 (m, 2H), 2.62 (dd, J= 12.1, 9.7 Hz, 1H), 2.57 - 2.46 (m, 1H), 2.44 - 2.37 (m, 2H), 2.36 - 2.27 (m, 1H), 1.96 - 1.89 (m, 1H), 1.79 - 1.68 (m, 1H), 1.35 (t, J= 7.5 Hz, 3H), 1.11 -1.06 (m, 2H), 1.02 - 0.94 (m, 2H).
Example 113: 2-(3,3-difluoro-l-(2-methyl-6-(l-methyl-5-(((3-propylpyridin-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-4-yl)acetic acid
Step 1: 3-bromo-2-methyl-6-(l-methyl-5-(((3-propylpyridin-2-yl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridine
[0472] To a solution of (4-(5-bromo-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methanol (500 mg, 1.76 mmol) in DMF (10 mL) was added NaH (106 mg, 2.65 mmol, 60% dispersion in mineral oil) in portions at 0 °C and the mixture was stirred this temperature for 30 min. A solution of 2-chl oro-3 -propylpyridine (300 mg, 1.92 mmol) in DMF (3 mL) was added to the above mixture drop-wise at 0 °C and the resulting mixture was stirred at r.t. for 4 hrs. The mixture was quenched with saturated aq.NFLCl solution and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0 - 30 EtOAc in PE) to give the title compound (620 mg, 86.1% yield) as white solid. LC/MS (ESI) m/z: 402 (M+H)+.
Step 2: tert-butyl (E)-3,3-difluoro-4-(2-methoxy-2-oxoethylidene)piperidine-l-carboxylate [0473] To a solution of ethyl 2-(diethoxyphosphoryl)acetate (500 mg, 2.23 mmol) in THF (10 mL) was added NaH (116 mg, 2.9 mmol, 60% dispersion in mineral oil) in portions at 0 °C and the mixture was stirred this temperature for 30 min. A solution of tert-butyl 3,3-difluoro-4- oxopiperidine-1 -carboxylate (524 mg, 2.23 mmol) in THF (5 mL) was added drop-wise at 0 °C to the above mixture and the resulting mixture was stirred at r.t. for 2 hrs. The mixture was quenched with ice-cooled saturated aq.NH-tCl solution and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0 - 40 EtOAc in PE) to give the title compound (260 mg, 40% yield) as light-yellow oil. LC/MS (ESI) m/z: 292 (M+H)+.
Step 3: tert-butyl 3,3-difluoro-4-(2-methoxy-2-oxoethyl)piperidine-l-carboxylate
[0474] To a solution of tert-butyl (E)-3,3-difluoro-4-(2-methoxy-2-oxoethylidene)piperidine-l- carboxylate (260 mg, 0.89 mmol) in MeOH (5 mL) was added Pd/C (30 mg, 10%wt) and the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at r.t. for 3 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (240 mg, 92% yield) as light yellow oil. LC/MS (ESI) m/z: 294 (M+H)+.
Step 4: methyl 2-(3,3-difluoropiperidin-4-yl)acetate hydrochloride
[0475] To a solution of tert-butyl 3, 3 -difluoro-4-(2-methoxy-2-oxoethyl)piperi dine- 1 -carboxylate (240 mg, 0.82 mmol) in 1,4-dioxane (3 mL) was added 4N HCl/l,4-di oxane solution (2 mL) and the mixture was stirred at r.t. for 3 hrs. The mixture was concentrated to dryness and the residue was washed with MTBE, dried under vacuum to give the title compound (170 mg, 90% yield) as yellow solid. LC/MS (ESI) m/z: 194 (M+H)+.
Step 5: 2-(3,3-difluoro-l-(2-methyl-6-(l-methyl-5-(((3-propylpyridin-2-yl)oxy)methyl)-lH-
1.2.3-triazol-4-yl)pyridin-3-yl)piperidin-4-yl)acetic acid
[0476] To a mixture of 3-bromo-2-methyl-6-(l-methyl-5-(((3-propylpyridin-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridine (50 mg, 0.12 mmol) and methyl 2-(3,3-difluoropiperidin-4- yl)acetate hydrochloride (29 mg, 0.12 mmol) in 1,4-dioxane (10 mL) was added t-BuONa (36 mg, 0.37 mmol), the mixture was degassed under N2 for three times and Pd(OAc)2 (10 mg, 0.044 mmol) and XantPhos (26 mg, 0.044 mmol) were added under N2 atmosphere. The resulting mixture was stirred at 110 oC for 16 hrs. H2O (10 mL) was added and the mixture was stirred at r.t. for 1 hr. The mixture was washed with MTBE (2 x 5 mL) and the aqueous layer was acidified with 1 N aq.HCl to pH~4, extracted with DCM (3 x 5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep.HPLC to give the title compound (11 mg, 17.7% yield) as white solid. LC/MS (ESI) m/z: 501 (M+H)+. 1H NMR (400 MHz, CD3OD) 8 7.96-7.94 (dd, J= 5.2, 2 Hz, 1H), 7.81 -7.78 (d, J= 7.6 Hz, 1H), 7.54 - 7.52 (d, J= 8.0 Hz, 1H), 7.47 - 7.45 (dd, J= 7.2, 1.6 Hz, 1H), 6.91 - 6.88 (m, 1H), 5.95 (s, 2H), 4.22 (s, 3H), 3.35-3.33 (m, 1H), 3.19 - 3.01 (m, 3H), 2.86 - 2.75 (m, 2H), 2.44 - 2.40 (m, 1H), 2.42 (s, 3H), 2.31 - 2.27 (m, 1H), 2.06 - 2.00 (m, 1H), 1.75 - 1.69 (m, 2H), 1.46 - 1.40 (m, 2H), 0.80 - 0.76 (t, J= 7.6 Hz, 3H).
Example 114: (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)oxy)methyl)-l-methyl-lH-
1.2.3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: methyl (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0477] To a mixture of methyl (S)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol- 4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (40 mg, 0.098 mmol) and 3-chloro-5- cyclopropyl-l,2,4-oxadiazole (21.2 mg, 0.15 mmol) in THF (2 mL) was added t-BuOK (0.2 mL, 0.20 mmol, IM in THF) drop-wisely at 0 °C and the mixture was stirred at r.t. for 2 hrs. The mixture was quenched with ice-water and extracted with EtOAc (2 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (50 mg, 98.9% yield) as yellow solid, which was used in next step directly. LC/MS (ESI) m/z: 518 (M+H)+.
Step 2: (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0478] To a solution of methyl (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)oxy)methyl)- l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (50 mg, 0.097 mmol) in THF (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOH.ELO (40.5 mg, 0.97 mmol) and the mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (5 mL). The mixture was washed with EtOAc (2 x 3 mL), acidified with IN aq.HCl to pH = 4 and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (6.7 mg, 13.8% yield) as white solid. LC/MS (ESI) m/z: 504 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.88 (d, J= 8.2 Hz, 1H), 7.56 (d, J= 8.2 Hz, 1H), 6.05 (s, 2H), 4.20 (s, 3H), 3.23 (t, J= 10.2 Hz, 2H), 3.12 - 3.01 (m, 1H), 2.92 - 2.84 (m, 2H), 2.64 - 2.56 (m, 1H), 2.53 - 2.45 (m, 1H), 2.43 - 2.36 (m, 2H), 2.34 - 2.24 (m, 1H), 2.17 - 2.09 (m, 1H), 1.79 - 1.65 (m, 1H), 1.29 - 1.20 (m, 5H), 1.11 - 1.04 (m, 2H).
Example 115: (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)amino)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: methyl (R)-2-(l-(2-ethyl-6-(5-formyl-l-methyl-lH-l,2,3-triazol-4-yl)pyridin-3-yl)- 5,5-difluoropiperidin-3-yl)acetate
[0479] To a solution of methyl (S)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (80 mg, 0.20 mmol) in DCM (5 mL) was added DMP (331 mg, 0.78 mmol) and the mixture was stirred at 25 °C for 1 hr. The mixture was quenched with saturated aq.NaHCCh solution and extracted with DCM (3 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (50 mg, 62.8% yield) as yellow oil. LC/MS (ESI) m/z:
408 (M+H)+.
Step 2: methyl (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)amino)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0480] To a solution of methyl (R)-2-(l-(2-ethyl-6-(5-formyl-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (25 mg, 0.061 mmol) and 5-cyclopropyl-l,2,4- oxadiazol-3 -amine (15.4 mg, 0.12 mmol) in MeOH (2 mL) was added AcOH (3 drops) under N2 atmosphere and the mixture was stirred at 65 °C for 16 hrs. NaBHsCN (38 mg, 0.61 mmol) was added to the above mixture at 25 °C and the resulting mixture was continued to stirr at 25 °C for 2 hrs. The mixture was quenched with saturated aq.NaHCOs solution and extracted with DCM (2 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (35 mg, 110.4% yield) as yellow oil, which was used in the next step directly. LC/MS (ESI) m/z: 517 (M+H)+.
Step 2: (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3-yl)amino)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0481] To a solution of methyl (R)-2-(l-(6-(5-(((5-cyclopropyl-l,2,4-oxadiazol-3- yl)amino)methyl)-l -methyl- 1H- 1,2, 3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperi din-3- yl)acetate (35 mg, 0.068 mmol) in THF (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOH.H2O (28.4 mg, 0.68 mmol) and the reaction mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (5 mL). The aqueous solution was washed with EtOAc (2 x 3 mL), acidified with IN aq.HCl to pH~3 and extracted with DCM (3 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 10- 95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (12.5 mg, 36.5% yield) as white solid. LC/MS (ESI) m/z: 503 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.90 (d, J= 8.2 Hz, 1H), 7.60 (d, J= 8.4 Hz, 1H), 4.78 (s, 2H), 4.21 (s, 3H), 3.27-3.20 (m, 2H), 3.14-3.06 (m, 1H), 3.02-2.96 (m, 2H), 2.65-2.58 (m, 1H), 2.55-2.46 (m, 1H), 2.43-2.37 (m, 2H), 2.34-2.25 (m, 1H), 2.09-2.01 (m, 1H), 1.81-1.65 (m, 1H), 1.38-1.31 (m, 4H), 1.18-1.10 (m, 2H), 1.07-1.02 (m, 2H).
The examples list in the table were prepared according to the same method as described for the synthesis of example 114 and 115.
Example 121: (S)-2-(l-(2-ethyl-6-(l-methyl-5-(((l-propyl-lH-l,2,4-triazol-5-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0482] To a solution of methyl (S)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (30 mg, 0.073 mmol ) and 3-bromo-4- propyl-4H-l,2,4-triazole (21 mg, 0.11 mmol ) in DMF (1 mL) was added t-BuOK (0.15 mL, 0.15 mmol, 1 M in THF) at 0 °C and the mixture was stirred at r.t. for 16 hrs. The reaction was quenched
with ice water (5 mL) and the mixture was stirred at r.t. for 1 hr. The mixture was washed MTBE (2 x 3 mL) and the aqueous layer was acidified with IN aq.HCl and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (10 mg, 27.2% yield) as white solid. LC/MS (ESI) m/z: 505 (M+H)+. XH NMR (400 MHz, CD3OD) 8 7.88 (d, J= 8.4 Hz, 1H), 7.60 (s, 1H), 7.56 (d, J= 8.4 Hz, 1H), 6.11 (s, 2H), 4.24 (s, 3H), 3.79 (t, J = 6.8 Hz, 2H), 3.25 - 3.18 (m, 2H), 3.13 - 2.99 (m, 1H), 2.84 (t, J = 7.2 Hz, 2H), 2.61-2.26 (m, 5H), 1.74 - 1.59 (m, 3H), 1.22 (t, J= 7.2 Hz, 3H), 0.73 (t, J= 7.6 Hz, 3H).
The examples list in the below table were prepared according to the same method as described for the synthesis of example 121.
Example 124: (S)-2-(l-(2-ethyl-6-(5-(((2-isobutyl-2H-tetrazol-5-yl)oxy)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: 2-(2-methylpropyl)-5-(methylsulfanyl)-2H-l,2,3,4-tetrazole
[0483] To a mixture of 5-(Methylthio)-lH-tetrazole (1 g, 8.61 mmol), 2-methyl-l -propanol (1.28 g, 17.2 mmol) and PPI13 (4.06 g, 15.5 mmol) in DCM (50 mL) was added TEA (1.31 g, 12.92 mmol) followed by drop-wise addition of DIAD (1.74 g, 8.61 mmol) at 0 °C under N2 atmosphere and the mixture was stirred at r.t. for 16 hrs. The mixture was concentrated to dryness and the residue was purified by silica gel chromatography (PE: EtOAc= 2: 1) to give the title compound (810 mg, 54.6% yield) as white solid. LC/MS (ESI) m/z: 173 (M+H)+. 'H NMR (400 MHz, CDCk) 64.37 (d, J= 7.2 Hz, 2H), 2.68 (s, 3H), 2.31-2.43 (m, 1H), 0.97 (d, J= 6.7 Hz, 6H).
Step 2: 5-methanesulfonyl-2-(2-methylpropyl)-2H-l,2,3,4-tetrazole
[0484] To a solution of 2-(2-methylpropyl)-5-(methylsulfanyl)-2H-l,2,3,4-tetrazole (800 mg, 4.64 mmol) in chloroform (40 mL) was added TBAB (75 mg, 0.23 mmol), aq.AcOH (25 mL, 10% wt) followed by KMnCh (1.47 g, 9.29 mmol) and the mixture was stirred at r.t. for 18 hrs. The mixture was diluted with DCM (20 mL) and washed with water (3 x 10 mL) and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (530 mg, 55.9% yield) as white solid. LC/MS (ESI) m/z: 205 (M+H)+.
Step 3: (S)-2-(l-(2-ethyl-6-(5-(((2-isobutyl-2H-tetrazol-5-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0485] To a solution of methyl (S)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (30 mg, 0.073 mmol) and 5- methanesulfonyl-2-(2-methylpropyl)-2H-l,2,3,4-tetrazole (29 mg, 0.15 mmol) in CH3CN (1 mL) was added NaOH (14 mg ,0.37 mmol) and the mixture was stirred at 80 °C for 3 hrs. The mixture was diluted with water (10 mL), washed with MTBE (2 x 3 mL), acidified with IN aq.HCl to pH~4 and extracted with DCM (3 x 5 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-HPLC (Cl 8, 0 ~ 90 % acetonitrile in H2O with 0.1 % HCOOH) to give the title compound (11 mg, 29.0% yield) as white solid. LC/MS (ESI) m/z: 520 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.87 (d, J = 8.4
Hz, 1H), 7.56 (d, J= 8.0 Hz, 1H), 6.17 (s, 2H), 4.28 (d, J= 7.2 Hz, 2H), 4.23 (s, 3H), 3.25 - 3.20 (m, 2H), 3.12 - 3.02 (m, 1H), 2.90 - 2.84 (q, J= 7.7 Hz, 2H), 2.62 - 2.57 (t, J= 10.8 Hz, 1H), 2.52 - 2.38 (m, 3H), 2.31 - 2.15 (m, 2H), 1.72 - 1.68 (m, 1H), 1.25 - 1.21 (t, J= 7.5 Hz, 3H), 0.89 (d, J= 7.2 Hz, 6H).
Example 125: (S)-2-(l-(6-(5-(((2-(cyclopropylmethyl)-2H-tetrazol-5-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0486] The title compound was prepared from cyclopropylmethanol using the same sequence that was synthesized example 124. LC/MS (ESI) m/z: 518 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.89 - 7.86 (d, J = 8.3 Hz, 1H), 7.57 - 7.54 (d, J = 8.3 Hz, 1H), 6.18 (s, 2H), 4.32 - 4.29 (d, J = 7.4 Hz, 2H), 4.23 (s, 3H), 3.27 - 3.19 (m, 2H), 3.15 - 3.07 (m, 1H), 2.91 - 2.84 (m, 2H), 2.63 - 2.56 (m, 1H), 2.54 - 2.46 (m, 1H), 2.39 - 2.26 (d, J = 6.0 Hz, 2H), 2.33 - 2.26 (m, 1H), 1.79 - 1.64 (m, 1H), 1.32 -1.28 (m, 1H), 1.25 - 1.21 (t, J= 7.2 Hz, 3H), 0.64 - 0.59 (m, 2H), 0.45 - 0.37 (m, 2H).
Example 126: (S)-2-(l-(6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: ethyl 4-hydroxy-l-(4-methoxybenzyl)-lH-l,2,3-triazole-5-carboxylate
[0487] To a newly prepared EtONaZEtOH solution (22 mmol in 50 mL of EtOH) was added diethyl malonate (3.54 g, 22 mmol) under N2 atmosphere and the mixture was stirred at r.t. for 0.5 hr. To the above mixture, a solution of l-(azidomethyl)-4-methoxybenzene (2.4 g, 14.7 mmol) in ethanol (4 mL) was added drop-wisely and the resulting mixture was stirred at 85 °C for 5 hrs. The mixture was concentrated to dryrness and diluted with water, the aqueous solution was acidified with IN aq.HCl to pH = 2 and extracted with DCM (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 20: 1 to 1 : 1) to give the title compound (1.82 g, 50.1% yield) as red solid. LC/MS (ESI) m/z: 278 (M+H)+.
Step 2: ethyl 4-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methoxy)-l- (4-methoxybenzyl)-lH-l,2,3-triazole-5-carboxylate
[0488] To a solution of 3-bromo-6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyridine (970 mg, 2.7 mmol) and ethyl 4-hydroxy-l-(4-methoxybenzyl)-lH-l,2,3-triazole-5- carboxylate (747 mg, 2.7 mmol) in DMF (10 mL) was added CS2CO3 (2.63 g, 8.08 mmol) under N2 atmosphere and the mixture was stirred at r.t. for 1 hr. The mixture was diluted with water (20 mL) and extracted with EtOAc (2 x 15 mL). The combined organic layers were washed with saturated aq.NH4Cl solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 20: 1 to 2: 1) to give the title compound (839 mg, 56% yield) as white solid. LC/MS (ESI) m/z: 556/558 (M+H)+. Step 3: ethyl 4-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methoxy)- lH-l,2,3-triazole-5-carboxylate
[0489] To a solution of ethyl 4-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methoxy)-l-(4-methoxybenzyl)-lH-l,2,3-triazole-5-carboxylate (800 mg, 1.44 mmol) in MeCN (20 mL) was added a solution of CAN (1.97 g, 3.59 mmol) in water (20 mL) drop-wisely at 0 °C and the mixture was stirred at r.t. for 16 hrs. The slurry was filtered and the filter cake was washed with water, dried under vacuum to give the title compound (600 mg, 76.5% yield) as white solid. LC/MS (ESI) m/z: 436/438 (M+H)+.
Step 4: 4-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methoxy)-lH- l,2,3-triazole-5-carboxylic acid
[0490] To a solution of ethyl 4-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methoxy)-lH-l,2,3-triazole-5-carboxylate (600 mg, 1.17 mmol) in THF (10 mL), EtOH (10 mL) and H2O (5 mL) was added NaOH (468 mg, 11.69 mmol) and the mixture was stirred at 60 °C for 5 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (10 mL). The aqueous layer was acidified with IN aq.HCl to pH = 3 and extracted with DCM (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered
and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 1 : 1) to give the title compound (500 mg, 83.8% yield) as white solid. LC/MS (ESI) m/z: 408/410 (M+H)+.
Step 5: 6-(5-(((lH-l,2,3-triazol-4-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-3-bromo-2- ethylpyridine
[0491]' A solution of 4-((4-(5-bromo-6-ethylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methoxy)-lH-l,2,3-triazole-5-carboxylic acid (500 mg, 0.98 mmol) in DMF (10 mL) was stirred at 120 °C for 16 hrs. The mixture was diluted with EtOAc (20 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give title compound (290 mg, 77.2% yield) as white solid. LC/MS (ESI) m/z: 364/366 (M+H)+.
Step 6: 3-bromo-6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridine (7 A) & 3-bromo-6-(5-(((2-(cyclopropylmethyl)-2H-
1.2.3-triazol-4-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridine (7B)
[0492] To a solution of 3-bromo-2-ethyl-6-{ l-methyl-5-[(lH-l,2,3-triazol-4-yloxy)methyl]-lH-
1.2.3-triazol-4-yl}pyridine (140 mg, 0.38 mmol) in DMF (5 mL) was added K2CO3 (159 mg, 1.15 mmol) followed by (bromomethyl)cyclopropane (0.18 mL, 1.92 mmol). After stirring at r.t. for 2 hrs, the reaction mixture was diluted with ice-water and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0- 100% EtOAc in PE) to give 3-bromo-6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4-yl)oxy)methyl)- l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridine 7A (45 mg, yield 28.0%) and 3-bromo-6-(5-(((2- (cyclopropylmethyl)-2H-l,2,3-triazol-4-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyridine 7B (85 mg, yield 52.9%) as white solid. 7A: XH NMR (400 MHz, DMSO-fifc) 6 8.12 (d, J = 8.4 Hz, 1H), 7.87 (d, J= 8.4 Hz, 1H), 7.71 (s, 1H), 5.89 (s, 2H), 4.16 (s, 3H), 4.10 (d, J = 7.2 Hz, 2H), 2.87 (q, J= 7.6 Hz, 2H), 1.24 - 1.15 (m, 1H), 1.18 (t, J= 7.6 Hz, 3H), 0.53-0.48 (m, 2H), 0.37-0.32 (m, 2H). 7B: 'H-NMR (400 MHz, DMSO-tL) 6 8.11 (d, J= 8.4 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.31 (s, 1H), 5.90 (s, 2H), 4.16 (s, 3H), 4.06 (d, J= 7.2 Hz, 2H), 2.87 (q, J= 7.6 Hz, 2H), 1.20-1.14 (m, 1H), 1.16 (t, J = 7.6 Hz, 3H), 0.52 - 0.46 (m, 2H), 0.33 - 0.30 (m, 2H). LC/MS (ESI) m/z: 420/422 (M+H)+.
Step 7: methyl (S)-2-(l-(6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0493] To a mixture of 3-bromo-6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4- yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridine (45 mg, 0.11 mmol), methyl 2- [(3S)-5,5-difluoropiperidin-3-yl]acetate (21 mg, 0.11 mmol) and CS2CO3 (105 mg, 0.32 mmol) in
1,4-dioxane (2 mL) was added Ru-Phos (5 mg, 0.011 mmol ) followed by Ru-Phos Pd G3 (9 mg, 0.011 mmol). Then the mixture was degassed under N2 atmosphere for three times and stirred at 120 °C under N2 atmosphere for 16 hrs. The mixture was diluted with ice-water and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep.TLC (PE: EtOAc= 2: 1) to give the title compound (35 mg, 61.3% yield) as yellow solid. LC/MS (ESI) m/z: 531(M+H)+.
Step 8: (S)-2-(l-(6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4-yl)oxy)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0494] To a solution of methyl (S)-2-(l-(6-(5-(((l-(cyclopropylmethyl)-lH-l,2,3-triazol-4- yl)oxy)methyl)-l -methyl-lH- 1,2, 3-tri azol -4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperi din-3- yl)acetate (35 mg, 0.066 mmol) in THF (1 mL) and MeOH (0.5 mL) was added a solution of LiOH (8 mg, 0.33 mmol) in water (0.5 mL) at 0 °C and the mixture was stirred at r.t. for 1 hr. The reaction mixture was acidified with IN aq.HCl to pH= 3 and extracted with EtOAc (2 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-10% MeOH in DCM) and further purified by prep-HPLC to give the title compound (10 mg, 27.9% yield) as white solid. LC/MS (ESI) m/z: 517 (M+H)+. XH NMR (400 MHz, CD3OD) 8 7.89 (d, J= 8.4 Hz, 1H), 7.57 (d, J= 8.4 Hz, 1H), 7.56 (s, 1H), 5.98 (s, 2H), 4.21 (s, 3H), 4.10 (d, J= 7.6 Hz, 2H), 3.28 - 3.20 (m, 2H), 3.13 - 3.02 (m, 1H), 2.90 (q, J= 7.6 Hz, 2H), 2.63 - 2.26 (m, 5H), 1.80 - 1.65 (m, 1H), 1.25 (t, J= 7.6 Hz, 3H), 1.21 - 1.13 (m, 1H), 0.58 - 0.53 (m, 2H), 0.35 - 0.30 (m, 2H).
Example 127: ((S)-2-(l-(6-(5-(((2-(cyclopropylmethyl)-2H-l,2,3-triazol-4-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0495] The title compound was prepared from 3-bromo-6-(5-(((2-(cyclopropylmethyl)-2H-l,2,3- triazol-4-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridine using the same procedure as the synthesis of example 126. LC/MS (ESI) m/z: 517 (M+H)+. 'H-NMR (400 MHz,
CD3OD) 8 7.86 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 8.4 Hz, 1H), 7.14 (s, 1H), 5.99 (s, 2H), 4.20 (s, 3H), 4.01 (d, J= 7.2 Hz, 2H), 3.26-3.20 (m, 2H), 3.13-3.02 (m, 1H), 2.90 (q, J=7.6 Hz, 2H), 2.63- 2.28 (m, 5H), 1.80 - 1.65 (m, 1H), 1.27 (t, J= 7.6 Hz, 3H), 1.24 - 1.14 (m, 1H), 0.55 - 0.50 (m, 2H), 0.34 - 0.29 (m, 2H).
Example 128: (S)-2-(l-(2-ethyl-6-(5-(((l-isobutyl-lH-l,2,3-triazol-4-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Example 128
[0496] The title compound was prepared according the same sequence for the synthesis of example 126. LC/MS (ESI) m/z: 519 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.88 (d, J = 8.2 Hz, 1H), 7.57 (d, J= 8.4 Hz, 1H), 7.49 (s, 1H), 5.97 (s, 2H), 4.21 (s, 3H), 4.07 (d, J = 7.2 Hz, 2H), 3.26 - 3.19 (m, 2H), 3.13-3.01 (m, 1H), 2.94 - 2.86 (m, 2H), 2.59 (t, J = 10.8 Hz, 1H), 2.55 - 2.46 (m, 1H), 2.40 - 2.24 (m, 3H), 2.11-2.00 (m, 1H), 1.80 - 1.64 (m, 1H), 1.25 (t, J= 7.6 Hz, 3H), 0.84 (d, J= 6.8 Hz, 6H).
Example 129: (S)-2-(l-(2-ethyl-6-(5-(((2-isobutyl-2H-l,2,3-triazol-4-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Example 129
[0497] The title compound was prepared according the same sequence for the synthesis of example 126. LC/MS (ESI) m/z: 519 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.86 (d, J= 8.4 Hz, 1H), 7.56 (d, J= 8.4 Hz, 1H), 7.13 (s, 1H), 5.99 (s, 2H), 4.20 (s, 3H), 3.97 (d, J = 7.2 Hz, 2H), 3.26 - 3.18 (m, 2H), 3.11 - 3.00 (m, 1H), 2.94 - 2.87 (m, 2H), 2.59 (t, J= 10.6 Hz, 1H), 2.54 - 2.42 (m, 1H), 2.38 - 2.25 (m, 3H), 2.17 - 2.06 (m, 1H), 1.79 - 1.59 (m, 1H), 1.27 (t, J= 7.6 Hz, 3H), 0.83 (d, J = 6.8 Hz, 6H).
Example 130: (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
Step 1: prop-2-yn-l-ylcyclopropane
[0498] To a solution of ethynyltrimethylsilane (3 g, 30.5 mmol) in anhydrous THF (15 mL) was added n-BuLi (16 mL, 40 mmol, 2.5 M in THF) drop-wisely at -70 °C under N2 atmosphere and the mixture was stirred at 0 °C for 10 min. The mixture was re-cooled to -70 °C and HMPA (8.0 mL, 45.8 mmol) was added. Then the mixture was stirred at -70 °C for 30 min. (Bromomethyl)cyclopropane (3.0 mL, 30.54 mmol) was added to the above mixture and the resulting mixture was stirred at -70 °C to r.t. for 16 hrs. The mixture was quenched with water and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give (3-cyclopropylprop-l-yn-l- yl) trimethylsilane (3.2 g, 68.8% yield) as colorless oil. To a solution of (3-cyclopropylprop-l-yn- 1-yl) trimethyl silane (3.2 g, 21 mmol) in THF (9 mL) was added TBAF (15 mL, 30 mmol, 2M in THF) and the mixture was stirred at room temperature for 4 hrs. The mixture was washed with saturated aq.tSTLCl solution (10 mL) once and the solution was used to next step directly.
Step 2: l-benzyl-4-(cyclopropylmethyl)-lH-l,2,3-triazole
[0499] To the above solution was added a solution of (azidomethyl)benzene (4 g, 29.8 mmol) in THF (10 mL) followed by a solution of sodium ascorbate (1.2 g, 6 mmol) in water (10 ml) and CuSO4 (0.5 g, 3 mmol) and the resulting mixture was stirred at 25 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 50: 1 to 1 : 1) to give the title compound (2 g, 31.4% yield) as yellow oil. LC/MS (ESI)
m/z: 214 (M+H)+.
Step 3: 4-(cyclopropylmethyl)-lH-l,2,3-triazole
[0500] To a solution of l-benzyl-4-(cyclopropylmethyl)-lH-l,2,3-triazole (2 g, 9.38 mmol) in EtOH (20 mL) were added Pd(OH)2 (300 mg, 10% wt) and aq.HCl (0.5 mL, 36% wt). After addition, the mixture was degassed under N2 atmosphere for three times and stirred under a H2 balloon at 50 °C for 16 hrs. The mixture was filtered and the filtrate was concentrated to dryness to give the title compound (1.52 g, 100% yield) as colorless oil, which was used to next step directly. LC/MS (ESI) m/z: 124 (M+H)+.
Step 4: 6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethyl-3-iodopyridine
[0501] To a solution of (4-(6-ethyl-5-iodopyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl) methanol (500 mg, 1.45 mmol) in DCM (5 mL) was added PBn (984 mg, 3.63 mmol) drop-wisely at 0 °C under N2 atmosphere and the mixture was stirred at 25 °C for 2 hrs. The mixture was quenched with saturated aq.NaHCOs solution and extracted with DCM (2 x 10 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc = 20: 1 to 2: 1) to give the title compound (529 mg, 89.5% yield) as white solid. LC/MS (ESI) m/z: 407/409 (M+H)+.
Step 5: 6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethyl-3-iodopyridine (7A) & 6-(5-((5-(cyclopropylmethyl)-lH-l,2,3-triazol-l- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethyl-3-iodopyridine (7B) & 6-(5-((4-
(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethyl-3- iodopyridine (7C)
[0502] To a solution of 6-(5-(bromomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethyl-3- iodopyridine (300 mg, 0.74 mmol) and 4-(cyclopropylmethyl)-lH-l,2,3-triazole (136 mg, 1.11 mmol) in DMF (3 mL) was added K2CO3 (306 mg, 2.21 mmo 1) under N2 atmosphere and the mixture was stirred at 70 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (eluted with PE: EtOAc= 20: 1 to 2: 1) to give compound 7A (103 mg, yield 31.1%) and a mixture of 7B and 7C (190 mg, 57.1% yield) as white solid. The mixture of 7B&7C was isolated by prep.HPLC to give 7B (35 mg, 10.6% yield) and 7C (80 mg, 24.1% yield) as white solid. LC/MS (ESI) m/z: 450 (M+H)+. The absolute configurations were confirmed by NOE. 6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-ethyl-3-iodopyridine (7 A): ’H NMR (400 MHz, CDCh) 67.76 (d, J = 8.4 Hz, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.26 (s, 1H), 6.19 (s, 2H), 3.88 (s, 3H), 2.83 (q, J = 7.6 Hz, 2H), 2.37 (d, J = 7.2 Hz, 2H), 1.16 (t, J = 7.6 Hz, 3H), 0.83-0.73 (m, 1H), 0.36 - 0.31 (m, 2H), 0.02-0.00 (m, 2H). 6-(5-((5-(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-
yl)-2-ethyl-3 -iodopyridine (7B): XH NMR (400 MHz, CD3OD) 8 8.29 (d, J= 8.4 Hz, 1H), 7.70 (d, J= 8.4 Hz, 1H), 7.64 (s, 1H), 6.34 (s, 2H), 4.07 (s, 3H), 3.00 (q, J= 7.6 Hz, 2H), 2.54 (d, J= 7.2 Hz, 2H), 1.25 (t, J= 7.6 Hz, 3H), 0.90-0.82 (m, 1H), 0.54 - 0.48 (m, 2H), 0.07 - 0.02 (m, 2H).
6-(5-((4-(cy cl opropylmethyl)-lH- 1,2, 3-tri azol- l-yl)m ethyl)- 1 -methyl- 1H- 1,2, 3-triazol-4-yl)-2- ethyl-3-iodopyridine (7C): ’H NMR (400 MHz, CD3OD) 8 8.29 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.64 (s, 1H), 6.34 (s, 2H), 4.07 (s, 3H), 3.06 (q, J = 7.6 Hz, 2H), 2.56 (d, J = 7.2 Hz, 2H), 1.27 (t, J = 7.6 Hz, 3H), 0.90 - 0.82 (m, 1H), 0.54 - 0.48 (m, 2H), 0.07 - 0.02 (m, 2H).
Step 6: methyl (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate
[0503] To a solution of 6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl-lH-
1.2.3-triazol-4-yl)-2-ethyl-3-iodopyridine (103 mg, 0.23 mmol) and methyl (S)-2-(5,5- difluoropiperi din-3 -yl)acetate (44 mg, 0.23 mmol) in 1,4-dioxane (3 mL) were added CS2CO3 (149.4 mg, 0.46 mmol), RuPhos-Pd-G3 (11.2 mg, 0.013 mmol) and RuPhos (21.4 mg, 0.046 mmol ) under N2 atmosphere, after addition, the mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The mixture was diluted EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give title compound (120 mg, yield 100%) as yellow solid, which was used in next step directly. LC/MS (ESI) m/z: 515 (M+H)+.
Step 8: (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl-lH-
1.2.3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetic acid
[0504] To a solution of methyl (S)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2- yl)methyl)-l -methyl-lH- 1,2, 3-tri azol -4-yl)-2-ethylpyridin-3-yl)-5, 5-difluoropiperidin-3- yl)acetate (120 mg, 0.23 mmol) in THF (2 mL), MeOH (0.5 mL) and water (0.5 mL) was added lithium hydroxide monohydrate (98 mg, 2.33 mmol) and the reaction mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water. The mixture was washed with EtOAc twice and the aqueous layer was acidified with IM aq.HCl to pH = 4 and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep- HPLC (C18, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (19.2 mg, 13.2% yield) as white solid. LC/MS (ESI) m/z: 501 (M+H)+. XH NMR (400 MHz, CD3OD) 8 7.72 (d, J= 8.2 Hz, 1H), 7.39 (d, J= 8.4 Hz, 1H), 7.34 (s, 1H), 6.23 (s, 2H), 3.96 (s, 3H), 3.13-3.03 (m, 2H), 2.91 (m, 1H), 2.77 (q, J= 7.4 Hz, 2H), 2.47 - 2.41 (m, 1H), 2.37 (d, J= 7.0 Hz, 2H), 2.35 - 2.29 (m, 1H), 2.28 - 2.22 (m, 2H), 2.19 - 2.09 (m, 1H), 1.66 - 1.48 (m, 1H), 1.15 (t, J = 7.4 Hz, 3H), 0.85 - 0.76 (m, 1H), 0.35 - 0.29 (m, 2H), 0.02 - 0.00 (m, 2H).
The examples in the following table were prepared by using method analogous to the examples as indicated in the method column in the table.
Example 137: 2-[(3S)-l-[6-(5-{[5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazol-l-yl]methyl}-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3-yl]acetic acid & example 138 2-[(3S)-l-[6-(5-{[5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazol-l-yl]methyl}-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3-yl]acetic acid
Step 1: 5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazole (2)
[0505] To a solution of 2-cyclopropylacetonitrile (1 g, 12.33 mmol) in 1-Butanol (20 mL) was added NaNs (0.96 g, 14.80 mmol) and ZnCh (1.7 g, 12.33 mmol). The reaction mixture was stirred under N2 atmosphere at 110 °C for 16 hrs. After cooling to room temperature, 1 -Butanol was removed under reduced pressure. To the mixture was added 0.5M aq.NaOH (2.0 eq) and the resulting suspension was filtered. The filtrate was acidified with IM aq.HCl to pH = 4 and extracted with EtOAc (2 x 10 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (800 mg, 52.3% yield) as white solid. LC/MS (ESI) m/z: 125 (M+H)+.
Step 2: methyl 2-[(3S)-l-[6-(5-{[5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazol-l-yl]methyl}-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3-yl]acetate (3A) and methyl (S)-2-(l-(6-(5-((5-(cyclopropylmethyl)-lH-tetrazol-l-yl)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (3B)
[0506] To a solution of methyl (S)-2-(l-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol-4-yl)pyridin-3-yl)-5,5-difluoropiperidin-3-yl)acetate (80 mg, 0.20 mmol) in toluene (10 mL) was added 5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazole (49 mg, 0.39 mmol) followed by PPI13 (102 mg, 0.39 mmol) and DIAL) (79 mg, 0.39 mmol) under N2 atmosphere at 0 °C and the reaction mixture was stirred at 60 °C for 16 hrs. The mixture was concentrated to dryness and the residue was purified by prep-TLC (PE: EtOAc= 1 : 1) to give compound 3A (20 mg, yield 19.9 %) and compound 3B (40 mg, yield 39.7 %) as white solid. LC/MS (ESI) m/z: 516 (M+H)+. The
configuration of two isolated products was confirmed in the next reaction.
Step 3: 2-[(3S)-l-[6-(5-{[5-(cyclopropylmethyl)-2H-l,2,3,4-tetrazol-2-yl]methyl}-l-methyl- lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3-yl]acetic acid
[0507] To a solution of methyl 2-[(3S)-l-[6-(5-{[5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazol-l- yl]methyl]-l -methyl- 1H-1, 2, 3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperi din-3- yl]acetate (20 mg, 0.04 mmol) in THF (4 mL), MeOH (1 mL) and water (1 mL) was added LiOH (16 mg, 0.39 mmol) and the reaction mixture was stirred at 25 °C for 2 hrs. The mixture was concentrated to dryness and the residue was dissolved in water (10 mL). The mixture was washed with EtOAc (2 x 3 mL) and the aqueous layer was acidified with IM aq.HCl to pH = 4 and extracted with DCM (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (Cl 8, 10- 95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (5 mg, 25.7% yield) as white solid. LC/MS (ESI) m/z: 502 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.90 (d, J = 8.4 Hz, 1H), 7.55 (d, J= 8.4 Hz, 1H), 6.65 (s, 2H), 4.24 (s, 3H), 3.28-3.19 (m, 2H), 3.13-3.01 (m, 1H), 2.91 (q, J= 7.6 Hz, 2H), 2.73 (d, J= 7.0 Hz, 2H), 2.64 - 2.55 (m, 1H), 2.54 - 2.45 (m, 1H), 2.44 - 2.36 (m, 2H), 2.31 - 2.26 (m, 1H), 1.80 - 1.63 (m, 1H), 1.29 (t, J= 7.6 Hz, 3H), 1.12 - 1.00 (m, 1H), 0.56 - 0.45 (m, 2H), 0.22 - 0.17 (m, 2H).
Example 138: 2-[(3S)-l-[6-(5-{[5-(cyclopropylmethyl)-lH-l,2,3,4-tetrazol-l-yl]methyl}-l- methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl]-5,5-difluoropiperidin-3-yl]acetic acid
[0508] The title compound was prepared using the same method for the synthesis of example 137. LC/MS (ESI) m/z: 502 (M+H)+. XH NMR (400 MHz, CD3OD) 8 7.94 (d, J= 8.3 Hz, 1H), 7.62 (d, J = 8.4 Hz, 1H), 6.43 (d, J= 8.8 Hz, 2H), 4.09 (s, 3H), 3.22-3.13 (m, 2H), 3.06 - 2.99 (m, 1H), 3.90 - 2.88 (m, 2H), 2.71 (d, J = 7.0 Hz, 2H), 2.58 - 2.50 (m, 1H), 2.48-2.40 (m, 1H), 2.34-2.30 (m, 2H), 2.28 - 2.17 (m, 1H), 1.72 - 1.57 (m, 1H), 1.16 (t, J = 7.5 Hz, 3H), 0.91 - 0.82 (m, 1H), 0.43 - 0.38 (m, 2H), 0.02 - 0.00 (m, 2H).
Example 139: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-
(((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3- yl)acetic acid
Step 1: Methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((((4- nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3- yl)acetate
[0509] To a mixture of methyl (S)-2-(5,5-difluoro-l-(6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3- triazol -4-yl)-2-methylpyri din-3 -yl)piperi din-3 -yl)acetate (350 mg, 0.89 mmol) and 4-nitrophenyl chloroformate (535 mg, 2.67 mmol) in DCM (15 mL) was added pyridine (348 mg, 4.41 mmol) and the reaction was stirred at r.t. for 1 hr. The mixture was diluted with DCM (20 mL) and was washed with saturated aq.NaHCCh solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified via silica gel chromatography (eluted with PE: EtOAc=5: 1 to 3: 1) to give the title compound (460 mg, 92.8% yield) as yellow solid. LC/MS (ESI) (m/z): 561 (M+H)+.
Step 2: Methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5- (((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3- yl)acetate
[0510] To a solution of methyl (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-((((4- nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (120 mg, 0.21 mmol) in THF(10 mL) was added DIPEA (135 mg, 1.04 mmol) followed by methyl(propyl)amine (76 mg, 1.04 mmol) at 0 °C and the reaction was stirred at r.t. for 2 hrs. The mixture was diluted with EtOAc (10 mL) and was washed with IM aq.NaOH solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-TLC (50% EtOAc in PE) to give the title compound (55 mg, 52.0% yield) as yellow solid. LC/MS (ESI) (m/z): 495 (M+H)+.
Step 3: (S)-2-(5,5-difluoro-l-(2-methyl-6-(l-methyl-5-
(((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3- yl)acetic acid
[0511] To a solution of methyl (S)-2-(5,5-difhioro-l-(2-methyl-6-(l-methyl-5- (((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3- yl)acetate (55 mg, 0.11 mmol) in THF (4 mL) /H2O (4 mL)/MeOH (4 mL) was added LiOH.JLO (47 mg, 1.11 mmol) and the reaction mixture was stirred at r.t. for 2 hrs. The reaction mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was washed with EtOAc (2 x 5 mL), acidified with IN aq.HCl to pH~4 and extracted with DCM (2 x 3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (28.7 mg, 53.8% yield) as white solid. LC/MS (ESI) (m/z): 481 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.82 (d, J = 8.3 Hz, 1H), 7.53 (d, J= 8.3 Hz, 1H), 5.70 (d, J= 5.1 Hz, 2H), 4.17 (s, 3H), 3.30 - 3.20 (m, 3H), 3.15 - 3.00 (m, 2H), 2.84 (d, J= 20.0 Hz, 3H), 2.64 - 2.57 (m, 1H), 2.56 (s, 3H), 2.54 - 2.46 (m, 1H), 2.44 - 2.38 (m, 2H), 2.36 - 2.25 (m, 1H), 1.82 - 1.64 (m, 1H), 1.59 - 1.32 (m, 2H), 0.89 - 0.67 (m, 3H).
The Examples in the following table were synthesized according to the procedures described as the synthesis of example from appropriate starting materials.
Example 147 and 148: (S) and (R)-l-((6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3- carboxylic acid
Step 1: Methyl l-((6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-methylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate
[0512] To a mixture of Methyl 5,5-difhioro-l-((6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol- 4-yl)-2-methylpyridin-3-yl)methyl)piperidine-3 -carboxylate (50 mg, 0.13 mmol) and 2-chloro-4- cyclobutylpyrimidine (21 mg, 0.13 mmol) in DMF (5 mL) was added t-BuOK (0.25 mL, 0.25 mmol, 1.0 M in THF) drop-wisely at 0 °C and the reaction was stirred at 0 °C for 2 hrs. The mixture was
quenched with saturated aq.bflLCl solution at 0 °C and acidified with IN aq.HCl to pH~4. The mixture was extracted with EtOAc (3 x 5 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 50% EtOAc in PE) to give the title compound (40 mg, 60.0% yield) as yellow solid. LC/MS (ESI) (m/z): 528 (M+H)+.
Step 2: (S) or (R)-l-((6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-methylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid and (R) or (S)-l-((6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid
[0513] To a solution of methyl l-((6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l -methyl- 1H- l,2,3-triazol-4-yl)-2-methylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (40 mg, 0.076 mmol) in THF (4 mL)/H20 (4 mL)/MeOH (4 mL) was added LiOH.EEO (32 mg, 0.76 mmol) and the reaction was stirred at r.t. for 2 hrs. Volatiles were removed under vacuum and the residue was diluted with H2O (5 mL). The mixture was adjusted with IN aq.HCl to pH~4 and extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was firstly purified by prep- HPLC (Cl 8, 5-95%, MeCN in H2O with 0.1% HCOOH) and further purified by chiral SFC to give example 147 (Peak 1, retention time: 6.433 min) (6.5 mg, 16.7% yield) as white solid and example 148 (Peak 2, retention time: 6.662 min) (5.5 mg, 14.1% yield) as white solid. Absolute stereochemistry of these two isomers has not been assigned.
[0514] Example 147: LC/MS (ESI) (m/z): 514 (M+H)+. ’H NMR (400 MHz, DMSO-t/e) 6 8.55 (d, J = 5.0 Hz, 1H), 7.97 (d, J = 7.9 Hz, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.09 (d, J = 5.1 Hz, 1H), 6.17 (d, J = 1.6 Hz, 2H), 4.22 (s, 3H), 3.67 (s, 2H), 3.61 - 3.54 (m, 2H), 3.05 - 2.95 (m, 2H), 2.76 - 2.67 (m, 1H), 2.44 (s, 3H), 2.25 - 2.20 (m, 2H), 2.27 - 2.20 (m, 4H), 2.05 - 1.93 (m, 2H), 1.83 -
1.74 (m, 1H).
[0515] Example 148: LC/MS (ESI) (m/z): 514 (M+H)+. ’H NMR (400 MHz, DMSO-t/e) 6 8.55 (d, J= 5.0 Hz, 1H), 7.97 (d, J= 7.9 Hz, 1H), 7.79 (d, J= 7.9 Hz, 1H), 7.09 (d, J= 5.1 Hz, 1H), 6.24 - 6.08 (m, 2H), 4.22 (s, 3H), 3.67 (s, 2H), 3.62 - 3.55 (m, 2H), 3.04 - 2.96 (m, 2H), 2.76 - 2.70 (m, 1H), 2.44 (s, 3H), 2.34 - 2.28 (m, 2H), 2.26 - 2.20 (m, 4H), 2.06 - 1.95 (m, 2H), 1.82 -
1.75 (m, 1H).
SFC condition: Column: ChiralPak AD, 250x21.2 mm I.D., 5 pm; Mobile phase: A for CO2 and B for Methanol (0.1% NH4OH); Gradient: B 30%; Flow rate: 50 mL /min; Column temperature: 35 °C.
Example 149 and 150: (S) and (R)-l-((2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid
Step 1: Methyl l-((2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate
[0516] To a solution of methyl l-((2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (100 mg, 0.25 mmol ) in DCM (10 mL) were added TEA (51 mg, 0.51 mmol) and MsCl (43 mg, 0.38 mmol) at 0 °C and the reaction was stirred at r.t. for 2 hrs. The mixture was washed with saturated aq.NaEICCh solution and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The crude product was used in the next reaction without further purification. LC/MS (ESI) (m/z): 488 (M+H)+.
Step 2: Methyl l-((2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate
[0517] To a mixture of methyl l-((2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-
1.2.3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (90 mg, 0.190 mmol) and 4-propylpyridin-2(lH)-one (39 mg, 0.285 mmol) in toluene (5 mL)/H20 (1 mL) was added K2CO3 (53 mg, 0.380 mmol) followed by TBAF (5 mg, 0.019 mmol) and the reaction mixture was stirred at 100 °C for 16 hrs. The mixture was partitioned between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (0 ~ 40% EtOAc in PE) to give the title compound (75 mg, 76.7% yield) as yellow solid. LC/MS (ESI) (m/z): 529 (M+H)+.
Step 3: (S) or (R)-l-((2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-
1.2.3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid and (R) or (S)-l-((2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid
[0518] The title compounds were synthesized according the same procedure as example 147 and 148. The final product was purified by chiral SFC to give example 149 (Peak 1, retention time:
3.513 min) (6.5 mg, 28.5% yield) as white solid and example 150 (Peak 2, retention time: 3.839 min) (4.4 mg, 19.3% yield) as white solid.
[0519] Example 149: LC/MS (ESI) (m/z): 515 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.90 (d, J= 7.8 Hz, 1H), 7.80 (d, J= 7.8 Hz, 1H), 7.70 (d, J= 2.4 Hz, 1H), 7.39 (dd, J= 92, 2.4 Hz, 1H), 6.53 (d, J= 92 Hz, 1H), 5.91 (s, 2H), 3.70 (d, J= 4.4 Hz, 2H), 3.14 - 3.02 (m, 1H), 3.00 (t, J = 7.5 Hz, 2H), 3.04 - 2.92 (m, 1H), 2.88 - 2.66 (m, 1H), 2.38 - 2.28 (m, 2H), 2.21 (t, J= 7.6 Hz, 2H), 1.38 (q, J= 14.7, 7.4 Hz, 2H), 1.30 (t, J= 7.5 Hz, 3H), 0.75 (t, J= 7.4 Hz, 3H).
[0520] Example 150: LC/MS (ESI) (m/z): 515 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.90 (d, J= 7.9 Hz, 1H), 7.80 (d, J= 8.0 Hz, 1H), 7.70 (s, 1H), 7.39 (dd, J= 9.2, 2.5 Hz, 1H), 6.53 (d, J= 92 Hz, 1H), 5.91 (s, 2H), 4.17 (s, 3H), 3.70 (s, 2H), 3.14 - 3.09 (m, 1H), 2.99 (t, J= 7.4 Hz, 2H), 2.99 - 2.94 (m, 1H),2.82 - 2.74 (m, 1H), 2.50 - 2.30 (m, 3H), 2.21 (t, J= 7.4 Hz, 2H), 2.05 - 1.92 (m, 1H), 1.38 (q, J= 7.4 Hz, 2H), 1.30 (t, J= 7.4 Hz, 3H), 0.75 (t, J= 7.4 Hz, 3H).
SFC condition: Column: ChiralPak IG, 250x21.2mm I.D., 5pm; Mobile phase: A for CO2 and B for Methanol (0.1% NH4OH); Gradient: B 30%; Flow rate: 50 mL /min; Column temperature: 35
Example 151: l-((6-(5-(((4-cyclopropylpyrimidin-2-yl)amino)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid
Step 1: Methyl l-((6-(5-(azidomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3- yl)methyl)-5,5-difluoropiperidine-3-carboxylate
[0521] To a solution of methyl l-((2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (300 mg, 0.62 mmol) in DMF (5 mL) was added NaNs (60 mg, 0.923 mmol) and the reaction was stirred at 60 °C for 16 hrs. The mixture was diluted with EtOAc (10 mL) and was washed with water and brine, dried over
anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (0 ~ 30% EtOAc in PE) to give the title compound (208 mg, 77.8% yield) as yellow solid. LC/MS (ESI) (m/z): 435 (M+H)+. ’H NMR (400 MHz, CDCh) 6 8.03 (d, J= 7.9 Hz, 1H), 7.66 (d, J= 7.9 Hz, 1H), 5.17 (s, 2H), 4.13 (s, 3H), 3.69 (s, 3H), 3.64 - 3.60 (m, 2H), 3.13 - 2.99 (m, 2H), 2.92 (q, J= 7.4 Hz, 2H), 2.94 - 2.89 (m, 1H), 2.46 - 2.37 (m„ 1H), 2.35 - 2.25 (m, 1H), 2.23 - 2.21(m, 1H), 2.0 2- 1.98 (m, 1H), 1.36 (t, J= 7.4, 3H).
Step 2: Methyl l-((6-(5-(aminomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-ethylpyridin-3- yl)methyl)-5,5-difluoropiperidine-3-carboxylate
[0522] To a solution of methyl l-((6-(5-(azidomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (200 mg, 0.46 mmol) in EtOAc (5 mL) was added 10% Pd/C (40 mg, 0.038 mmol) and the mixture was degassed under N2 for three times and stirred under a H2 balloon at r.t. for 2 hrs. The reaction mixture was filtered through a pad of Celite and the filtrate was concentrated to dryness to give the title compound (190 mg, 100% yield), which was used in the next step without further purification. LC/MS (ESI) (m/z): 409 (M+H)+.
Step 3: Methyl l-((6-(5-(((4-cyclopropylpyrimidin-2-yl)amino)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate
[0523] To a mixture of methyl l-((6-(5-(aminomethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- ethylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (70 mg, 0.17 mmol) and 2-chloro- 4-cyclobutylpyrimidine (29 mg, 0.17 mmol) in NMP (2 mL) was added DIPEA (44 mg, 0.34 mmol) and the reaction was stirred in a CEM microwave reactor at 150 °C for 2 hrs. The mixture was diluted with EtOAc (10 mL) and was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by perp-TLC (40% EtOAc in PE) to give the title compound (50 mg, 54.0% yield) as yellow oil. LC/MS (ESI) (m/z): 527 (M+H)+.
Step 4: methyl l-((6-(5-(((4-cyclopropylpyrimidin-2-yl)amino)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate
[0524] The title compound was synthesized according to the same procedure as Example 149. LC/MS (ESI)(m/z): 513 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 8.02 (d, J= 5.2 Hz, 1H), 7.89 (d, J= 8.0 Hz, 1H), 7.77 (d, J= 8.0 Hz, 1H), 6.51 (d, J= 5.2 Hz, 1H), 5.06 (s, 2H), 4.23 (s, 3H), 3.70 (s, 2H), 3.14 - 3.09 (m, 1H), 3.05 - 2.99 (q, J= 7.5 Hz, 2H), 3.00 - 2.94 (m, 1H), 2.83 - 2.73 (m, 1H), 2.50 - 2.38 (m, 1H), 2.36 - 2.26 (m, 2H), 2.04 - 1.88 (m, 1H), 1.87 - 1.80 (m, 1H), 1.36 (t, J= 7.5 Hz, 3H), 0.94 - 0.86 (m, 4H).
The Examples in the below Table were synthesized and separated by chiral SFC by the same
methods exemplified by the preparation of the examples as indicated. As a convertion, the fatsereluting enantiomer is always listed as enantiomer Pl and the slower-eluting enantiomer is listed as enantiomer P2. The symbol * at the chiral centre denotes that this chiral center has been resolved and the absolute stereochemistry at that center has not been determined.
Example 164 and 165: (S) and (R)-l-((2-ethyl-6-(l-methyl-5- (((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5- difluoropiperidine-3-carboxylic acid
Step 1: Methyl l-((2-ethyl-6-(l-methyl-5-((((4-nitrophenoxy)carbonyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate
[0525] To a mixture of methyl l-((2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate (120 mg, 0.29 mmol) and 4- nitrophenyl chloroformate (177 mg, 0.88 mmol) in DCM (5 mL) was added pyridine (116 mg, 1.47 mmol) and the reaction was stirred at r.t. for 1 hr. The mixture was diluted with DCM (10 mL) and
was washed with saturated aq.NaHCCh solution and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (170 mg, 100% yield). The crude product was used in the next step without further purification. LC/MS (ESI) (m/z): 575 (M+H)+.
Step 2: Methyl l-((2-ethyl-6-(l-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-lH-
1.2.3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylate
[0526] To a solution of methyl l-((2-ethyl-6-(l-methyl-5-((((4- nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)methyl)-5,5- difluoropiperidine-3 -carboxylate (120 mg, 0.21 mmol) in THF(10 mL) was added DIPEA (135 mg, 1.04 mmol) followed by methyl(propyl)amine (76 mg, 1.04 mmol) at 0 °C and the reaction was stirred at r.t. for 2 hrs. The mixture was diluted with EtOAc (10 mL) and was washed with IM aq.NaOH solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by perp-TLC (50% EtOAc in PE) to give the title compound (23 mg, 21.7% yield) as yellow solid. LC/MS (ESI) (m/z): 509 (M+H)+.
Step 3: (S) and (R)-l-((2-ethyl-6-(l-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-lH-
1.2.3-triazol-4-yl)pyridin-3-yl)methyl)-5,5-difluoropiperidine-3-carboxylic acid
[0527] The title compound was synthesized according the same procedure as example 147. Example 164: (Peak 1, retention time: 6.385 min) (7.5 mg, 19.2% yield). LC/MS (ESI) (m/z): 495 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.84 (d, J= 8.0 Hz, 1H), 7.74 (d, J= 8.0 Hz, 1H), 5.78 (s, 2H), 4.19 (s, 3H), 3.67 (d, J = 5.2 Hz, 2H), 3.25 - 3.17 (m, 1H), 3.13 - 3.08 (m, 2H), 3.00 - 2.97 (m, 1H), 2.95 (q, J= 7.5 Hz, 2H), 2.82 (d, J= 25.1 Hz, 3H), 2.77 - 2.68 (m, 1H), 2.44 - 2.36 (m, 1H), 2.30 (t, J= 7.5 Hz, 2H), 2.00 - 1.85 (m, 1H), 1.60 - 1.50 (m, 1H), 1.38 - 1.30 (m, 1H), 1.35 (t, 7.5 Hz, 3H), 0.76 (dt, J= 81.3, 7.5 Hz, 3H). Example 165: (Peak 2, retention time: 6.663 min) (7 mg, 18.3% yield) as white solid. XH NMR (400 MHz, CD3OD) 6 7.84 (d, J= 7.9 Hz, 1H), 7.74 (d, J= 7.9 Hz, 1H), 5.78 (s, 2H), 4.19 (s, 3H), 3.67 (d, J= 4.5 Hz, 2H), 3.25 - 3.17 (m, 1H), 3.14 - 3.07 (m, 2H), 3.00 - 2.92 (m, 1H), 2.95 (q, J= 7.4 Hz, 2H), 2.82 (d, J= 25.1 Hz, 3H), 2.76 - 2.70 (m, 1H), 2.44 - 2.35 (m, 1H), 2.31 (t, J= 7.2 Hz, 2H), 2.01 - 1.85 (m, 1H), 1.42 - 1.36 (m, 1H), 1.35 (t, 7.4 Hz, 3H), 0.76 (dt, J= 81.6, 7.2 Hz, 3H). SFC condition: Column: ChiralPak IG-H, 250^4.6 mm I.D., 5 pm; Mobile phase: A for CO2 and B for Methanol (0.05% NH4OH); Gradient: B 5%-40%; Flow rate: 50 mL /min; Column temperature: 35 °C.
Example 166: 4-((2-methyl-6-(l-methyl-5-(((methyl (propyl)carbamoyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methyl)morpholine-2-carboxylic acid
Step 1: methyl 6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-methylnicotinate
[0528] To a solution of methyl 2-methyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)- lH-l,2,3-triazol-4-yl)nicotinate (500 mg, 1.44 mmol) in MeOH (10 mL) was added PPTS (181 mg, 0.72 mmol) and the mixture was stirred at 50 °C for 3 hrs. The mixture was diluted with EtOAc (20 mL), washed with saturated aq.NaHCCh solution and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 50% EtOAc in PE) to give the title compound (290 mg, 76.6% yield) as white solid. LC/MS (ESI) (m/z): 379 (M+H)+.
Step 2: methyl 2-methyl-6- (l-methyl-5- ((((4-nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)nicotinate
[0529] To a solution of methyl 6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- methylnicotinate (290 mg, 1.1 mmol) in DCM (10 mL) was added pyridine (1.47 g, 5.53 mmol) followed by 4-Nitrophenyl chloroformate (669 mg, 3.32 mmol) at 0 °C and the mixture was stirred at r.t. for 3 hrs. The solvent was removed to give the title compound (450 mg, 95.2% yield) as yellow oil, which was used directly in the next step. LC/MS (ESI) (m/z): 428 (M+H)+.
Step 3: methyl 2-methyl-6-(l-methyl-5-(((methyl (propyl)carbamoyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)nicotinate
[0530] To a solution of methyl 2-methyl-6- (l-methyl-5- ((((4- nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)nicotinate (450 mg, 1.05 mmol) in THF (10 mL) was added DIPEA (0.52 ml, 3.16 mmol) followed by methyl (propyl)amine (154 mg, 2.10 mmol) and the mixture was stirred at r.t. for 2 hrs. The mixture was diluted with EtOAc (20 mL), washed IN aq.NaOH solution and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 60% EtOAc in PE) to give the title compound (320 mg, 84.1% yield) as yellow oil. LC/MS (ESI) (m/z): 362 (M+H)+.
Step 4: (4-(5-(hydroxymethyl)-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methyl (propyl)carbamate
[0531] To a solution of methyl 2-methyl-6-(l-methyl-5-(((methyl (propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)nicotinate (320 mg, 0.89 mmol) in THF (20 mL) was added LiBH4 (1.11 mL, 2.21 mmol, 2M in THF) drop-wisely at 0 °C. After addition, the reaction was stirred at 55 °C for 3 hrs. The mixture was poured into saturated aq.NHiCl solution and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 50% EtOAc in PE) to give the title compound (250 mg, 84.7% yield) as yellow oil. LC/MS (ESI) (m/z): 334 (M+H)+.
Step 5: (4-(5-formyl-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5-yl)methyl methyl(propyl)carbamate
[0532] To a solution of (4-(5-(hydroxymethyl)-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol- 5-yl)methyl methyl (propyl)carbamate (250 mg, 0.75 mmol) in DCM (10 mL) was added Dess- Martin periodinane (477 mg, 1.12 mmol) at 0 °C. The reaction was stirred at r.t. for 3 hrs. The mixture was washed with saturated aq.NaHCOs solution and brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 30% EtOAc in PE) to give the title compound (180 mg, 72.4% yield) as yellow solid. LC/MS (ESI) (m/z): 332 (M+H)+.
Step 6: methyl 4-((2-methyl-6-(l-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)methyl)morpholine-2-carboxylate
[0533] To a solution of (4-(5-formyl-6-methylpyridin-2-yl)-l-methyl-lH-l,2,3-triazol-5- yl)methyl methyl(propyl)carbamate (100 mg, 0.30 mmol) in DCE (6 mL) was added methyl morpholine-2-carboxylate (87 mg, 0.60 mmol) followed by NaBH(OAc)3 (191 mg, 0.90 mmol) at 0 °C and the reaction mixture was stirred at r.t. for 16 hrs. The mixture was diluted with DCM (20 mL), washed with brine, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by flash chromatography (silica gel, 0 ~ 50% EtOAc in PE) to give the title compound (30 mg, 21.6% yield) as yellow solid. LC/MS (ESI) (m/z): 461 (M+H)+.
Step 7: 4-((2-methyl-6-(l-methyl-5-(((methyl (propyl)carbamoyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)methyl)morpholine-2-carboxylic acid
[0534] To a solution of methyl 4-((2-methyl-6-(l-methyl-5- (((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)methyl)morpholine- 2-carboxylate (30 mg, 0.065 mmol) in THF (2 mL) /H2O (1 mL) /MeOH (41 mL) was added
LiOH.ILO (27 mg, 0.65 mmol) and the reaction was stirred at r.t. for 2 hrs. Volatiles were removed under vacuum and the residue was diluted with H2O (5 mL). The mixture was adjusted with IN aq.HCl to pH~4 and extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 5-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (13 mg, 44.7% yield) as white solid. LC/MS (ESI) (m/z): 447 (M+H)+. 'H NMR (400 MHz, CD3OD) 6 7.84 (d, J = 7.9 Hz, 1H), 7.76 (d, J = 7.9 Hz, 1H), 5.73 (s, 2H), 4.19 (s, 3H), 4.18 - 4.12 (m, 1H), 4.01 - 3.95 (m, 1H), 3.76 - 3.70 (m, 1H), 3.69 - 3.62 (m, 2H), 3.25 - 3.19 (m, 1H), 3.17 - 3.09 (m, 1H), 3.00 - 2.94 (m, 1H), 2.89 - 2.80 (m, 3H), 2.70 - 2.64 (m, 1H), 2.62 (s, 3H), 2.52 - 2.39 (m, 2H), 1.57 - 1.36 (m, 2H), 0.93 - 0.65 (m, 3H).
Example 167&168&169: (R)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H- 1 ,2,3-triazol-2- yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3- yl)acetic acid & (R)-2-(l-(6-(5-((5-(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l- methyl-lH-l,2,3-triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetic acid & (R)-2-(l-(6-(5-((4-(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetic acid
Step 1: ethyl (R)-2-(l-(2-(difluoromethyl)-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate
[0535] To a mixture of ethyl (R)-2-(l-(2-(difluoromethyl)-6-(5-(hydroxymethyl)-l-methyl-lH- l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (68 mg, 0.17 mmol), TEA (60 mg, 0.6 mmol) in DCM (5 mL) was added drop-wisely MsCl (28 mg, 0.25 mmol) at 0 °C. After the addition, the resulting solution was stirred at r.t. for another 2 hrs. The mixture was diluted with DCM (10 mL), washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (75 mg, 92.8% yield) as colorless oil, which was directly used in the next reaction without purification. LC-MS (ESI) m/z: 488 (M+l)+.
Step 2: ethyl (R)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetate (3) & ethyl (R)- 2-(l-(6-(5-((5-(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol- 4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetate (3a) & ethyl (R)-2-(l-(6-(5-((4- (cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)-2- (difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetate (3b)
[0536] To a mixture of ethyl (R)-2-(l-(2-(difluoromethyl)-6-(l-methyl-5- (((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)piperidin-3-yl)acetate (75 mg, 0.15 mmol), 4-(cyclopropylmethyl)-2H-l,2,3-triazole (19 mg, 0.15 mmol) in MeCN (2 mL) was added DBU (45.6 mg, 0.3 mmol) and the mixture was stirred in a CEM microwave reactor at 105 °C for 1 hr. The mixture was diluted with DCM (10 mL), washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-40% of EtOAc in PE) to give compound 3 (22 mg, 27.8% yield) and a mixture of compound 3a and 3b (50 mg, 63.1% yield) as colorless oil. LC-MS(ESI) m/z: 515 (M+l)+.
Step 3: (R)-2-(l-(6-(5-((4-(cyclopropylmethyl)-2H-l,2,3-triazol-2-yl)methyl)-l-methyl-lH- l,2,3-triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetic acid
[0537] To a solution of ethyl 2-[(3R)-l-[6-(5-{[4-(cyclopropylmethyl)-2H-l,2,3-triazol-2- yl]methyl}-l-methyl-lH-l,2,3-triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl]piperidin-3-yl]acetate (22 mg, 0.04 mmol) in MeOH (1 mL), water (1 mL) and THF (2 mL) was added LiOH (13 mg, 0.4 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was acidified with IM aq.HCl to pH~3 and extracted with DCM (2 x 3 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep.HPLC to give the title compound (5.2 mg, 30.6% yield) as white solid. LC/MS (ESI) m/z: 487 (M+l)+. 'H NMR (400 MHz, CD3OD) 8 8.00 (d, J= 8.6 Hz, 1H), 7.66 (d, J= 8.6 Hz, 1H), 7.36 (s, 1H), 6.91 (t, J= 54.4 Hz, 1H), 6.25 (s, 2H), 3.90 (s, 3H), 3.06 (d, J= 9.7 Hz, 1H), 2.97 (d, J= 11.8 Hz, 1H), 2.71 - 2.61 (m, 1H), 2.47 - 2.41 (m, 1H), 2.38 (d, J= 7.0 Hz, 2H), 2.16 (d, = 6.3 Hz, 2H), 2.13 - 2.03 (m, 1H), 1.76 (d, J= 12.8 Hz, 1H), 1.72 - 1.58 (m, 2H), 1.13 - 1.00 (m, 1H), 0.89 - 0.76 (m, 1H), 0.38 - 0.30 (m, 2H), 0.06 - 0.03 (m, 2H).
Example 168: (R)-2-(l-(6-(5-((5-(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl- lH-l,2,3-triazol-4-yl)-2-(difluoromethyl)pyridin-3-yl)piperidin-3-yl)acetic acid and example 169: (R)-2-(l-(6-(5-((4-(cyclopropylmethyl)-lH-l,2,3-triazol-l-yl)methyl)-l-methyl-lH-l,2,3- triazol -4-yl)-2-(difluoromethyl)pyri din-3 -yl)piperi din-3 -yl)acetic acid were prepared as the same manner of example 167, the absolute configuration was confirmed by NOE.
Example 168: LC/MS (ESI) m/z: 487 (M+l)+. XH NMR (400 MHz, CD3OD) 8 8.22 (d, J= 8.6 Hz, 1H), 7.84 (d, J= 8.6 Hz, 1H), 7.63 (s, 1H), 7.13 (t, J= 54.4 Hz, 1H), 6.35 (s, 2H), 4.14 (s, 3H), 3.21 (d, J= 11.3 Hz, 1H), 3.16 - 3.07 (m, 1H), 2.83 (td, J= 11.2, 3.6 Hz, 1H), 2.63 - 2.55 (m, 3H), 2.31 (d, = 6.5 Hz, 2H), 2.29 - 2.20 (m, 1H), 1.96 - 1.88 (m, 1H), 1.88 - 1.71 (m, 2H), 1.27 - 1.18 (m, 1H), 0.94 - 0.85 (m, 1H), 0.54 - 0.44 (m, 2H), 0.09 - 0.02 (m, 2H).
Example 169: LC/MS (ESI) m/z: 487 (M+l)+. ’H NMR (400 MHz, CD3OD) 8 8.22 (t, J= 4.3 Hz, 2H), 7.86 (d, J= 8.6 Hz, 1H), 7.23 (t, J= 54.4 Hz, 1H), 6.23 (s, 2H), 4.33 (s, 3H), 3.23 (d, J = 11.3 Hz, 1H), 3.17 - 3.10 (m, 1H), 2.89 - 2.78 (m, 1H), 2.65 - 2.58 (m, 1H), 2.55 (d, J= 7.0 Hz, 2H), 2.35 - 2.31 (m, 2H), 2.30 - 2.22 (m, 1H), 1.97 - 1.78 (m, 3H), 1.28 - 1.17 (m, 1H), 1.00 - 0.90 (m, 1H), 0.54 - 0.44 (m, 2H), 0.20 - 0.11 (m, 2H).
Example 170: 2-(4-(2-ethyl-6-(l-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetic acid
Step 1: ethyl 2-(4-(2-ethyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate
[0538] To a mixture of 3-bromo-2-ethyl-6-{ l-methyl-5-[(oxan-2-yloxy)methyl]-lH-l,2,3-triazol- 4-yl}pyridine (760 mg, 2.0 mmol), ethyl 2-[(3R)-piperidin-3-yl]acetate (210 mg, 2.0 mmol) and CS2CO3 (1.9 g, 5.9 mmol) in 1,4-dioxane (20 mL) was added RuPhos (46 mg, 0.1 mmol) and Ruphos-Pd-G3 (80 mg, 0.1 mmol) under N2 atmosphere. The resulting mixture was degassed under N2 atmosphere for three times and stirred at 110 °C for 16 hrs. The reaction mixture was diluted with EtOAc (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-30% of EtOAc in PE) to give the title compound (810 mg, 85.8% yield) as colorless oil. LC/MS (ESI) m/z: 474 (M+H)+. XHNMR (400 MHz, CDCh) 6 7.99 (d, J= 8.3 Hz, 1H), 7.37 (d, J= 8.4 Hz, 1H), 5.52
- 5.31 (m, 2H), 4.76 - 4.71 (m, 1H), 4.20 - 4.16 (m, 2H), 4.15 (s, 3H), 4.03 - 3.96 (m, 1H), 3.92 - 3.83 (m, 2H), 3.51 (d, J= 4.5 Hz, 1H), 3.11 - 3.02 (m, 1H), 2.95 - 2.80 (m, 4H), 2.68 - 2.56 (m, 2H), 2.52 - 2.43 (m, 1H), 1.82 - 1.68 (m, 3H), 1.55 - 1.50 (m, 3 H), 1.36 (t, J= 7.5 Hz, 3H), 1.28 (t, J= 7.1 Hz, 3H), 1.17 (d, J = 6.1 Hz, 1H), 1.01 (d, J= 6.0 Hz, 1H).
Step 2: ethyl 2-(4-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4-yl)pyridin-3- yl)morpholin-2-yl)acetate
[0539] To a mixture of ethyl 2-(4-(2-ethyl-6-(l-methyl-5-(((tetrahydro-2H-pyran-2- yl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate (810 mg, 1.7 mmol) in MeOH (10 mL) was added PPTS (610 mg, 4 mmol) and the mixture was stirred at 60 °C for 16 hrs. The reaction mixture was diluted with DCM (20 mL), washed with saturated aq.NaHCCh solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 0-50% of EtOAc in PE) to give the title compound (520 mg, 78.1% yield) as white solid. LC/MS (ESI) m/z: 390 (M+H)+.
Step 3: ethyl 2-(4-(2-ethyl-6-(l-methyl-5-((((4-nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate
[0540] To a mixture of ethyl 2-(4-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)morpholin-2-yl)acetate (60 mg, 0.15 mmol) and pyridine (200 mg, 0.75 mmol) in DCM (5 mL) was added a solution of 4-nitrophenyl chloroformate (90 mg, 0.45 mmol) in DCM (1 mL) drop-wisely at 0 °C and the mixture was stirred at r.t. for 3 hrs. The reaction mixture was diluted with DCM (10 mL), washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (80 mg, 92.3% yield) as yellow solid. LC/MS (ESI) m/z: 555 (M+H)+.
Step 4: ethyl 2-(4-(2-ethyl-6-(l-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate
[0541] To a mixture of ethyl 2-(4-(2-ethyl-6-(l-methyl-5-((((4- nitrophenoxy)carbonyl)oxy)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate (80 mg, 0.14 mmol) and DIEA (190 mg, 0.15 mmol) in THF (4 mL) was added methyl(propyl)amine (22 mg, 0.3 mmol) at 0 °C and the reaction mixture was stirred at r.t. for 2 hrs. The mixture was diluted with EtOAc (10 mL), washed with IN aq.NaOH solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (50 mg, 71.0% yield) as white solid. LC/MS (ESI) m/z: 489 (M+H)+.
Step 5: 2-(4-(2-ethyl-6-(l-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-lH-l,2,3- triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetic acid
[0542] To a solution of ethyl 2-[(3R)-l-{2-ethyl-6-[l-methyl-5-
({[methyl(propyl)carbamoyl]oxy}methyl)-lH-l,2,3-triazol-4-yl]pyridin-3-yl}piperidin-3- yl]acetate (50 mg, 0.11 mmol) in MeOH (1 mL), water (1 mL) and THF (4 mL) was added LiOH (18 mg, 0.5 mmol) and the mixture was stirred at 25 °C for 1 hr. The mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was washed with EtOAc twice and acidified with IN aq.HCl to pH= 3. The mixture was extracted with EtOAc (3 x 5 mL) and the combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to give the title compound (20.1 mg, 42.6% yield) as white solid. LC/MS (ESI) m/z: 461 (M+H)+. ’H NMR (400 MHz, CD3OD) 8 7.84 (d, J = 8.3 Hz, 1H), 7.53 (d, J= 8.4 Hz, 1H), 5.76 (s, 2H), 4.18 (s, 3H), 4.15 - 4.08 (m, 1H), 4.00 -3.94 (m, 1H), 3.88 - 3.80 (m, 1H), 3.22 (t, J= 7.0 Hz, 1H), 3.12 (dd, J= 13.0, 7.3 Hz, 2H), 2.99 - 2.88 (m, 4H), 2.83 (d, J= 17.1 Hz, 3H), 2.66 - 2.58 (m, 1H), 2.57 - 2.46 (m, 2H), 1.59 - 1.49 (m, 1H), 1.42 - 1.33 (m, 4H), 0.78 (dt, J= 74.8, 7.2 Hz, 3H).
Example 171: 2-(4-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3- triazol-4-yl)-2-ethylpyridin-3-yl)morpholin-2-yl)acetic acid
Step 1: ethyl 2-(4-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol- 4-yl)-2-ethylpyridin-3-yl)morpholin-2-yl)acetate
[0543] To a mixture of ethyl 2-(4-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)morpholin-2-yl)acetate (50 mg, 0.13 mmol) and 2-chloro-4-cyclobutylpyrimidine (32.5 mg, 0.19 mmol) in THF (2 mL) was added t-BuOK (0.26 mL, 0.26 mmol, IM in THF) drop- wisely at 0 °C and the mixture was stirred at r.t. for 2 hrs. The mixture was quenched with icewater and extracted with EtOAc (2 x 5 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to give the title compound (60 mg, 89.6% yield) as yellow solid, which was used in the next step directly. LC/MS (ESI) m/z: 522 (M+H)+.
Step 2: 2-(4-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l-methyl-lH-l,2,3-triazol-4-yl)- 2-ethylpyridin-3-yl)morpholin-2-yl)acetic acid
[0544] To a solution of ethyl 2-(4-(6-(5-(((4-cyclobutylpyrimidin-2-yl)oxy)methyl)-l -methyl- 1H- l,2,3-triazol-4-yl)-2-ethylpyridin-3-yl)morpholin-2-yl)acetate (60 mg, 0.12 mmol) in THF (2 mL), MeOH (0.5 mL) and H2O (0.5 mL) was added LiOH.LLO (24 mg, 0.6 mmol) and the mixture was stirred at r.t. for 2 hrs. The reaction mixture was concentrated to dryness and the residue was
dissolved in water. The mixture was washed with EtOAc twice, acidified with IN aq.HCl to pH = 4 and extracted with EtOAc (3 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC (C18, 10-95%, MeCN in H2O with 0.1% HCOOH) to give the title compound (11.9 mg, 20% yield) as white solid. LC/MS (ESI) m/z: 494 (M+H)+. XH NMR (400 MHz, CD3OD) 8 8.41 (d, J= 5.1 Hz, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.55 (d, J= 8.4 Hz, 1H), 6.99 (d, J= 5.1 Hz, 1H), 6.20 (s, 2H), 4.23 (s, 3H), 4.13 - 4.06 (m, 1H), 3.99 - 3.93 (m, 1H), 3.87 - 3.79 (m, 1H), 3.56 - 3.47 (m, 1H), 3.15 - 3.09 (m, 1H), 2.95 - 2.83 (m, 4H), 2.65 - 2.58 (m, 1H), 2.56 - 2.46 (m, 2H), 2.28 - 2.18 (m, 4H), 2.08 - 1.97 (m, 1H), 1.85 -1.76 (m, 1H), 1.24 (t, J = 7.5 Hz, 3H).
Example 172: 2-(4-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetic acid
Step 1: ethyl 2-(4-(2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH-l,2,3-triazol-4- yl)pyridin-3-yl)morpholin-2-yl)acetate
[0545] To a solution of ethyl 2-(4-(2-ethyl-6-(5-(hydroxymethyl)-l-methyl-lH-l,2,3-triazol-4- yl)pyridin-3-yl)morpholin-2-yl)acetate (60 mg, 0.154 mmol) in DCM (2 mL) was added TEA (47 mg, 0.46 mmol) followed by MsCl (35 mg, 0.3 mmol) at 0 °C and the mixture was stirred at r.t. for 2 hrs. The mixture was diluted with DCM (5 mL), washed with saturated aq.NaHCOs solution and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (59 mg, 81.9% yield) as yellow solid, which was directly used in the next reaction without purification. LC/MS (ESI) m/z: 468 (M+H)+.
Step 2: ethyl 2-(4-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)-yl)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate
[0546] To a solution of ethyl 2-(4-(2-ethyl-6-(l-methyl-5-(((methylsulfonyl)oxy)methyl)-lH- l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate (59 mg, 0.13 mmol) in toluene (3 mL) and
H2O (0.5 mL) was added 5-propyl-l,2-dihydropyridin-2-one (35 mg, 0.25 mmol), K2CO3 (52 mg, 0.38 mmol) and TBAF (5 mg, cat.) and the mixture was stirred at 110 °C for 3 hrs. The mixture was diluted with EtOAc (5 mL), washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness to give the title compound (55 mg, 85.7% yield) as yellow solid, which was directly used in the next step. LC/MS (ESI) m/z: 509 (M+H)+.
Step 3: 2-[(2R)-4-(2-ethyl-6-{l-methyl-5-[(2-oxo-5-propyl-l,2-dihydropyridin-l-yl)methyl]- lH-l,2,3-triazol-4-yl}pyridin-3-yl)morpholin-2-yl]acetic acid
[0547] To a solution of ethyl 2-(4-(2-ethyl-6-(l-methyl-5-((2-oxo-5-propylpyridin-l(2H)- yl)methyl)-lH-l,2,3-triazol-4-yl)pyridin-3-yl)morpholin-2-yl)acetate (55 mg, 0.11 mmol) in THF (4 mL) was added MeOH (1 mL), water (1 mL), LiOH (26 mg, 1.08 mmol) and the mixture was stirred at 25 °C for 1 hr. The reaction mixture was concentrated to dryness and the residue was dissolved in H2O (5 mL). The mixture was acidified with IN aq.HCl to pH~4 and extracted with EtOAc (3 x 3 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by pre.HPLC to give the title compound (20 mg, 38.5% yield) as white solid. LC/MS (ESI) m/z: 481 (M+H)+. TH NMR (400 MHz, CD3OD) 8 7.90 (d, J= 8.4 Hz, 1H), 7.69 -7.65 (m, 1H), 7.61 (d, J= 8.4 Hz, 1H), 7.44 - 7.37 (m, 1H), 6.54 (d, J= 92 Hz, 1H), 5.89 (s, 2H), 4.17 (s, 3H), 4.15 - 4.10 (m, 1H), 4.03 - 3.97 (m, 1H), 3.91 - 3.83 (m, 1H), 3.20 - 3.12 (m, 1H), 3.04 - 2.93 (m, 4H), 2.69 - 2.61 (m, 1H), 2.59 - 2.50 (m, 2H), 2.23 (t, J= 7.5 Hz, 2H), 1.41 - 1.32 (m, 5H), 0.78 (t, J= 12 Hz, 3H).
BIOLOGICAL ASSAYS
LPA1 Calcium Flux Assays
[0548] The effectiveness of compounds of the present invention as LPA1 inhibitors can be determined in an LPA1 functional antagonist assay as follows:
[0549] PathHunter® CHO-K1 EDG2 P- Arrestin Cell Line (Eurofins DiscoverX Corporation, Cat#93-0644C2) were plated overnight (11,500 cells/well) in poly-D-lysine coated 384-well microplates (Corning, Cat#356697) in AssayComplete™ Cell Plating 35 Reagent (Eurofins DiscoverX Corporation, Cat#93-0563R35). Following overnight culture, cells were loaded with calcium indicator dye from the HitHunter Calcium No WashPLUS Assay kit (Eurofins DiscoverX Corporation, Cat#93-0091) for 45 minutes at 37°C. Test compounds solubilized in DMSO (Sigma, Cat#276855) on 384-well polypropylene microplates (Greiner bio-one, Cat#781280) were then diluted to intermediate concentration with assay buffer [IX HBSS calcium/magnesium (Coming, Cat#21-023 -CM) and 20mM HEPES (Coming, Cat#25-060-Cl)]
before addition to cells by Agilent Velocity 11 with a final concentration of 0.4% DMSO. After compound addition, assay plates were equilibrated to room temperature for 30 minutes. Cells were then stimulated by addition of EC80 concentration of LPA (Cat#, 10010093) in assay buffer containing [1X HBSS calcium/magnesium (Coming, Cat#21-023 -CM), 20mM HEPES (Corning, Cat#25-060-Cl), and 0.1% BSA (Sigma, Cat#A8806)] using Molecular Devices FLIPR Tetra PLUS®. IC50 values were determined by Chemical and Biological Information System from Chemlnnovation Software, Inc.
[0550] The compounds of this invention were tested for their activity to inhibit LPA1 as determined in an LPA1 functional antagonist assay as described herein. Results of LPA1 assay are given in Table 1.
Table 1. Activity data in LPA1 assay*
* A: <100 nM; B: 100 ~ 500 nM; C: 500 ~ 5000 nM; D: 5000 nM ~ 10 pM
Claims (1)
- WE CLAIM:1. A compound of formula (I), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:L1 is a covalent bond or CH2 optionally substituted with 1 or 2 methyl groups;L2 is a covalent bond or (CR7R7)P;L3 is a covalent bond, O or NR7, provided that at least one of L2 and L3 is not a covalent bond;Q is C(=O)NR9R10, C(=O)OR10, or a ring selected from a 5- or 6-membered heteroaryl group or a 5- or 6-membered heterocyclyl group, wherein the ring comprises at least one carbon atom, at least one nitrogen atom, and optionally 1-4 additional heteroatoms selected from nitrogen, oxygen and sulfur wherein oxygen may be a ring member and/or an oxo group attached to a ring member, and wherein the ring is substituted with (R3)n and one R4;X1 is N, O or CR6a;X2 is N or NR6;X3 is N, NR6 or CR6, wherein the dashed circle denotes bonds forming a five-membered aromatic ring;Y1, Y2, Y3 and Y4 are each independently N or CR5, provided that at least one but no more than two of Y1, Y2, Y3 and Y4 are N;Z is CH2 or O; R1 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi -ealkyl, OH, Ci- ealkyl-OH, Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, Ci-ealkyl-NRaRb, or 4-6- membered heterocylyl, or two R1 groups, together with the carbon atom to which they are attached, form C=O;R2 is (CR7R7)q-R8;R3 at each occurrence is independently hydrogen, halogen, CN, Ci-ealkyl, or C3-7cycloalkyl;R4 is independently hydrogen, halogen, Ci-ealkyl, haloCi-ealkyl, C2-ealkenyl, C2-ealkynyl, Ci- ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-ealkenyl-C3-7cycloalkyl, C2-ealkynyl-C3-7cycloalkyl, O(CH2)P-C3- 7cycloalkyl, (CH2)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CH2)q-5-7- membered heterocyclyl ring substituted with 1-4 R11, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy;R5 at each occurrence is independently hydrogen, halogen, Ci-ealkyl, haloCi -ealkyl, OH, Ci- ealkyl-OH, Ci-ealkoxy, Ci-ealkyl-Ci-ealkoxy, haloCi-ealkoxy, CN, C3-7cycloalkyl, NRaRb, or Ci- 6alkyl-NRaRb; each occurrence of R6a and R6 is independently hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;R7 at each occurrence is independently hydrogen, Ci-4alkyl, C3-5cycloalkyl, or twoR7 groups together with the carbon atom to which they are attached, form a 3-5-membered cycloalkyl ring;R8 is C(=O)OR7, C(=O)NRaRb, CN, C(=O)NHC(=O)R7, C(=O)NHS(=O)2R7, each occurrence of R9 and R10 is independently hydrogen, Ci-ealkyl substituted with 1-4 R11, (CR12R12)q-C2-ealkenyl substituted with 1-4 R11, (CR12R12)q-C2-ealkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11; or R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur;R11 at each occurrence is independently hydrogen, Ci-ealkyl, haloCi -ealkyl, C2-ealkenyl, C2- ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3- vcycloalkyl, (CH2)p-C3-7cycloalkyl, C2-ealkenyl-C3-7cycloalkyl, C2-ealkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy;R12 at each occurrence is independently hydrogen, Ci-4alkyl, C3-7cycloalkyl, or two R12 groups, together with the carbon atom to which they are attached, form a 3-6-membered cycloalkyl ring; each occurrence of Ra and Rb is independently hydrogen or Ci-ealkyl, or Ra and Rb, together with the nitrogen atom to which they are attached, form a saturated or unsaturated heterocyclic ring containing from three to seven ring atoms, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and may be optionally substituted by from one to three groups which may be the same or different selected from the group consisting of Cwalkyl, phenyl and benzyl; m is 1, or 2; n is 0, 1, or 2; p at each occurrence is independently 1, 2, 3 or 4; and q at each occurrence is independently 0, 1, 2, 3 or 4.2. The compound of Claim 1, wherein Z is CH2.3. The compound of Claim 1, wherein Z is O.4. The compound of any one of Claims 1-3, wherein L1 is a covalent bond.5. The compound of any one of Claims 1-3, wherein L1 is CH2 optionally substituted with 1 or 2 methyl groups.6. The compound of any one of Claims 1-3, wherein L1 is CH2.7. The compound of any one of Claims 1-6, wherein each occurrence of R1 is independently hydrogen.8. The compound of any one of Claims 1-6, wherein each occurrence of R1 is independently halogen. The compound of any one of Claims 1-6, wherein m is 2, one R1 is hydrogen, and the other R1 is halogen. The compound of any one of Claims 1-6, wherein m is 2, one R1 is hydrogen, and the other R1 is F. The compound of any one of Claims 1-6, wherein m is 2, each occurrence of R1 is F. The compound of any one of Claims 1-11, wherein Y2 is N, and each of Y1, Y3 and Y4 is independently CR5. The compound of any one of Claims 1-11, wherein Y1 is CR5, Y2 is N, and each of Y3 and Y4 is independently CH. The compound of any one of Claims 1-11, wherein Y1 is CR5, Y2 is N, Y3 is N, and Y4 CH. The compound of any one of Claims 1-14, wherein R5 at each occurrence is independently hydrogen, methyl or ethyl. The compound of any one of Claims 1-14, wherein R5 at each occurrence is independently hydrogen, CHF2 or CF3. The compound of any one of Claims 1-14, wherein R5 at each occurrence is independently hydrogen, or CN. The compound of any one of Claims 1-17, wherein X1 is N, X2 is N, and X3 is NR6. The compound of any one of Claims 1-17, wherein X1 is CH, X2 is N, and X3 is NR6. The compound of any one of Claims 1-17, wherein X1 is O, X2 is N, and X3 is CR6. The compound of any one of Claims 1-20, wherein R6 is methyl. The compound of any one of Claims 1-21, wherein L2 is a covalent bond. The compound of any one of Claims 1-21, wherein L2 is (CR7R7)P. The compound of any one of Claims 1-21, wherein L2 is CH2. The compound of any one of Claims 1-24, wherein L3 is a covalent bond. The compound of any one of Claims 1-24, wherein L3 is O. The compound of any one of Claims 1-24, wherein L3 is NR7. The compound of any one of Claims 1-27, wherein q is 0. The compound of any one of Claims 1-27, wherein q is 1. The compound of any one of Claims 1-27, wherein q is 2. The compound of any one of Claims 1-30, wherein R8 is COOH. The compound of any one of Claims 1-31, wherein R9 is Ci-4alkyl. The compound of any one of Claims 1-32, wherein R10 is Ci-ealkyl substituted with 1-4 R11, (CR12R12)q-C2-ealkenyl substituted with 1-4 R11, (CR12R12)q-C2-ealkynyl substituted259 with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11.34. The compound of any one of Claims 1-33, wherein R10 is Ci-ealkyl.35. The compound of any one of Claims 1-33, wherein R10 is (CH2)p-C3-7cycloalkyl.36. The compound of any one of Claims 1-33, wherein R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.37. The compound of any one of Claims 1-36, wherein Q is C(=O)NR9R10.38. The compound of any one of Claims 1-36, wherein Q is a ring selected from 5-membered heteroaryl or heterocyclyl and 6-membered heteroaryl or heterocyclyl, wherein the ring comprises at least on carbon atom, at least one nitrogen atom and optionally 1-3 heteroatoms selected from nitrogen, oxygen and sulfur wherein oxygen may be a ring member and/or a carbonyl attached to a ring member, and wherein the ring is substituted with (R3)n and R4.39. The compound of Claim 38, wherein Q is: is substituted with (R3)n and one R4 at any available carbon or nitrogen position.40. The compound of Claim 38, wherein Q is: which is substituted with (R3)n and one R4 at any available carbon or nitrogen position.26041. The compound of any one of Claims 1-40, wherein each occurrence of R3 is independently hydrogen, halogen, or Ci-4alkyl.42. The compound of any one of Claims 1-40, wherein each occurrence of R3 is independently Ci-4alkyl.43. The compound of any one of Claims 1-40, wherein each occurrence of R3 is independently methyl.44. The compound of any one of Claims 1-43, wherein R4 is independently hydrogen, Ci- ealkyl, C2-ealkenyl, C2-ealkynyl, Ci-ealkoxy, (CH2)p-Ci-6alkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy.45. The compound of any one of Claims 1-43, wherein R4 is independently (CH2)q-5-6- membered heteroaryl ring substituted with 1-4 R11, or (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11.46. The compound of any one of Claims 1-43, wherein R4 is independently Ci-ealkyl, C2- ealkynyl, Ci-ealkoxy, (CH2)P-Ci-6alkoxy, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, or C2- 6alkenyl-C3-7cycloalkyl.47. The compound of any one of Claims 1-46, having a structure of Formula (II), wherein:Q is a ring selected from the group consisting of 5-membered heteroaryl, 5-membered heterocyclyl, 6-membered heteroaryl, and 6-membered heterocyclyl, wherein the ring comprises at least one carbon atom, at least one nitrogen atom and optionally 1-4 additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur wherein oxygen may be a ring member and/or an oxo attached to a ring member, and wherein the ring is substituted with (R3)n and one R4;X1 is N, or CR6a;R6a is hydrogen, or methyl;R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;R13 at each occurrence is independently hydrogen, Ci-4alkyl, or Cs-scycloalkyl; and t is 0, 1, 2 or 3; and w is 0 or 1, provided that when L1 is a covalent bond, w is 1; and further provided that when L1 is CH2 optionally substituted with 1 or 2 methyl groups, w is 0.48. The compound of Claim 47, wherein Z is CH2.49. The compound of Claim 47, wherein Z is O.50. The compound of any one of Claims 47-49, wherein L1 is a covalent bond.51. The compound of any one of Claims 47-49, wherein L1 is CH2 optionally substituted with1-2 methyl.52. The compound of any one of Claims 47-49, wherein L1 is CH2.53. The compound of any one of Claims 47-52, wherein each occurrence of R1 is independently hydrogen.54. The compound of any one of Claims 47-52, wherein each occurrence of R1 is independently halogen.55. The compound of any one of Claims 47-52, wherein one R1 is hydrogen, and the other R1 is halogen.56. The compound of any one of Claims 47-52, wherein one R1 is hydrogen, and the other R1 is F.57. The compound of any one of Claims 47-52, wherein each occurrence of R1 is independently F.58. The compound of any one of Claims 47-57, wherein the moiety59. The compound of any one of Claims 47-58, wherein each R5 is independently hydrogen, halogen, Ci-ealkyl or haloCi -ealkyl.60. The compound of any one of Claims 47-58, wherein each R5 is independently Ci-ealkyl.61. The compound of any one of Claims 47-58, wherein each R5 is independently methyl or ethyl.62. The compound of any one of Claims 47-58, wherein each R5 is independently CHF2 or CF3.63. The compound of any one of Claims 47-62, wherein X1 is N.64. The compound of any one of Claims 47-62, wherein X1 is CH.65. The compound of any one of Claims 47-64, wherein R6 is methyl.66. The compound of any one of Claims 47-65, wherein L2 is a (CR7R7)P.67. The compound of any one of Claims 47-65, wherein L2 is a CH2.68. The compound of any one of Claims 47-65, wherein L3 is a covalent bond.69. The compound of any one of Claims 47-65, wherein L3 is O.70. The compound of any one of Claims 47-65, wherein L3 is NR7.71. The compound of any one of Claims 47-70, wherein Q is: substituted with (R3)n and one R4 at any available carbon or nitrogen position, and n is 0, 1 or 2.72. The compound of Claim 71, wherein substituted with (R3)n and one R4 at available any carbon or nitrogen position, and n is 0, 1 or 2.73. The compound of any one of Claims 47-70, wherein Q is:263 which is substituted with (R3)n and one R4 at available any carbon or nitrogen position, and n is 0, 1 or 2.74. The compound of any one of Claims 47-73, wherein each occurrence of R3 is independently hydrogen, halogen, or Ci-4alkyl.75. The compound of any one of Claims 47-73, wherein each occurrence of R3 is independently Ci-4alkyl.76. The compound of any one of Claims 47-73, wherein each occurrence of R3 is independently methyl.77. The compound of any one of Claims 47-76, wherein R4 is independently hydrogen, Ci- ealkyl, C2-ealkenyl, C2-ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, phenyl, (CH2)P-phenyl, O(CH2)P-phenyl, CN, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, C2-6alkenyl-C3-7cycloalkyl, C2-6alkynyl-C3-7cycloalkyl, O(CH2)P-C3-7cycloalkyl, in which each phenyl is independently optionally substituted with 1-3 of halogen, Ci-ealkyl, or Ci-ealkoxy.78. The compound of any one of Claims 47-76, wherein R4 is independently (CH2)q-5-6- membered heteroaryl ring substituted with 1-4 R11, or (CH2)q-5-7-membered heterocyclyl ring substituted with 1-4 R11.79. The compound of any one of Claims 47-76, wherein R4 is independently Ci-ealkyl, C2- ealkynyl, Ci-ealkoxy, (CH2)p-Ci-ealkoxy, C3-7cycloalkyl, (CH2)P-C3-7cycloalkyl, or C2-6 alkynyl-C3-7cycloalkyl.80. The compound of any one of Claims 47-79, wherein the moiety is81. The compound of any one of Claims 47-80, wherein R13 is hydrogen.82. The compound of any one of Claims 47-80, wherein R13 is methyl.83. The compound of any one of Claims 47-80, wherein R13 is cyclopropyl.84. The compound of any one of Claims 1-46 or 48-83, having the structure of Formula (III),264wherein:X1 is N, or CR6a;R6a is hydrogen, or methyl;R6 is hydrogen, halogen, CN, methyl, ethyl, propyl, or cyclopropyl;R13 at each occurrence is independently hydrogen, Ci-4alkyl, or Cs-scycloalkyl; and t is 0, 1, 2 or 3; and w is 0 or 1, provided that when L1 is a covalent bond, w is 1, and further provided that when L1 is CH2 optionally substituted with 1 or 2 methyl groups, w is 0;.85. The compound of Claim 84, wherein Z is CH2.86. The compound of Claim 84, wherein Z is O.87. The compound of any one of Claims 84-86, wherein L1 is a covalent bond.88. The compound of any one of Claims 84-86, wherein L1 is CH2 optionally substituted with1-2 methyl.89. The compound of any one of Claims 84-86, wherein L1 is CH2.90. The compound of any one of Claims 84-89, wherein each occurrence of R1 is independently hydrogen.91. The compound of any one of Claims 84-89, wherein each occurrence of R1 is independently halogen.92. The compound of any one of Claims 84-89, wherein one R1 is hydrogen, and the other R1 is halogen.265 The compound of any one of Claims 84-89, wherein one R1 is hydrogen, and the other R1 is F. The compound of any one of Claims 84-89, wherein each occurrence of R1 is independently F.The compound of any one of Claims 84-94, wherein the moiety The compound of any one of Claims 84-95, wherein each R5 is independently hydrogen, halogen, or Ci-ealkyl. The compound of any one of Claims 84-95, wherein each R5 is independently Ci-ealkyl. The compound of any one of Claims 81-95, wherein each R5 is independently methyl or ethyl. The compound of any one of Claims 84-98, wherein X1 is N. The compound of any one of Claims 84-98, wherein X1 is CH. The compound of any one of Claims 84-100, wherein R6 is methyl. The compound of any one of Claims 84-101, wherein L2 is a (CR7R7)P. The compound of any one of Claims 84-101, wherein L2 is a CH2. The compound of any one of Claims 84-101, wherein L3 is a covalent bond. The compound of any one of Claims 84-101, wherein L3 is O. The compound of any one of Claims 84-101, wherein L3 is NR7. The compound of any one of Claims 84-106, wherein R9 is Ci-4alkyl. The compound of any one of Claims 84-107, wherein R10 is Ci-ealkyl substituted with 1-4 R11, (CR12R12)q-C2-ealkenyl substituted with 1-4 R11, (CR12R12)q-C2-ealkynyl substituted with 1-4 R11, (CR12R12)q-C3-7cycloalkyl substituted with 1-4 R11, (CR12R12)q-phenyl substituted with 1-4 R11, (CR12R12)q-5-6-membered heteroaryl ring substituted with 1-4 R11, (CR12R12)q-5-7-membered heterocyclyl ring substituted with 1-4 R11. The compound of any one of Claims 84-107, wherein R10 is Ci-ealkyl. The compound of any one of Claims 84-107, wherein R10 is (CH2)q-C3-7cycloalkyl. The compound of any one of Claims 84-107, wherein R9 and R10, together with the nitrogen atom to which they are attached, form a saturated or unsaturated 3-7-membered heterocyclic ring substituted with 1-4 R11, which ring may optionally contain additional one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.266118. The compound of Claim 1, selected from:268The compound of Claim 1, selected from: A pharmaceutical composition comprising the compound of any one of Claims 1-119, and a pharmaceutically acceptable carrier. A method for treating or preventing a disease associated with dysregulation of lysophosphatidic acid receptor 1 (LPAi) in a subject in need thereof, comprising administering an effective amount of a compound of any one of claims 1-119 to the subject. The method of Claim 121, wherein the disease is pathological fibrosis (e.g., pulmonary, liver, renal, cardiac, dernal, ocular, or pancreatic fibrosis), idiopathic pulmonary fibrosis269 (IPF), non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, or systemic sclerosis.270
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020108325 | 2020-08-11 | ||
CNPCT/CN2020/108325 | 2020-08-11 | ||
PCT/IB2021/059266 WO2022034568A1 (en) | 2020-08-11 | 2021-10-09 | Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2021323515A1 true AU2021323515A1 (en) | 2023-03-09 |
Family
ID=78179477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2021323515A Pending AU2021323515A1 (en) | 2020-08-11 | 2021-10-09 | Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as LPA receptor antagonists |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP4196220A1 (en) |
JP (1) | JP2023544476A (en) |
CN (1) | CN116669727A (en) |
AU (1) | AU2021323515A1 (en) |
CA (1) | CA3191452A1 (en) |
IL (1) | IL300525A (en) |
MX (1) | MX2023001812A (en) |
WO (1) | WO2022034568A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
KR20230019880A (en) | 2020-06-03 | 2023-02-09 | 길리애드 사이언시즈, 인코포레이티드 | LPA receptor antagonists and uses thereof |
TW202344504A (en) | 2020-06-03 | 2023-11-16 | 美商基利科學股份有限公司 | Lpa receptor antagonists and uses thereof |
IL308035A (en) * | 2021-04-30 | 2023-12-01 | Viva Star Biosciences Suzhou Co Ltd | Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists |
US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
TW202342017A (en) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | Compounds and compositions for treating conditions associated with lpa receptor activity |
WO2024022314A1 (en) * | 2022-07-25 | 2024-02-01 | 武汉人福创新药物研发中心有限公司 | Triazole compounds and use thereof as lpar1 antagonist |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2443248B1 (en) * | 2009-06-16 | 2017-12-27 | E. I. du Pont de Nemours and Company | IMPROVEMENT OF LONG CHAIN OMEGA-3 AND OMEGA-6 POLYUNSATURATED FATTY ACID BIOSYNTHESIS BY EXPRESSION OF ACYL-CoA LYSOPHOSPHOLIPID ACYLTRANSFERASES |
US8785442B2 (en) * | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
US9663513B2 (en) | 2012-11-20 | 2017-05-30 | Merck Sharp & Dohme Corp. | Pyrimidine PDE10 inhibitors |
US20140200215A1 (en) * | 2013-01-15 | 2014-07-17 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
BR112015023267B1 (en) * | 2013-03-15 | 2023-01-31 | Epigen Biosciences, Inc | COMPOUND, AND DRUG FOR TREATMENT OF AN INDIVIDUAL WITH ACID-DEPENDENT LYSOPHOSPHATID DISEASE OR CONDITION |
CN112074515A (en) * | 2017-12-19 | 2020-12-11 | 百时美施贵宝公司 | Cyclohexyl acid isoxazoles as LPA antagonists |
WO2019126098A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
-
2021
- 2021-10-09 JP JP2023510342A patent/JP2023544476A/en active Pending
- 2021-10-09 WO PCT/IB2021/059266 patent/WO2022034568A1/en active Application Filing
- 2021-10-09 CA CA3191452A patent/CA3191452A1/en active Pending
- 2021-10-09 EP EP21791479.5A patent/EP4196220A1/en active Pending
- 2021-10-09 MX MX2023001812A patent/MX2023001812A/en unknown
- 2021-10-09 AU AU2021323515A patent/AU2021323515A1/en active Pending
- 2021-10-09 CN CN202180067597.XA patent/CN116669727A/en active Pending
- 2021-10-09 IL IL300525A patent/IL300525A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022034568A1 (en) | 2022-02-17 |
EP4196220A1 (en) | 2023-06-21 |
CA3191452A1 (en) | 2022-02-17 |
CN116669727A (en) | 2023-08-29 |
MX2023001812A (en) | 2023-06-19 |
IL300525A (en) | 2023-04-01 |
JP2023544476A (en) | 2023-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021323515A1 (en) | Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as LPA receptor antagonists | |
AU2017295863B2 (en) | Inhibitors of cyclin-dependent kinase 7 (CDK7) | |
KR101181194B1 (en) | Biaryl ether urea compounds | |
EP2318408B1 (en) | Tri-cyclic pyrazolopyridine kinase inhibitors | |
BR112016011024B1 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION AND USES OF THE SAME | |
JP6378759B2 (en) | Heteroaryl compounds useful as SUMO activating enzyme inhibitors | |
AU2017304761B2 (en) | Pharmaceutical compounds | |
EP2464641B1 (en) | Pyrimidine compounds as tuberculosis inhibitors | |
AU2014362231A1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
AU2019385905B2 (en) | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | |
WO2014029193A1 (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
US20230265116A1 (en) | Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use | |
JP2022517901A (en) | Cyclic urea | |
AU2017388376A1 (en) | Poly-ADP ribose polymerase (PARP) inhibitors | |
WO2022165513A1 (en) | Cdk2 inhibitors and methods of using the same | |
CN112135818A (en) | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin-specific protease 19(USP19) | |
WO2016154075A1 (en) | Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathway | |
WO2022232459A1 (en) | Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists | |
WO2023141570A2 (en) | Compounds and methods for the targeted degradation of kras | |
WO2023069700A1 (en) | Compounds that mediate protein degradation and methods of use thereof | |
JP2024517769A (en) | Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2H-pyranyl acetic acid compounds as LPA antagonists | |
WO2024026483A2 (en) | Cdk2 inhibitors and methods of using the same | |
WO2023086521A1 (en) | Btk inhibitors | |
WO2024092039A1 (en) | Compounds that mediate protein degradation and methods of use thereof | |
WO2023201185A1 (en) | Pyrido[3,2-d]pyrimidines as hpk1 inhibitors |